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Abstract 
In the last decade unprecedented improvement in cure rates and overall survival was 
achieved in diffuse large B-cell Lymphoma (DLBCL) through the introduction of 
rituximab and anthracyclin-based chemotherapy (R-CHOP) as first line treatment. 
However, 40% of patients are refractory or relapse after R-CHOP and are hardly 
salvaged. To date, only age, International Prognostic Index (IPI) stratification and 
genetic aberrations defining gray-zone lymphomas have been used in clinical trials to 
select high-risk patients for more aggressive regimens. However, these prognostic 
features do not take into account the full biological heterogeneity of DLBCL. This 
reflects our limited knowledge on comprehensive prognostication in this group of 
disorders and supports our choice to investigate old and new prognostic factors for 
DLBCL in this thesis.  
Molecular characterization is generating opportunities for personalized therapy in 
poor-risk DLBCL. In order for targeted therapies to succeed in this disease, reliable 
and reproducible strategies that adequately segregate patients into distinct 
molecular groups are needed. While gene expression profiling (GEP) is the gold 
standard method, there is presently a lack of standardized methodology for array 
analysis, which can lead to variable results. The lack of a routine methodology for GEP 
has led investigators to develop immunohistochemistry (IHC) based approaches for 
the molecular classification in DLBCL. In fact, the Hans algorithm is being used to 
identify non-GCB DLBCLs in clinical trials offering NF-kB targeting agents to patients 
with this subtype. By performing a systematic comparison of nine IHC algorithms for 
molecular classification in a new large dataset of diagnostic DLBCL, we document an 
extremely low concordance across all classifiers (<21%) when classifying each 
individual patient,  and a lack of outcome impact of all strategies, demonstrating that 
IHC is not a reliable alternative to molecular-based methods to be used for clinical 
decisions in DLBCL.  
GEP studies also suggested that the microenvironment could provide prognostic 
biomarkers in DLBCL in the R-CHOP era. Most authors have focused on the use of IHC 
to enumerate and functionally characterize the microenvironment in DLBCL. In our 
second study, by comparing two methods of semi-automated analysis for IHC staining 
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of the microenvironment, we demonstrate that the computerized results are highly 
reproducible, add the required robustness to IHC studies and should be used in the 
future instead of manual analysis. By applying comprehensive statistical analysis we 
propose that CD3 and FoxP3 should be validated as predictors of response to R-CHOP 
in clinical trials. 
 
Whereas a number of mechanisms by which cancer cells influence macrophage 
function have been described, currently there is very limited understanding of the 
macrophage polarisation status and effector function in human DLBCL. In our third 
study we analysed the GEP of macrophages sorted from human DLBCL samples. 
Unsupervised hierarchical clustering does not resolve DLBCL macrophage samples 
from reactive macrophage samples, indicating that macrophage heterogeneity in 
DLBCL should be considered. 202 genes are differentially expressed in DLBCL relative 
to controls. Functional annotation supports that these genes are macrophage-
specific. We demonstrate that DLBCL macrophages have a bidirectional M1 and M2 
functional activation, challenging the concept, widespread in the literature, that 
macrophages in tumours have a predominant M2 transcriptome.  
In our fifth study we used a two-cell co-culture model in an attempt to demonstrate 
that DLBCL cells influence macrophage transcriptome and proteome. The 
heterogeneity of the results, which precludes the confirmation of our hypothesis, is 
fully discussed.  
In our last study we tease out the DLBCL macrophage GEP heterogeneity and  
propose IFN- as a culprit B-cell derived molecule influencing macrophage activation 
status. Finally, using immunofluorescence we demonstrate that both M1 and M2 
proteins are expressed in DLBCL macrophages.
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Chapter 1 Introduction and Objectives 
PART ONE 
 
 
1.1 Diffuse Large B-cell Lymphoma: background 
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive lymphoma in 
the western world, accounting for 30-40% of all cases.1 The incidence of DLBCL has 
risen slowly over the last 20 years. An estimated age-adjusted incidence of 
9.8/100.000 cases in Europe in 2012 has been recently reported, with predominance 
for males.2 However disease-related mortality has significantly decreased, 
recognisably due to the introduction of rituximab chemo-immunotherapy into first-
line treatment, together with better supportive care and intention to treat in the 
elderly population. DLBCL is in fact a disease of the elderly, with a median age at 
diagnosis in population-based studies of 71 years. 
The aetiology of DLBCL remains largely unknown. Although most commonly arising de 
novo, DLBCL can be the result of transformation from indolent non-Hodgkin 
lymphomas (NHL).3 Potential etiological factors include: a family history of 
lymphoproliferative diseases, prior history of malignancy, primary or treatment-
related immunodeficiency, auto-immune diseases or viral infections including human 
immunodeficiency virus4, human herpes virus 8 and Epstein Barr virus (EBV).5 
 
Patients generally present with a rapidly growing lymph node (LN), accompanied in a 
third of the cases by B-symptoms (fever, night sweats, and weight loss). Extranodal 
involvement at presentation occurs in 40% of the cases.6 Half of the patients are 
diagnosed in advanced stage disease as defined by the Ann Arbor system,7 with bone 
marrow involvement reported in 11-27% of the cases.8 A revised staging system has 
been recently proposed incorporating results from the diagnostic positron emission 
tomography-computed tomography (PET-CT) that will likely change the distribution of 
patients according to stage.9 
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A tissue-based histopathology examination remains the standard tool to establish a 
diagnosis of DLBCL. This disease is described microscopically as a neoplasm of large B 
lymphoid cells with a diffuse pattern often effacing the normal LN architecture. The 
malignant B-cells exhibit a nuclear size at least twice that of normal lymphocytes.1 
The malignant cells express pan–B-cell markers including CD19, CD79a, CD20, PAX5, 
and CD22, although some of these markers can be lost in individual cases.10 The 
proliferation fraction, as detected by Ki-67 staining, is generally high. 
 
However, the diagnosis of DLBCL encompasses a large number of sub-diagnoses, 
reflecting the heterogeneity of this disease.1 What has accelerated the sub-
classification of DLBCL has undoubtedly been the use of gene expression profiling 
(GEP). This technology generated evidence that certain conditions amalgamated 
within the DLBCL diagnosis and previously recognized by their particular clinical 
behaviour, morphology or immunophenotype had a distinct molecular background 
and hence likely a distinct cell of origin. For example, T-cell/histiocyte-rich B-cell 
lymphomas (THRBCL) constitute a rare aggressive subtype of DLBCL with abundant T-
cell and macrophage infiltration in the microenvironment.11 Only a minority of the 
cells are large CD20+ B-cells. Although not pathognomonic, most of these cases carry 
a GEP characterized by a host immune response that differs from the majority of 
DLBCL cases.12 Another example is the provisional entities of unclassified large cell 
lymphomas with intermediate features between DLBCL and Burkitt’s Lymphoma (BL) 
or classical Hodgkin’s lymphoma (cHL). For many years, pathologists encountered 
cases with intermediate morphologic features between DLBCL and BL or cHL that 
posed diagnostic dilemma. Microarray technology again helped recognizing that 
these cases constitute a real biological gray zone of lymphomas.13-16 
 
Taking into consideration the prolific number of publications characterizing new 
DLBCL “entities” it is envisaged that the next World Health Organization (WHO) 
lymphoma classification will incorporate changes in how we define what is now 
termed DLBCL. The issue of misdiagnosis in DLBCL is still debated, highlighting the 
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importance of expert central review. A large-scale assessment in the United Kingdom 
highlighted that there is still up to a 25% rate of discordance between  primary and 
revised diagnosis of DLBCL.17 
 
DLBCL has an aggressive natural history, with a median survival of less than one year 
if left untreated, but is readily treatable. The anthracycline-based combination CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone) was introduced in 1976 
and has been the standard of care for 30 years.18 However survival rates were 
suboptimal, with 10-year progression-free survival (PFS) of 30% and overall survival 
(OS) rates of 35%. Attempts to add treatment efficacy with more intensified 
chemotherapy regimens failed.19  
In the last decade unprecedented advances were made in the standard of care of 
patients with DLBCL that translated in an improvement in cure rates and OS. With 
modern therapeutic combinations, approximately 60% of patients with this disease 
are now being cured. This progress is largely due to the addition of the anti-CD20 
antibody rituximab to CHOP chemotherapy (R-CHOP).20-26 Long-term follow-up of the 
first randomised clinical trial (RCT) comparing R-CHOP to CHOP demonstrated a 16% 
absolute improvement in the 10-year OS rate in favour of R-CHOP.21 The higher costs 
associated with the use of rituximab are offset by the significant advantage in survival 
and by the decrease in the number of patients requiring expensive salvage therapies. 
 
Currently there are a number of research priorities in the treatment of patients with 
DLBCL.  
A substantial 40% of patients will be primary refractory or relapse after R-CHOP, and 
this constitutes a real management challenge. The estimate of PFS at 3 years for this 
group is only 23%, even with subsequent high-dose chemotherapy and autologous 
stem-cell transplantation (ASCT), proving that salvage regimens remain largely 
ineffective for this sub-group of patients.27 In fact, in keeping with the findings of 
other groups, we have confirmed in our patient cohort that R-CHOP refractoriness is a 
strong predictor of a worse OS. Identification of these high-risk patients at diagnosis, 
incorporation of novel therapies into RCTs where they are enrolled and recognition of 
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the mechanisms for rituximab-refractoriness are of paramount priority. On the other 
hand it is hypothesized that some patients with better prognosis disease might do as 
well with four rather than six or eight cycles of R-CHOP, an issue that is being 
addressed by the German high-grade non-Hodgkin’s Lymphoma study group. 
 
To date, only age, the International Prognostic Index (IPI) stratification and genetic 
aberrations defining gray-zone lymphomas have been used in clinical trials to select 
high-risk DLBCL patients for more aggressive regimens, most of them incorporating 
front-line consolidation with ASCT. However, these prognostic features do not take 
into account the full biological heterogeneity partially responsible for disease 
aggressiveness. Moreover, despite different approaches taken in RCTs, there is no 
current evidence for offering treatments other than R-CHOP according to risk factors 
in DLBCL.  
 
This reflects our limited knowledge on comprehensive prognostication in this 
heterogeneous group of disorders and supports our choice to investigate old and new 
prognostic factors for DLBCL in this thesis. The treatment scenario is, however, 
changing rapidly owing to a deeper knowledge of the molecular biology and the 
drivers of oncogenic transformation of DLBCL, leading to the development of rational 
targeted therapeutic approaches (see section 1.4). 
 
 
1.2 Prognostication in DLBCL 
Despite the number of scientific publications describing potential prognostic markers 
in medicine, the field of outcome prediction is complex. This is even more so in 
heterogeneous disorders such as DLBCL. It is argued that only modest outcome 
predictive accuracy can be achieved with clinical data or single biochemical or 
molecular markers.28 
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The statistical validation of prognostic variables is dependent on the number of 
patients enrolled in a study. If the objective of a particular study is to validate a new 
prognostic marker, then other formerly validated markers need to be taken into 
account. With a growing amount of markers to be incorporated in multivariate 
analyses, a large number of patients are required to accomplish statistical validity. In 
practice, however, the results in highly cited biomarker studies often significantly 
overestimated their findings. 
 
To ascertain the impact of a clinical or biologic feature on patient’s survival or 
treatment response, robust clinical validation under prospective RCTs or large multi-
institutional cohorts is needed. However, this is rarely performed. It has been 
reported that only around 3% of studies describing potential clinical applications in 
genomic medicine moved to assessment of clinical utility under RCT.29 Moreover, 
studies using patients enrolled in RCT are essential for predictive marker validation as 
it guarantees uniformity in clinical characteristics from both the experimental and the 
control arm.  
 
Only after scrutiny in this manner can a clinical or biologic marker predictive of 
response to R-CHOP help us to individualize treatment in DLBCL. The final and 
essential step in this validation process is developing robust, simple and reproducible 
methodologies for assessment of these biomarkers so as to guarantee their 
implementation in the clinical practice. 
 
GEP and genomic studies in DLBCL were of paramount importance in deepening our 
understanding of the biology of DLBCL. These studies were the starting point for 
many others detailing the classification of the heterogeneous group of DLBCL, not 
otherwise specified (NOS), and searching for the functional roles of specific 
aberrations. More importantly they provided new prognostic biomarkers and 
treatment approaches. Details on the molecular biology of DLBCL will be covered in 
section 1.4. 
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1.2.1 Clinical prognostic factors 
The IPI is a prognostic score incorporating five factors reflecting patients’ clinical and 
biological characteristics. Based on the number of negative factors detected at the 
time of diagnosis (age >60 years, stage III/IV disease, elevated serum lactate 
dehydrogenase [LDH] level, Eastern Cooperative Oncology Group [ECOG] 
performance status ≥2, >1 extranodal site of disease), four groups were identified, 
with 5-year OS ranging from 26%-73%.30 The IPI was devised in the pre-rituximab era 
and its power to discriminate outcome has declined after introduction of R-CHOP, 
particularly for higher risk patients.31-33  
 
The prognostic value of the individual factors incorporated in the IPI, however, 
remains unchanged. The National Comprehensive Cancer Network (NCCN)-IPI33 was 
recently developed based on DLBCL patients treated in academic centres and in the 
community with R-CHOP (Table 1.1). It incorporates the same markers as the IPI and 
is able to better discriminate patients with low and high risk disease that might merit 
different treatment approaches.  
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Table 1.1 The NCCN enhanced IPI 
Variables Score 
Age, years                    >40 to ≤60 1 
                                       >60 to ≤75 2 
                                       >75 3 
LDH, normalised         >1 to ≤3 1 
                                       >3 2 
Ann Arbor stage III-IV 1 
Extranodal disease  
Bone marrow, central nervous system, liver, gastrointestinal tract or lung 
1 
Performance status ≥2 1 
 
    Low risk: 0 – 1    High-intermediate risk: 4 - 5 
    Low-intermediate risk: 2 – 3  High risk:  6 
 
 
However, many authors acknowledge that patients belonging to the same IPI group 
have significant survival differences, likely reflecting different biological backgrounds. 
Moreover a number of papers suggest that some biomarkers, such as the GEP-based 
stromal signatures34 or chromosomal translocations involving MYC,35 B-cell 
lymphoma/leukaemia-2 (BCL2),36 or B-cell lymphoma/leukaemia-6 (BCL6),37 have an 
IPI-independent prognostic impact. These data demonstrate that there is opportunity 
to improve upon the IPI with new biomarkers. Although not yet available due to the 
reasons discussed above, it is likely that a clinico-biological index will be more 
comprehensive for prognostic stratification than the NCCN-IPI. 
 
Zhou et al. recognize advanced age as being associated with incremental risk even 
with R-CHOP treatment. In fact, aging seems to be a determinant of the molecular 
biology of DLBCL and a surrogate of aggressive disease.38 
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Other clinical variables not incorporated in the IPI have been suggested as prognostic 
markers in DLBCL:  
 
1. Male gender has been associated with worse outcome in independent studies in 
DLBCL.39 In fact, pharmacokinetic (PK) studies of rituximab demonstrated that elderly 
males have a faster clearance of rituximab and hence might be sub-optimally treated 
with the standard dose of the monoclonal antibody. This hypothesis formed the basis 
of two German clinical trials: the SMART-E-R-CHOP-14 trial demonstrated that a PK-
guided rituximab schedule benefited older patients with high tumour burden, 
regardless of the patient’s gender;40 the SEXIE-R-CHOP-14 trial showed that 
increasing rituximab dose eliminates the increased risk of elderly males as well as 
young male and female patients with low rituximab serum levels. 
 
2. A high body mass index has provocatively been stated as a favourable outcome 
predictor after R-CHOP treatment in DLBCL.41 However others have disputed this 
association.42,43 
 
3. The maximum tumour diameter has an adverse impact on OS in R-CHOP-treated 
patients,44,45 and is helpful for stratifying patients with low-risk IPIs. 
 
4. Bone marrow (BM) involvement is associated with a poor outcome, particularly 
with concordant rather than discordant low-grade histology. Those patients who have 
diffuse large cell infiltrates in the BM have a particularly bad outcome, with reported 
10% OS at 5 years.8,46 
 
5. Primary involvement of the Waldeyer ring appears to confer a better outcome.6,47 
In fact, the role of rituximab in the treatment of primary extranodal DLBCL is a matter 
of debate.48 
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1.2.2. Prognostic impact of Fluorodeoxyglucose (FDG)-PET-CT  
FDG-PET-CT has currently replaced standard CT scan for staging and response 
assessment of FDG-avid lymphomas.9 A negative FDG-PET-CT at the end of treatment 
is an excellent predictor of good outcome in DLBCL. The role of interim FDG-PET scan 
is, however, controversial. Recent reports show an increase in PFS (and OS in some 
studies) in patients with a negative PET after 2 or 4 cycles of R-CHOP. Yet others have 
reported contrary results. In an attempt to validate the biological significance of mid-
treatment PET results, Moskowitz et al.49 re-biopsied all lesions deemed positive and 
found that 87% of PET positive were indeed false positive. The absence of strict 
scoring criteria, best standard scoring method50 and a high inter-observer variability 
are given as potential explanations for this controversy. Using PET-CT to guide 
optimal treatment is not established in DLBCL. 
 
1.2.3. Morphology and Immunophenotype prognostic factors 
Although morphology has been disregarded as a method to gather prognostic insight 
in DLBCL, a thorough pathological report at diagnosis is required to appropriately 
allocate patients according to the WHO classification and might in fact provide some 
information on patient’s outcome.  
 
A recent analysis from a large cohort of patients enrolled in the Ricover-60 trial 
showed that immunoblastic morphology51 is an adverse prognostic factor at 
diagnosis. Similarly, a plasmablastic phenotype52 in cases of DLBCL-NOS was 
associated with shorter survival after R-CHOP. 
 
CD5 expressing DLBCLs constitute 10% of cases and seem to represent an 
independent entity with a distinct genomic and transcriptomic profile and to be 
associated with a poorer outcome.53-55 The intensity of CD20 expression is 
heterogeneous in patients with DLBCL. Cases showing decreased CD20 expression 
appear to have a worse survival, independently of clinical prognostic factors.56  
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1.3 B-cell Ontogeny in DLBCL  
B-cell malignancies arise from a subversion of the differentiation and proliferation 
patterns of a normal B-cell. B-cells are specialized in the recognition and elimination 
of foreign antigens, with these functions mediated through the B-cell receptor (BCR). 
In order for the BCR to recognize non-self antigens it has to go through molecular 
modifications, which lead to increased epitope specificity and affinity. This 
dependency on physiological genetic changes in the BCR coding region potentiate the 
acquisition of oncogenic aberrations and help to explain why B-cells are particularly 
prone to malignant transformation.57 
 
The process of B-cell differentiation initiates in the BM where a precursor cell 
undergoes sequential rearrangements of the heavy and light chain locus of the Ig 
gene. This molecular process involves a modulated series of genetic events which 
ultimately leads to the expression of a functional BCR at the surface of the B-cell.58 
Assembly of the Ig gene segments, required to produce a functional BCR, occurs 
through three recombination events catalysed by the enzymatic complex 
recombinase.59 If in any event a non-productive rearrangement occurs, cells undergo 
apoptosis. 
 
The recombinase enzymatic complex starts this process by introducing double strand 
DNA (deoxyribonucleic acid) breaks.60 Repair mechanisms introduce a high potential 
for oncogenic chromosomal translocations to occur. The element responsible for 
regulating the expression of a specific gene is replaced by a regulatory element that is 
constitutively active and hence leads to aberrant gene expression. An illustrative 
example is the t(14;18)/IgH-BCL2, which brings the BCL2 gene under the control of 
the active regulatory element of the Ig heavy (H) locus, ultimately leading to  BCL2 
protein overexpression.61,62 The occurrence of a potential initial oncogenic event does 
not undermine the differential potential of the malignant cell, allowing for further 
genetic events to occur later on the living pathway of the lymphoma cell. 
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Precursor B-cells expressing a functional BCR are positively selected into the antigen 
inexperienced, B-cell compartment in the peripheral blood. Once they encounter 
foreign antigens, naïve B-cells follow one of three pathways:59 (1) travel to the 
peripheral lymphoid tissues and initiate the germinal centre (GC) reaction; (2) 
differentiate into short lived plasmablasts outside the germinal centre; or (3) enter 
into an anergic state. 
 
1.3.1 The GC reaction 
The GC reaction occurs in the follicles of lymphoid tissues and is a physiological 
process required for final B-cell maturation.60 Through molecular mechanisms known 
as somatic hypermutation (SHM) and class switch recombination (CSR), an efficient 
humoral response against the antigen is carried out with the production of high-
affinity antibodies.  
 
After contacting with the antigen presenting cells (APC), naïve B-cells uptake, 
internalize and expose the antigen through the major histocompatibility complex 
(MHC)-class II molecule. B-cells are then driven to the T-cell rich areas of the 
lymphoid organs, where they become activated through interaction with CD4+ helper 
T-cells. This activation requires not only the interaction between the MHC class-II and 
the T-cell receptor (TCR) but also ligation of the co-stimulatory molecules CD28 and 
CD40L with their ligands on APCs. This is essential for the initial formation of the GC 
reaction, as has been demonstrated in murine models of genetic or pharmacological 
disturbance of CD40 or CD40L function.58 
 
Within the dark zone of the GC, B-cells exhibit an impressively high proliferation rate 
and can be histologically recognized as centroblasts. It has been demonstrated that 
the major gene expression changes between a resting naïve B-cell and a centroblast 
are regulated by the BCR signalling and nuclear factor-kB (NF-kB) and result on the 
over-expression of the proliferation machinery and down-regulation of the DNA 
damage sensing machinery.63 Centroblasts producing antibodies with improved 
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antigen binding capacity progress through the GC reaction, stop proliferating (now 
denominated centrocytes) and undergo further selection. Centrocytes engage with 
antigen-exposing follicular dendritic cells (FDCs) and CD40L-expressing T follicular 
helper cells (TFH) and are selected based on their antigen affinity. Finally, centrocytes 
exit the GC either as plasma cells or memory B-cells. 
 
The SHM64 molecular event involves the introduction of single nucleotides, small 
deletions and duplications into the Ig variable locus or genes other than the Ig genes, 
such as the BCL-6 proto-oncogene.65 CSR is the molecular mechanism by which Ig 
isotype switching occurs, leading to a modification of the effector functions of an 
antibody while retaining specificity. Both the SHM and CSR events require the activity 
of the enzyme activation-induced cytidine deaminase (AID). AID deaminates cytosines 
leading to the initiation of DNA repair mechanisms that ultimately allow the 
introduction of somatic mutations and the generation of IgV clonal diversity.66 
 
The transcriptome of the B-cells encompassing the GC is tightly regulated and 
involves many molecules. However, BCL6 is regarded as the master regulator of the 
GC reaction. BCL6 knock-in mice are unable to mount a GC reaction upon antigen 
triggering. These mice develop lymphoma that recapitulates the biology of human 
DLBCL.67  
 
BCL6 is a transcriptional repressor that targets genes involved in cellular processes 
fundamental for the GC reaction. BCL6 is known to repress apoptosis68 and cell-cycle 
arrest responses as well as DNA damage sensor related genes,69 enabling persistent 
proliferation and tolerance to genetic transformation required for B-cell antigen 
affinity maturation. Furthermore, BCL6 down-regulates the expression of genes 
involved in B-cell activation,70 enabling centroblasts to complete clonal expansion and 
undergo SHM. Finally, BCL6 has been shown to repress GC B-cell differentiation into 
plasma cells by direct or indirect (via targeting Interferon regulatory factor 4, IRF4) 
repression of a master regulator of B-cell terminal differentiation, Blimp-1 (B-
lymphocyte-induced maturation protein 1).71  
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Overall BCL6 functions to sustain the GC B-cell phenotype and hence needs to be 
repressed for conclusion of B-cell maturation. Its repression in centrocytes is 
mediated by IRF4. Once BCL6 is “turned-off”, Blimp-1 establishes the characteristic 
plasma cell phenotype by inactivating PAX5 (paired box protein 5). Continued 
signalling through CD40 is crucial for driving centrocytes towards memory B-cell 
differentiation, and continued PAX5 expression maintains B-cell identity in memory B 
cells.  
 
1.3.2 The GC reaction and B-cell Lymphomas 
Nearly all B-cell NHLs harbour SHM in the IgV genes, indicating that the malignant B-
cell is blocked within or has passed through the GC. Moreover the commonest 
oncogenic events in B-cell neoplasms are chromosomal translocations and aberrant 
SHM, which represent errors in the physiological process of B cell differentiation and 
maturation. With the exception of the t(14;18), and a subset of t(8;14) involving the 
Ig and MYC loci in endemic-type BL, most breakpoints in chromosomal translocations 
involving the Ig genes arise in the switch region or in the target regions for SHM.16 
AID is absolutely required for the SHM to occur and has been detected in exceedingly 
high levels in some DLBCLs. This again indicates the occurrence of malignant 
transformation during the GC reaction.  
 
The consequence of these genetic abnormalities is the transcriptional deregulation of 
genes involved in GC B-cell development or the aberrant expression of genes 
restricted to other B-cell developmental stages. As an example, chromosomal 
translocations involving BCL6 prevent silencing of its expression at the end of the GC 
reaction, leading to a block in post-GC differentiation.72 Cells harbouring BCL6 
translocations maintain a centroblast-specific functional program, with typical pro-
proliferative, DNA-damage-tolerant phenotypes, with a high potential to acquire 
further genetic alterations, eventually leading to lymphomagenesis. 
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The understanding of B-cell development, the physiological process of the GC 
reaction and the mechanisms of B-cell transformation were instrumental for the 
seminal discovery of the molecular subtypes of DLBCL described in the following 
section. 
 
1.3.4 The Cell-of-Origin (COO) Classification in DLBCL 
Up to the year 2000 molecular heterogeneity in DLBCL was recognized only by the 
detection of chromosomal translocations, numerical chromosomal abnormalities, 
mutations and deletions in tumour suppressor genes. It was by then also accepted 
that these molecular changes arose in B-cells in different developmental stages. 
However the normal cellular counterpart of DLBCL was still unknown. GEP, a high 
throughput technique for interrogation of the whole transcriptome of cells or tissues 
was by then starting to be used to study human cancer.73  
 
In this scenario, Alizadeh et al. performed GEP in normal human B-cells in different 
stages of development or stimulated in vitro, in parallel with a variety of snap-frozen 
single-cell suspensions derived from B-cell malignancies.74 They wanted to test the 
hypothesis that the concerted gene transcription in lymphomas is similar to the one 
from the normal counterpart from which they derive; and to deepen the current 
understanding of the lymphoma biological phenotypes. The Lymphochip array was 
purposely designed to detect transcripts related to the GC biology.75 By visually 
comparing, in a completely unsupervised fashion, how all samples clustered 
according to similarities between them (hierarchical clustering), the authors indeed 
recognized that around half of the DLBCL cases studied expressed genes that are 
hallmarks of normal centroblasts (e.g. BCL6). By contrast, another DLBCL subgroup 
lacked the expression of GC B-cell–restricted genes and instead had a transcriptome 
similar to the one of a B-cell triggered to divide (e.g. NF-kB, IRF4). To consolidate 
these findings, patient division according to resemblances with normal B-cell 
transcriptomes was later confirmed in larger datasets of more than 200 patients, 
either before76 or after the introduction of R-CHOP.34  
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Importantly all GEP studies recognized that the two subgroups had disparate survival 
rates independently of the treatment given. The prognostic significance of this 
classification of DLBCL was also corroborated by GEP studies done on formalin-fixed 
paraffin embedded (FFPE) tissue using different systems of nucleic acid amplification 
and done using low input, partially degraded RNA (ribonucleic acid).77-79 
 
GEP studies in DLBCL12,74,76,80 could also recognize groups of genes involved in 
different biological processes, which had synchronous expression. These gene 
signatures were differentially expressed by the lymphomas profiled, and helped to 
elucidate the biological processes that are being exploited by the malignant cells and 
to predict outcome independently of the IPI. 
 
These analyses led to the COO classification, recognizing two molecularly distinct 
entities in DLBCL: the germinal centre B-cell–like (GCB) DLBCL and the activated B-
cell–like (ABC) DLBCL. Mutational analysis showed that the GCB-DLBCLs have ongoing 
SHM of the IgV genes,81 suggesting that the malignant B-cells result from a block 
within the centroblast stage in the GC reaction; whereas ABC-DLBCLs have a high 
mutational burden in the IgV genes, supporting that the malignant B-cells have 
passed through the GC but fail to fully mature. 
 
Additional work helped to allocate previously known genetic aberrations (such as the 
t(14;18) translocation) into each molecular subgroup, and to describe novel genetic 
lesions that are mutually exclusive to each subgroup.82 Importantly, the COO 
classification accelerated functional studies exploring the role of cytokines, signalling 
pathways and transcription factors differentially involved in the pathogenesis of 
these lymphomas.  
 
The COO classification led to the design of RCTs incorporating targeted therapies, 
with the perspective of improving survival of the high-risk ABC-DLBCLs. These trials 
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might demonstrate that the COO is predictive of response to R-CHOP, but as yet 
there is no controlled data supporting it. 
 
 
1.4 Main oncogenic mechanisms in DLBCL  
Despite having genetic and epigenetic alterations in common, GCB and ABC-DLBCLs 
utilize mutually exclusive oncogenic pathways, providing compelling evidence for 
their different origin. Pathway activation depends on gain-of-function mutations in 
signalling effectors, loss-of-function mutations in negative signalling regulators, or 
autocrine receptor activation.83 Here we will first describe the most relevant genetic 
alterations, followed by the commonest oncogenic pathways utilized by the DLBCL 
cells and the epigenetic changes in this disease, paying particular attention to the 
changes with potential for therapeutic targeting. For a comprehensive list of genetic 
aberrations see Figure 1.1. 
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Genetic aberrations proportion of patients (%) GCB ABC 
t(14;18)/BCL2 50 x  
EZH2 mutations 20 x  
MEF2B mutations ~10 x  
TP53 mutations/deletions 20 x x 
MLL2 mutations 40 x x 
CREBBP/EP300 mutations 40 x x 
MYD88 L265P mutations 30  x 
CD79 A/B mutations 20  x 
t(3;x)/BCL6 10 - 25 x x 
SPIB translocations/gains/amplifications 20 - 50  x 
CDKN2A deletions 20 - 50  x 
INK4a/ARF deletion 20 - 50  x 
A20 deletions/mutations 20 - 50  x 
PRDM1 20 - 50   
BCL2 amplifications 20  x 
MYC translocations 5 - 20 x x 
MDM2 amplifications < 20 x  
IRF4 rearrangements < 20 x  
CARD11 mutations 10 x x 
MYD88 mutations (other) 10 x x 
B2M mutations < 20 x x 
CD58 mutations < 20 x x 
PTEN deletions < 20 x  
TNFRSF14 mutations 5 - 20 x  
FOXO1 mutations ~8 x x 
FAS mutations/deletions < 20 x  
GNA13 mutations ~25 x  
SGK1 mutations  x  
miR-17-92 amplifications 12 x  
 
Figure 1.1 Recurrent genetic aberrations and oncogenic pathways in DLBCL according to the 
cell-of-origin molecular profile.  
The most common changes of each molecular group are highlighted. 
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Next-generation sequencing (NGS) technologies have been used to deepen our 
understanding of the coding genome of DLBCL (reviewed by Jardin84). More than 200 
cases have been reported to date and the findings support that DLBCL has a high 
degree of genomic complexity, harbouring on average between 30-100 changes/case. 
However the modest overlap of lesions described among the four studies published85 
and the limited depth of detection of the technologies used, suggests that the full 
genomic landscape is yet to be unravelled. Apart from confirming previously 
acknowledged genetic aberrations, NGS uncovered novel targeted genes, some of 
which have prognostic impact in the R-CHOP era (e.g. Forkhead box protein O1 
(FOXO1) mutations). Some of these somatic mutations conduct to changes in 
signalling pathways that play crucial roles in B-cell function, immunity, cell death, or 
epigenetic regulation, as will be detailed. 
 
The TP53 (tumour protein 53) gene is targeted by mutations (20% of cases),86 and by 
deletions irrespective of the COO of DLBCL. This gene encodes for the tumour-
suppressor protein p53. Loss-of-function mutations in TP53 impair the regulation of 
many biological processes controlled by p53: cell cycle, apoptosis, cell differentiation, 
DNA repair, angiogenesis, and genomic stability. All aberrations were associated with 
worse survival in DLBCL.87-89 Importantly, it was suggested that TP53 mutations might 
help to stratify GCB patients into different prognostic subgroups.89,90 
 
Chromosomal abnormalities can be detected by karyotype, targeted in-situ 
hybridisation (fluorescence or colorimetric) or, in a more detailed and comprehensive 
fashion, by chromosomal genomic hybridisation (CGH) arrays. CGH-arrays 
demonstrated that GCB and ABC-DLBCLs harbour distinct chromosomal aberrations.91 
As an example, copy number alterations on chromosome 3 are exclusively diagnosed 
in ABC-DLBCL, whereas amplifications of C-REL are exclusively detected in GCB cases.  
 
Around half of GCB-DLBCLs exhibit the t(14;18) translocation, leading to BCL2 
overexpression and subsequent escape from apoptosis. BCL2 overexpression is also 
detected in the majority of ABC-DLBCLs, driven by transcriptional deregulation and 
Chapter 1 Introduction 
 
41 
gene amplifications rather than translocations.76,92 BCL2 protein is highly expressed in 
both molecular groups (70% in our series93), and is accepted as a predictor of poor 
outcome.94-97 Hence BCL2 represents an excellent candidate for therapeutic 
targeting. Several molecules targeting it at the DNA and protein level, including ABT-
199 are under study and represent an opportunity to improve the outcome of GCB-
cases. 
 
 
A number of gene transcriptional regulators exhibit chromosomal changes in DLBCL. 
Translocations involving the transcription factor MYC are detected in 5-10% of 
DLBCLs irrespective of the COO and are usually associated with complex 
karyotypes.13,16 Amplifications and somatic mutations have also been described. 
These genetic aberrations lead to MYC protein overexpression and activation of a 
proliferative phenotype. In RCTs, the presence of MYC aberrations was associated 
with poorer OS and EFS, independently of the IPI and the COO classification.98 Other 
studies correlated MYC aberrations with worse survival.35,99-101 The presence of MYC 
staining as detected by IHC was correlated with MYC rearrangements in two 
independent studies.99,102 MYC+ and BCL2 or BCL6+ double-hit lymphomas103 have a 
very poor outcome, which cannot be solely explained by the presence of a MYC 
breakpoint, hence suggesting a synergism between these genetic events. Applying an 
IHC BCL2 and MYC double-hit score102 might help to recognize patients with worse 
OS, and PFS, independently of the IPI and COO. Targeting DNA secondary structures 
within the MYC promoter region is emerging as a potential intervention in DLBCL.104 
 
As already stated, BCL6 is a transcriptional repressor essential for the formation of 
the GC reaction, and, hence, a key molecule involved in the lymphomagenesis of GCB-
DLBCLs. Most genetic aberrations involving BCL6 lead to its overexpression. Although 
these are more common in ABC-DLBCLs, translocations involving BCL6 can occur in 
both molecular subtypes.83 BCL6 mutations have also been described.105 It has been 
shown that BCL6 inhibitors are toxic for GCB-DLBCL cell lines even in the absence of 
chromosomal translocations.106 
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A common event in ABC-DLBCLs is the acquisition of genetic or epigenetic events in 
PRDM1 (PR domain zinc finger protein 1) leading to repression of Blimp-1, the key 
transcription factor involved in the terminal differentiation of B-cells.  
 
Similarly, IRF4 is a transcription factor that has an important role in plasma cell 
differentiation and in the survival of post-GC neoplasms such as the ABC-DLBCLs. In 
GCB-DLBCLs, IRF4 was found to be involved in rearrangements with the Ig genes. 
These cases exhibited a specific GEP and presented a favourable outcome.107 
 
Addiction to IRF4 in ABC-DLBCLs is independent of genetic aberrations. Its 
overexpression is attributed to NF-kB constitutional activation. On the other hand, 
SPIB, its essential partner for DNA binding is targeted by chromosomal translocations, 
gains and amplifications in ABC-DLBCLs.82 
 
The most commonly exploited signalling pathway by malignant B-cells is the NF-kB 
pathway.83 Crosslinking of different B-cell membrane receptors, including the BCR, 
CD40 and Toll-like receptors (TLR), leads to phosphorylation of IKBα (nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), unleashing the NF-
kB complex of transcription factors from the cytoplasm to the nucleus, where they 
alter gene expression. The NF-kB pathway activates the transcription of an anti-
apoptotic module highly convenient for lymphoma cell survival and chemotherapy 
resistance. NF-kB constitutive activation constitutes a hallmark for the poor risk ABC-
DLBCLs108 and is a promising candidate for targeted therapies (see below). The 
mechanisms by which NF-kB activation occurs in DLBCL are diverse.83 The CBM 
protein complex, constituted by CARD11 (Caspase recruitment domain-containing 
protein 11), BCL10 (B-cell lymphoma-10), MALT1 (Mucosa-associated lymphoid tissue 
lymphoma translocation protein 1) and casein kinase 1α, is activated downstream of 
Bruton’s tyrosine kinase (BTK) and Protein Kinase Cβ (PKCβ) after BCR ligation and is 
required for activation of NF-kB, either directly or indirectly by inactivation of 
negative regulators such as A20.109,110 Gain-of-function CARD11 somatic mutations, 
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which are detected in 10% of the ABC-DLBCLs,111 or loss of A20112 both lead to NF-kB 
constitutive signalling. 
 
Targeting the NF-kB and other pathways activated via BCR is under scrutiny in clinical 
trials for DLBCL. Bortezomib is known to block NF-kB by avoiding degradation of IκBα. 
It has been combined with chemotherapy and immunochemotherapy in phase 2 trials 
and, as expected, seems more effective in ABC-DLBCLs, improving CR rates and 
OS.113,114 Although phase 3 RCTs currently recruiting are trying to demonstrate 
whether this proteasome inhibitor is really selective against the ABC-DLBCLs, this is 
not entirely expected given that the drug has a broad activity against protein 
function. However more selective signalling inhibitors are available. 
 
Despite harbouring molecular aberrations in the Ig genes, B-cell malignancies retain 
the BCR in the cell surface to profit from its downstream survival and proliferation 
signals. Mouse models support the role for BCR signalling for normal B-cell survival 
and malignant transformation.115  
 
As already mentioned, the CD79A/B molecules sustain the BCR receptor assembly 
and transmit signals to a variety of downstream pathways. Activation of spleen 
tyrosine kinase (SYK) and its downstream targets leads to engagement of NF-κB, 
Phosphoinositide 3-kinase (PI3K), Mitogen-activated protein (MAP) kinase, and RAS 
signalling pathways, leading to cell survival and proliferation. Around 20% of ABC-
DLBCL tumours harbour gain-of-function mutations in CD79A/B, which are rarely, if 
ever, found in GCB-DLBCLs.116 Theoretically, the mutant isoforms are selected as this 
may allow premalignant B-cells to escape anergy and expand in the GC 
microenvironment, where they can engage in Ig affinity maturation and further 
expand. CD79A/B mutations increase the expression of the BCR in the surface 
membrane and reduce activation of tyrosine-protein kinase (LYN), a negative 
regulator of the BCR signalling.  
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ABC-DLBCLs with wild type CARD11 exhibit a chronic “antigen-like” BCR engagement 
able to sustain their survival.116 In concordance, knockdown of any of the 
components of the BCR or of its downstream effector molecules, including BTK, or 
CARD11 itself, leads to cell death.  Most of the GCB cell lines are unresponsive to the 
knockdown of BCR or related molecules.  
 
Ibrutinib, a BTK inhibitor, showed exclusive in vitro cytotoxicity against ABC-DLBCL 
cell lines, and it has recently been suggested that it has synergistic activity with 
lenalidomide in blocking the NF-κB pathway in this subset of DLBCLs.117 In a phase 2 
RCT enrolling relapsed/refractory patients, ibrutinib induced a high overall response 
rate, showing preferential activity against the ABC-DLBCLs.118 Activity against the GCB 
subtype is, however, not depreciated and the mechanisms behind this are not 
entirely clear.  
 
Preclinical studies with Fostamatinib, a SYK inhibitor, revealed its ability to inhibit BCR 
signalling and induce cell-cycle arrest in cases relying on tonic BCR signalling for 
survival.119,120 Fostamatinib showed activity against relapsed DLBCL in early phase 
trials.121 
 
PKCβ inhibitors have been effective in preclinical studies against ABC-DLBCL cell lines 
with CD79A/B mutations122 and are being used in monotherapy or in combination 
with Everolimus in patients with the CD79-mutant or the ABC subtype of DLBCL.  
 
PI3K inhibitors also have prominent activity against ABC-DLBCLs with CD79B 
mutations,123 as well as in cases with FOXO1 mutations85 or PTEN (Phosphatase and 
tensin homolog) deletions.124  
 
RNA interference screening in ABC cell lines hinted that innate immune signalling is 
involved in the biology of this DLBCL subgroup.117 Nearly 30% of ABC-DLBCLs have 
L265P mutations and an additional 10% have other gain-of-function mutations in the 
MYD88 (Myeloid differentiation primary response gene 88) gene.125 These occur with 
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CD79A/B mutations, suggesting oncogenic cooperation, as these pathways are non-
redundant.  MYD88 is an adaptor molecule that in coordination with IRAK 
(Interleukin-1 receptor-associated kinase) kinases, is able to couple receptors like 
TLRs with downstream signalling pathways such as NF-kB and type-I interferon (IFN) 
circuit. The oncogenic MYD88 forms express IL-6 and IL-10, which in turn activate JAK-
STAT3 (Janus tyrosine kinase-Signal Transducers and Activators of Transcription 3) 
and NF-kB pathways.126 Type-I IFN might be beneficial for tumour cells, since IFN-β 
secretion might dampen the immune microenvironment. Inhibitors of IRAK kinases 
selectively kill ABC cell lines harbouring MYD88 mutations.125 IRAK kinases inhibitors 
targeting the TLR signalling, probably in combination with other agents with efficacy 
against the BCR signalling, are promising strategies for these patients with MYD88 
mutations.127 
 
Recent cancer genomics studies in lymphoma unveiled recurrent events in molecules 
that induce epigenetic changes in the DNA. Histone modifications can have a 
permissive or repressive effect in gene transcription by altering chromatin structure.  
 
Mutations in histone modifying enzymes are common in DLBCL. Genes coding for the 
histone acetyltransferases cAMP response element-binding protein (CREBBP), E1A 
binding protein p300 (EP300) and the hystone H3K4 methyl transferase mixed-lineage 
leukemia protein 2 (MLL2) are mutated in up to 40% of DLBCLs, irrespective of the 
molecular subtypes,128 suggesting an important role for epigenetic changes in 
lymphomagenesis. The precise oncogenic mechanism behind these mutations is, 
however, unclear. 
 
EZH2 is a member of the epigenetic regulator polycomb repression complex-2 (PRC2), 
responsible for restraining transcription through the methylation of the histones 
H3K27. Experiments inhibiting EZH2 proved its role in Ig affinity maturation in the GC 
by transiently suppressing B-cell differentiation.129 In concordance, heterozygous 
gain-of-function mutations in EZH2 are found exclusively in 21% of GCB-DLBCLs.130 
Hence, targeting EZH2 represents an opportunity to personalize treatment based on 
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the COO classification. In fact EZH2 inhibitors were found to be effective in halting 
proliferation of GCB-DLBCL cell lines and EZH2 mutant DLBCL xenografts in mouse 
models.131 A clinical trial in the United Kingdom will explore the clinical activity of 
EZH2 inhibitors (GSK2816126) in relapsed/refractory GCB-DLBCLs and will study the 
EZH2 mutational status irrespective of the molecular subtype (clinicaltrial.gov 
number NCT02082977). 
 
microRNAs are also altered in DLBCL. It has been shown that the locus that encodes 
for the miR-17-92 cluster is amplified in 12,5% of GCB-DLBCL tumours, while it is 
never targeted in ABC cases.82 miR-17-92 works in collaboration with MYC and 
induces a proliferative and anti-apoptotic phenotype in cancer cells, as well as 
promoting escape from senescence and cell cycle checkpoints.83  
The expression of certain miRNAs was associated with prognosis together with the IPI 
and the COO in RCTs.132,133 
 
 
1.5 GEP-based prognostic models suggests that a host inflammatory/immune 
response plays a role in the biology of DLBCL 
GEP studies performed in whole LNs infiltrated with DLBCL captured not only the 
transcriptome of the malignant B-cells and its resemblance with the putative COO but 
also other relevant aspects of the biology of the disease that could be implicated in 
the outcome of patients. One such biological feature is the host immune response to 
the tumour.  
 
Using unsupervised hierarchical clustering, Alizadeh et al.74 firstly recognized that 
DLBCL samples had a coherent overexpression of genes known to be expressed by 
natural killer (NK)-cells and macrophages (including CD14, CD105, CSF-1R) and of 
transcripts involved in matrix remodelling (e.g. MMP9 and TIMP-3). This LN-signature 
was also highly expressed in normal LNs, but not in other B-cell malignancies. The 
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intensity of this signature varied, possibly reflecting the relative proportion of tumour 
and host cells in the biopsy. 
 
A larger study exploring the use of GEP to define prognostic algorithms demonstrated 
that the molecular COO classification explained only part of the survival variability in 
DLBCL.76 Indeed, prognostically significant genes selected by supervised analysis 
could be grouped into signatures according to their involvement in physiological 
processes:  GC B-cell, LN, MHC class II, and proliferation.  
 
Expectedly, a proliferative signature was associated with a worse outcome, whereas 
the expression of the MHC class II signature genes by the malignant B-cells improved 
survival independently of the COO. It was speculated that malignant cells devoid of 
surface MHC class II molecules could escape T-cell immune checkpoints that would 
help them to survive, emphasizing the role of the immune system in controlling 
malignancy.  
 
Genes from the LN-signature incorporated in this model, however, were expressed by 
the non-malignant cells in the tumours.134 Importantly, a higher transcriptional 
activity of these genes was associated with improved outcome even in the poor risk 
ABC-DLBCLs. Whether this was due to a mere heavier infiltration of immune cells in 
the samples that would increase the signal intensity of those transcripts in the arrays, 
or a qualitative difference was unclear.  
 
Another GEP study applied different unsupervised clustering algorithms to model 
outcome in DLBCL.12 Comparison of these methods allowed devising robust subsets 
of patients again highlighting tumour biological features. The “host response” cluster 
had high expression of T-cell molecules, IFN-induced genes, cytokine receptors, TNF 
ligands/receptors and extracellular matrix (ECM) component transcripts. Additionally, 
some of the transcripts of this signature codify for proteins with established roles in 
macrophage development and function, including CSF-1R, CD14 and CD163. This 
cluster was enriched for genes from the LN-signature previously described. Finally, 
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samples allocated to this group had a significantly higher numbers of T-cells and DCs 
by IHC.  
 
The relevance of the stromal compartment in DLBCL was later substantiated by a 
large study using samples of R-CHOP treated cases.34 Their research used GEP of 
sorted malignant and non-malignant cells from a few DLBCL samples to help clarify 
the relative input of these two compartments on the prognostic algorithm designed. 
Transcripts that had a differential signal value in either the malignant or non-
malignant cells were used to build multivariate survival models that were validated in 
whole GEP data from almost 400 patients. A malignant-derived GCB signature, 
together with two others derived from the non-malignant cells were able to predict 
OS and PFS in the R-CHOP treated patients. Additionally, the IPI and the GEP-based 
model added to the predictive power of each other, suggesting a shared role for 
clinical and biological features contributing to patient outcome. The stromal-1-
signature was enriched for genes derived from macrophages and ECM components 
and was predictive of a good outcome. The stromal-2-signature was enriched for 
genes involved in angiogenesis and conferred an adverse outcome. Importantly, the 
two stromal signatures were strongly synergic. The relative expression of each of the 
stromal signatures in each sample was what most predicted length of survival, 
highlighting the power of GEP to unveil quantitative differences in immune responses 
that are prognostically significant. These data partially supports the model derived 
from solid tumours, in which mononuclear phagocytic cells are involved in stromal 
remodelling, drive the angiogenic switch and contribute to disease aggressiveness. 
The authors also demonstrated that the LN- signature, which shares a large amount 
of transcripts with the stromal-1-signature remained a good survival predictor in the 
R-CHOP era.  
 
In an attempt to satisfy critical standpoints regarding the complexity of the models 
discovered and its impossible applicability to the clinical practice, other studies tried 
to define simplified predictive models. Similarly, those models incorporated genes 
encoding for microenvironment components. A model comprising four genes of the 
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GCB/ABC signature and two genes related to immune response (APOBEC3G and 
RAB33A), showed to be predictive of outcome in patients receiving R-CHOP.135 Two of 
the genes included in the six-gene model of Lossos et al.136  (SCYA3 and FN1), reflect 
the tumour microenvironment. FN1 was expressed at very low levels by B-cells, 
supporting that the transcript is being expressed by the accessory cells. Its expression 
has been associated with a better outcome, highlighting again the positive prognostic 
impact of a stromal response in DLBCL. 
 
Alizadeh’s group explored bioinformatics methods to analyse the extensive paired 
clinical and GEP data available online. By univariate analysis, LMO2 was one of the 
best genes at predicting OS in DLBCL. Bivariate survival predictor models 
incorporating LMO2 and a second gene more highly expressed in non-malignant cells 
were explored. TNFRSF9/CD137 was also a strong predictor of good outcome on 
univariate analysis and the best in bivariate combination with LMO2. This bivariate 
model synergizes with the IPI for predicting outcome in DLBCL.137 TNFRSF9 expression 
was restricted to a minority of infiltrating T-cells of DLBCL.  
 
The above studies consistently highlight that biological features of DLBCL are derived 
from the stromal microenvironment. Interestingly, in contrast to what is generally 
accepted in solid tumours and other lymphoid malignancies, in DLBCL the expression 
of genes derived from macrophages and from the ECM components of the malignant 
LNs confers an improved outcome.  
 
Functional studies approaching this phenomenon are lacking, but potential 
hypotheses can be made. The most compelling is that the stromal cells are 
contributing to an immune response against the tumour that, although not fully 
efficient, might control some features associated with tumour aggressiveness. Within 
this hypothesis it can be speculated that the malignant cells of high-risk cases have 
found ways to dampen and escape this microenvironmental control. Chromosomal 
copy number changes are associated with differential expression of the LN-
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signature,134 suggesting that oncogenic changes might lead to dependence from 
tumour microenvironmental signals. 
 
 
1.6 Limitations of GEP-based predictive algorithms 
High throughput strategies such as GEP, NGS or proteome analysis are extremely 
useful to generate hypotheses for subsequent studies where simpler, affordable and 
highly reproducible methodologies are applied in real world patient’s samples. The 
COO and other GEP-based strategies have the potential to improve prognostication in 
DLBCL and offer an unforeseen opportunity for tailored treatment in this disease. 
However a large body of criticism is out there regarding the implementation of these 
strategies in the context of RCTs and in the clinical practice.  
 
The studies here described, although proving the importance of the molecular 
subgroups or the tumour microenvironment in the biology of DLBCL, have used 
different gene lists for their survival algorithms. After more than 10 years after the 
first study proposing a strategy for classifying patients according to the COO, other 
GEP-based algorithms are still being proposed.79 This failure to implement and 
validate previously proposed methodologies suggests difficulties in standardization 
and arbitrary analysis approaches. In fact there is a lack of standard operating 
procedures for the analysis of GEP.  
 
Another limitation is the number of samples explored in the original studies. 
Statisticians highlighted that inadequate sample sizes compromise any correlation of 
high throughput data with survival information, most times generating results that 
overestimate the prognostic value of a certain gene or algorithm. Additionally, there 
is some criticism of the use of cohort splitting into training and validation sets, which 
further reduces the size of the already small training group that is used for the 
development of the risk prediction model thus increasing problems of overfitting. In 
consequence results might not be replicated in subsequent validation studies. 
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Alternative strategies to sample splitting are proposed, such as the bootstrap cross-
validation approach.138 Since there are GEP results of over 700 patients with DLBCL 
available for the scientific community, techniques that can integrate this information, 
such probabilistic Bayesian modelling,139 would almost certainly generate more 
coherent strategies.  
 
The contribution of the microenvironment in algorithms developed using whole 
tumour cells is going to be variable. It will probably depend not only on the extent of 
non-malignant cells infiltrating the primary samples, but also on the differential 
sensitivity of particular cell types to the harvesting, RNA extraction and other 
techniques used prior to sample arraying. 
 
Finally the lack of controlled prospective data is one of the main hindrances of gene-
based prognostic models that might be overcome in the near future once results from 
RCTs applying GEP are reported.  
 
The aspects exposed above hamper the implementation of the findings of GEP into 
the clinical arena. This contributed to the search for other methods that could be 
predictive of the COO, such as IHC classifiers. We will challenge the current use of 
COO IHC classifiers in Chapter 3. 
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PART TWO 
1.7 Cancer and Immunity 
Cancer cells are equipped with the ability to subvert the physiological processes that 
control the progression from a normal to a neoplastic state (reviewed by Hanahan 
and Weinberg140). One component of such physiological mechanisms is their close 
interaction with the immune microenvironment.  
 
Whereas the original theory of a vigorous immune cell infiltration being an indicator 
of the host antitumoural response against the tumour still holds true for certain 
immune cell subsets in specific cancer types,141 a more recent theory recognizes a 
double-faced immune system with both host-protecting and tumour-promoting 
features.142 
 
As early as 1863, Virchow recognized the infiltration of cancer tissues with cells of the 
innate immune system, including macrophages, and hypothesised that mechanisms 
of immune activation such as chronic inflammation enhanced cell proliferation, 
creating the soil for cancer development.143 Following Virchow’s original hypothesis, a 
large body of work published over the last 20 years supports that tumour-associated 
inflammation could indeed be permissive to cancer formation.144-146 
 
An inflammatory response can give rise to a number of molecules that are 
fundamental in cancer development. For example, reactive oxygen species (ROS) 
released in the context of an inflammatory response enhance the acquisition of 
oncogenic events in mammalian cells.147 Additionally, inflammatory cells produce an 
array of molecules that have tumour-promoting functions: growth factors that 
sustain cancer proliferation; survival factors that limit cancer cell death; 
proangiogenic and matrix remodelling molecules that facilitate angiogenesis, 
invasion, and metastasis; cytokines and chemokines that amplify the inflammatory 
response; and immune suppressive molecules that are crucial for tumour cell escape. 
Cancer associated-inflammation closely resembles wound healing and subsequent 
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tissue remodelling responses.148 Importantly, B-cells have been implicated in the 
recruitment, activation, 
and persistence of such wound-healing and tumour-promoting innate immune 
cells.149,150  
 
However the scenario is more complex and highly dependent on the type of tumour, 
on where the inflammatory cells lie within the tumour, and on the temporal evolution 
of the tumour, which endangers a general view and therapeutic approach of 
inflammation in cancer.  
 
 
1.8 Evolving models of macrophage ontogeny 
Macrophages are an obligatory component of all tissues in humans, constituting 5-
20% of their cell content.151 Macrophages were recognized as phagocytic cells 
involved in tissue function and homeostasis in the late 19th century, by Elie 
Metchnikoff. Only 100 years later van Furth et al.152 described the mononuclear-
phagocyte system (MPS) as a linear model where macrophages were terminally 
differentiated cells derived from monocytes arising from a common progenitor in the 
BM. The discovery of a common progenitor to macrophages and DCs led to the 
inclusion of the latter in this system.153  
 
Colony stimulating factor-1 (CSF-1 or M-CSF) is the main cytokine involved in the 
development and function of cells of the MPS. This has been demonstrated in mice 
lacking functional Csf-1 or Csf-1 receptor (CSF-1R) genes.154 The intriguingly worse 
phenotype of CSF-1R null mice led to implication of an alternative CSF-1R ligand, IL-
34, in maintaining normal phagocytes, especially epidermal macrophages and 
microglia.155 The E-twenty six (ETS) family transcription factor PU.1 controls the 
expression of CSF-1R. It has been demonstrated that by introducing PU.1 in PU.1-/- 
cells it is possible to rescue differentiation of CSF-1R deficient cells.156 
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Over the last decade studies on the dynamic evolution of monocytes and 
macrophages conducted to major breakthroughs in the field of macrophage ontogeny 
and previewed opportunities to selectively target recruited macrophages in the 
context of chronic diseases such as cancer without disturbance of local homeostatic 
macrophages. We will now highlight some of those findings. 
Monocyte heterogeneity has been acknowledged. Two monocyte subsets exist in 
mice that show different phenotype, namely the expression of Ly6C, and 
function.157,158 The Ly6C+ “inflammatory” monocytes have a short life span and are 
bound to traffic to sites of infection and inflammation, whereas another population 
crawls along the luminal surface of the vessels and patrols for integrity of the 
endothelial cells. These two populations might have a differential contribution to the 
resident macrophage pool.159 What remains to be clarified is whether theses subsets 
derive from a common progenitor or whether the minor population of “patrolling” 
monocytes originates from the “inflammatory” subset.153  
 
Importantly, there is evidence for functional homologues of mouse monocyte subsets 
in humans.160 A small population of monocytes with dimmer expression of CD14 
compared to the classical monocytes was described in humans which has a similar 
cytokine profile and antigen presentation capacity that the mouse “patrolling” 
monocytes. The impact of human monocyte subsets in pathological conditions is yet 
to be defined.  
 
Another seminal finding was that embryonic phagocytes derived from non-
haematopoietic cells in the yolk-sac and the foetal liver can persist after birth in most 
tissues and can repopulate them in the absence of a functional haematopoietic 
system.161,162 These are self-maintained by slow but steady proliferation in 
homeostatic conditions163,164 under the regulation of the transcription factor 
MAFB/cMAF.165 The suggested contribution of this proliferation is to populate tissues 
with macrophages during organogenesis and at a lower rate thereafter to maintain 
tissue integrity. Such phenomenon would explain why haematopoietic stem-cell 
transplantation leads to inefficient replacement of tissue macrophages. Nonetheless 
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adult organs are infiltrated, with the exception of the gut,166 by a mixed population of 
embryonic and bone marrow-derived macrophages. Macrophages from distinct 
progeny both rely on CSF-1.167  
 
The balance of pre-natal and bone marrow-derived macrophages has been shown to 
change in pathological conditions. 
In acute inflammation,168 including IL-4-driven parasitic infections169 the dynamics of 
resident macrophages changes: the proliferation capacity of resident macrophages is 
boosted, whereas monocytes recruited from circulation only transiently repopulate 
tissues and differentiate in situ to macrophages.170  
 
The discovery of proliferation enhancement by IL-4171 raises the possibility that 
accumulation of macrophages in tumours might also be partly due to local 
macrophage proliferation. Recent evidence, however partially disproves this 
hypothesis. Using a model of mammary cancer genetically driven by the expression of 
an oncogene, Franklin et al.172 demonstrated that two populations of macrophages 
co-inhabited the tumour, which were phenotypically and transcriptionally diverse. 
One subset accumulated upon tumour growth and was required for tumour support 
by impeding infiltration of cytotoxic T-cells and by promoting tumour growth. These 
tumour-associated macrophages (TAM) had origin mostly on attracted peripheral 
blood inflammatory monocytes and exhibited high proliferative capacity. Targeted 
genetic knockout experiments implicated Notch signalling in the differentiation of 
TAM. On the other hand, another subset of macrophages relied solely on the input 
from circulating monocytes and seemed oblivious to the presence of the tumour 
cells, showing less proliferation and a transcriptome that equipped them to maintain 
tissue homeostasis. Importantly, this population persisted despite inhibition of Notch 
signalling. This study teasing out the origins of TAM in mice was able to describe a 
new pathway dependency for these cells. Moreover, the formal demonstration of the 
existence of “non-malignant” macrophages independent of the same signalling 
pathway suggests that TAM targeting strategies that do not compromise innate 
immunity and tissue homeostasis might be possible.   
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Although studies such as the one described change current paradigms in the 
understanding of macrophage biology, their translational potential has, however, to 
be questioned. The lack of any data in humans paralleling elegant findings in the 
murine model hinders the relevance of such findings. Additionally, the expansion of 
innate cells necessary for pathogen control or wound repair independently of 
monocyte recruitment puts into question standard methodology used to obtain 
human macrophages in the laboratory. The reasons for limited validation of 
macrophage studies in humans will be discussed later to highlight the relevance and 
novelty of the studies we undertook in the context of DLBCL. 
 
 
1.9 Macrophage functions in normal physiology 
Understanding the functions in which macrophages take part in normal physiology is 
important, as in the context of cancer those attributes are subverted via permanent 
contact with the tumour cells or products produced by the tumour cells, generally to 
favour tumour progression. We will next expose some of the fundamental functions 
of macrophages in healthy conditions. TAM functional diversity will be discussed in 
the next section. 
Macrophages are cells from the innate immune system that play important roles in 
the immediate response to pathogens and in the regulation of humoral and cell-
mediated immune responses.149  
The recognition of moieties such as lipopolysaccharide (LPS) induces functional 
activation of macrophages towards a pro-inflammatory and pro-apoptotic 
phenotype. While pro-inflammatory molecules induce oxidative processes that 
contribute to the killing of invading organisms,173 macrophages release soluble 
pattern-recognition molecules that activate the complement system and amplify the 
killing process. Additionally macrophages skew the differentiation of T-cells towards 
Th1 and Th17 phenotypes, boosting the whole inflammatory process.174 During the 
resolution phase and on subsequent encounters with bacterial products macrophages 
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should skew towards wound healing and immune-regulatory properties that 
minimize tissue damage and re-establish equilibrium. A failure of this control 
mechanism leads to chronic inflammation and auto-immunity.  
 
Besides host defence, macrophages are involved in many other aspects of tissue 
homeostasis (reviewed by Wynn, Chaula and Pollard175). Specialized tissue 
macrophages including Kuppfer cells, osteoclasts, microglia, and alveolar 
macrophages, all display functions that help keeping the integrity of the organs 
where they reside.  
 
Macrophages contribute to tissue remodelling and repair under homeostatic and 
damage conditions. This role is observed in the prenatal stage and in adult animals. 
During embryogenesis macrophages are localized in areas of active tissue 
reconstruction, such as the inter-digit areas during limb formation.155 This has been 
demonstrated by using the MacGreen mouse model176 in which macrophages express 
a green fluorescent protein (GFP) from the Csf-1r promoter. In this site, macrophages 
scavenge cell debris and produce a myriad of molecules responsible for ECM 
degradation, reconstruction and angiogenesis. Additionally, macrophages reduce 
immune responses against auto-antigens that naturally occur during this process.177 
Studies of Csf-1 null mutant mice, which lack many macrophage populations, 
highlighted the role of macrophages in morphogenesis. These mice had tissue-
remodelling defects involving the bone, mammary gland and pancreas. The same 
macrophage homeostatic and reparative attributes are recapitulated in the process of 
wound healing. 
 
Macrophages ensure homeostasis in haematopoiesis in a number of ways, from 
controlling the egress of haematopoietic cells from the bone marrow to engulfing 
apoptotic neutrophils and red blood cells in the spleen. Bone marrow macrophages 
ingest the extruded erythrocyte nuclei from erythroblasts, a process fundamental to 
ensure normal erythropoiesis.175  
The main iron supply for erythropoiesis derives from recycling after phagocytosis of 
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senescent red blood cells by macrophages.178 These sequester the iron intra-cellularly 
in the context of infection in an attempt to withhold it from the invading pathogens. 
Recent evidence suggests, however, that iron storage homeostasis is influenced by 
the activation pattern of macrophages.179 Macrophages also contribute to 
maintaining metabolic homeostasis,180 such as promoting peripheral insulin 
resistance to increase nutrient supply to innate immune cells during bacterial 
infection. 
 
 
1.10 Shifting the paradigm of macrophage polarisation 
Macrophages are highly plastic cells, assuming unique phenotypes and functions 
consequent to their diverse ontogeny and contextualized in their ever-changing 
microenvironment. The complexity of macrophage polarisation is only recently being 
recognized. For ease of understanding immunologists attempted to categorize the 
spectrum of macrophage functional activation.  
 
1.10.1 Classical and alternative macrophage activation 
Using murine models of infection, Mackaness and collaborators observed 
reproducible changes in the morphology and antibacterial activation of macrophages 
that were induced by cellular factors upon second exposure to the pathogens.181 
Those cells were later identified as T-cells and the key soluble factor IFN-γ.182 Under 
the influence of this cytokine and the bacterial product LPS, macrophages were 
potently activated to respond to foreign antigens by increasing antigen presentation 
and phagocytosis and by producing chemokines and proinflammatory cytokines, such 
as IFN-γ, IL-12, tumour necrosis factor (TNF), IL-6, and IL-1β. This reproducible 
phenomenon induced by intracellular pathogens and tumour cells183 was coined 
macrophage classical activation. Granulocyte macrophage colony-stimulating factor 
(GM-CSF) was later found to induce a secretory pattern and function similar to IFN-γ 
and LPS. 
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In 1984 Mossman and Coffman184 made an important discovery in the field of T-cell 
immunology that would help to understand macrophage polarisation even further. 
The authors found that IFN-γ and its then recently discovered opposing cytokine, IL-4, 
were produced by mutually exclusive CD4+ helper T-cell populations after TCR 
stimulation and hence were able to inhibit each other’s functions. These were named 
Th1 and Th2 helper cells. Meanwhile other Th2 cytokines were beginning to be 
discovered, including IL-10 and IL-13.185 Th2-mediated immune responses were found 
to be required to control infections by extracellular parasites, including helminths and 
protozoa.  
Similar to the findings with IFN-γ, it was then hypothesized that Th2 cytokines such as 
IL-4 could also influence macrophage behaviour. Investigations recognized that IL-4 
inhibited the production of pro-inflammatory cytokines and induced the expression 
of MHC class II and mannose receptor (MR) in macrophages. IL-4 induced 
macrophage fusion and decreased phagocytosis. This consistent response led to the 
recognition of the macrophage alternative activation response.186 The alternative 
macrophage phenotype was entirely different from the IFN-γ-induced classical 
phenotype and served different purposes in an immune response. 
 
It was later recognized that this dichotomic classification represented the extremes of 
a variety of macrophage activation patterns that could be elicited by different 
triggers. To acknowledge that, Mantovani et al.187 proposed that the alternative pole 
should be ramified according to the stimuli used to trigger macrophage activation 
other than IL-4, including IL-10, glucocorticoids and immune complexes. 
 
1.10.2 M1 and M2 activation 
Hsieh and collaborators188 recognized that Th1 and Th2 T-cell responses in mice were 
influenced by their genetic background. T-cells from C57BL/6 mice preferentially 
produced IFN-γ, whereas those from BALB/c mice favoured Th2 responses by 
producing high levels of IL-4. These polarised T-cell responses were independent of 
the function of antigen-presenting cells in the different strains and were linked to the 
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differences in susceptibility to Leishmaniasis that were observed in the mice.  
While studying arginine metabolism, Mills et al.189 recognized that macrophages from 
C57BL/6 and BALB/c mice metabolized arginine in different ways, but also had 
qualitative differences in the macrophage responses to the classical stimuli IFN-γ and 
LPS. The researchers hence proposed a new macrophage polarisation classification: 
M1 and M2 macrophage responses. M1 paralleled the classical whereas M2 
paralleled the alternative macrophage responses. This simplified classification 
suffered ramifications to appreciate the combined effect of IFN-γ and LPS or the 
effect of the multiple M2 stimuli just described.  
 
The polarised macrophage subsets were and still are defined according to responses 
induced by in vitro cytokine stimulation. The read-out of such experiments is usually 
limited to morphology, intracellular or surface protein detection and molecule 
release to the culture media. 
 
Classical/M1 macrophages produce high levels of pro-inflammatory cytokines, 
including IL-12 and IL-23 and TNF-α; have an IL-12high, IL-23high, IL-10low phenotype; 
express high levels of MHC molecules and co-stimulatory molecules, and Th1 cell–
attracting chemokines such as CXCL9 and CXCL10. M1 cells metabolize arginine to 
nitric oxide and are proficient at engulfing pathogens, presenting antigen, and killing 
tumour cells.190 On the other hand alternative/M2 macrophages have high expression 
of IL-10, IL-1 decoy receptor and IL-1RA and low expression of IL-12; express the 
chemokines CCL17, CCL22 and CCL24, have high levels of scavenger, mannose and 
galactose receptors, and the arginine metabolism is shifted towards ornithine and 
polyamines. Functionally, M2 macrophages induce Th2 responses, clear intracellular 
parasites and remodel the extracellular-matrix. 
 
1.10.3 Problems of macrophage activation nomenclature 
We should at this point acknowledge the chief problems of the classification systems 
just described, which galvanized seminal advances on the understanding of 
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macrophage polarisation. 
 
The number of molecules known to activate macrophages has grown beyond LPS, 
IFN-γ, IL-4 and other alternative stimuli contemplated in the current classifications 
and include tissue oxygen tension191 or pH.  
 
Macrophage activation is influenced by factors other than the activator itself that are 
disregarded in the current classifications, including: the macrophage origin, the 
source of the stimulus and the multitude of concentrations and longevities of 
exposure to the stimulus, among others. 
 
The lack of robust markers for macrophage polarisation hinders the evaluation of 
studies exploring this subject. 
 
 
Macrophages do not form clear-cut activation subsets. Indeed they can develop 
mixed M1/M2 phenotypes in vitro and certain pathological conditions, including the 
resolution phase of bacterial infections.192 By stimulating macrophages with a panel 
of six triggers, Stout et al. documented that macrophages can reversibly shift their 
functional phenotype through a multitude of patterns very different from the 
categorized classifications.193 Sequential treatment of macrophages with multiple 
cytokines led to a progression through multiple functional phenotypes, suggesting 
that macrophage functional adaptivity is retained and can be therapeutically 
manipulated. 
 
In the same line, a polarised macrophage phenotype can be reversed by applying 
triggers of the opposite pole. As Stout et al.193 have shown treatment of macrophages 
with the Th2 cytokine IL-4, before LPS stimulation strongly enhanced production of 
inflammatory cytokines (TNF-α and IL-12 production), whereas inhibited anti-
inflammatory IL-10 production. The impact of intermediate stages of activation 
during this process is unclear. 
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Complex in vivo systems where numerous cytokines and growth factors interact to 
determine the function of macrophages is difficult to mimic in vitro. It is 
unreasonable to accept that such simplified classifications replicate different tissue-
specific and pathological scenarios. 
 
1.10.4 Transcriptional analysis of macrophages 
Until recently, macrophage classifications were hampered by the lack of 
methodologies for analysis of the influence of a certain stimulus administered to 
macrophages. Since the advent of GEP, a body of work has acknowledged that 
macrophages harbour specific gene expression signatures according to the animal 
species, the location where they reside within the organism and the different 
environmental signals they received. Moreover this technology helped predicting 
novel transcriptional regulators implicated in discrete activation conditions. 
 
Due to their seminal role in maintaining tissue homeostasis, it is accepted that 
macrophages are kept in a restrained functional mode, which is unleashed once the 
cell receives “danger” signals from the microenvironment. Since macrophages play a 
large number of functions in tissues and are instructed by a multitude of molecules 
and other immune cells, plasticity in gene expression makes sense and leads to rapid 
functional adaptation according to their ever changing surroundings. Ultimately there 
is no macrophage identical to another as minute changes in the microenvironment 
have a great potential to influence the cell transcriptome and ultimately the function. 
 
Martinez et al.194 pioneered the field by describing the cardinal changes in the 
transcriptome during monocyte-to-macrophage differentiation and by comparing the 
GEP of resting and polarised macrophages in humans. Besides providing an extensive 
list of novel genes associated with maturation and activation, this study 
demonstrated that CSF-1, the standard cytokine used for maturation of macrophages 
in vitro and known to circulate at high levels in normal blood, inclined macrophages 
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towards an M2 transcriptome. Thus it could be suggested that an M2 GEP is a 
standard pathway in macrophage differentiation. This in our opinion also highlights 
the need for well-standardized cell maturation protocols. 
 
Other GEP studies of IL-4 stimulated macrophages had been undertaken to illuminate 
the biology of alternative activation in humans.195,196 Some prototypic mouse M2 
genes have no homologues in humans or do not undergo transcriptional regulation 
by the standard cytokines and hence are irrelevant in pre-clinical models. By 
analyzing the 1000 most highly expressed genes, Martinez et al.195 could recognize 87 
with concordant protein expression that constituted conserved markers in mice and 
humans, and as such could be useful for translational research. One example is the 
enzyme transglutaminase-2 (TGM2). This gene signature helped predicting the extent 
of macrophage infiltration in human lungs. Finally, this study recognized that the G-
protein coupled receptor signalling had the greatest number of genes affected by IL-4 
activation in humans. Pello et al.197 also reported novel human markers of alternative 
activation, including Scavenger receptor class B member 1 (SCARB1) and 
Arachidonate 15-Lipoxygenase (ALOX15), which the authors validated at the protein 
level in physiological and pathological conditions. 
 
A study recently published198 undertook the extraordinary task of analysing GEP data 
from human macrophages obtained in a standardized manner and activated by 28 
different signals (single or in combination), including pattern recognition receptor 
ligands, cytokines, and metabolic factors. This comprehensive approach addressed 
the criticism directed against oversimplified in vitro procedures to mirror in vivo 
complex systems, and demonstrated what has long been suggested but not formally 
proven: that macrophage activation in humans works in a spectrum much broader 
than the current M1 versus M2-polarisation model. Nine distinct macrophage 
activation programs were identified and correlated to transcriptional regulators. IFN-
γ selectively induced FEM1C gene expression, which could constitute a potential 
specific marker of classical activation.  
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In a similar comprehensive way, the “Immunological Genome Project” has assessed 
the transcriptional profiling of resident mouse macrophages.199 Supporting the 
relevance of the anatomical context on functional diversity, macrophages sorted from 
different organs exhibited remarkable transcriptional diversity with minimal overlap. 
The authors also suggested which transcriptional regulators could be implicated in 
universal and specific macrophage programs and recognized well-characterized and 
novel protein markers, including CD14, CD64, and MerTK that help identifying all 
tissue macrophages. Importantly, proteins previously predicted to distinguish 
macrophages from other cell types, such as CD68 and CSF-1R, did not emerge as the 
most powerful markers of macrophages.  
 
Studies such as these require substantial financial investment, alongside complex 
analysis done by researchers fully dedicated to the field of bioinformatics. However, 
they form an unprecedented platform for future validations in the setting of human 
diseases where macrophages are implicated, such as cancer. Moreover, they open 
the perspective of selectively targeting macrophages in diseased organs without 
affecting others cell types.  
 
The molecular mechanisms that trigger and sustain macrophage transcriptional 
patterns of activation are being unravelled. By signalling through TLR4 and IFN 
receptors, the classical stimulants IFN-γ/LPS induce activation of the NF-kB 
pathway,200 together with activator protein 1 (AP-1), IRF3, STAT1, and EGR (early 
growth response) family members, ultimately leading to the M1 transcriptome. 
Studies demonstrated that inhibition of the NF-kB pathway by conditional gene 
knockout201 leads to a switch from M2 to M1 phenotypes, providing a proof-of-
concept for the plasticity of mature activated macrophage phenotype. 
 
By contrast, signalling downstream of IL-4 involves the activation of JAK kinases and 
STAT6, the master regulator of the M2 transcriptome.202 Other transcription factors 
have been implicated in the regulation of subsets of M2-induced genes, including 
IRF4, peroxisome proliferator-activated receptor-γ (PPAR-γ),203 MYC,196 or CCAAT-
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enhancer-binding protein beta (C/EBP).204 
 
Recently the role of epigenetic mechanisms in the control of the macrophage 
functional repertoire has been described (reviewed by Ivashkic205). Mice genetically 
engineered to have a non-functional NF-kB displayed impaired chromatin 
remodelling, emphasizing the role of NF-kB not only as a transcription factor, but also 
as a mediator of genetic transcription. The histone demethylase jumonji domain 
containing-3 (JMJD3) has a potential role in the modulation of macrophage 
activation, as has been shown to upregulate a restricted subset of M2 markers, 
whereas downregulate M1 genes.206  
Finally, PU.1 has been described as the master regulator of gene expression in 
macrophages. Genome-scale chromatin immunoprecipitation analysis to identify 
PU.1 binding sites has shown that this transcription factor determines the 
macrophage GEP repertoire by generating open chromatin around cell-specific 
enhancers.207 This mechanism currently explains functional heterogeneity. 
 
The confirmation of the functional influence of a gene or genetic program activated 
by a transcription factor would ultimately require animal models where the activity of 
the gene under study could be manipulated specifically in macrophages. This is 
enabled by enzymatic knock-in experiments on gene promoters or by macrophage 
ablation through the expression of the Diphtheria toxin receptor. However, there is 
no specific promoter of macrophage genes that can be exploited. These are also 
expressed in most macrophage types, making it difficult to discriminate the functions 
of sub-classes of macrophages. Investigators acknowledge the limited availability of 
these models that could specifically dissect functionality in mature tissue 
macrophages in steady state or under activation. 
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1.10.5 Obstacles to the understanding of human macrophage biology 
Much work published in high impact factor journals using mouse models of 
macrophage biology strikingly lacks human correlations. This hinders a good 
understanding of human macrophage biology, and is related to a number of barriers. 
 
The first obstacle is obtaining human tissue samples. Macrophage functional studies 
should be done using single cell suspensions, ideally fresh but acceptably stored in 
liquid nitrogen under well-standardized conditions. This implies the existence of 
tissue banks, dedicated staff and ethical approval in place. 
 
The use of cell sorting allows obtaining highly pure cell populations. However, 
difficulties in obtaining sufficient, highly purified cells from tissue specific 
populations, such as macrophages from LNs are well accepted. Although some work 
has been done using laser captured macrophages from FFPE tissue,208 issues related 
to purity and sample quality compromise results. Hence this methodology has not 
been generally pursued, although this may change with technical improvements that 
allow characterisation of smaller samples.   
 
A number of central differences exist between mouse and human macrophages209 
that put into question much of the translational relevance of murine data.  One 
difference relates to nitric oxide (NO),210 an indispensable product of macrophage 
defence responses against pathogens in mice. Although IHC studies suggest that 
iNOS, the source of NO, is expressed in human macrophages,211 in vitro experiments 
failed to demonstrate production of NO. Similarly, human macrophages also have 
restricted activation markers that consequently cannot be functionally validated in 
mouse models.195 The reasons underlying these discrepancies, either technical or 
truly biological, remain unclear. 
 
Comparative analyses of mouse and human macrophages have been performed using 
peripheral blood or BM-derived cells subjected to artificial stimulation in vitro; 
studies using other tissues are lacking. GEP comparative studies have highlighted 
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important differences.212 Similarly, there is limited comparison of results obtained 
from tissue macrophages in a disease context and the results obtained from in vitro 
matured monocytes, the latter being usually accepted as adequate to predict the 
macrophage activation status of in vivo. This is particularly true in the human setting.  
 
Finally, as genomic and proteomic data becomes available underlining macrophage 
heterogeneity between samples and within the same sample, novel techniques to 
label several proteins and RNA transcripts simultaneously in situ will be required to 
validate potential prognostic subsets in large datasets of patients. Only a combination 
of markers can ascribe activation outcomes.213 Moreover, single-cell studies would be 
the only way to tease out whether subsets of macrophages within the same tissue 
have different activation profiles or whether a macrophage can acquire a unique and 
hybrid activation pattern. Novel techniques for single-cell studies are becoming 
available and could be exploited.214,215  
 
In our studies we set out to compare the transcriptome of human DLBCL-associated 
macrophages with their “normal” counterparts. During this endeavour we faced the 
same obstacles highlighted in the literature to justify the scarcity of human 
macrophage data. However we feel we have provided data with enough quality to 
allow the recognition of a lymphoma-specific macrophage GEP and the generation of 
hypotheses for functional studies. 
 
 
1.11 Tumour-associated macrophages (TAM) 
Macrophages infiltrate all tumours in varying densities and constitute a hallmark of 
tumour-associated inflammation. A recent meta-analysis216 of studies evaluating the 
prognostic impact of macrophage infiltration in human cancer confirmed that, with a 
few exceptions217,218 TAM density inversely correlates with OS. Our own research has 
shown the same association in cHL.219 However these data are correlative and the 
functional role of TAM in human cancer is not well established. As a consequence the 
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data discussed here is extrapolated from murine models and needs to be interpreted 
with care. 
 
Macrophages in tumours mainly originate from recruited monocytes by CCL2 and 
CSF-1. In a model of breast cancer, stromal and tumour-derived CCL2 instructed 
inflammatory monocytes to migrate to metastatic niches.220 Blocking of the 
chemokine halted monocyte recruitment and metastasis formation. CCL2-mediated 
monocyte recruitment has also been observed in primary follicular lymphoma.221 In 
Csf-1 null mice susceptible to development of spontaneous mammary tumours, 
transgenic expression of the cytokine in the mammary epithelium led to an 
accelerated infiltration of macrophages into the primary tumour.222 Our own research 
has shown that CSF-1R inhibition reduces TAM infiltration and tumour growth in a 
transplantable model of MYC-driven mature aggressive B-lymphoma (Hallam et al., 
under submission). In human cancer, CSF-1 protein expression at the tumour invasion 
edge correlated with macrophage infiltration.222 
 
Although a few functional studies suggest that macrophages retain tumouricidal 
function,223,224 clinical and experimental data more compellingly supports the 
opposite: that a strong inflammatory response and macrophage infiltration enhances 
tumour formation and progression. Indeed, there are a number of well-recognized 
tumour-promoting features of macrophages that are reminiscent of their functional 
diversity in health. It is accepted that tumour cells find direct or indirect ways of 
exploiting the repertoire of functions with which macrophages are equipped in 
physiological conditions to help them thrive. 
 
In Figure 1.2 we provide a list of tumour-derived molecules that have been implicated 
in cancer facilitating features of TAM. Data on the crosstalk between B-cells and 
macrophages will be discussed in a separate section. 
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Figure 1.2 Origins of tumour-associated macrophages and crosstalk with tumour cells and 
other cells of the microenvironment.  
TAMs can originate from the tissue resident pool, but mainly derive from inflammatory 
(Ly6C+) monocytes recruited from peripheral blood by CSF-1, CCL2 or CCL5. Within the 
microenvironment TAM can be influenced by a number of tumour-derived molecules, 
including CSF-1, CCL2, VEGF, TGF-β and others. T and B-cells in the tumour stroma can also 
influence macrophage behaviour through a variety of molecules. TAM play an number of pro-
tumoural functions; examples and respective instrumental molecules are detailed in the 
bottom left box.  
MDP, macrophage and DC precursor; CDC, common DC precursors; FLT3L, FMS-like tyrosine 
kinase 3 ligand; Ly6C/G, lymphocyte antigen 6C/G; cMoP, common monocyte progenitor; 
uPA, urokinase; SPARC, secreted protein acid and rich in cysteine; EGF, epidermal growth 
factor; MSF, mitochondrial important stimulation factor; PDGF, platelet derived growth 
factor; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; WNT, 
wingless-type MMTV integration site family; PD-L1, programmed death-ligand 1; Arg, 
arginine; PGE2, Prostaglandin E2.
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The protumoural attributes of TAM stem from their inability to switch-off activated 
phenotypes as described below. 
 
1.11.1 Protumoural features in the context of a macrophage classical activation 
Although an M1 phenotype can be efficient at eliciting tumour killing, the release of 
classical pro-inflammatory cytokines such as IFN-γ, TNF-α or IL-6, contributes to 
sustained inflammation and creates a mutagenic environment. A paradigmatic 
example of this mechanism is colitis-induced carcinogenesis.225 
 
Macrophage-derived IL-6 can lead to STAT3/NF-kB activation and subsequent 
proliferation of tumour cells. Using a mouse model of B-cell lymphoma, Gilbert and 
Hemann propose that stromal derived IL-6 sustains malignant B-cells within a chemo-
resistant niche. In gastric MALT lymphoma, it has been suggested that persistent 
infection with Helicobacter pylori induces macrophages to produce a proliferation 
inducing ligand (APRIL) that in turn promotes the survival and proliferation of 
neoplastic B-lymphocytes.226 
 
Furthermore, it has been demonstrated that M1-derived cytokines affect the dynamic 
of T-cell infiltration and proliferation in tumours. Genetic deletion or antibody-
mediated elimination of IL-23 increased infiltration of cytotoxic T-cells into the 
transformed tissue, rendering a protective effect against chemically induced 
carcinogenesis.227 
Additionally, Kryczek et al.228 hypothesized that CD80+ TAM could suppress cancer-
associated T-cell immunity. After co-stimulatory blockade with an anti-CD80 
antibody, macrophages regained the capacity to stimulate T-cells, contributing to 
regression of ovarian cancer in mice.  
 
1.11.2 Protumoural features in the context of a macrophage alternative activation 
An M2-like activation pattern specialized in resolving inflammation through tissue 
remodelling and immunoregulation, is more common in the context of cancer mainly 
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in the later stages of the disease. This phenotype promotes immunossupression,229 
tumour invasion and metastasis.220  
 
Tumours invade the surrounding ECM by exploiting macrophages trophic ability, a 
functional attribute of alternatively/M2-activated macrophages. Destruction of the 
tumour edges facilitates metastasis formation by allowing tumour cells to escape into 
the circulatory or lymphatic system. A number of macrophage-derived molecules can 
reshape the ECM and promote cancer invasion, including metalloproteases,230 
cathepsin proteases231,232 and EGF.233,234 Macrophage-specific depletion of cathepsins 
resulted in reduced tumour cell invasion in mammary cancer models. The fibronectin 
isoform MSF (migration-stimulating factor) has also been shown to promote invasion 
at the tumour front by enhancing tumour cell motility.235 Importantly a crosstalk 
between adaptive and innate immunity has been implicated in this process, as CD4+ 
T-cells are the required secretors of IL-4 that polarises macrophages towards this 
invasion enabling phenotype.231,234 
 
Macrophage alternative activation has been shown to impair T-cell activation and 
effector functions by secreting a variety of immunosuppressive factors including IL-
10, Prostaglandin E2236 (PGE2), and arginase. M2 macrophages expressing 
programmed death-ligand 1 (PD-L1) have also been implicated in the suppression of 
cytotoxic T-cell responses against tumours.237,238 Furthermore, M2-like TAM enhance 
recruitment of suppressive regulatory T-cells through production of the chemokine 
CCL22.239 
 
Tumours also exploit M2 TAM-mediated angiogenesis. This function is triggered in 
avascular regions in tumours, where hypoxia240 induces the expression of 
macrophage attractant molecules, such as vascular endothelial growth factor 
(VEGF),241,242 CSF-1, TNF-α, IL-1β or IL-8.146 Macrophages are then shifted towards a 
pro-angiogenic phenotype, and hypoxia-inducible factor-1α (HIF-1α) has a key role in 
controlling this response.243 In addition, HIF-1α activation also potentiates 
macrophage-mediated T-cell suppression in vitro.244 In concordance, a unique 
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population of angiogenic TAM has been characterized that also displays an 
immunossupressive function.245 
 
By blocking distinct mechanisms of macrophage-induced angiogenesis, different 
groups substantiated the relevance for this process in tumourigenesis. Ablation of 
specialized angiogenic macrophages inhibited tumour angiogenesis, growth and 
metastasis246 in murine models. On the other hand, blocking CSF-1 in tumours has 
also been shown to inhibit angiogenesis and decrease tumour growth in mammary 
cancer model. Additionally, blockade of the Semaphorin 3A/neuropilin-1 signalling 
pathway in macrophages impeded their migration to hypoxic tumour regions and 
relented angiogenesis.247 Importantly, this mechanism is currently being tested in 
clinical trials. Finally, low-doses of anti-VEGFR2 have also been demonstrated to 
normalise angiogenesis and reprogram TAM towards a tumour surveillance 
phenotype.248 
 
1.11.3 “Gray areas” of TAM activation  
However this clear-cut scenario does not completely hold true, as TAM exhibit 
substantial heterogeneity depending on the type of tumour; and undergo dynamic 
changes in phenotype and function according to the temporal evolution of the 
tumours175 or to their location within the tumours.224,229,247,249-251 This might account 
for the detection of independent subsets of macrophages with M1 or M2-like 
features,252 or “hybrid” M1/M2 TAM populations with both tumour permissive and 
opponent functions in tumours.172,236,250,253 The role of macrophages in mediating 
efficacy of monoclonal antibody therapies is of particular relevance and will be 
discussed in a separate section.  
 
These results caution against the overestimation of studies on the basis of whole 
TAM populations and compel to independently studies of TAM in each cancer type. 
Unravelling the network of signalling molecules and transcription factors that 
underlie these different activation states in TAM will help to devise conservative 
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strategies targeting the “malignant” macrophage population. In fact, important 
studies have demonstrated that it is possible to revert TAM towards an anti-tumour 
phenotype.201,254-256 
 
 
1.12 Crosstalk between B-cells and macrophages and their relevance for antibody 
therapies 
By studying the secretory phenotype of macrophages after crosslinking of the Fcγ 
receptors (FcγR), researchers documented a shift towards an M2-like phenotype with 
production of IL-10257 and PGE2.258 
B1 cells, initially identified in mice and recently proved to exist in humans,259 are a 
subset of B-cells that constitutively produce IL-10. B-1-derived IL-10, in the presence 
of LPS, has been shown to also upregulate IL-10 production by macrophages.260 
 
These studies provide evidence for two mechanisms whereby B-cells influence 
macrophage effector functions towards immunossupression. It has been recently 
suggested that these mechanisms can regulate the recruitment and effector function 
of TAM to induce cancer-related inflammation and tumour progression.  
 
 
Using a mouse model of multistage skin carcinogenesis, Andreu et al.261 
demonstrated that macrophages were skewed towards a M2 pro-tumoural 
phenotype after crosslinking of the FcγR with autoantibodies against the ECM. The 
production of autoantibodies was T-cell dependent. 
Similarly, in a transplanted tumour model of melanoma, B1 cells induced M2 
polarisation of TAM, likely due to IL-10 production. On the other hand, in B cell–
deficient mice transplanted with melanoma, TAM polarisation occurred towards a 
classical phenotype, suggesting that the acquisition of pro-tumoural features by 
macrophages in this model is entirely dependent on B-cells.260 
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The efficacy of rituximab in T cell-mediated autoimmune diseases,262 together with 
studies on T-cell function upon antigen stimulation in mice transiently depleted of B-
cells demonstrated that B-cells are involved in both suppressing and enhancing T-cell 
mediated immunity independently of antibody production (reviewed by Lund and 
Randall263). The mechanisms by which effector B-cells can affect T-cell responses are 
multiple: by presenting antigen,264 by expressing co-stimulatory molecules,265 and by 
producing cytokines.266 Aside from IL-10 production, T-cell primed B-cells can in fact 
produce other Th1 and Th2 cytokines,267 including IFN-γ, IL-12, IL-4 and IL-13. Their 
impact on macrophage activation can be hypothesized, but has not been 
demonstrated. 
 
One of the mechanisms of action of rituximab and other monoclonal antibody (mAb) 
is by engaging activatory FcRs and by boosting antibody-dependent cytotoxicity 
(ADCC) of immune effector cells such as macrophages.268 The relevance of 
macrophage-mediated ADCC comes from two animal models whereby the activity of 
mAb’s was halted by genetically abolishing the common FcRγ269 chain or by ablating 
macrophages.270 Recognizing the importance of this mechanism of action, Roche has 
developed Obinutuzumab (GA101), an anti-CD20 mAb with improved binding affinity 
to FcγRIII on effector cells and hence improved ADCC. 
 
Some research has explored other mechanisms by which macrophages mediate the 
efficacy of rituximab against B-cell malignancies. Using a murine model of NHL, 
Cittera et al.271 showed that rituximab induced the expression of the CCL3 in 
lymphoma cells and blocking the chemokine’s activity abrogated rituximab activity in 
this model. The authors demonstrated that CCL3 activates cytotoxic cells towards 
tumour killing. 
The same group proposed that the macrophage phenotype has an impact on the 
cell’s cooperation with rituximab. Indeed the authors demonstrated that human M2 
polarised macrophages had greater capacity for killing lymphoma cells opsonised 
with rituximab compared with M1 macrophages, which was further up-regulated by 
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IL-10.272 The authors suggest that, although M2 macrophages enable tumourigenesis, 
their improved phagocytic might be beneficial if therapeutic mAbs are to be used. 
 
As already mentioned, rituximab-refractoriness constitutes one of the most 
challenging clinical situations in DLBCL. The mechanisms of resistance are not entirely 
clear, but one such mechanism is the acquisition of expression of surface CD47 by 
cancer cells. CD47+ cancer cells evade macrophage-induced phagocytosis, even when 
coated with targeting antibodies. Weiskopf et al.273 exploited this phenomenon to 
demonstrate that human NHL can be eradicated in mice by sole stimulation of the 
immune system, with macrophages playing a central role. Treatment with blocking 
anti-CD47 antibodies synergized with rituximab, allowing elimination of lymphoma in 
engrafted mice. Macrophage depletion abrogated the therapeutic effect. The authors 
demonstrated that this synergism involved FcR-independent enabling of phagocytosis 
by anti-CD47 antibody and FcR-dependent stimulation of phagocytosis by rituximab. 
 
 
 
1.13 Correlative IHC studies of the DLBCL-associated macrophages 
The demand for comprehensive studies approaching macrophage biology in DLBCL is 
supported by the GEP studies already discussed in section 1.5. In brief, prognostic 
models of transcriptomic analysis performed in whole DLBCL tumours incorporate 
genes recognized to be expressed by macrophages. Contrary to most cancers and 
cHL,274 the expression of those genes identifies patients with better outcome. 
However, these interesting findings are merely correlative and a coherent 
explanation for the association between mRNA levels and DLBCL biology should 
follow. Protein expression is generally the starting point. With very few exceptions, 
protein validation studies of the microenvironment genes discovered are surprisingly 
rare in the literature. We suspect this is due to the lack of specificity of the transcripts 
for macrophages and to difficulties that are posed to IHC analysis of macrophages. 
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Translational studies evaluating macrophage biology in human NHL are mostly limited 
to the interrogation of FFPE tissue for individual proteins. Immunostaining for the 
lysosomal glycoprotein CD68 is taken as a surrogate of the extent of infiltration of 
macrophages in tissues.275 However this protein can be detected in other cells, 
including dendritic cells,276 rendering the staining unspecific and an overestimate of 
macrophage content. Moreover, as a cytoplasmic marker, CD68 is intrinsically difficult 
to analyse.  
 
Contrary to most cancers and cHL,219 the published literature does not provide a 
reproducible association between macrophage numbers and survival in patients with 
DLBCL. Importantly, some studies were performed in the pre-rituximab era277-280 and 
are hence irrelevant for the current prognostic scenario of DLBCL.  
 
 
Two studies merit further discussion, as they were performed with samples from R-
CHOP treated patients and tried to explore the potential of using IHC to recognize 
macrophage subsets.  
Secreted protein, acidic and rich in cysteine (SPARC),281 a glycoprotein involved in 
matrix remodelling, adhesion, cytokine signalling and apoptosis, has emerged as a 
potential marker for individualizing macrophages subsets in DLBCL with potential 
prognostic impact. In order to validate some of the markers depicted in the “stromal-
1” as representative of macrophage subsets, Lenz34 and collaborators performed 
double immunofluorescence staining for CD68 and SPARC and connective-tissue 
growth factor (CTGF). While being expressed in other cells in the microenvironment, 
SPARC and CTGF were indeed confined to only a proportion of the CD68+ cells, 
substantiating macrophage phenotypic heterogeneity that certainly could not be 
unravelled by morphology or immunostaining with a prototypic marker. However, the 
additional prognostic examination for SPARC expression is misleading. Firstly, the 
analysis was performed in a CHOP treated cohort. Moreover SPARC density is based 
the protein’s single staining, scored in a fairly crude way: four cohorts of 0 to 4 
according to density and then dichotomized in high versus low expression. This 
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methodology does not take advantage of the elegant findings of the double staining 
and the simplified analysis is hardly replicable in validation studies.  
 
Following this report, Meyer et al.282 revisited the prognostic value of CD68 and 
SPARC in a 262 R-CHOP treated patient dataset. CD68 staining was not predictive of 
any survival measure. The presence of any SPARC positive cells in the 
microenvironment correlated with longer OS, whereas those in a “high” SPARC 
category had longer event free survival (EFS) compared to the remaining.  This 
positive impact of SPARC was restricted to ABC-DLBCLs as defined by GEP but 
retained its value on multivariate analysis together with the IPI and the COO 
classification.  
 
The shortcomings of these data arise again from the methodology: the number of 
positive stromal cells was estimated visually as a percentage of all cells present within 
the tumour area, and graded in 5 or 10% increments; cases were then divided in 
“negative”, “low” and “high” categories. Moreover SPARC staining on endothelial 
cells was recognized but ignored for any further analysis. We believe this strategy 
leads to data reduction, turns validation problematic and encapsulates the limitations 
of IHC analysis when automated systems are not applied.  
 
The Osaka Lymphoma Study Group283 has also studied a small cohort of 101 R-CHOP 
cases and reported a direct correlation of macrophage density and worse OS. 
Additionally the authors explored whether fairly accepted M1 (human leukocyte 
antigen (HLA)-DR) and M2 (CD163) markers could help establishing a relationship 
between outcome and macrophage subsets. The authors demonstrated that a large 
number of CD163+/CD68+ correlated with a worse OS, whereas the presence of M1 
macrophages portrayed no relevant impact. As already discussed, the validation of in 
vitro defined markers of macrophage polarisation has limited value when the disease 
idiosyncrasies are ignored; and single markers are rarely faithful of a whole 
population of polarised macrophages. All in all, the Japanese data adds little value to 
our understanding of macrophage biology in DLBCL. 
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1.14 Functional studies exploring the role of macrophages in lymphoma 
Due to the fundamental differences between murine and human macrophages 
(discussed in section 1.10.5), research hypotheses on the interactions between 
macrophages and B-cell lymphoma should be generated using human samples. The 
GEP studies on DLBCL are an excellent example of hypotheses generating subsequent 
macrophage research. In vitro studies using primary lymphoma cells are feasible221,284 
and should follow, but it should be acknowledged that a potential allogeneic reaction 
and the lack of other immune cells in the systems could deviate the results from the 
tumour context in situ. Murine models should finally be used to confirm the 
hypotheses, as they provide, with all the limitations, the closest approximation of an 
in vivo tumour microenvironment. The challenges posed to macrophage research 
have also been discussed previously. 
 
We shall here debate data suggesting a heterogeneous and less accepted role for 
macrophages in lymphomagenesis. Their role in the context of treatment with 
rituximab has already been discussed. Further studies involving co-culture systems of 
macrophages and primary lymphoma samples will be approached in experimental 
chapter 6. 
 
Murine macrophages have been shown to exert phagocytosis of lymphoma cells in 
the early 70’s. Comprehensive work by Evans285,286 and others appreciated that this 
was a highly regulated process, requiring for maximum efficacy preliminary priming of 
the effector cells and the presence of T-cells and soluble factors. Intuitively tumour 
cells could overcome immune surveillance by influencing any of these factors. Indeed, 
it was simultaneously reported that macrophages from lymphoma-bearing mice 
could produce the immunossupressive enzyme PGE2 to halt T-cell function and 
favour tumour growth.287 
 
A murine model recurrently used as a surrogate of human DLBCL is the Eμ-myc 
transgenic model, with constitutive expression of the MYC oncogene in lymphocytes 
and inexorable progression to a highly proliferative lymphoma. As a transplantable 
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lymphoma, it constitutes a useful model to study the microenvironment. In this 
model macrophages are highly engaged in the clearance of lymphoma apoptotic cells, 
which has both protumoural and antitumoural consequences.288,289 We believe that 
the mechanisms described below highlight the complexity of potential roles for 
macrophages in mediating lymphomagenesis and would apply to all DLBCL cases with 
high proliferative index. 
 
Cell-free supernatant of lymphoma dying cells induces macrophage chemotaxis. 
Lymphocyte-derived CX3CL1290 appears to be the culprit macrophage attractant. 
Once in the tumour microenvironment macrophages actively phagocyte apoptotic 
debris and amplify macrophage recruitment by producing CX3CR4. On the other 
hand, macrophages produce cytokines, including TGF-β and IL-10 that are implicated 
in shifting other macrophages towards an immunossupressive and pro-proliferative 
lymphoma permissive phenotype.291 On the other hand, Reimann and colleagues292 
have shown that macrophage-derived TGF-β arising in the context of active apoptosis 
can limit MYC-driven lymphomagenesis by feedback induction of terminal cell-cycle 
arrest. By genetic inactivation of senescence or neutralization of TGF-β the authors 
observed an acceleration lymphomagenesis. 
 
Perhaps the most intriguing data comes from Haabeth et al.,293 who proposed a 
mechanism by which inflammation, if developed in the context of an efficient T-cell 
response against the tumour cells, protects against B-cell lymphomas. To clarify the 
process of CD4+ T-cell-mediated immune surveillance against B-cell lymphoma, the 
authors used an idiotype (Id)-specific TCR transgenic mouse model, which was made 
homozygous for the severe combined immunodeficiency (SCID) mutation to prevent 
rearrangement of endogenous TCR chains. In these mice, CD4+ T cells exclusively 
recognize an Id peptide from the IgV chain of a plasmacytoma cell line, rendering 
them resistant against inoculation with syngeneic plasmacytoma cell lines or with Id-
transfected B-cell lymphoma cell lines.  
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The authors developed a strategy whereby tumour cells are embedded in a collagen 
gel prior to injection in mice. The collagen can then be studied ex vivo for immune cell 
infiltration and cytokine production. Using this method, the authors uncovered that, 
in the presence of Id-specific CD4+ T-cells, macrophages infiltrate the gel and capture 
the lymphoma-specific antigen. On recognition of tumour peptides presented by 
macrophages, T-cells were shown to secrete IFN-γ. This cytokine in turn activated 
macrophages to efficiently kill lymphoma cells. When the host was capable of 
initiating an antigen specific Th1 response, tumouricidal macrophages produced the 
proinflammatory cytokines IL-1β and IL-6.  
 
Macrophage-induced inflammation accepted by experts as tumour permissive and 
here dissonantly associated with tumour surveillance, highlights in our opinion one 
main aspect that encapsulates the complexity of designing immunology studies:  the 
functional spectrum of one immune cell cannot be fully understood in the absence of 
the other cells of the immune system. This paradigm renders in vitro studies quite 
simple and translationally meaningless and explains why a body of data developed in 
murine models does not move forward to the human setting. 
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1.15 Objectives 
DLBCL is an aggressive lymphoma curable with R-CHOP in a sizable proportion of 
patients. The remaining patients have a dismal outcome and ideally should be 
selected at diagnosis for experimental therapies. Devising robust prognostic markers 
is hence a priority for this disease. 
 
This study was set out to review prognostic biomarkers derived from the GEP studies 
performed in DLBCL. Using samples from patients with DLBCL, we aimed to: 
 
 Construct tissue microarray (TMAs) of patients with known clinical outcome 
and follow up; 
 
 Explore the applicability of IHC-based algorithm for molecular stratification of 
DLBCL; 
 
 Reconsider the role of IHC-based studies for the immune microenvironment 
by applying novel strategies of analysis; 
 
 Explore the macrophage heterogeneity in DLBCL based upon transcriptomic 
studies of highly pure cell populations; 
 
 Confirm the existence of macrophage subsets in DLBCL by using novel proteins 
derived from the transcriptomic analysis; 
 
 Develop in vitro co-culture systems to test whether the malignant B-cells are 
directly influencing macrophage polarisation in the microenvironment. 
 
 
Chapter 2 Materials and Methods 
82 
 
Chapter 2 Materials and Methods 
 
2.1 Patient Samples 
Patient samples were obtained after informed consent and stored under conditions 
compliant with the Human Tissue Act 2008. All sample collection was done under 
current regulatory permission from the local research ethics committee and 
according to the Declaration of Helsinki. 
 
2.1.1 Formalin-Fixed Paraffin-Embedded Tissue 
Immunohistochemistry studies were performed using FFPE. Samples were selected 
based on the availability of stored good quality paraffin blocks of the diagnostic 
biopsy and clinical and extended clinical and follow-up data. Only cases with de novo 
DLBCL were included. Patients with an immunodeficiency-associated lymphoma, 
central nervous system or primary mediastinal lymphomas were excluded from the 
study. December 2009 was selected as the cut-off date of diagnosis to include 
patients in the study to guarantee an acceptable follow-up. 
 
Two patient cohorts were used for this study. The first cohort was diagnosed and 
treated at St. Bartholomew’s Hospital (Bart’s), London. Patients were identified by 
consultation of the clinical database, created in the 60’s and used since then to 
document clinical details of all patients presenting initially to, or referred from local 
hospitals to Bart’s for treatment. Subsequently, clinical information was compared 
with the tissue database for final confirmation of FFPE material available for research. 
Between 1977 and end of 2009, 651 patients were diagnosed with de novo DLBCL at 
Bart’s. Finally, 225 patients with FFPE material stored amenable to be arrayed were 
identified. From these, 71 were treated in the rituximab era with R-CHOP. The 
remaining patients were treated with different approaches, from anthracycline-based 
therapy to palliative care. 
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The second cohort was diagnosed and treated at the Instituto Português de 
Oncologia Francisco Gentil (IPO), Lisbon. Patients were selected by Dr Maria Gomes 
da Silva, the lead haematologist responsible for clinical review, and Dr José Cabeçadas 
(JC), the lead haematopathologist responsible for research material review. All 
Portuguese patients were treated with R-CHOP. 
Tissue sections were made and Haematoxylin and Eosin (H&E) staining was used to 
carry out tumour area selection for TMA.  
 
2.1.2 Frozen Single Cell Suspensions 
Single cell suspensions (SCSs) from DLBCL, tonsil and reactive LNs were obtained from 
the centre for Haemato-Oncology tissue bank storage. Surplus material from samples 
for diagnostic or treatment purposes was collected under sterile conditions in media. 
Samples were dissected on a pre-cooled tray (Biocision) and homogenised by passage 
through a 70µm filter (BD biosciences) under gravity. Cell suspensions were washed 
twice in media by centrifugation at 1500rpm for 5min. After assessing cell count and 
viability in an automated cell counter by trypan blue exclusion (ViCell, Beckman 
Coulter), samples were cryopreserved in 10% Di-Methyl Sulphoxide (DMSO, Sigma-
Aldrich) in foetal calph serum (FCS, PAA Laboratories Ltd) for two hours at -80oC in 
adapted containers (CoolCell, BioCision) and transferred to liquid nitrogen tanks 
(Custom Biogenic Systems (CBS) Isothermal V-1500 series) for long-term storage.  
All studies described here were performed on previously cryopreserved SCSs with the 
purpose of normalising for storage effects. SCSs were thawed in a water bath at 37oC, 
treated with 0.5mg/ml of DNAse (DNAse I from bovine pancreas, Sigma-Aldrich) for 
5min at room temperature (RT), washed by centrifugation at 1400rpm for 5min in 
phosphate buffered saline (PBS, Sigma-Aldrich) with 100 U/ml penicillin and 
100µg/ml streptomycin (both from Invitrogen) and filtered through a 70µm mesh to 
exclude cell clumps. Viability and cell count was assessed using either an automated 
or a manual cell counter. 
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2.1.3 Healthy Donor Buffy Cones 
Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated from 
buffy cones supplied by the National Blood Service. After a 5-fold dilution in sterile 
PBS, 10ml of this solution was gently layered with an automated pipette (Pipetboy, 
Integra) in a 30o angle over 5ml of Ficoll-Paque (Lymphoprep, Axis Shield) in a 15ml 
conical centrifugation tube (Corning). Samples were centrifuged at 1500rpm for 
25min at 22oC with slow acceleration and brake off. The PBMC layer was carefully 
removed using a pastette, diluted to a maximum of 40ml in PBS and centrifuged at 
1200rpm for 10min at 4oC for platelet removal. A second wash by centrifugation at 
1800rpm for 10 min was performed after which cell pellets were resuspended in 10ml 
of diluted red blood cell lysis buffer (Pharm Lyse, Beckton Dickson) for 7min at RT. 
Finally, cells were washed and resuspended in PBS prior to cell counting.  
 
2.1.4 Cell Lines 
The DLBCL cell lines used in this study were maintained at 37°C in a 5% CO2 
humidified incubator in sterile flasks in Roswell Park Memorial Institute (RPMI)-1640 
(Sigma-Aldrich) or Iscove’s Modified Dulbecco’s Medium (IMDM, Sigma-Aldrich) as 
recommended. The GCB cell line Su-DHL4 was gifted from Dr. A Letai and the ABC cell 
line Ri1 was gifted from Dr. M Capasso. All culture medium was supplemented with 
10% heat inactivated FCS, 100U/ml penicillin and 100µg/ml streptomycin. Cells were 
passaged every 2-3 days to maintain optimal cell concentration and viability. 
 
 
2.2 Immunohistochemistry 
2.2.1 Tissue Microarray Assembly 
TMAs consist of tissue cylinders, extracted from FFPE tissue by an arraying machine 
that are aligned and embedded in a new paraffin block.294 About 200 sections 2-5µm 
thick can be cut from each block and stained for large-scale protein expression 
profiles, allowing the study of large patient cohorts under controlled experimental 
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conditions. It has been previously shown that this technology can reproduce 
lymphoma tissue heterogeneity with the same accuracy as conventional sections 
when duplicate or triplicate cylinders are applied.295,296  
After patient selection, each original FFPE block was cut and stained with H&E. Well 
represented tumour areas free of necrosis and fibrosis were marked with a pen on 
the slide. Donor blocks were then aligned with the marked slides.  
A semi-automated arrayer (Beecher Scientific) was used as previously described.294 
Each patient block was cored in duplicate (1.5mm2 diameter) or triplicate (1mm2 
diameter) and these inserted in a new recipient paraffin block. Reactive tonsils were 
used as internal staining controls and myocardium or pancreas as orientation. The 
British patient set was separated into eight blocks and the Portuguese into two 
blocks. Before sectioning each block was placed over an ice block for 10-15min. A 
standard microtome technique was used for sectioning 3µm sections into slides. 
 
2.2.2 Principles of Immunohistochemistry  
IHC uses direct labelling of a target protein antigen with an antibody or, alternatively, 
with a more sensitive secondary antibody labelling system. The detection of the 
antigen-antibody interaction requires an amplification step that is achieved by the 
use of multimeric molecules that are able to link to multiple proteins. The avidin-
biotin complex (ABC) and the polymer-based systems (e.g. Biogenix Supersensitive 
Polymer horseradish peroxidase, HRP) are the most widely used amplification 
methods. The first relies on the use of biotinilated secondary antibodies to which 
multiple avidin-enzyme complexes bind strongly, providing antigen signal 
amplification. The second utilizes a unique technology based on a polymer sugar 
backbone to which multiple antibodies and enzyme molecules are conjugated. A 
Catalyzed Signal Amplification method is being incorporated in this polymer-based 
technique. Final visualisation of an antibody-antigen interaction is achieved by the 
use of enzyme modifiable chromogens.297 The chromogen most commonly used is 
Diaminobenzidine (DAB) due to its crisp brown staining. 
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2.2.3. Primary antibodies for Immunohistochemistry  
IHC staining was carried out using commercial available primary antibodies (clone, 
dilution and source detailed in each experimental chapter in Table 3.2, Table 4.1 and 
Table 7.1). Primary antibodies against GCET1 (clone Ram341, Novocastra), FOXP1 
(clone JC12, Abcam), and LMO2 (clone SP51, Abcam) were first used in our laboratory 
for this study and required optimisation. Appropriate controls for titration and 
antigen retrieval were provided by the manufacturer. Serial 1/50, 1/100 and 1/200 
antibody dilutions were used and three antigen retrieval techniques tried: no pre-
treatment, pronase enzyme digestion for 15min and pressure-cooking. The primary 
antibody was diluted with 1% bovine serum albumin (BSA, Sigma A-70906) and 
sodium azide (Sigma – S8032). After first assessment, further dilution titrations were 
performed.  
 
2.2.4 Staining Protocol using the Dako Autostainer System 
TMA slides were placed in plastic racks at 60oC overnight. For paraffin removal slides 
were incubated in xylene (VWR Chemicals – 28975.325) for 2 consecutive periods of 
5min. Subsequently, slides were incubated for 3 consecutive periods of 2min in 
Industrial Methylated Spirits (IMS, Fisher Chemical – 11482874) and further 2 periods 
of 2min in hydrogen peroxide (BDH – 101284N) in order to dehydrate tissue and 
reduce non-specific staining from the action of endogenous peroxidises on the 
chromogen. A final incubation of 2min in IMS is required prior to antigen retrieval. 
While performing first incubation steps, 3000ml of a working solution of antigen 
unmasking solution (Citrate buffer, pH 6, Vector Laboratories – CA94010) was 
warmed up in a pressure cooker. When boiling, the plastic racks with slides were 
immersed and left for 10min at high heat (120-130oC). When finished, the pressure 
cooker was left to cool down under cold tap water for 5min and the slides quickly 
transferred to washing buffer (DAKO – S3006).  
Slides were marked using hydrophobic pen around the edge of the array field and 
kept wet with wash buffer throughout remaining procedure. 
The DAKO Autostainer System is composed of a robot arm with nozzles and a pump 
system, which allows for timed dispensing of reagents into the slides.  Before using, 
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the software (Dako Autostainer Plus) is programmed for the number of slides, 
reagents and incubation times and rinse steps. The Super Sensitive™ Polymer-HRP 
IHC Detection System (Biogenix - QD430-XAKE) was used for signal detection. The 
Autostainer was run for 2-3 hours as specified. After finishing all slides were replaced 
in plastic racks and rinsed in tap water for 5min. As a counterstain, the slides were 
suspended in haematoxylin solution for 5min, rinsed for 2min in running water and 
plunged into acid alcohol solution (1% hydrochloric acid in 70% IMS), quickly, for 5 
times, after which were transferred into tap water wash.  Finally the tissue is re-
hydrated using IMS and clarified by incubation in xylene baths. Using DPX mounting 
media (VWR – 360294H), which provides a high quality durable mounting with 
refractive properties, cover slips were applied leaving no trapped air bubbles. Finally, 
slides were left to dry and labelled appropriately. 
 
2.2.5. Immunohistochemistry analysis 
2.2.5.1 Automated Image analysis using the Ariol SL-50 visual analysis software 
Slides were scanned using an Olympus BX61 microscope with an automated platform 
(Prior). A review of all cores was performed manually. Whole cores with less than 
50% of tumour representation were excluded from analysis. Fibrotic and necrotic 
areas were also excluded. Representative regions were selected for training. Positive 
stained cells acquire a brown/black colour characteristic of DAB. Colour hue, 
saturation and intensity were manipulated to allow contrast with the background. 
This was achieved by selection of individual pixels from positive events and avoiding 
the negative cells and the non-specific stained areas. Training is improved by limiting 
the size and the shape of the areas considered positively stained with DAB. In order 
to estimate areas of representative tumour tissue, a second colour training for non-
cellular areas was included (Figure 2.1). The area of viable tissue was calculated by 
subtracting the non-cellular areas from the total area analysed. Using this system we 
calculated the number of positive cells as well as the area of DAB stained per area of 
lymphoma tissue. The values obtained were corrected to a 1mm2 area and a mean for 
each patient was calculated. 
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Figure 2.1 Training Optimization using the Ariol System 
A&D: Representative example of training protocol, showing the DLBCL areas selected for training for CD3 (A) and CD68 (D). Magnification x20. B&C: 
Optimal results for % stained area of CD3 (B), where DAB staining is represented in red and non-cellular areas are represented in green; and for CD3+ 
cells (C), where individual cells are represented by white dots. E&F: Optimal results for % stained area of CD68 (E), where DAB staining is represented 
in pink and non-cellular areas are represented in blue; and for CD68+ cells (F), where individual cells are represented by white dots.
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2.2.5.2 Automated Image analysis using the Pannoramic Viewer System 
Slides were scanned using the Pannoramic 250 Flash II scanner (3DHISTECH). Each 
core was observed on a computer screen using the Pannoramic Viewer computer 
interface. Meticulous marking of representative tumour areas was done and areas 
quantified. After selection of representative tumour areas, the DensitoQuant module 
was used to quantify the number of DAB stained pixels. This module distributes pixels 
to 3 grades of positive classes using their RGB values. We used only the top red and 
orange levels for identification of stained areas. After adjusting the brown tolerance 
and the score levels an optimal script was saved for each antibody and applied for 
analysis in all areas. Finally, the number of brown pixels/selected area was calculated 
and a mean value was estimated for each patient. 
 
2.2.6 Cutpoint Determination and Survival Analysis 
Cut-point discrimination was assessed using a recursive partitioning algorithm in the 
rpart package (http://cran.r-project.org/web/packages/rpart/index.html) within the R 
statistical software version 3.0.2. 
Although data validation in independent datasets is a more robust method for 
confirming a certain IHC marker as a prognostic biomarker, this is still seldom done. 
 
The recursive splitting method with cross-validation is a statistical approach well 
accepted to develop outcome prediction models from novel variables. This algorithm 
involves finding a cutpoint in the variable under study that best divides the dataset in 
two groups with different outcome. The data is separated accordingly and novel splits 
are applied to each sub-group, in a recursive manner, until no improvement can be 
made in outcome prediction. This method requires that some limitations to the 
stepwise procedure are established in order to avoid developing too complex or 
suboptimal models for the problem under study. A “bucket size” approach that 
excludes data splitting where only a minority of patients are included in a given group 
is commonly used to increase robustness of results. The second stage of this method 
consists of using cross-validation to estimate the performance of cutpoints 
Chapter 2 Materials and Methods 
 
90 
considered predictive of survival.  
For every quantified measurement, survival has been estimated using Kaplan-Meier 
estimators, and differences between groups of the same measurement have been 
assessed with the Log-rank test. To accommodate for the optimization method within 
the splitting algorithm we considered as significant only Log-rank p-values <0.01.  
 
 
2.3 Immunofluorescence Staining and analysis 
Three colour Immunofluorescence (IF) was used in this study to detect co-expression 
of two proteins of interest in macrophages in FFPE tissue. Nuclei counterstaining is 
performed by incubation with a third colour, 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI, Sigma – D9564). 
This technique requires the use of primary antibodies against a target antigen 
epitope, ideally raised in different species; and secondary antibodies raised against 
Igs of the primary antibody species. The last are conjugated to a fluorochrome that 
allows visualisation of the proteins of interest. The secondary fluorescent antibodies 
must emit colour at different and non-overlapping wavelengths. The most commonly 
used wavelengths for this purpose are 488 (excitation: 495/emission: 519), which 
produces a green fluorescence and 546 (excitation: 556/emission: 573) which 
produces a red fluorescence. Optimization for these experiments involved changing 
the order of the primary antibodies incubation as well as the fluorochrome 
combinations. If both primary antibodies were raised in mouse species, an 
intermediate incubation step with mouse-on-mouse block reagent (Vector Labs) was 
required. Primary antibodies and conditions of use and secondary reagents are 
described in Chapter 6.  
Slide deparaffinisation and antigen retrieval steps were performed as described in 
section 2.2.4. After placing the slides in the DAKO Autostainer the software was 
programmed. A template of the staining procedure is provided below: 
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1. Primary antibody (mouse) (40’ incubation)  
2. Rinse with buffer 
3. Secondary reagent (anti-mouse Texas red secondary antibody) (10’ incubation) 
4. Rinse with buffer 
5. Mouse-on-mouse blocking step 
6. Primary antibody (mouse/rabbit) (40’ incubation)  
7. Rinse with buffer 
8. Secondary reagent (anti-rabbit FITC secondary antibody) (5’ incubation) 
9. Rinse with buffer 
 
Slides were then transferred to plastic racks and immersed in buffer solution. 
Immersion for 2min in 3 pots of graded ethanol (70/80/96%) was used for slide 
rehydration. Finally slides were mounted using 5 µL of Vectashield mounting medium 
(Vector Labs) with DAPI fluorochrome and kept at -20oC.  
Slides were scanned using an Olympus BX61 microscope and analysed using the Ariol 
SL-50 visual analysis software. The fluorescence wizard-training module was used to 
optimize capturing conditions. The DAPI channel capturing nuclei staining was used to 
focus at 5x amplification. All channels were subsequently observed at 40x 
amplification and adjustments on background capturing and exposure times were 
done. Selected cores were finally scanned and observed later on a computer screen. 
Single channel and overlapping images were used for final analysis quantifying single 
and double positive cell counts/core.  
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2.4 Multicolour flow cytometry 
Flow cytometry is a single cell analysis technique, which enables the recognition and 
quantification of expression of multiple molecules simultaneously. Cells are stained 
with fluorochrome-conjugated monoclonal antibodies against the molecules of 
interest; moved through a fluidics system and forced to pass one by one through an 
integrated laser bean which results in fluorochrome excitation and light emission. The 
light side and forward scattering properties provides information on the size and 
intracellular organelle complexity of each cell, whereas the fluorescence emission and 
intensity delivers qualitative and quantitative information on molecule previously 
labelled. Besides non-specific fluorescence and background noise, the emission 
spectral overlap of different fluorochromes is frequently involved in interference with 
the final read-out and can be overcome by careful combination of fluorochromes 
with minimal overlap, adjustment of voltages of the light detectors and compensation 
of the detected data. The information acquired is studied using specific software 
packages. Data can be displayed as one-dimensional histograms showing detected 
fluorescence distribution and intensity, or multidimensional histograms combining 
different parameter intensities, each cell being represented by a dot.  
This technology was used for single cell sorting (Chapters 5 and 6), carried out using a 
BD FACSAria II sorter, and macrophage surface marker staining (Chapter 6), carried 
out using a four laser LSR Fortessa (both from BD Biosciences). 
 
2.4.1 Single cell sorting 
Flow sorting is a technique that allows separating different cell populations from 
heterogeneous samples, based on the physical (such as the size) or chemical (such as 
expression of cell specific surface antigens) properties of the cells. The FACSAria 
sorter uses the electrostatic method in which the cells are ejected through a vibrating 
nozzle and broken up into a stream of regular droplets. A charge is applied to the 
droplets that contain particles of interest, deviating them from the main stream into 
plates at high voltage. Finally, cells are collected under sterile conditions as they 
move to the waste stream and can then be used for a variety of studies. The 
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efficiency of the sorting is tested by different parameters. Decisions regarding priority 
for recovery or purity of the population are important when programming the sorting 
experiment.  
This technique is particularly useful for isolation of rare cell populations with high 
purity, such as macrophages in previously stored LN SCSs from patients with 
lymphoma or reactive conditions. When sorting a rare population that needs to be 
highly pure, a second sorting procedure might be needed at the expense of loss of 
cell yield.  
 
Primary LN SCSs (2-3 vials/case) were processed according to section 2.1.2. Cell count 
and viability were confirmed using an automated cell counter by trypan blue 
exclusion (ViCell, Beckman Coulter). Cells were split into 1x107 aliquots, resuspended 
in PBS with penicillin, streptomycin and 2% FCS (wash buffer) and centrifuged at 1400 
rpm for 5min at RT. Smaller aliquots (0.25x106 cells/tube) were used for optimization 
controls. Excess supernatant was discarded and cell pellets incubated at 4oC for 
20min in 2% human anti-γ-globulins (Sigma) with the purpose of reducing non-
specific antibody binding to Ig FcR. Cells were then incubated with the appropriate 
antibodies (Table 2.1) for 30min in the dark, at 4oC, washed and resuspended in wash 
buffer with DAPI (1µL/2ml), the fluorochrome used for dead cell exclusion. 
Polypropylene tubes with 1ml of 50% filtered FCS in wash buffer were used for cell 
collection.  
 
An example of the sorting strategy is illustrated in Figure 2.2. Firstly, DAPI negative, 
live cells were selected, followed by doublet exclusion and positive selection of total 
leukocytes according to CD45 expression. Total T-cells were separated according to 
the expression of CD3. B-cells were sorted based on the expression of the pan-B-cell 
marker CD20. Back gating confirmed these were viable and negative for CD3. Finally 
macrophages were isolated based on the expression of CD36, a membrane scavenger 
receptor. As CD36 is also expressed on endothelial cells, CD45 positivity was 
confirmed by back gating of this population prior to sorting. Purity was assessed by 
centrifuging and re-suspending cells in wash buffer/DAPI prior to re-analysis. If cell 
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purity was <90%, re-sorting was performed. Finally, B-cells were stored in liquid 
nitrogen in FCS/20% DMSO after centrifugation at 3000 rpm for 7min. T-cells and 
macrophages were pellet by centrifugation at 8000 rpm for 10min and subjected to 
RNA extraction immediately. 
 
 
Table 2.1 Staining strategy for cell sorting 
 CD45 PE CD3 FITC CD36 APC CD20 APC-H7 
Unstained sample     
CD45 PE 5 µL    
CD3 APC  5 µL   
CD20 APC-H7    5 µL 
CD36 FITC   5 µL  
FMO APC 5 µL 5 µL  5 µL 
FMO PE  5 µL 5 µL 5 µL 
FMO FITC 5 µL  5 µL 5 µL 
FMO APC-H7 5 µL 5 µL 5 µL  
Sample (/107 cells) 15 µL 15 µL 30 µL 30 µL 
 SS: single staining; FMO: fluorescence-minus-one 
 
 
 95 
 
 
Figure 2.2 Sorting strategy for isolation of macrophages, B-cells and T-cells from single cell suspensions of DLBCL and reactive LNs 
Viable cells were selected based on the lack of DAPI staining (A); doublets were excluded by two consecutive gatings (B,C); Leukocytes were selected 
based on the expression of CD45 (E); T-cells and macrophages were sorted based on the expression of CD3 and CD36, respectively (F); B-cells were 
isolated according to the expression of CD20 (G). 
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2.4.2 Immunophenotyping of macrophage cell surface markers  
These experiments were carried out in V-bottomed 96 well plates and staining was 
performed after antibody cocktail preparation. This increased efficiency of protocols 
and reduced preparation times and costs. 
Staining cocktails including all antibodies were prepared, with adequate volumes for 
control and experimental conditions (+10% for pipetting errors). The cocktails were 
pipetted into a 96 well plate prior to multichannel staining of the samples. 
 
Unstained cells were used to measure intrinsic autofluorescence in each wavelength 
prior to acquiring stained cells. Fluoresce-minus-one (FMO) tubes allowed 
discriminating non-specific fluorescence and apparent fluorescence resulting from 
spectral overlap and setting the gating for positivity for each marker/channel.  
 
Macrophages were harvested from culture plates (see section 2.8.6), re-platted into 
96 well plates and centrifuged at 3000 rpm for 5min. Supernatant was discarded by 
turning plates upside down and cells were resuspended in 50µl of wash buffer. 
Staining cocktails (antibodies described in Chapter 6) were applied in a volume of 
50µl/well, mixed by partial volume pipetting and left to incubate for 30min on ice in 
the dark. Wash buffer was then added (200µl/well) and the plate centrifuged at 
3000rpm for 5min. Samples were transferred to 1ml labelled polypropylene adaptor 
tubes in 100µl of wash buffer.  
 
Data was acquired using the four laser BD Fortessa flow cytometer. A minimum of 
5000-10000 target events gated on compensated viable-singlet cells were acquired. 
The main read-out was the median fluorescence intensity (MFI), which was measured 
in all experimental conditions and retrieved as the difference compared to the un-
manipulated sample in each individual experiment. FlowJo (Tree Star Inc) software 
was used for analysis. 
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2.5 RNA extraction  
QIAGEN provides well-standardized protocols that were followed in these 
experiments with minimal changes after optimization.  
RNA was extracted from sorted macrophages and B cells using the QIAGEN RNeasy® 
micro kit recommended for samples with a low cell number. The QIAGEN RNeasy® 
mini kit was used for RNA extraction in samples with higher cell yield. The protocol 
here described was used for low cell number samples. 
Cell pellets were mixed twice by pipetting with 75+75µl of denaturing buffer (RLT+β-
mercaptoethanol), transferred to a QIAshredder spin column and centrifuged at full 
speed (~14000rpm) for 2min. The homogenised lysate was mixed with 150µL of 70% 
ethanol, transferred to an RNeasyMinElute spin column and centrifuged for 15sec at 
10000 rpm. This facilitates binding of the RNA to the column. The Buffer RW1 (350µl) 
was added to the column after discarding the flowthrough and a centrifugation step 
of 15sec at 13000 rpm was done. RW1 was re-added and an on-column DNase 
digestion step was also performed with the purpose of eliminating genomic DNA. 
350µl of buffer RW1 was then added to the membrane and centrifuged for 15sec at 
13000rpm. The membrane was washed 2× by incubation with 500µl buffer RPE 
followed by 500µl of 80% ethanol with intermediate centrifugations at high speed. 
The column was dried by centrifugation at 13300 for 5min with the lid open. Finally, 
the RNA was eluted by incubation of the membrane with 14µl RNase-free water for 3-
5min at RT followed by centrifugation at 13300rpm for 1min; and stored at -80oC. 
 
 
2.6 RNA Quantity and Quality Assessment 
2.6.1 NanoDrop Spectrophotometer  
RNA quantity and purity was determined using the NanoDrop ND-1000 
spectrophotometer (Nanodrop technologies). Concentration was calculated by 
determining the optical density (OD) or ultraviolet light absorbed at 260nm of 1µl of 
RNA, knowing that 1 OD unit is equal to 50ng/µl of RNA. The ratio of absorbance at 
260/280nm indicates purity and should be ~2 for good quality. Lower ratios suggest 
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18S 
28S marker 
contamination with protein or other impurities, which absorb strongly at 280nm. The 
260/230nm ratio is often taken as a secondary measurement of purity and should be 
in the range of 1.8 - 2.2, although cut-offs are not well standardized. A lower ratio 
may suggest contamination by compounds such as guanidine thiocyanate,298 which 
are known to have limited effect on downstream analysis. 
 
2.6.2 Agilent Bioanalyzer 
The Agilent 2100 Bioanalyzer system enables researchers to determine the quality 
and integrity of an RNA sample.299 The Agilent RNA 6000 Pico Kit is particularly useful 
to assess low concentrated RNA samples (50pg/µL), for which NanoDrop readings 
are inaccurate. Results are based on the electrophoretic trace of the sample (Figure 
2.3). The RNA Integrity Number (RIN) generated is calculated based on the 
identification of degraded RNA products and the height of the 18S peak. 
 
 
 
Figure 2.3 Representative Electropherograms generated by the Agilent 2100 Bioanalyser 
 
 
The samples illustrated have excellent quality, the electropherogram traces showing a 
single marker peak and two peaks of ribosomal RNA (18S subunit, 28S subunit) 
migrating in the correct timing. RINs near 1 indicate poor quality, while values near 10 
suggest intact RNA. 
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The kit reagents were equilibrated to RT prior to use. RNA concentrations were 
estimated using the NanoDrop and samples with higher RNA concentrations were 
diluted with RNAse free water. The RNA gel matrix (550µl) was transferred to a spin 
filter and centrifuged at 4000 rpm for 10min. A gel-dye mix (65µl of gel + 1µl of dye) 
was prepared and centrifuged for 10min at 11800 rpm. The gel-dye mix was loaded to 
RNA Pico chips in 9µl aliquots pipetted onto the wells marked ‘G’, followed by the 
conditioning solution. Subsequently, 5µl of RNA marker was added to each well 
including the ladder well. Sample and control RNA aliquots and the RNA 6000 Pico 
ladder were heat denatured and added to each well (1µl). After vortexing the chip 
was run on the Agilent 2100 Bioanalyzer using the Eukaryote RNA Pico chip assay.  
 
 
2.7 Gene Expression Analysis  
2.7.1 Gene Expression Profiling by Microarray technology 
Microarray technology, developed in the mid-1990’s, allows examining the 
expression of thousands of genes simultaneously. It exploits the ability of 
complementary strands of nucleic acids to base pair with each other and bind. The 
DNA samples under study are fluorescently labelled and put in contact with DNA 
copies corresponding to different mRNAs known to codify for a particular gene. If 
hybridisation occurs, fluorescence can be identified, indicating that a particular gene 
is being transcribed in that sample. Differences in fluorescence, and hence gene 
expression can be measured between “disease” and “control” samples. 
This technology was used in our studies to compare the transcriptome of 
macrophages selected from DLBCL lymph nodes with macrophages extracted from 
reactive lymph nodes. The clinical features of the respective patients are described in 
the experimental chapter 5. 
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2.7.1.1 cDNA Synthesis and Amplification using the Nugen Ovation® Pico WTA 
System V2 
RNA is unstable and readily degraded by ubiquitous RNases, making it unsuitable for 
direct analysis. Complementary DNA (cDNA), a stable template for RNA-based assays 
can be generated from RNA. The Ovation® Pico WTA System V2 enables preparation 
of amplified complementary cDNA from low concentrated RNA samples for 
microarray or quantitative real-time PCR (qRT-PCR) applications. Amplification occurs 
through a highly reproducible method using DNA/RNA chimeric primers, DNA 
polymerase and RNase H in an isothermal assay (Figure 2.4). 
 
 
 
 
 
 
Figure 2.4 Ribo-SPIA® Technology used for cDNA synthesis and amplification 
A: Generation of First Strand cDNA. Total RNA is mixed with random and oligo dT DNA/RNA 
chimeric primers, allowing for priming to occur across the whole transcript. Reverse 
transcriptase (RT) promoted extension occurs from the 3’ DNA end of each primer generating 
first strand cDNA. B: Generation of a DNA/RNA Heteroduplex Double Strand cDNA. The cDNA 
is then fragmented to generate priming sites for DNA polymerase to synthesize a second 
cDNA strand containing DNA complementary to the RNA tag sequence localized at 5’ on the 
first strand cDNA. The final product is a double-stranded cDNA with a DNA/RNA 
heteroduplex. C: Single Primer Isothermal Amplification (SPIA®). The RNA portion of the 
heteroduplex is firstly removed by RNase H. DNA polymerase then synthesizes cDNA starting 
at the 3’ end of the SPIA primer, displacing the existing forward strand. The process of 
DNA/RNA primer binding, DNA replication, strand displacement and RNA cleavage is 
repeated, resulting in accumulation of amplified cDNA. 
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All samples were lyophilized in a 60Hz speed vac instrument and resuspended in 5µl 
nuclease-free water. This allowed decreasing sample volumes without compromising 
RNA concentration.  
In a 0.2mL PCR, 2μL of first strand primer mix and 5μL of each sample were mixed and 
subsequently placed in a pre-warmed thermal cycler programmed to run Program 1 
(Appendix, last section). Once primer annealing was complete, 2.5μL first strand 
buffer mix and 0.5μL first strand enzyme mix were added and samples were run on 
the thermal cycler, Program 2 (Appendix, last section). In order to perform Second 
Strand cDNA Synthesis, 10 μL of the second strand master mix (9.7μL buffer + 0.3μL 
enzyme mix) were mixed to each first strand reaction tube and Program 3 was run on 
the pre-cooled thermal cycler. 
 
cDNA was purified using Agencourt RNAClean XP beads. At RT, 32μL of resuspended 
beads were admixed with each reaction and left to incubate for 10min. Samples were 
transferred to a magnet (SPRIplate® 96-ring, Agencourt Biosciences Corporation) with 
a strong magnetic field for 5min to completely clear the solution of beads. The 
solution was carefully discarded by pipetting and the beads washed with 200μL of 
70% ethanol in triplicate. After completely removing the ethanol, the beads were left 
to air dry on the magnet for 15-20min. 100μL of the SPIA amplification mix (50μL 
buffer + 25μL primer + 25 μL enzyme) was mixed to each tube containing the double-
stranded cDNA bound to the dried beads. Samples were then place on a pre-cooled 
thermal cycler programmed to run Program 4 (Appendix, last section). Tubes were 
transferred back to the magnet for 5min. The eluted amplified cDNA was removed 
and subsequently purified using the QIAGEN QIAquick PCR Purification Kit according 
to the company’s instructions. The amplified cDNA was mixed with 500μL of Buffer 
PB, added to QIAquick spin columns and centrifuged for 1min at 13300 rpm. After 
discarding the flow-through, 700μL of 80% ethanol were added twice to the column, 
with intermediate 1min 13,300 rpm centrifugations. Columns were blotted onto 
absorbent paper to remove any residual wash buffer and placed into new 1.5mL 
eppendorfs. 30μL of nuclease-free water was added to the column, left to incubate 
for 5min at RT and forced through by spinning at maximum speed for 1min.  
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cDNA yield and purity were measured using the Nanodrop (single stranded DNA 
setting, where 1 OD unit at 260nm= 33μg/mL). cDNA quality was assessed using the 
Agilent Bioanalyzer RNA 6000 Nano Kit (protocol described in section 2.6.2, with 
minimal changes as required by manufacturer).  
 
2.7.1.2 cDNA fragmentation and biotin labelling using the Nugen Encore Biotin 
Module  
5μg of amplified cDNA in 25μL volume were fragmented by admixing with 7μL of 
fragmentation master mix (5μL buffer + 2μL enzyme mix) and placing in a pre-
warmed thermal cycler programmed to run Program 5 (Appendix, last section). 
Subsequently, 18μL of biotin labelling master mix (15μL buffer + 1.5μL labelling 
reagent + 1.5μL enzyme mix) was added to each fragmented cDNA sample and tubes 
were placed in a pre-warmed thermal cycler programmed to run Program 6 
(Appendix, last section). The fragmented and labelled cDNA was processed 
immediately for array hybridisation. Fragmentation efficiency was assessed using the 
Bioanalyzer. 
 
2.7.1.3 cDNA hybridisation to Affymetrix GeneChip® Human Gene 1.0 ST Arrays 
The GeneChip® Hybridisation, Wash and Stain kit was used. The hybridisation cocktail 
was prepared according to the specifications for Mini Arrays (labelled cDNA, 
5μg/25μl; control oligonucleotide B2 (3nM), 1.9μL; 20x hybridisation controls, 5.5μL; 
2x hybridisation buffer, 55μL; DMSO, 11.6μL) and heated at 99oC for 5min. The probe 
cartridges were meanwhile washed with 80μL of pre-hybridisation mix and incubated 
in rotation for 10min at 45oC. The hybridisation cocktail was transferred to a 45°C 
heat block for 5min and spun at maximum speed in a microcentrifuge for 5min. 
Finally the arrays were refilled with 90μL of the warmed hybridisation cocktail, left to 
hybridise for 16h at 45oC at 60rpm and analysed using the GeneChip Fluidics station 
450. Details on the approach taken to analyse the data will be detailed in the 
experimental Chapter 5. 
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2.7.2 Gene Expression Analysis by quantitative Real-Time PCR 
qRT-PCR was used in these studies for validation of the GEP results and for 
interrogation of expression changes of target genes in macrophages after co-culture 
with reactive or malignant B-cells.  
 
2.7.2.1 cDNA Synthesis 
cDNA prepared as in section 2.7.1.1 was used for the array validation studies. RNA 
extracted from macrophages after co-culture was converted to cDNA using the high 
capacity reverse transcription kit (Applied Biosystems). RNA (0.5-1.5μg) in a volume 
of 10μl was mixed with the reaction master mix (Table 2.2) in a 0.2ml PCR reaction 
tube (final volume: 20μl). Reverse transcription took place on an automated thermal 
cycler with initial annealing for 10min at 25°C, followed by extension for 120min at 
37°C, reverse transcriptase inactivation for 5min at 85°C and cooling at 4°C. 
 
 
 
Table 2.2 Components of the 2x reverse transcription (RT) master mix used for cDNA 
synthesis 
 
Components Volume per reaction (μL) 
10x RT buffer 2 
25x dNTP mix (100mM) 0.8 
10x RT random primers 2 
Multiscribe reverse transcriptase 1 
Nuclease free water 4.2 
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2.7.2.2 Quantitative Real Time quantitative PCR 
This technique is used to quantify specific RNA transcripts in real-time. The reaction 
happens in a fluid mixture containing the template cDNA, an enzyme (Taq DNA 
polymerase), fluorescently-tagged primers-probes and water. The enzymatic cleavage 
of cDNA-bound probes in each round of PCR reaction leads to the releasing the 
fluorescent dye (FAM). The quantity of the detectable fluorescence is proportional to 
the amount of PCR product and the abundance of the RNA species of interest. 
RNA transcripts were assayed in triplicate for each sample using TaqMan gene 
expression assays (Applied Biosystems). The housekeeping genes chosen were B2M 
for the microarray validation studies and GAPDH for the gene expression analysis 
performed in Chapter 6.  
 
The reactions were set up in 386 well optical plates. Taqman 2x universal PCR Master 
Mix (Applied Biosystems) and expression assays were mixed first and placed into a 
loading reservoir and from here 11µl transferred to the designated well. cDNA were 
added in a 15μl final volume per reaction. The plate was sealed, centrifuged for 1min 
at 3300rpm to collect the reaction at the bottom of the well and loaded on the ABI 
HT-7900 system (Applied Biosystems). An initial 95oC incubation for 10min enabled 
enzyme activation and cDNA denaturation. The reaction was then cycled for 40 cycles 
at 95oC for 15 seconds and 60oC for 1 minute.  
 
 
 
Table 2.3 Components of Reaction Mix for qRT-PCR 
 
Components Volume per 15μl reaction 
20x TaqMan gene expression assay 0.75 
2x TaqMan gene expression master mix 7.5 
RNase-free Water 2.75 
cDNA template 4 
 
Chapter 2 Materials and Methods 
105 
 
Data was converted to relative quantities (RQ) for comparison between samples. A 
cycle threshold (CT), representing the number of PCR cycles at which the fluorescence 
signal for each target and control gene crosses a user defined threshold, was 
calculated. CT values are inversely proportional to mRNA abundance. An average of 
CT values for each sample was calculated, where replicate reactions with CT standard 
deviation (SD) ≥0.5 were discarded. Wells with a CT value of >35 were excluded from 
further analysis.  
Target CT values were normalised to the housekeeping gene, generating a delta CT 
value (∆CT= CT Target Gene – CT Endogenous Control Gene). The delta ∆CT (∆∆CT) 
value, which represents the quantity of mRNA present in each condition, was 
determined by subtracting the ∆CT of a user-defined calibrator sample from the ∆CT 
of test samples. The Log2 scaled data was finally transformed to a linear scale using 
the formula: RQ=2-ΔΔCT. RQ values were compared by T-test and fold changes (FC) 
calculated from the mean of each group as described in each chapter.  
 
 
2.8 Co-culture systems involving primary human macrophages and malignant and 
reactive B-cells 
Functional studies are the only ones able to provide a definitive biological explanation 
towards the impact of cell-cell interactions happening in vivo. In vitro cell systems are 
used in an attempt to mimic the cell-cell interactions and their functional effects. A 
dual-cell system such as the one used here, although limited to understand the 
relevance of the whole microenvironment in the biology of DLBCL, would help to 
explore one of our hypothesis for this study: the malignant DLBCL cells are inducing 
functional changes in the lymphoma-associated macrophages. 
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2.8.1 Positive selection of monocytes from using magnetic microbeads and 
macrophage maturation in vitro  
Positive cell selection was performed using the magnetic cell sorting system 
developed by Miltenyi Biotec. PBMCs from healthy donors were isolated from buffy 
cones using the Ficoll method described in section 2.1.3. After cell counting, samples 
were divided in 1.5x108 aliquots, pelleted by centrifugation and resuspended in 
1000μl of cold buffer (PBS/0.5M EDTA/2% FCS) and 100μl CD14 antibody conjugated 
microbeads. After incubating for 15-20min in the dark at 4°C, cells were washed with 
10ml of buffer, centrifuged at 1200rpm for 10min at 4°C and resuspended in 500μl of 
buffer. The LS columns were adapted to the QuadroMACS® magnet, rinsed with 3ml 
of buffer and loaded with the cell suspensions. Each column was washed 3 x 3ml of 
cold buffer.  The positive cell fraction was forced through the column in 5ml of buffer 
by plunging, resuspended in Dulbecco's Modified Eagle's (DMEM) medium with high 
glucose and sodium pyruvate (Sigma-Aldrich), 10% filtered human AB serum (Sigma-
Aldrich) and penicillin/streptomycin and centrifuged for 5min at 1500rpm at RT. 
Aliquots were taken for analysis of cell purity by flow cytometry (described in 
experimental Chapter 6). After automated cell counting, monocytes were plated in 
90mm Petri dishes (Sterilin) in a 15ml volume at 4.5x106/ml concentration and place 
at 37°C in a 5% CO2 humidified incubator for 7 days. 
 
2.8.2 Positive selection of reactive B-cells from tonsils using magnetic microbeads 
Tonsil SCSs were prepared, stored and resuscitated according to section 2.1.2. 
Viability and cell count was assessed using an automated cell counter.  
Cell separation was performed according to the protocol described in section 2.8.1 
with minor adjustment. The concentration of CD19 antibody conjugated microbeads 
used was kept as per manufacturers recommendations (20μl/107 cells). 
After sorting, cell counting was assessed on a haemocytometer by mixing 5μl cell 
suspension with 5μl trypan blue dye 0.4% (Cell Viability Inc). The trypan blue is 
absorbed through the cell membrane of dead cells but not the intact membrane of 
live cells. For each sample 4x1mm2 squares were counted on the haemocytometer 
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noting the number of live and dead cells. The average number of live and dead cells 
was multiplied by the dilution factor (2), giving a cell number x104/ml.  
Finally, B-cells needed for co-culture were resuspended in DMEM medium with 10% 
filtered human AB serum and penicillin/streptomycin. Aliquots were kept for flow 
cytometry purity assessment. 
 
2.8.3 Macrophage harvesting and replatting for co-culture experiments 
After 1 week of incubation macrophages adhere to the bottom of the Petri dishes and 
need to be harvested by manual scrapping. The petri dishes were taken out of the 
incubator, transferred to the hood and sat on ice. Culture medium with unattached 
cells was gently harvested to 50ml centrifuge tubes using an automated pipette, 
leaving the bottom of the dish untouched. The adherent fraction was washed twice 
by stirring with 10ml of cold PBS and harvested together with the non-adherent cell 
fraction. 5ml cold PBS was added to each dish. A 1.8cm blade cell scraper (BD Falcon) 
was then used to detach the macrophages, with particular attention not to use 
circular movements and to keep the scrapper in a 45o angle with the dish. The 
harvesting was repeated once to increase cell yield and a final wash with cold PBS 
was done. After centrifuging at 1400rpm for 10min at 4oC, macrophages were 
resuspended in DMEM with 10% human serum and penicillin/streptomycin and 
counted on an automated counter. Finally, cells were adhered at a concentration of 
2-5 x104/ml at 37oC into 24-well plates for 24h prior to co-culture set-up. 
 
2.8.4 Co-culture set-up 
The following day, the DLBCL cell lines Su-DHL4 and Ri1 were washed and 
resuspended in DMEM with 10% human serum and penicillin/streptomycin in the 
concentration required for co-culture. Reactive B-cells were prepared according to 
section 2.8.2.  
The 24-well plates were taken from the incubator and adequate adherence 
confirmed using the microscope (10x amplification). All work was then performed 
under the hood.  
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Reactive and malignant B-cells were layered in triplicate over the adherent 
macrophages at a 1:1 concentration. Transwell inserts with 0.4µm pore size and 
1x104/cm2 pore density (Costar, Corning) were also used, allowing cell separation but 
passage of small molecules across the membrane. After transwell insertion, cells 
were added to the upper chamber at a 1:1 concentration in a 100µl volume. As a 
positive control, macrophages were treated with LPS at a concentration of 100ng/ml. 
Finally, as negative internal controls for each biological experiment, macrophages 
were cultured alone for an additional 24h. Figure 2.5 below illustrates the 
experimental set-up. 
 
 
 
 
 
Figure 2.5 Macrophage and B-cells co-culture system employed in this study 
Reactive tonsillar B-cells and DLBCL cell lines were plated in a 1:1 ratio in contact (B) or on the 
top layer of a transwell insert (C) in 24 microwell plates where macrophages were allowed to 
adhere for 24 hours. As negative internal controls for each biological experiment 
macrophages were cultured alone for additional 24h (A). Finally, macrophages were treated 
with 100ng/ml of LPS (D). 
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2.8.5 Macrophage harvesting after co-culture 
After 24h, plates were placed over an icebox. 1ml of co-culture supernatant from all 
experimental conditions was collected in 1.5ml eppendorfs and centrifuged at 
4000rpm for 5min at 4oC in a microcentrifuge. The top layer was aspirated carefully 
(~0.5ml) and stored at -20oC for cytokine quantification. The remaining supernatant 
was replaced by 200µl of cold fresh PBS with 2%FCS. Adherent cells were scrapped 
with a cell scraper with the blade cut on both sides, avoiding circular movements. 
Once the cell suspension was collected to 1.5ml eppendorfs, additional scrapping was 
done if significant residual adherent cells were seen under the microscope. Finally, all 
tubes were centrifuged at 4000rpm for 5min at 4oC. The cell pellets were 
resuspended immediately for flow cytometry (section 2.4.2). In order to guarantee a 
pure population after co-culture, macrophages were sorted using size and 
intracellular complexity differences compared to B-cells and stored at -80oC for future 
RNA extraction. 
 
2.9 Cytokine profiling of co-culture supernatants using cytometric bead arrays  
The human Th1/Th2/Th17 Cytometric Bead Arrays (CBA, Beckton Dickinson) were 
used to quantify IL-2, IL-4, IL-6, IL-10, IL-17, TNF, and IFN-γ in supernatants from the 
co-culture experiments just described. The CBAs are a flow cytometry based assay, 
which enables highly sensitive quantification of multiple proteins simultaneously in a 
50μl sample volume. As a result, this method significantly reduces sample 
requirements and time to results in comparison with ELISA and Western blotting. The 
system relies on the addition of multiple antibody-coated beads, which capture the 
specific proteins in solution. These beads have unique fluorescence intensity emitted 
on the PE-FL2 channel of the flow cytometer and hence can be analysed 
simultaneously in a single tube.  
 
 
 
 
Chapter 2 Materials and Methods 
110 
The protocol recommended by the manufacturer was strictly followed.  
The cytokine lyophilized standards were reconstituted in 2ml of Assay Diluent. After 
incubation at RT for 15min, 9 serial dilutions (1:1 - 1:256) were prepared. Diluent 
represented the negative control. An aliquot of 10μl/sample of each cytokine Capture 
Bead were mixed in a single tube and 50μl of mixed beads were distributed to the 
appropriate assay tubes. 50μl of the standard dilutions were added to the control 
assay tubes. Finally, 50μl of each test sample and 50μl of the PE Detection Reagent 
were added to the test assay tubes. All tubes were left to incubate for 3 hours at RT 
and protected from direct exposure to light. After incubation all samples were 
washed with 1ml of Wash Buffer and centrifuged at 1000rpm for 5min. Supernatant 
was discarded and pellets resuspended in 300μl of Wash Buffer. Data was acquired 
on a BD Fortessa II flow cytometer with FACS Diva Software. The beads were excited 
off the 488nm laser and detected in the PE (FL-2) detector (Figure 2.6). Approximately 
2000 events were acquired per sample. 
 
 
 
Figure 2.6 Outline of the cytokine profiling using the Cytokine Bead Array (CBA) System (BD 
Biosciences)  
Cytokine specific beads are incubated with the sample and detector antibodies conjugated to 
the PE fluorochrome. After incubation, cytokine/antibody/detector antibody complexes are 
detected by flow cytometry. The concentration of each cytokine in a given sample is directly 
proportional to its fluorescence intensity on the PE-FL2 channel and is calculated based on 
the standard curve fitted from the concentration on the control assay tubes. 
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2.9.1 FCAP Array analysis of cytokine secretion 
Data analysis was performed using FCAP Array software (Becton Dickinson). The 
software allows determination of the analyte concentrations in the samples based on 
know concentrations from the standards run in the same conditions.  
The CBA beads were gated based on the forward scatter versus side scatter features, 
after which individual bead sets representing each cytokine were gated individually. 
Finally the MFI of each gated population on the PE detector was measured. A 
standard curve based on a 4-parameter logistic mathematical model was used to 
calculate the concentration of measured proteins in each condition. The results were 
expressed as a pattern code representing the MFI of the sample population and 
finally in pg/ml (Figure 2.6). 
 
 
2.10 Statistical analysis 
Details on statistical analyses applied are given within the relevant experimental 
chapter. Statistical tests were performed using Prism software Version 5.03, SPSS 
Version 19.0 and Excel.
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Chapter 3 Reliability of immunohistochemistry classifiers of cell-of-
origin for diffuse large B-cell lymphoma 
 
 
3.1 Introduction 
As discussed in Chapter 1, DLBCL represents a heterogeneous group of lymphoid 
malignancies with distinct oncogenic events and clinical behaviour that cannot be 
distinguished only by morphology and immunophenotype.34,74,92 This biological 
diversity explains the heterogeneous responses to the current standard treatment, R-
CHOP, and provides a rational for investigation of novel targeted therapies.  
Through the use of microarray technology, Alizadeh et al.74 described the two 
molecularly distinct forms of DLBCL, which replicate GEPs typical of different stages of 
B-cell differentiation. GCB-DLBCLs assume a transcriptome superimposable to that of 
normal GC B-cells. In concordance with this, GCB cases exhibit immunoglobulin gene 
ongoing somatic hypermutation.81 ABC-DLBCLs express genes more characteristic of 
plasma cells,76 but are blocked in their differentiation capacity. The two entities are 
very distinct in their genetic changes, and signalling pathway deregulation. Numerous 
studies are trying to pinpoint the biological features that explain outcome differences 
and could be used as markers for targeted therapy. Importantly, it has been shown 
that patients with GCB-DLBCLs have an improved OS compared with ABC-DLBCLs 
after treatment with R-CHOP.34 In fact, the molecular classification is regarded the 
most robust biological prognostic tool available for DLBCL. 
 
Molecular characterization is opening up opportunities for personalized therapy in 
poor-risk DLBCL. Emerging in vitro and clinical data support that the two main DLBCL 
molecular subtypes, the ABC and GCB-DLBCLs may benefit from different treatment 
approaches, with agents including bortezomib,300 lenalidomide117,301 or ibrutinib118 
appearing particularly active against the worse prognosis ABC subtype.  
 
In order for targeted therapies to succeed in this disease, reliable and reproducible 
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strategies that adequately segregate patients into distinct molecular groups are 
needed. While GEP is the gold standard method for molecular stratification of DLBCL 
in the laboratory, this technique has only recently been incorporated into clinical 
trials for treatment stratification. The REMoDLB phase 3 clinical trial (NCT01324596) 
aims at determining whether the addition of bortezomib to standard R-CHOP 
improves EFS and if that benefit is related to the molecular features of the tumour 
cells, which is being characterized by GEP in the FFPE tissue. However, since the 
application of GEP is still restricted to research purposes, there is presently a lack of 
standardized methodology for array analysis, which can lead to variable results both 
at the inter- and intra-laboratory level. This issue, which may impact on its results and 
on patient care, is generally unreported. 
 
The lack of a routine methodology for GEP based COO assessment has led 
investigators to develop IHC based approaches for the molecular classification in 
DLBCL, using proteins that either were already known to be expressed in GC and post-
GC cells or that were unravelled by the GEP studies. In 2005 Hans and co-workers302 
established the first IHC algorithm, allegedly with high sensitivity for GEP 
classification. Subsequently, eight further strategies303-308 have been published, most 
of which reported a better concordance with molecular-based classification than the 
Hans algorithm and the ability to segregate two groups with significantly different 
outcome. However, many investigators continue to question the clinical applicability 
of these algorithms.26,51,94,309-313 Results are typically inconsistent and are generally 
poorly reproducible by independent groups. Nevertheless, IHC is attractive as a 
surrogate for molecular stratification in DLBCL and the Hans algorithm is being used 
to define DLBCL of the ABC-type in clinical trials offering NF-kB targeting agents to 
patients with this subtype. 
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3.2 Objectives 
This study set out to provide an up-to-date systematic comparison of nine IHC scores 
(Figure 3.1) for molecular classification in a new large dataset of diagnostic DLBCL. 
Our primary objective was to test the reliability of these methodologies in classifying 
individual cases of this cohort. IHC profiles for single proteins and each algorithm 
were assessed and agreed among three expert observers. A consensus matrix based 
on all scoring combinations and the number of subjects for each combination was 
constructed in order to assess reliability. As a secondary aim, the survival impact of 
individual markers and the nine classifiers was evaluated. 
We hypothesized that the IHC algorithms are not reliable predictors of the molecular 
classification of DLBCL. The approach used in this study addresses the important 
question of whether IHC is or not a reliable alternative to molecular-based methods 
to be used for clinical decisions in DLBCL. 
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Figure 3.1 Algorithms applied in the current study.  
(A) Hans; (B) Hans modified; (C) Nyman; (D) Muris; (E) Choi; (F) Choi modified; (G) Tally; (H) Natkunam; (I) Visco-Young.
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3.3 Materials and Methods 
3.3.1 Patients 
Patients with de novo DLBCL included in the studies detailed here were treated in 
two institutions, as already described in Chapter 2. Patient selection was dependent 
on the availability of good quality FFPE tissue of the diagnostic biopsy and extended 
clinical and follow-up data. December 2009 was selected as the cut-off date of 
diagnosis to include patients in the study to guarantee an acceptable follow-up.  
Overall, 161 R-CHOP chemo-immunotherapy treated patients and 148 patients 
treated with other regimens were included in these studies. Survival according to 
treatment era and institution is detailed in Figure 3.2. Whenever no prognostic 
studies were planned, data from all patients were included. Clinical data for the R-
CHOP cohort, including response to chemotherapy is detailed in Table 3.1. The 
median follow-up of the R-CHOP cohort is of 55 months. 
Due to TMA tissue loss and technical obstacles a variable number of cases were 
included in the final analysis. A comparison of clinical features and outcome between 
cases included and the ones lost was done in parallel and will be presented in the 
results. 
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Figure 3.2 Kaplan Meier curves according to treatment regimens and treating institution.  
A&B: OS and PFS of patients according to treatment regimen. 114 of 148 patients received anthracycline based regimens (CHOP, MACOP-B, VAPEC-
B) and are highlighted in the curve. The remaining were managed palliativelly or did not receive treatment and were excluded from analysis;  
C&D: OS and PFS of patients stratified by treatment institution. Differences between groups were determined using the chi-square method with 
significance defined as p<0.05
A B 
C D 
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Table 3.1 Clinical features of the R-CHOP series 
 Barts (77 patients) IPO (84 patients)  
Clinical characteristics number % number % p-value 
Male 53 68,8 39 46,4 0,004 
Age, years (Median, range) 57 (19 - 86)  64,5 (16 - 85)  NS 
Age > 60 years 34 44,2 50 59,5  
Stage III-IV 44 57,1 44 52,4 NS 
"B-symptoms" 18 26,5 21 25,3 NS 
≥ 2 Extranodal sites  13 16,9 16 18,8 NS 
High LDH 38 51,4 67 79,8 < 0.001 
ECOG PS ≥2 8 10,5 15 17,9 NS 
IPI     0,01 
Low 39 50,6 26 31,0  
Low-intermediate 11 14,3 22 26,2  
High-intermediate 22 28,6 21 25,0  
High 5 6,5 15 17,9  
IPI ≥3 27 35,1 36 42,9 NS 
Response     < 0.001 
CR/CRu 47 61,0 68 81,0  
PR 16 20,8 11 13,1  
SD 2 2,6 0 0,0  
PD/failure 11 14,3 4 4,8  
Relapse rate (from CR/CRu)  11 23,4 16 23,5 NS 
Death rate 26 33,8 21 25,0 NS 
Causes of death     NS 
Lymphoma 19 73,1 12 57,1  
Toxicity 2 7,7 6 28,6  
Follow-up (median, range) 65.5 (16.3 - 110.4)  47.3 (0.6-94)   
ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; IPI: International 
Prognostic Index; Low-int: low-intermediate; High-int: high-intermediate; CR: complete 
response; PR: partial response; SD: stable disease; PD: progressive disease; NS: not significant 
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3.3.2 TMA and IHC 
Sample collection followed informed consent in accordance to the declaration of 
Helsinki. Ethical approval for this study was obtained from local ethics regional 
committees.  
For the Bart’s TMAs triplicate 1 mm2 cores were taken from regions of biopsy material 
rich in malignant cells identified on H&E stained sections. Representative tumour 
regions had been previously marked by me and an expert Haematopathologist [Dr 
Maria Calaminici (MC)]. Tonsils were cored in all TMAs as internal controls. For the 
IPO TMA, duplicate 1.5 mm2 cores were taken after selection of representative 
tumour areas by JC. Staining for the pan B-cell marker CD20 was performed on TMA 
sections to confirm adequate tumour representation. TMAs were sectioned and 
transferred onto glass slides. After dewaxing, blocking in hydrogen 
peroxide/methanol solution, rehydration, and pressure-cooker antigen retrieval, the 
slides were subjected to immunostaining. Primary antibody reaction for CD10, BCL6, 
BCL2, MUM1, FOXP1, GCET1 and LMO2 was detected using a peroxidase-labelled 
system (Super-Sensitive Polymer-HRP IHC Detection System, BioGenex). An 
immunological amplification method (CSA II, Catalyzed Amplification System, Dako) 
was used exclusively for BCL6. Heat induced antigen retrieval using a pressure cooker 
was used for all antibodies. In each batch of staining, tonsil sections were analyzed 
simultaneously for all markers. All IHC was performed in the same laboratory. Primary 
antibodies, conditions of use and source are provided in Table 3.2. Representative 
negative, positive and control cases are shown in Figure 3.3. 
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Table 3.2 Primary antibodies and conditions of use 
Antibody Clone Species Dilution Source 
CD10 56c6 Mouse 1/250 Novocastra 
BCL2 124 Mouse 1/200 Dako 
BCL6 LN22 Mouse 1/500 Novocastra 
MUM1 MUM1p Mouse 1/400 Dako 
FOXP1 JC12 Mouse 1/500 Abcam 
LMO2 SP51 Rabbit 1/500 Abcam 
GCET1 Ram341 Mouse 1/100 Abcam 
CD20 L26 Mouse 1/2000 Dako 
 
 
3.3.3. Slide scanning, scoring and analysis 
Slides were scanned using the Hammamatsu Virtual Slide Scanner NanoZoomer 2.0 
(Hammamatsu), and viewed using the NDP.scan software.  
All cores were jointly visualized on a computer screen at low and high magnification 
by MC and Dr Abigail Lee and myself to standardize the scoring criteria for each 
antibody applied. Each case was scored as positive or negative according to the cut-
points defined in the original publications, as detailed in Figure 3.1. Thus, some 
antibodies were scored using more than one cut-point, as detailed in Table 3.3. As 
most publications report only scant methodological details, negative cases with 
absent internal controls were deemed unclassifiable, as recommended by the 
Lunenburg Lymphoma Biomarker Consortium (LLBC) guidelines.314 This and the 
absence of whole cores in the TMA were the primary causes for the inability to score 
(unclassifiable cases are detailed for each antibody in Table 3.3). Whenever individual 
cores of a given case showed non-concordant results, the core with highest large cell 
infiltration was used. After all observers had assessed each staining, a meeting was 
organized to reach consensus on discordant cases. In almost all cases a 3:0 decision 
was reached, but in less than 5% of the cases a 2:1 score was accepted. 
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As expected, consensus was higher for the antibodies in use in the diagnostic setting, 
such as CD10, BCL2 and MUM1. LMO2 shows a nuclear distribution and is also 
expressed by T-cells so analysis also included nuclear size. FOXP1 scoring was difficult 
in some cases due to the background staining and inter-patient differences in staining 
intensity. 
 
3.3.4 Statistical analysis 
Correlations between the expression of specific proteins or allocation to a particular 
algorithm and clinical parameters were tested using the Pearson’s test. 
 
3.3.4.1 Outcome analysis 
Results regarding single marker expression and algorithm distribution refer only to 
the more recently diagnosed and R-CHOP treated cohort, given that biomarker 
distribution was under prognostic scrutiny. Differences in clinical characteristics 
between the two R-CHOP series were tested using chi-square or Fisher’s exact test, 
when appropriate.  
In the univariate analysis, log-rank tests were performed. All parameters of the IPI 
were assessed for prognostic impact. Relevant interactions of the markers studied 
with the IPI factors were assessed. Cox proportional hazards models were used to 
obtain estimates of the hazard ratios (HR) with 95% confidence intervals (CI). Models 
included all variables with a p-value ≥ 0.2 on univariate analysis. Both backward and 
forward selection methods were used to test independent significance of each 
variable included in the models.  
 
The outcomes, measured from date of diagnosis to occurrence of event or date of 
last follow-up, were: OS, the event being death from any cause; and PFS, the event 
being failure of treatment (including not achieving complete response (CR) or 
progressing after achieving CR) or death of any cause. Median follow-up was 
calculated for patients alive at last follow-up. Statistical analysis was performed using 
SPSS version 19.0 (SPSS, Chicago, IL) and Prism version 5.03 (GraphPad Software, La 
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Jolla, CA). 
3.3.4.2 Comparison of IHC COO algorithms 
All cases included in the arrays at the time of the current study were used in the 
comparison of algorithm performance, independently of the treatment received. 
Firstly data compiling the classification of all cases according to each of the IHC 
classifiers was gathered. Subsequently, a consensus matrix based on the nine 
classifiers and number of subjects for each combination was built. Concordance 
across all methods was measured using the kappa statistics.  
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Figure 3.3 Immunohistochemistry results for each antibody.  
Original magnification: x20. Cases were considered CD10 negative if CD10 staining fibroblasts 
were encountered in the tumour. In LMO2 negative cases was common to observe positive T-
cells in the microenvironment, constituting an ideal internal control. GC, germinal centre.
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3.4 Results 
3.4.1. Analysis of individual markers  
With the exception of the Natkunam algorithm, all classifiers tested use a 
combination of antigens for final allocation. In fact, it is generally accepted that no 
single protein expression appears able to mirror the GEP classification.  
Although our main aim was to compare the results from the different algorithms, we 
hypothesized that the comparison of single antigen expression patterns from our 
series with those from others reported in the literature would give us an indication of 
the reliability of IHC for protein studies in this setting. Results from single protein 
expression of the R-CHOP treated cases (positive, negative and unclassifiable cases) 
are illustrated in Table 3.3. We could not document a survival impact of the 
expression of any the proteins studied, including BCL2 or BCL6. 
 
CD10 is a glycoprotein detected in normal lymphoid ontogeny on pro-B cells and 
mature GC B-cells. In normal and malignant LNs, CD10 expression is also seen in cells 
from the stromal compartment. In the context of lymphoma it helps identifying cases 
of GC derivation, such as follicular lymphoma or a subset of GCB-DLBCLs. In our series 
its expression was detected in 28%, in keeping with previous results.51,302,303,306,311 As 
has been previously suggested, CD10 positive cases might have a better OS, although 
the data available is not entirely concordant. For the purposes of ascertaining true 
outcome impact of each marker, we tested potential interactions with clinical 
parameters. In our series, the CD10 expressing cohort was enriched for younger 
patients (p=0.03), whereas negative cases had higher LDH (p=0.02). However, no 
differences in the IPI distribution were detected. We observed a positive correlation 
between CD10 expression and other GCB-“specific” proteins, including BCL6 
(Pearson´s 0.311, p<0.001) and GCET1 (Pearson´s 0.45, p<0.001), and a negative 
correlation with the post-GC marker MUM1 (Pearson´s -0.164, p=0.05). 
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Table 3.3 Single marker analysis of the R-CHOP cohort 
Antigens (cut-off) positive [n (%)] negative [n (%)] unclassifiable (n) 
CD10 (30%) 41 (28) 106 (72) 4 
BCL6 (30%) 86 (61) 54 (39) 11 
MUM1 (30%) 109 (76) 35 (24) 7 
MUM1 (80%) 60 (42) 84 (58) 7 
GCET1 (30%)a 29 (20) 118 (80) 4 
GCET1 (80%) 12 (8) 135 (92) 4 
FOXP1 (30%) 116 (82) 25 (18) 10 
FOXP1 (60%) 102 (72) 39 (28) 10 
FOXP1 (80%)b 77 (55) 64 (45) 10 
LMO2 (30%) 79 (56) 62  (44) 10 
BCL2 (50%) 96 (69) 43 (31) 12 
Absolute number and percentage of classifiable cases is highlighted for each antigen. Staining 
and analysis were performed centrally. a a significantly higher proportion of GCET1+ cases 
(30% cut-off) was detected in patients diagnosed at Bart’s Hospital (p=0.006); b a significantly 
higher number of patients diagnosed in IPO were considered positive for FOXP1 at the cutoff 
of 80% (p=0.001). n: number; NS: not significant 
 
 
Both GCB and ABC-DLBCLs can haorbour genetic aberrations involving BCL6, a 
transcription repressor molecule essential for the formation of the GC reaction. Most 
genetic aberrations involving BCL6 lead to protein overexpression. In consequence, B-
cells cannot differentiate into plasma cells but continue to divide and proliferate. 
GCB-DLBCLs harbour mutations within the BCL6 auto-regulatory domain, whereas 
ABC-DLBCLs exhibit translocations deregulating BCL6. Nevertheless, BCL6 protein is 
considered a GC marker.  
BCL6 expression in our series was comparable to previous reports.302,311,313,315 A weak 
positive correlation was observed with other GCB-related proteins (CD10; GCET1, 
Pearson´s 0.39, p<0,001; and LMO2, Pearson’s 0.51, p<0.001). BCL6+ patients were 
more likely to have low-risk IPI (p=0.05), and in this IPI subgroup BCL6 expression 
alone conferred a better 3-year OS (79 vs 93%, p=0.04). When the whole dataset was 
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analysed, BCL6 was unable to differentiate patients with distinct outcome. This 
contrasts with recent data suggesting that BCL6 protein overexpression alone is 
associated with an adverse prognosis, independently of the IPI score.316 
 
The MUM1 gene codifies for a lymphoid-specific transcription factor. MUM1 was 
introduced in the first IHC algorithm for prediction of the molecular stratification as a 
post-GC marker. Its expression at a cut-off of 30% was detected in 109 (76%) of our 
subjects, higher than previously reported.302,305  However, using an 80% cut-off, 42% 
of the patients were deemed positive for MUM1, which is in keeping with Choi’s 
data.306 Moreover, this higher cut-off improved correlation with other post-GC 
markers, such as FOXP1 (Pearson´s 0.19 to 0.37, p<0.01). A significant correlation 
between BCL2 and MUM1 expression was also documented (Pearson´s 0.36 to 0.37, 
p<0.01). 
 
Centerin (GCET1) protein expression is restricted to a subset of GCB cells317 and 
should specifically identify GCB DLBCLs. However, expression of this marker was 
detected in only 8% of cases when assessed at a cut-point of 80%, and this only 
increased to 20% at the lower cut-off of 30%. At both cut-points, although positive 
patients were more likely to be younger (p=0.003), there was no association with IPI. 
At the 30% cut-off for expression, weak positive correlations with other GC markers, 
including CD10 and LMO2 (Pearson’s 0.34, p<0.001), and negative correlation with 
MUM1 (Pearson’s -0.19, p=0.03) were detected, with weaker correlations at the 
higher cut-point. 
 
FOXP1 is a transcription factor, which has been detected at high levels in cases lacking 
GCB markers and expressing BCL6 and MUM1.318 In our cohort, 82% of the patients 
had >30% and 72% had >60% of FOXP1+ cells. If a higher cut-off of 80% was used, a 
higher proportion of patients treated in the Portuguese institution were allocated to 
the FOXP1+ group (67% vs 40%, p=0,001).  
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LMO2 emerged from GEP studies as a strong prognostic marker in DLBCL. The LMO2 
protein is expressed in LN solely by the nucleus of normal GC B-cells and by a subset 
of GCB-DLBCLs.319 Natkunam et al.304 proposed that LMO2 alone has a high predictive 
power for GCB allocation and consequently a positive impact on patient survival, 
even after the introduction of rituximab. We detected LMO2 staining in 79 (56%) 
cases, which is in keeping with the original data. However we were not able to detect 
any prognostic value in our cohort. 
 
BCL2 is an oncogene commonly targeted in DLBCL, activating an anti-apoptotic 
program in the malignant cells. Forty-five per cent of GCB-DLBCLs are associated with 
t(14;18) translocations and consequently have BCL2 overexpression. This oncogenic 
event was divergently correlated with outcome. The majority of ABC-DLBCLs have 
BCL2 overexpression due to transcriptional deregulation. Studies have reported a 
negative outcome impact in these cases. The expression of BCL2 by the malignant B-
cells has been associated with poor outcome in most studies.94,96,320,321 However, its 
survival impact appears to be dependent on the COO allocation, rituximab 
treatment322,323 and by the coexistence of MYC genetic aberrations. In our series, 
BCL2 was expressed in 96 (69%) patients, with no association with survival being 
detected.  
 
3.4.2 Algorithm classification: distribution and consistency 
According to the original and most widely utilized Hans method302 we classified 53 of 
our subjects as GCB (Table 3.4). CD10 expression was determinant for this allocation, 
as 41 of these patients were positive for this antigen. This is in keeping with the 
original publication. The remaining 12 cases were all BCL6+ and MUM1-. Within the 
non-GCB cohort, BCL6 expression was detected in half of the cases. Hans’s allocation 
was similar between the two R-CHOP cohorts and no association with clinical 
characteristics was found. 
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The modified Hans was proposed to decrease inconsistency introduced by the anti-
BCL6 antibody.307 According to modified Hans criteria, 61 (42%) patients were 
classified as GCB, including all GCB patients from the Hans method and a further eight 
patients scored CD10-/MUM1-.  
 
The Choi classifier306 relies on the expression of three antigens (GCET1, MUM1 and 
CD10) for initial allocation and on a further two (BCL6 and FOXP1) for final decision. 
Cut-off points were adopted according to appropriate detection of a single series of 
molecularly profiled patients. Using the cut-offs defined in the original paper, 
allocation into GCB and non-GCB groups in our cohort was 65 (45%) and 79 (55%) 
patients, respectively.  
 
Acknowledging the complexity of the Choi algorithm, Meyer et al.307 proposed the 
modified Choi. In our hands, only 35 (25%) of patients were classified as GCB. 
Compared to the Choi algorithm, the modified version re-classified both GCB (64 
cases) and non-GCB cases (8 cases). Due to the different proportion of FOXP1+ 
patients between the two R-CHOP series, the Portuguese series was enriched for ABC 
cases using the Choi (p=0.05) and the modified Choi (p=0.01) criteria. The Choi ABC 
cohort was enriched for older patients (p=0.01). 
 
From the clinical point of view it would be more relevant to use a method that is 
highly sensitive at identifying ABC patients, the subgroup that may be more amenable 
to targeting with new agents. Nyman et al.305 proposed a method for this purpose, 
using only post-GC antibodies (MUM1 and FOXP1). Due to a high proportion of 
positive cases for both markers, in our series only 18 patients (13%) were considered 
non-ABC using this approach.
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Table 3.4 Distribution of R-CHOP treated patients according to the nine IHC classifiers 
 
Classifiers      Bart’s [n (%)]                      IPO [n (%)]  original data (%)  
 
GCB non-GCB GCB non-GCB GCB non-GCB p-value 
Hans 29   (44) 37   (56) 24   (32) 50   (68) 42 58 NS 
Hans* 35   (51) 34   (49) 26   (34) 50   (66) 54 56 NS 
Choi 37   (54) 32   (46) 28   (37) 47   (63) 58 42 0.05 
Choi* 22   (34) 43   (66) 13   (17) 62   (83) 49 51 0.01 
Natkunam 37   (57) 28   (43) 42   (55) 34   (45) 55 45 NS 
Nyman 13   (19) 55   (81) 5   (7) 71   (93) 45 55 0.03 
Muris 36   (56) 28   (44) 35   (45) 42   (55) 55 45 0.03 
Tally 17   (26) 48   (74) 13   (17) 62   (83) 45 55 NS 
Visco-Young 29   (43) 38   (57) 24   (32) 52   (68) 53 47 NS 
* modified; p-values refer to differences between patients treated in the different 
institutions. 
 
 
The Muris classifier303 is the only method using BCL2. In our series 71 (50%) patients 
were classified as GCB, 43 of which were BCL2-, suggesting that this marker plays a 
predominant role at defining this COO subgroup. 
 
The Tally algorithm307 has the unique feature of attributing similar weight to GCB and 
post-GCB specific markers for allocation. There was a predominance of ABC cases 
(110, 78%) in our cohort. In 34 cases LMO2 expression had to be used for decision, 
being positive in half of the cases.  
 
Finally Visco et al.308 recently launched another method with an increased overlap 
with GEP data. Similarly to Hans, CD10 plays the central role for GCB allocation (41 of 
the 53 GCB patients were CD10+). Regarding non-GCB allocation, BCL6 plays less of a 
role than in the Hans classifier as in only 15 CD10-/FOXP1- patients was BCL6 
expression taken into account for allocation. As with the Choi classifier, there was 
enrichment for older patients in the Visco ABC subset (p=0.02).  
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To address the question of how an individual case is classified across all methods, we 
then performed a parallel classification of all tumours using the nine COO algorithms.  
 
Results for all classifiers were available for 242/298 cases (81%). Surprisingly, only 
4.1% of the tumours were classified as GCB by all methods. The degree of agreement 
in allocation of patients to the non-GCB group was significantly higher, with 21% of 
patients being allocated to this group by all methods and 20.6% being classified as 
non-GCB by all methods except one - either the Choi (2 cases), the modified Choi (2 
cases), the Natkunam (33 cases), or the Muris (13 cases) algorithms. Of note, the last 
two are the only methods in which allocation to the GCB subset was higher.  
 
We then sought to assess pair wise agreement using the general kappa statistics, a 
method that tests for inter-scoring reliability. The kappa is considered a robust 
statistical method since it takes into account the agreement occurring by chance. Fig. 
3.2 illustrates the strength of agreement among all scoring systems. Poor and fair 
kappa values were detected in 44.4% on pair wise concordance assessment; and in 
only 20% was kappa excellent or good. The Natkunam algorithm is the least 
concordant with the remaining, showing a poor agreement with four algorithms and 
only fair agreement with the other four. The highest level of agreement was found 
between the Choi and the Visco algorithms (Kappa=0.85). From all the methods 
investigated, the Hans and the Hans modified exhibited the highest degree of 
consistency with other algorithms.
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Kappa Hans Hans* Nyman Choi Choi* Natkunam Tally Muris Visco 
Hans          
Hans*          
Nyman          
Choi          
Choi*          
Natkunam          
Tally          
Muris          
Visco          
 
 Poor Fair Moderate Excellent Very good 
K < 0.20 0.21 - 0.40 0.41 - 0.60 0.61 - 0.80 0.81 - 1.00 
 
Figure 3.4 Pair wise agreement according to kappa statistics.  
*modified 
 
 
3.4.3 Survival Analysis 
As the IPI remains the most robust prognostic discriminator in DLBCL, we assessed 
whether its individual variables or subgroups had value in predicting outcome in the 
R-CHOP cohort. On univariate analysis, age, stage, performance status and IPI groups 
were significant in predicting OS, whereas number of extranodal sites, staging, 
performance status and IPI groups were significant in predicting EFS.  
No immunohistochemical marker alone achieved significance for outcome prediction 
in R-CHOP treated patients. Although patients expressing FOXP1 (60% cut-point) had 
a lower OS (72% vs 82%, p=0.09), and patients expressing BCL2 had a lower EFS (57% 
vs 77%, p=0.06), none reached significance on forward stepwise multivariate analysis 
together with either the IPI factors or the IPI subgroups.  
 
As shown in Table 3.5, none of the algorithms rival the IPI for OS or PFS prediction in 
R-CHOP treated patients. We also looked at survival differences between patients 
classified as either GCB or non-GCB by all methods versus the remaining patients with 
heterogeneous classification. Although OS was similar among groups, 3-year EFS was 
significantly better for the GCB set (100%) compared to the ABC set (78%) or the 
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remaining patients (60%)(p=0.004). 
 
As survival was similar across all classifiers, we sought to determine whether outcome 
stratification could be improved by analysing the expression of additional proteins 
not included in the original algorithms. If this was demonstrated, it would suggest 
that IHC classifiers are over-simplified methods for the purpose of outcome 
stratification. As an example, BCL2 expression was associated with worse PFS in GCB 
cases only, when incorporated into the Hans (54% vs 88% p=0.006), Hans modified 
(52% vs 83%, p=0.009), Visco (54 vs 86%, p=0.01), Natkunam (45% vs 78% p=0.02) 
and Choi modified (53% vs 86% p=0.02) methods. Similarly, expression of the post-GC 
markers FOXP1 and MUM1 was associated with worse survival in those cases defined 
as GCB using the Hans and Natkunam algorithms (data not shown). 
 
 
Table 3.5 Survival analysis according to clinical characteristics, IPI and COO classifiers 
Variables 3-year OS  3-year PFS  
         %  p-value           %     p-value 
Sex (male vs female) 74 vs 77 NS 58 vs 72 NS 
Age (<60 vs >60 y) 83 vs 68 0.03 66 vs 64 NS 
Number extranodal sites (<2 vs ≥2) 79 vs 53 0.09 71 vs 33 0.003 
Ann Arbor stage (I-II vs III-IV) 87 vs 63 0.001 83 vs 49 <0.001 
ECOG performance status (<2 vs ≥2) 81 vs 48 <0.001 73 vs 23 <0.001 
LDH (low vs high) 79 vs 72 NS 73 vs 60 NS 
International Prognostic Index  
(Low/ Low-int/ High-int/High) 
90 vs 72 vs 
73 vs 45 
<0.001 79 vs 80 vs 
53 vs 21 
<0.001 
Algorithms (GCB vs non-GCB/ABC)     
Hans 77 vs 74 NS 66 vs 66 NS 
modified Hans 75 vs 75 NS 63 vs 66 NS 
Choi 75 vs 75 NS 63 vs 62 NS 
modified Choi 74 vs 75 NS 63 vs 62 NS 
Muris 79 vs 71 NS 67 vs 64 NS 
Nyman 76 vs 75 NS 75 vs 64 NS 
Tally 78 vs 73 NS 72 vs 64 NS 
Natkunam 71 vs 78 NS 59 vs 74 NS 
Visco-Young 75 vs 75 NS 62 vs 68 NS 
OS: overall survival; PFS: progression-free survival; ECOG: Eastern Cooperative Oncology 
Group; LDH: lactate dehydrogenase; IPI: International Prognostic Index; Low-int: low-
intermediate; High-int: high-intermediate; NS: not significant
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3.5 Discussion 
The tumour molecular profiling is for the first time opening prospects for 
personalized therapy in DLBCL. Clinical trials utilizing GEP for COO allocation are 
underway and will clarify the utility of targeted therapies in the poor risk ABC 
subtype. However, the applicability of molecular classification into clinical practice 
will require a robust, affordable and reproducible methodology for designation of 
molecular sub-types with clinical and prognostic relevance.  
 
It was hypothesized that IHC approaches would be useful surrogates for classification 
of DLBCL subsets, would be readily applicable in clinical practice and would be 
incorporated into diagnostic work-up within haematopathology clinical laboratories. 
However, based upon previous work and the data presented here, we suggest that 
much work needs to be done to standardize IHC methods, which currently should be 
considered unreliable surrogates for molecular classification in DLBCL.  
 
We provide for the first time a systematic analysis of the nine IHC COO classification 
algorithms in a representative dataset of diagnostic DLBCLs. This study compares 
single marker and algorithm distribution with previous reports and analyses the 
survival impact of these data in conjunction with the well-established clinical 
prognostic score IPI. However, the main objective was to describe how each 
individual sample scored by all classifiers. This analysis does not imply any 
comparison across samples from different tumours (with inherent differences in the 
quality of the material and consequently in the results obtained), but only how each 
method performs within the same tumour sample to assign the sample to a specific 
sub-type. Whereas this study would have been enhanced by the availability of GEP as 
the “gold-standard”, the methodology employed here does not require such a 
comparison, since we sought to examine the robustness of the more commonly used 
IHC algorithms and their ability to classify DLBCL compared with each other. 
Using the kappa test, a statistical method that takes into account the agreement 
occurring by chance, we document an extremely low concordance across all 
classifiers, especially for cases more likely to represent the GCB subtype (only 6%). 
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Scoring allocation appeared more consistent across all methods for the non-GCB 
group (but still as low as 25%), confirming the data from previous groups using paired 
GEP and IHC.79,307,311 
 
Classifier distribution was heterogeneous. Allocation to the GCB subtype was less 
frequent compared to the non-GCB, in line with the findings of others.310,311 Using the 
most common Hans classifier, a proportion of molecularly defined GCB cases are 
likely being allocated to the non-GCB group due to higher expression of MUM1. The 
Nyman method appears to have too low specificity for detection ABC cases as only 18 
patients were considered non-ABC using this method. Similarly, a predominant 
number of cases were classified as ABC using the Tally method, driven by the high 
expression of FOXP1 and MUM1 in our series. The Choi classifier is too complex, as 
both GCET1 and MUM1 had almost no impact on patient allocation. This method is in 
our experience very similar to that of Visco.  
We report low but significant correlations of expression of GCB markers, including 
CD10, BCL6 and LMO2. BCL6 expression was associated with both GCB and ABC 
markers, supporting the evidence that BCL6 expression is not entirely restricted to 
GCB or ABC B-cells as both can harbour genetic aberrations that drive protein 
overexpression. However BCL6 detection required an amplification step, making it 
difficult to standardize across laboratories. 
We identified a smaller proportion of cases expressing GCET1 than previously 
reported. In the original study306 an amplification method was used to enhance 
GCET1 staining, while others used a different antigen retrieval strategy.307 This, 
together with the staining pattern of GCET1, might explain our results. However, as 
this antigen has been studied by relatively few groups, we propose that more 
experience has to be gathered on patterns of expression and optimal staining 
procedures for GCET1 before this is widely incorporated into DLBCL classification. The 
expression of the post-GC marker MUM1 is incorporated in most of the algorithms, in 
spite of the fact that IHC assessment for MUM1 is highly sensitive to laboratory 
variations and inter-interpreter scoring. We noted >30% expression of MUM1 in a 
higher proportion of patients than previously reported and this cannot be explained 
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by common reasons such as non-specific cytoplasmic background staining and target 
cell artefacts.314 Choi et al. claimed that a higher cut-off level of expression of 80% 
was required to achieve high specificity for ABC cases. Using this cut-point, 42% of 
our patients were deemed positive for MUM1 expression, in keeping with Choi’s 
data. This, however, highlights the difficulties of standardizing results based upon 
arbitrary cut-offs.  
 
We also documented significant differences in the proportion of cases expressing 
FOXP1 in 80% of malignant B-cells between the Portuguese and the English datasets. 
Although the biopsies were obtained in the two countries, staining and analysis were 
performed in the same laboratory. Whether this is a reflection of different fixation 
and storing methods, the use of arbitrary cut-offs or a true ethnic difference still has 
to be demonstrated and further population studies will be required to address this 
question. 
 
As has already been demonstrated in other cohorts324, we detected associations 
between clinical factors and protein expression. In both Choi and Visco classifiers, the 
ABC subset was enriched for older patients. This suggests that clinical prognostic 
factors might interact with biological predictors such as the COO classification for 
DLBCL.  
Many authors have questioned the prognostic impact of IHC classifiers. Thus, our 
secondary aim was to analyse survival according to these algorithms. It is recognized 
that samples collected over a long period of time have differences in quality that 
might impact adequate interpretation of immunostaining results. This is particularly 
important when survival analysis is undertaken. As only recently diagnosed R-CHOP 
treated cases were included, this problem is overcome in our studies. None of the IHC 
classifiers was able to predict outcome in this series. Others, particularly using the 
Hans method, previously demonstrated this. We acknowledge that the R-CHOP series 
analysed (151 cases) is limited and the number of events registered during the study 
period render it underpowered to detect differences in survival between the two 
groups. However, we believe this fact supports our hypothesis that IHC classifiers are 
Chapter 3 Results 
136 
inadequate to recognize the molecularly defined DLBCLs. Analysing individual 
markers not included in the algorithms can improve outcome prediction, as has been 
demonstrated by us and others97 using BCL2.  
Our study challenges the use of any IHC COO classifier in DLBCL, and it is important to 
resolve this, as this biological feature provides not only prognostic information but 
also offers the window for targeted therapies to improve outcome in this disease. 
 
Further studies approaching the COO molecular classification of DLBCL should only be 
made in the context of prospective clinical trials.  A large number of retrospective 
studies, including ours, have been published that had so far no impact on changing 
patient’s management apart from questioning the utility of IHC for this purpose. 
There is, together with our data, enough evidence to suggest that at the present time 
IHC is not a reliable surrogate of the molecular classification of DLBCL. Taking our 
data into consideration, it isn’t rational to recommend any specific classifier for 
further use in the clinical practice. Despite the advances in reagents and automation, 
the use of IHC is hampered by variable consistency, reduced reproducibility, and 
quality assurance disparities, resulting in poor concordance, validation and 
verification. Once a concerted multi-institutional effort towards a precise 
standardization of every single procedural step known to impact on IHC results is 
made, this technology might reunite potential for use in surrogate studies such as the 
COO. This would be ideal, as IHC is an inexpensive technology that can be entirely 
manually performed and that requires no batching of samples. The turnaround of the 
results is also extremely acceptable.  
Meanwhile simpler and more affordable molecular technologies are being explored 
for the molecular classification in DLBCL. FFPE samples from patients enrolled in the 
REMoDLB trial are being studied using the Illumina whole-genome DASL technology, 
which enables performing GEP in low yield, partially degraded RNA samples. 
Validation of GEP in FFPE tumour biopsies is in fact crucial for the clinical setting and 
has been previously done. More recently the Nanostring nCounter technology has 
been applied in FFPE samples from the LLMPP.79 The authors report a 20-gene GEP-
based assay (Lymph2Cx) developed with the objective of accurately assigning samples 
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to the same COO group as with Affymetrix-based original method. The new assay is 
robust, accurate and results can be retrieved in less than 36 hours. Importantly, both 
the DASL and the nCounter assays require low nucleic acid input and guarantee highly 
reproducible results for a much affordable cost than the original array technologies. 
However it needs to be taken into account that such assays demand sample batching, 
which might not be feasible in the clinical setting. Profiling individual patients might 
hence be more costly than suggested.  
Having in mind that the protocols recommended by the companies selling molecular 
biology solutions are very detailed and precise, it is not surprising that independent 
groups obtain similar end products. The problem lies on the analysis. Scott et al. 
describe in the supplementary data one phenomenon that illustrates this issue.  As is 
well known, a number of samples, generally described as “unclassified”, fail to be 
allocated to either the GCB or the ABC groups. The authors report that around 15% of 
samples “migrated” in and out of the “unclassified” group between the Lymph2Cx 
and “gold standard” GEP method. This significantly decreases the concordance 
between the 2 methods to around 80%, similar to the concordance reported with IHC 
algorithms. This phenomenon highlights for misclassification even with GEP and has 
fundamental consequences in the context of clinical trials testing agents with 
selective activity to a given molecular subtype.  
In conclusion, there is a lack of standardized methodology for array analysis, which 
can lead to variable results both at the inter- and intra-laboratory level. This issue, 
which may impact on results, but most importantly, patient care, is generally 
unreported and should be a matter of future debate. 
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Chapter 4 Revisiting the immune microenvironment of DLBCL using a 
tissue microarray and immunohistochemistry: robust semi-automated 
analysis reveals CD3 and FoxP3 as predictors of response to R-CHOP 
 
 
4.1 Introduction 
As highlighted in previous chapters, rituximab primary refractory DLBCL has emerged 
as a particularly difficult group to cure. Furthermore, approximately half of the 
patients will eventually relapse after R-CHOP. As such, there is an urgent need for 
novel therapeutic approaches in these patients.  
 
The role of the microenvironment in DLBCL biology and outcome gained relevance 
when independent GEP studies defined distinct biological traits that were driven by 
the non-malignant cells in the tumours.12,34,74,76 Data supervised analyses delineated 
prognostic signatures that are enriched in genes encoding for ECM components, T-
cell and macrophage markers, and angiogenic mediators. Importantly, all studies 
suggest that a high expression of genes characteristic from the non-malignant cells in 
the microenvironment confers a better outcome in DLBCL. Functional validation of 
recurrent mutations compellingly relates DLBCL biology with inflammation and 
immune surveillance.325 These studies identify the lymphoma microenvironment and 
host inflammatory response as defining features in DLBCL. 
 
However, GEP data requires further validation and needs to be made simpler in order 
to be useful for clinical trial design and for clinical practice. Many methods can be 
used to validate GEP information. Most authors have focused on the use of IHC to 
enumerate and functionally characterize the microenvironment in DLBCL and other 
lymphomas. IHC can be extended to clinical practice, which makes it highly attractive 
as a diagnostic and prognostic tool. Nevertheless the results published regarding IHC 
analysis of the immune microenvironment in DLBCL are often 
contradictory.278,279,282,283,326,327 The use of inconsistent methodology likely explains 
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these results. Moreover, it is known that it is difficult to count reproducibly cells 
across large tumour areas manually. Categorization of the density of cell infiltration is 
used to overcome this problem, but results might be misleading and there is a lack of 
validation of cutpoints. 
 
 
4.2 Objectives 
The main scope of our study was to revisit the immune microenvironment of 
diagnostic samples of 309 patients with DLBCL by two different methods of semi-
automated image analysis. The semi-automated analyses have the advantage of 
being capable of analysing large tumour areas, making them ideal for prognostic 
exploration of IHC studies. We expected to detect a high degree of inconsistency 
between the results of the two systems, similar to what is reported when manual and 
automated analysis is compared. Finally, we aimed at describing the prognostic role 
of different immune biomarkers in 161 R-CHOP treated cases. Total T-lymphocytes 
and their functional subsets and macrophages were studied.  
 
 
4.3 Methods 
4.3.1 Patient characteristics 
Patient selection,  clinical characteristics and outcome of the patients included in this 
study were already described. As in the previous chapter, cutpoint and outcome 
analysis was based on the R-CHOP dataset.  
 
4.3.2 Tissue Microarray and Immunohistochemistry 
Ethical approval for this study was obtained from Local Regional Ethics Boards. 
Sample collection followed informed consent in accordance to the declaration of 
Helsinki. Triplicate or duplicate 1-1.5 mm2 cores were taken from representative 
tumour regions identified on H&E stained sections and confirmed by CD20 staining. 
Chapter 4 Results 
140 
Dewaxed paraffin sections were rehydrated, blocked and subjected to heat antigen 
retrieval. CD3, CD4, CD8, CD68, TIA1 and FOXP3 were stained using a peroxidase-
labelled system (Super-Sensitive Polymer-HRP IHC Detection System, BioGenex) on 
the Dako-autostainer. Tonsil sections were simultaneously stained for all antibodies. 
Finally, sections were counterstained with haematoxylin. Detailed information on the 
staining protocol is provided in the Materials and Methods section. Primary 
antibodies and conditions of use are provided in Table 4.1. Heat induced antigen 
retrieval was used for all antibodies.  
 
 
 
Table 4.1 Primary antibodies and conditions of use 
Antibody Clone Species Source Dilution 
CD20 L26 mouse Dako 1/2000 
CD3 SP7 rabbit 
Lab Vision, 
Thermo Scientific 
1/500 
CD4 4B12 mouse 
Novocastra, 
Leica Biosystems 
1/500 
CD8 C8/144B mouse Dako 2,5/1000 
CD68 KP1 mouse Dako 1/8000 
FOXP3 263A/E7 mouse Abcam 1/100 
TIA1 2G9A10F5 mouse 
Immunotech, 
Beckman Coulter 
1/400 
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4.3.3. Semi-automated Image analysis  
4.3.3.1 Ariol SL-50 visual analysis software 
Slides were scanned using an Olympus BX61 microscope. Representative regions 
were selected manually using the tools available on the Ariol Software. Fibrotic and 
necrotic areas were excluded so that only representative tumour areas were brought 
forward for analysis (Figure 4.1).  Whole cores with less than 50% of tumour 
representation were also completely excluded from analysis.  
Using the methodology detailed in Chapter 2 and illustrated in Figure 2.1, the number 
of positive cells as well as the area of DAB stained per area of lymphoma tissue was 
estimated. The values obtained were corrected to a 1mm2 area and a mean for each 
patient was calculated.  
 
4.3.3.2 Pannoramic Viewer System 
Slides were scanned using the Pannoramic 250 Flash II scanner (3DHISTECH, 
Hungary). Meticulous marking of representative tumour areas was done on the 
Pannoramic Viewer computer interface and individual areas quantified. Using the 
DensitoQuant module the number of DAB stained pixels per area selected was 
quantified. This module distributes pixels to 3 grades of positive classes by their RGB 
values. We used only the top red and orange levels for identification of stained areas. 
After adjusting the brown tolerance and the score levels an optimal script was saved 
for each antibody. A preliminary analysis was undertaken to confirm the capacity of 
the script to identify DAB stained cells in independent cores. This optimal script was 
then applied for analysis in all areas. 
 
4.3.4. Cutpoint Determination 
Cutpoint discrimination was assessed using the recursive splitting algorithm in the 
rpart package (http://cran.r-project.org/web/packages/rpart/index.html) within the R 
statistical software.328  
To achieve a simple subdivision into two classes, the algorithm has been forced to 
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obtain a single split for each considered measurement, with a splitting criterion based 
on the Gini index. For robustness, only splits yielding ≥30 individuals in the smallest 
group by the recursive algorithm were considered. Two to ten cross validations have 
been performed for each measurement to check for consistency of each cutpoint, 
showing no modifications in the outcomes.  
A more comprehensive explanation of this method is provided in Chapter 2. Dr 
Emanuele Mazolla and Dr Donna Neuberg performed this analysis. 
 
 
4.3.5 Statistical Analysis 
Differences between patient’s groups were tested using χ2 or Fisher’s exact test, 
when appropriate. Association between pairs of biomarkers has been tested using 
the Fisher’s exact test. Pearson’s correlation was calculated for all IHC variables and 
clinical parameters.  
 
The outcomes measured were: OS, defined as the time from diagnosis to death from 
any cause, with surviving patients censored at last follow-up; and PFS, defined as time 
from diagnosis to failure of treatment (including not achieving CR or relapse after CR) 
or death from any cause. Median follow-up was calculated for patients alive at last 
follow-up. For every quantified measurement survival has been estimated using 
Kaplan-Meier estimators, and differences between groups of the same measurement 
have been assessed with the Log-rank test. To accommodate for the optimization 
method within the splitting algorithm we considered as significant only Log-rank p-
values <0.01.  
Multivariate analysis was performed using a Cox proportional hazards model 
(stepwise backward and forward methods) including IHC parameters together with 
the clinical factors included in the IPI with prognostic significance on univariate 
analysis. Statistical significance was set as p<0.05. Statistical analysis was performed 
using SPSS version 19.0 (SPSS) and Prism version 5.03 (GraphPad Software) and R 
version 3.0.2. 
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Figure 4.1 Selection of tumour representative regions.  
Fibrotic and necrotic areas were excluded using the tools available on the Ariol system.
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4.4 Results 
4.4.1 Heterogeneous density of immune cells in the microenvironment of DLBCL 
With minor exceptions, cells staining for the biomarkers investigated were 
homogeneously distributed across tumour sections. This was anticipated given the 
diffuse histological pattern of DLBCL and validates interpretation in partially 
represented cores where viable tissue is properly represented.  
 
As expected, patients with DLBCL had heterogeneous infiltration of total T-cells, their 
subsets and macrophages at diagnosis (Table 4.2 and Figure 4.2).  
 
CD3+ total T-cells were the most abundant cell type studied. We identified a balanced 
proportion of CD4 and CD8 towards a predominance of CD8+ T-cells when all cases 
were analysed simultaneously (Figure 4.2). The median ratio of CD4/CD8 for all 
measures taken was between 0.36 - 0.68. Using the antibody stated in Table 4.1, CD4 
expression was typically dim and more heterogeneous. Moreover the expression of 
CD3 and CD8 correlated better than the expression of CD3 and CD4 (Pearson’s-r for 
+cells/area 0.73 vs. 0.50, respectively). Although CD4 heterogeneity might represent 
biological inter-patient differences, a failure of IHC methods to properly identify CD4+ 
cells has to be considered as a possibility, specially when using a single antibody. 
 
FoxP3 is a nuclear CD4+ T-cell transcription factor expressed by regulatory and 
activated T-cells. Its expression is clear and discrete and therefore training and 
analysis was facilitated. As can be appreciated in Figure 4.2, FoxP3 expression shows 
a skewed distribution. The number of cells expressing FoxP3 varied between samples 
(median 228.6, range 0 - 3197), but less so than other markers (e.g. TIA1, median 
1648, range 31.7 - 5859).  
 
TIA1 is a cytoplasmic marker expressed by NK-cells and by cytotoxic T-cells 
independently of their activation status. CD56 staining was done to explore the 
extent of infiltration by NK-cells and was almost absent in our series (data not 
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shown). The absence of NK-cells suggests that TIA1 expression is specific to T-cells. 
However, the mean and standard deviation distribution suggests it is more abundant 
than CD8. This might be related to the punctate cytoplasmic expression of TIA1.  
 
CD68 is a cytoplasmic lysosomal protein expressed in all tissue macrophages.329 Large 
and interdigitant cells such as macrophages are difficult to quantify. Image analysis 
training was challenging and focused on capturing the areas of dark brown staining 
present in the cell bodies. CD68 expression was particularly heterogeneous in this 
cohort. 
 
 
 
 Table 4.2 Descriptive statistics showing heterogeneity of expression of biomarkers 
 Ariol Pannoramic Viewer 
 
Patients 
assessable, 
Number (%) 
Cells/mm2, 
Median 
(Range) 
% Stained 
area, Median 
(Range) 
Patients 
assessable, 
Number (%) 
Nr pixels/mm2, 
Median (Range) 
CD3 258 (84) 
2603 
(50-7480) 
11.8 (0-56.1) 243 (79) 
1.2x106 
(1.5x104-2.4x1012) 
CD4 206 (67) 
438.4 
(0-6730) 
5.23 (0-61.8) 231 (75) 
2.3x105 (147.4-
4.5x106) 
CD8 251 (81) 
857.5 
(25-3732) 
6.44 (0-37.6) 252 (82) 
5x105 (6566-6.6 
x107) 
FOXP3 253 (82) 
228.6 
(0-3197) 
0.68 (0-13.6) 246 (80) 
3.7 x104 (25.2-1.3 
x106) 
TIA1 249 (81) 
1648 
(32-5859) 
9.6 (0-80.5) 250 (81) 
1.6x105 (1079-2.5 
x106) 
CD68 252 (82) 
1380 
(85-6320) 
7.1 (0-44.4) 249 (81) 
6.5x105 (1.5x104-
6.1x106) 
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Figure 4.2 Biomarker distribution.  
A: Distribution of cases according to number of positive cells per area of viable tumour (mm2) as measured by the Ariol system. B: Distribution of 
cases according to % stained area as measured by the Ariol system. C: Distribution of cases according to number of stained pixels per area (µm2) as 
measured by the Pannoramic Viewer system. D: Distribution of cases for FoxP3 according to all parameters analysed. Bars represent the median 
values. 
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4.4.2 Excellent concordance between two systems of semi-automated image 
analysis for the characterization of the microenvironment 
Multiple studies have shown that manual quantification of abundantly expressed IHC 
markers is inconsistent. To this end a number of semi-automated systems for IHC 
analysis have been launched that allow analysing large stained areas and increase 
results consistency. However each one has its own features and scripts for analysis 
and it is unknown how robust results are when obtained from different computerized 
systems.  
 
We therefore expected to detect considerable inconsistency between two semi-
automated systems that use different methods of counting. This would have 
implications to the future of IHC studies utilising automated analysis. To test this 
hypothesis we examined the immune microenvironment in DLBCL by the Ariol and 
the Pannoramic Viewer systems. 
 
Firstly we compared two different measures obtained from the Ariol system: a) 
number of positive stained cells/ area of viable tumour and b) % stained area for each 
marker. Against our own expectations, we detected an excellent correlation between 
the two Ariol measures for each of the markers studied (Pearson’s r-values between 
0.92 and 0.98, p <0.0001) (Figures 4.3). Importantly the correlation was high even for 
the cytoplasmic markers TIA1 and CD68, for which training was more challenging and 
low interobserver agreements have been reported. These results suggest that, by 
applying our methodology, any of the two measures retrieved by the Ariol system can 
be used for future IHC studies.  
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Figure 4.3 Expression correlation for CD3, FoxP3 and TIA1.  
A-C: Correlation plots between the number of positive cells/area of viable tumour and % stained area for each case according to the Ariol System. D-
F: Correlation plots between the % stained area as quantified by the Ariol System and the number of positive pixels/area according to the 
Pannoramic Viewer.
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Figure 4.4 Expression correlation for CD4, CD8 and CD68.  
A-C: Correlation plots between the number of positive cells/area of viable tumour and % stained area for each case according to the Ariol System. D-
F: Correlation plots between the % stained area as quantified by the Ariol System and the number of positive pixels/area according to the 
Pannoramic Viewer. 
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We then compared the Ariol results with those obtained from the Pannoramic Viewer 
System, where quantification of the DAB stained pixels/area was performed. 
However, with the Pannoramic Viewer the tumour density is not taken into account 
and a precise selection of representative tumour areas is more demanding. Even so, 
we surprisingly detected significant correlations between the data retrieved from the 
two systems (Figure 4.3 and 4.4, D-F). Correlations were excellent for T-cells markers 
(Pearson’s r-values between 0.89 and 0.92) and more modest for cytoplasmic 
proteins (CD68, r - 0.77; TIA1, r - 0.67). This indicates that, contrary to manual 
analysis of IHC, semi-automated systems are robust and preferable for future IHC 
studies.  
 
4.4.3 CD3 and FoxP3 are potential predictors of response to R-CHOP 
Our secondary aim was to investigate the prognostic impact of the immune 
biomarkers in DLBCL. For this purpose we specifically selected the 161 R-CHOP 
treated dataset. Table 4.3 details survival, hazard ratios, confidence intervals and p-
values for all significant variables on univariate and multivariate analysis. 
 
We did not detect any interactions between the clinical variables detailed in Table 3.1 
and the biomarkers studied (data not shown). We applied strict quality criteria to 
image analysis to ensure robustness and reproducibility of the techniques. This meant 
that images were rejected for a number of markers that did not meet these criteria. 
The most common reason for exclusion was insufficient core size or degradation. 
 
The following clinical variables were predictive of worse OS by univariate analysis 
(Table 4.3): age >60 years (P=0.02), stage III-IV (P=0.001) and ECOG performance 
status ≥2 (P=0.0001). Patients with high IPI had a lower probability of survival 
(P=0.001). Achieving a complete response to R-CHOP was the strongest prognostic 
variable on univariate analysis of this cohort (P<0.0001). Using the rpart package 
within the R software and a recursive splitting algorithm according to the criteria 
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described previously, no cutpoint discrimination could be established for the studied 
biomarkers that helped discriminating patients with different OS. 
 
Regarding PFS, patients with stage III-IV (P=0.001), ECOG performance status ≥2 
(P<0.0001), ≥2 extranodal areas (P=0.001) and IPI ≥3 (P= 0.001) had a lower 
probability of survival (Table 4.3). Patients treated at Bart’s also had a lower PFS 
(three-year PFS of 52.4% vs 68.3%, P=0.03) compared to the ones treated at IPO. 
Using the rpart package we defined single cutpoints for CD3 and FoxP3 that 
segregated patients with different cell density and PFS. Although the number of 
pixels/area for CD3 presents with a Log-rank p-value slightly above the established 
0.01 limit for significance, the robustness of the split is confirmed by the 
corresponding 2x2 table in Figure 4.4. For both biomarkers, patients with a higher cell 
density had a higher PFS after R-CHOP (Figures 4.5 and 4.6). 
 
Using CD3+ cells/area, the median PFS was 78.7 months for patients with high CD3+ 
cell density  (>1897 cells/mm2, 86 patients) compared to 28 months for the remaining 
(p=0.005) (Figure 4.5C). When % stained area of CD3 was considered, 81 and 54 
patients had high and low density. For these, median PFS was 82.1 vs 29.1 months, 
p=0.001 (Figure 4.5D). Finally, 64 and 68 patients were included in the high and low 
cohorts according to the Pannoramic Viewer analysis. Again, patients with a high CD3 
infiltration exhibited a better median PFS (78.7 vs 30.3, p= 0.01) (Figure 4.5E).  
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Figure 4.5 CD3 Expression and Outcome.  
A&B: Examples of low (A) and high (B) expression of CD3. Magnification x20 and x40. CD3 expression is shown by HRP-DAB immunostaining. C-E: 
Kaplan Meier PFS analysis of patients based on low or high CD3 expressing cells/m2 (C), % stained area of CD3 (D) and number of stained pixels of 
CD3/area (E). F-H: Contingency tables representing the distribution of patients into low and high subgroups for each of the analyses.  
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We were also able to establish a cutpoint for each of the FoxP3 analyses performed 
using rpart (Figure 4.6). Patients allocated to the high FoxP3+ cohorts had significantly 
higher CD3 expression compared to the remainder (p=0.0001). 78/137 patients were 
allocated to the high FoxP3+ cell/area of viable tumour. High FoxP3 nuclei density was 
associated with a better median PFS (89.1 vs 26.2 months, p=0.0002) (Figure 4.6C). 
Similarly, patients in both the high FoxP3 % stained area (77/137 patients) and the 
high pixel number/area (72/132 patients) cohorts had a prolonged median PFS 
compared to patients in the low expression cohorts (undefined vs 27.9, and 82.1 vs 
27.1 months, respectively) (Figures 4.6D and 4.6E).  
 
Finally a Cox regression analysis was used to model PFS using the R-CHOP dataset 
(Table 4.3). All clinical variables significantly associated with PFS on univariate 
analysis together with the categorical data for CD3 and FoxP3 were included in the 
model. Using both backward and forward stepwise methods, the variables retaining 
independence for PFS prediction were stage III-IV and CD3 density quantified as % 
stained area of viable tumour according to Ariol. FoxP3 did not remain as 
prognostically significant on multivariate analysis. 
 
Since we have used different parameters (+ cells/area of viable tumour, % stained 
area and number of brown pixels/area) to quantify each of the biomarkers, rpart 
retrieved different discriminatory cutpoints for each. Presuming that cohort 
discrimination is truly based on a biological impact of the immune cell infiltration and 
not a reflection of a methodology induced bias, we hypothesized that the agreement 
in allocation of each individual patient to high and low subgroups for each CD3, FoxP3 
or TIA1 analyses would be high. To test this hypothesis, we plotted consensus 
matrices and explored the degree of allocation agreement for each subgroup. 
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Figure 4.6 FoxP3 Expression and Outcome.  
A&B: Examples of low (A) and high (B) expression of FoxP3. Magnification x20 and x40. C-E: Kaplan Meier PFS analysis of patients based on low or 
high FoxP3 expressing cells/m2 (C), % stained area of FoxP3 (D) and number of stained pixels of FoxP3/area (E). F-H: Contingency tables 
representing the distribution of patients into low and high subgroups for each of the analyses. 
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As can be appreciated in Figures 4.4 F-H and 4.5 F-H, allocation consistency is 
extremely good for CD3 and FoxP3 (Fisher’s exact test p-value <0.0001 for each 
presented table), even when the Ariol and Pannoramic Viewer results were 
compared. This suggests these biomarkers as predictors of outcome after R-CHOP 
and validates recursive partitioning as an adequate method for cutpoint selection in 
continuous data with unknown demographic distribution. 
 
 
 
Table 4.3 Univariate and multivariate survival analysis 
For IHC data, all hazard ratios with corresponding 95% confidence interval were calculated 
considering the HIGH versus LOW density for each variable. Results from backward stepwise 
(likelihood ratio) based on 120 cases. m: months; CI: confidence interval; Nr: number 
 
UNIVARIATE ANALYSIS 
Overall Survival 
Variable Median survival (m) Hazard ratio (95% CI) P 
Age >60 years 92.1 vs undefined 1.96 (1.13, 3.34) 0.02 
Stage III-IV 82.9 vs undefined 3.33 (1.51, 4.54) 0.0005 
ECOG PS ≥2 30 vs undefined 3.84 (1.96, 9.09) 0.001 
IPI ≥3 81 vs undefined 2.63 (1.44, 4.76) 0.001 
Not achieving CR 17.2 vs undefined 6.66 (3.44, 14.3) <0.0001 
Progression-free survival 
Stage III-IV 34.2 vs 89.1 2.27 (1.42, 3.57) 0.0005 
ECOG PS ≥2 11.1 vs 78.7 4.16 (1.85, 9.09) 0.0005 
≥2 extranodal areas 10.5 vs 78.7 2.78 (1.43, 5.55) 0.003 
Centre ( Bart’s vs IPO) 81 vs 52.9 1.6 (1.03, 2.59) 0.03 
IPI ≥3 24.9 vs 82.1 2.43 (1.47, 4.0) 0.0004 
CD3 +cells/area 78.7 vs 27.9 0.50 (0.31, 0.83) 0.005 
CD3 %stained area 82.1 vs 29.1 0.46 (0.28, 0.75) 0.001 
CD3 Nr pixels/area 78.7 vs 30.3 0.52 (0.31, 0.88) 0.01 
FoxP3 +cells/area 89.1 vs 26.2 0.40 (0.24, 0.67) 0.0003 
FoxP3 %stained area undefined vs 27.9 0.43 (0.26, 0.71) 0.0008 
FoxP3  Nr pixels/area 82.1 vs 27.9 0.45 (0.27, 0.76) 0.002 
MULTIVARIATE ANALYSIS FOR PFS 
Variable  Hazard ratio (95% CI) P 
Stage III-IV  3.4 (1.72, 6.66) < 0.0001 
High % stained area CD3  0.42 (0.24, 0.73) 0.003 
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4.5 Discussion 
Developing robust prognostic biomarkers that are able to discriminate R-CHOP 
refractory patients is a research priority in DLBCL. As can be appreciated in our data 
and as expected, response to R-CHOP appears as a robust prognostic indicator of OS 
or PFS.  
 
GEP studies suggested that the microenvironment has the potential for providing 
some of such prognostic biomarkers. However, a number of obstacles need to be 
acknowledged: 1) biomarkers need to be easily studied in any laboratory; 2) 
validation processes need to be robust and done under multi-institutional projects 
and clinical trials; 3) microarray technology is still reserved to the research setting and 
lacks well standardized procedural protocols and analysis; 4) only a few markers 
selected for the GEP studies mentioned have been evaluated by independent groups 
using different methodologies; 5) functional studies, the only ones able to provide 
definitive biological explanations towards the prognostic impact of specific molecules, 
are difficult to perform in the context of the lymphoma microenvironment. 
 
IHC can be extended to the clinical practice, which makes it highly attractive as a 
diagnostic and prognostic tool. Nevertheless the results published regarding IHC 
analysis of the immune microenvironment in DLBCL and other lymphomas are 
contradictory. This can be explained by several reasons, the most important being the 
study of patient cohorts which are not representative of the disease the way is 
currently managed and, most importantly, by the use of inconsistent methodology. It 
is well recognized by expert pathologists that manual scoring of IHC staining is 
difficult to standardize, particularly when large tissue areas are analysed. Semi-
automated image analysis is available, is ideal for scoring vast areas more 
representative of the microenvironment, and could help in improving scoring 
reproducibility. However each one has its own features and scripts for analysis and it 
is unknown how robust results are when obtained from different systems. 
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This study compares two different methods of semi-automated analysis for IHC 
staining using as a model the microenvironment of DLBCL and examining a large 
number of patients and area of diagnostic FFPE tissue per patient than any published 
work to date. Although our hypothesis was that using different systems, and hence 
different methodologies of analysis would decrease reproducibility and demonstrate 
that such approach is unreliable, if we could prove the opposite it would support 
semi-automated IHC as the way forward for assessing cell infiltration in large tissue 
areas using TMAs.  
 
We competed two image analysis systems developed by independent companies 
(Ariol and Pannoramic Viewer), three image analysis methods (absolute numbers, 
percentage area and numbers of stained pixels), and as a secondary aim examined 
the prognostic impact of individual elements of the immune microenvironment in a 
cohort representative of the current clinical scenario in DLBCL. To our knowledge this 
approach has not been previously undertaken for IHC studies in lymphoma.  
 
We demonstrate that the computerized results are highly reproducible, even when 
comparing different variables examined for each biomarker, such as cell density and 
% of area stained. Correlation data for the two Ariol measurements was extremely 
consistent, even for cytoplasmic proteins such as TIA1 or CD68. This was a surprising 
result given the difficulties in training the Ariol system to enumerate single cytotoxic 
T-cells or macrophages. Moreover, inter-observer variability of manual counting for 
macrophages is known to be very high. Even more surprising was the finding of highly 
acceptable reproducibility between the data retrieved from the Ariol and the 
Pannoramic Viewer. Correlations were excellent for T-cell surface markers, but more 
modest for cytoplasmic proteins. 
 
Our data is in agreement with a recent validation study promoted by the LLBC.329 This 
study, conducted by highly experienced haematopathologists, reports only low to 
moderate agreement in manual scoring of T-cell and macrophage markers when 4-5 
scoring categories are used. However, comparison of semi-automated analyses set up 
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by two different operators in two different instruments using the same methodology 
(Ariol) was highly reproducible for T-cells markers. This is an important finding 
suggesting that operator-induced bias is not as relevant as has been thought 
previously and should not prevent researchers from using this methodology. The 
current study adds upon this by examining a large population of 309 patients and by 
comparing the computerized quantifications for a larger panel of markers, 
particularly including cytoplasmic proteins such as CD68. Moreover, we performed 
comparisons across the results retrieved from two semi-automated systems 
developed by different companies and three different assays for each staining.  
 
Our own and the LLBC data indicates that automated systems of IHC analysis add the 
required robustness to IHC prognostic studies in an operator-independent manner 
and should be used in the future instead of manual analysis. Comparing manual and 
automated results was not the scope of this project and studies such as those of the 
LLBC support that manual scoring is highly variable and hence inadequate for 
outcome prediction studies. This is being explored further in Follicular Lymphoma by 
the LLBC. 
 
Finally we explored the outcome potential of microenvironment biomarkers as 
assessed using the semi-automated systems in a representative dataset of 161 
uniformly R-CHOP treated DLBCL patients. Whereas the clinical variables included in 
the IPI and achieving a complete remission after R-CHOP were predictive of OS, none 
of the biomarkers studied were, potentially reflecting the impact of salvage therapy. 
However we were able to validate CD3 and FoxP3 as predictors of PFS. For both 
biomarkers, patients with higher biomarker density had a lower risk of relapse after 
R-CHOP. Although studies highlighting CD3 as a potential marker in lymphoma are 
limited,330 previous IHC analyses predominantly showed that a high infiltration of 
FoxP3 improves patient survival.331 While functional studies point towards a negative 
prognostic impact for regulatory T-cells in lymphoma,332-334 it is possible that 
regulatory T-cells are directly suppressing the malignant B-cells or are counteracting 
tumour supporting T-cells. Notably, we saw no evidence that CD68 expression by any 
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method is prognostic in our R-CHOP treated DLBCL patients. While the role of 
macrophages in tumour promotion has been robustly demonstrated in biological 
models of solid cancers, evidence in lymphoma is limited.  GEP studies done in whole 
LN infiltrated with DLBCL suggested that the expression of macrophage and ECM 
related genes confer an improved outcome in the R-CHOP era. However, IHC studies 
are inconsistent, reflecting the difficulties in scoring CD68 but also likely relate to 
macrophage functional diversity in tissues that hardly can be mirrored by a single 
marker. While our results suggest that the problem of scoring inconsistency can be 
overcome by semi-automated analysis, macrophage functional complexity in 
lymphoma hasn’t yet been address and is the aim of our next chapters. 
 
While this study suggests that a high infiltration of T-cells is contributing, together 
with clinical parameters, for achieving and retaining a CR after R-CHOP in DLBCL, 
some limitations need to be acknowledged.  
One important limitation is the retrospective nature of the study and the relatively 
small size of the R-CHOP treated cohort. Given the myriad of prognostic biomarkers 
suggested for this disease, any study of this kind should explore the most well 
established factors, from the IPI to genetic biomarkers. This should be done under a 
clinical trial gathering enough patients so as to reach sufficient statistical power for 
outcome prediction. Only then a proper multivariate analysis incorporating the 
strongest biomarkers can clarify which of them should be included in the diagnostic 
workup for DLBCL or change the clinical practice. 
 
What this study clearly provides is evidence for considering semi-automated analysis 
of IHC for future studies exploring biomarkers in DLBCL or other diseases. This 
technology eliminates the underlying variability of manual analysis of IHC studies. 
However, we now face a challenge of what to suggest as methodology for future 
studies. It could be argued that discriminating prognostic cohorts based on analysis of 
immunohistochemical markers reflects only bias arising from this same methodology. 
Nevertheless, our use of multiple methodologies, technologies and markers, all 
suggesting a positive impact of increased immune cell infiltrate, supports the 
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hypothesis that this is representative of a real biological effect: that increased 
immune infiltrate leads to improved outcome. Moreover, is another finding 
supporting that the computerized analysis is a robust method for IHC analysis. Similar 
studies should now be done approaching other protein markers such as the COO or 
MYC.  
 
Clearly, the results reported here are exploratory. Now that we have established that 
semi-automated systems are the tool of choice for analysis of IHC biomarkers, larger 
validation studies are required. First, it is essential to conduct an intergroup analysis 
of all semi-automated systems available, devise a consensus methodological 
approach and select laboratories that would be responsible for similar analyses under 
clinical trials where other established molecular and cytogenetic prognostic factors 
are investigated. This, in our opinion, would definitely answer whether the lymphoma 
microenvironment plays a role in outcome prediction in DLBCL and other lymphomas 
and bring forward methods to incorporate such biomarkers into clinical practice. 
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Chapter 5 Defining the diffuse large B-cell lymphoma associated-
macrophage transcriptome 
 
 
5.1 Introduction 
As discussed in Chapter 1, GEP of DLBCL suggested that the stromal 
microenvironment might have an impact in outcome prediction in this disease. In 
contrast to what is generally found in solid tumours and other lymphoid 
malignancies, in DLBCL the expression of macrophage-related genes and ECM 
components was associated with an improved outcome. This data opens several 
hypotheses. The first is that in poor-risk DLBCL the malignant B-cells use strategies to 
change macrophages towards a tumour-permissive behaviour and that those changes 
are pictured in their transcriptome. The second is that a stromal response is 
associated with an improved response to R-CHOP or to an ability to control minimal 
residual disease after chemoimmunotherapy. Whereas the second possibility has 
been partially demonstrated by studies on the impact of macrophages in mediating 
efficacy of monoclonal antibody therapies, the first hypothesis has not yet been 
addressed. 
 
Macrophage functions can be subverted by tumour cells to facilitate disease 
progression and immune evasion. Whereas a number of mechanisms by which cancer 
cells influence TAM function have been described, currently there is very limited 
understanding of the TAM polarisation status and effector function in human 
lymphoma, including DLBCL.  
 
Mechanisms used by B-cells to influence macrophage activation have only recently 
been defined.  
Crosslinking of the macrophage FcγR with Igs leads to a shift towards an M2-like 
immunossupressive phenotype. While this process might be adaptive to establish 
tolerance to autoantigens, it can be used by cancer cells to potentiate progression.261  
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In mice transplanted with melanoma, B-cell depletion shifted TAM polarisation from 
a tumour-facilitating M2 phenotype towards a classical M1 phenotype. In this model 
B-cell-derived IL-10 has been implicated in TAM activation.260 However, using a 
mouse model of B-cell lymphoma, Leidi et al.272 proposed that human M2-polarised 
macrophages have improved cytotoxicity against lymphoma cells after treatment 
with rituximab, which was further up-regulated by IL-10. 
It is likely that B-cell-derived cytokines other than IL-10 can also influence 
macrophage activation. As has been discussed in Chapter 1, T-cell primed B-cells have 
been shown to produce Th1 and Th2 cytokines,267 including IFN-γ, IL-12, IL-4 and IL-
13, that were able to modify T-cell responses. It is likely that these impact on 
macrophage activation. However no data is available addressing this hypothesis, 
including in the context of B-cell malignancies. 
 
In this study we addressed the hypothesis that the malignant DLBCL-associated 
macrophages are functionally distinct from macrophages encountered in non-
malignant lymph nodes and that those differences are induced by the lymphoma cells 
to promote disease aggressiveness. Using methods other than IHC would overcome 
the well accepted phenomenon that the macrophage functional repertoire cannot be 
dissected using a limited number of markers.  
 
 
5.2 Aims 
We aimed to scrutinise the functional interactions between macrophages and 
malignant cells by exploring the transcriptome profile of highly pure populations of 
macrophages selected from human DLBCL samples compared to that from 
macrophages from reactive LN. Recognizing which genes are differentially expressed 
in DLBCL TAM might lead to a better understanding of their functions within the 
tumour microenvironment. 
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5.3 Materials and Methods 
5.3.1 Samples 
LN SCSs from patients with DLBCL were chosen based upon the availability of 
sufficient vials to perform these experiments. Table 5.1 provides clinical details and 
partial results from individual samples. Details on the methods used for cell 
suspension preparation, staining, flow-assisted cell sorting, RNA extraction, cDNA 
amplification, and final sample preparation for microarrays are provided in Chapter 2.  
 
5.3.2 Microarray quality control assessment 
Samples were run in two batches on separate days. In order to detect technical 
variability that could be reflected in the results, two samples were run in both 
experimental batches and the Pearson's correlation assessed. A series of quality 
control metrics provided by Affymetrix were utilized with the purpose of identifying 
failing samples and recognizing where along the processing chain potential problems 
occurred. 
Hybridisation efficiency was evaluated using results from purposely added transcripts 
derived from Bacillus subtiliis. Due to the lack of other transcripts competing for their 
probe sets, the binding intensity is directly related to the quality of the hybridisation. 
Chip intensity can be further assessed by the mean of perfect match (PM) probes raw 
intensities. Also by assessing how different the ratio of positive exon-level versus 
negative intron-level probes is from the expected value, one can predict whether any 
sample has potential hybridisation problems. Analysis of polyA control RNAs spiked to 
each sample prior to amplification helps monitoring the quality of the labelling 
reaction. 
Regarding sample quality controls, a number of parameters were assessed: the mean 
of the signal of all probe sets per sample; the mean relative log expression (RLE) and 
the expression signal. 
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Table 5.1 Samples used for transcriptomic analysis: patients characteristics and partial results 
ID Age Gender Date AA stage IPI Response Viability (%) Cell # (x10
7
) CD36 yield Purity (%) RNA (ng/uL) RIN cDNA (ng/uL) 260/280 
T2628 58 M 2009 I 0 CR 76 5.4 42357 90.5
 c
 0.62 7.5 385.7 1.94 
T3531 60 M 2009 III 1 CR 40 3.0 65721 96.4 2.1 9.8 308.4 1.95 
R3468 61 F 2004 IV 4 PR 45 3.0 47500 92.0 0.13 9.2 256.3 1.97 
R8639 34 M 2007 I 0 CR 74 4.2 3780 93.9
 c
 0.03 7.4 288.4 1.92 
T2114 42 F 2009 I 0 CR 50 0.7 20000 - 0.10 9.1 272.9 1.95 
T4570 50 M 2010 III 2 PD 74 3.0 159268 98.6 4 9.7 389.9 1.92 
R0433 86 M 2002
 b
 III 2 CR 35 2.1 22500 - 0.37 9.5 235.6 2.02 
F7615 51 M 2000
 b
 III 1 CR 69 3.0 244432 95 8.3 9.7 366.2 1.94 
T6932 48 M 2012 III 2 CR 62 2.0 46071 94.0 0.42 10 368.6 1.92 
R9516 79 M 2008 IV 4 SD 78 1.3 60000 90 0.38 8.2 372.62 1.97 
R6137 81 M 2005 IV 3 PR 77 2.0 22209 90 2.3 9.0 375.32 1.96 
F8146 61 F 2000
 b
 II 2 CR 61 3.0 152324 96.4 8 10 368.36 1.95 
R8756 59 M 2007 IV 2 CR 67 1.1 12310 92.1
c
 0.3 7.6 295.2 1.95 
T5900
a
 21 M 2011    85 5.0 200000 92.0 5.7 7.0 359.2 1.96 
T5353
a
 19 M 2011    89 4.3 190000 97.0 20 8.0 357.95 1.96 
T5996
a
 18 F 2011    95 5.1 78388 92 1.6 8.5 372.8 1.95 
T5848
a
 68 F 2011    70 2.7 90380 97.1 0.45 9.3 354.8 1.96 
T5424
a
 73 M 2011    75 7.0 510852 96 10 9.7 305.8 1.96 
T5175
a
 37 F 2011    90 2.9 117416 96.4 6 10 431.38 1.98 
a
 reactive LNs; 
b
 CHOP treated; 
c
 Double sorting; AA: Ann Arbor; IPI: International Prognostic Index; RIN: RNA integrity number; M: male; F: female; CR: complete response; PR: partial 
response; SD: stable disease; PD: progressive disease 
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5.3.3 Data normalisation  
This analysis was performed using Bioconductor packages (www.bioconductor.org) 
within the R statistical environment. A robust multi-array average (RMA)335 algorithm 
was applied for background signal adjustment and data normalisation.  
 
Background signal is an inherent problem to microarray technology imputed to 
optical noise and non-specific binding (NSB) that can lead to falsely overestimated 
gene expressions. The RMA algorithm estimates and adjusts background intensity 
using a set of approximately 17000 generic background probes.  
 
The background adjusted data is then normalised at the probe-level using a quantile 
method.336 Quantile normalisation orders the data from each array from highest to 
lowest expression and identifies the average value at each quantile. The observed 
expression is then transformed to the quantile average in order to give each data set 
an equivalent distribution. This data manipulation is required to extract experimental 
variability associated with sample batching, inconsistent use of reagents between 
arrays or as a systemic experimental bias present in the study design. 
 
Finally, to minimize statistical testing while retaining the highest probability of 
detecting differences in expression between samples, the data was filtered to obtain 
the 20% probes with higher binding variability across all samples using standard 
deviation. 
 
5.3.4 Data analysis 
To determine differentially expressed genes between the investigated groups, an 
empirical Bayes approach (limma package) was used. This method takes into account 
some characteristics of the whole data, including the variance of expression of all 
genes, the distribution of all variances and the number of samples under analysis to 
estimate a pooled pattern of expression for the study. Using this pattern it is possible 
to recognize data with unusual distribution that should be considered fortuitous but 
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would otherwise be taken as significant. This method is particularly important for 
studies with a low number of samples per group, where findings are not replicated 
enough and can merely be attributed to chance. 
 
The Benjamini and Hochberg (BH) method of multiple hypothesis testing correction 
was applied in order to rectify the p-values for error induced by multiple 
measurements, where the null hypothesis is incorrectly rejected (Type 1 error). A 
double cut-off of adjusted p-value <0.05 and Log2 FC >1 were set to specify a list of 
differential expressed genes. 
 
Genes that passed these criteria were selected for hierarchical clustering. This 
method allows estimating correlations between two samples by evaluating the 
distance between measurements inputted for the samples. The closer the 
measurements (in this case gene expression), the shorter the distance and greater 
the correlation estimated. Samples that are highly correlated can be clustered in a 
group. The distance metric used for this study was Euclidean distance. The clustered 
data was represented in a dendogram using the Ward linkage criterion. The height 
measured from the bottom of the dendogram to the point where samples diverge 
represents the distance/degree of similarity between samples. Jacek Marzec 
performed all data normalisation and analysis.  
 
5.3.5 Targeted gene expression validation by qRT-PCR 
Amplified cDNA generated for the microarray experiments was further used for 
validation by qRT-PCR. The transcripts were chosen amongst the most differentially 
expressed between DLBCL and reactive samples. The TaqMan® Gene Expression 
Assays tested were: ALOX15, Hs00609608_m1; AQP9, Hs01035888_m1; CDH1, 
Hs01023894_m1; IDO1, Hs00984148_m1; C3AR1, Hs00377780_m1, CD1E, 
Hs00954575_m1; CTSL1, Hs00964650_m1 and ANKRD22, Hs00944018_m1. All assays 
were bought from Life Technologies.  
The average of triplicate CT values was normalisedd to the house-keeping gene B2M 
due to it being the only one passing Levene’s F-test of equality of variance among the 
Chapter 5 Results 
167 
three explored (B2M, GAPDH, RPL34) across all samples. Results are expressed in RQ 
values with errors bars representing the standard error of the mean (SEM). 
 
5.3.6 Hierarchical clustering of RQ values  
RQ values were clustered in Cluster V3.0,337 using Euclidian distance. The clustered 
data was represented in a dendogram built in Tree View337 using the Average linkage 
criterion. 
 
5.3.7 Gene enrichment analysis 
The differentially expressed gene symbols were computed in Toppfun 
(http://toppgene.cchmc.org), an online bioinformatics tool that performs gene list 
functional enrichment. This data-mining tool compares the data inputted with 
annotated data from different categories: GO (gene ontology) terms, pathways, 
protein–protein interactions, transcription factor binding sites, gene tissue 
expressions and literature co-citation. Toppfun retrieves annotated information 
where the gene(s) of interest is/are over-represented, the significance of which is 
corrected with the BH test. 
 
5.3.8 Generation of resting and polarised macrophage gene signatures 
In order to perform a comparative analysis, we used bioinformatics approaches to 
develop macrophage gene signatures (Figure 5.1). Firstly, representative GEP datasets 
of human macrophages were chosen. The GEP dataset GSE22886338 was used to 
construct a resting macrophage signature. This study comprehensively profiled six 
immune cell types (B, T, NK-cells, plasma cells, monocytes and neutrophils) and their 
activated and differentiated states. A “resting” macrophage-specific gene signature 
was depicted by comparing the GEP of monocyte-derived macrophages to all other 
experimental conditions. Secondly, the GEP dataset GSE5099194 was chosen to 
delineate activated macrophage signatures. M1 and M2 signatures were defined by 
comparing IFN-γ/LPS and IL-4-treated macrophages, respectively, with the remaining 
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conditions. With the intention to exclude any gene that has been previously 
demonstrated to be expressed by DLBCL B-cells, Lenz et al.34 and Basso et al.339 
datasets were used to inquire for the expression levels of genes included in the 
signatures and filter out the ones that passed the expression criteria. The design of 
this approach was performed by me. The bioinformatics analysis was performed by 
Aaron Newman and Ash Alizadeh, from Stanford School of Medicine, Palo Alto, CA.
 
 
Figure 5.1 Development of macrophage gene signatures.  
DE: differential expression; FC: fold change
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5.4 Results 
5.4.1 CD36 is expressed by the majority of tonsil CD68+ cells, representing a good 
single marker for macrophage cell sorting 
Due to the limited number of LNs SCSs of DLBCL available in our tissue bank with 
enough vials to conduct this study, preliminary data was gathered using samples of 
other lymphoproliferative diseases and tonsils. Firstly we demonstrated, and 
posteriorly confirmed in our original data, that macrophages constitute a very rare 
population in SCSs as assessed by flow cytometry using CD68 intracellular staining 
(data not shown). Under this premise, we aimed at defining the simplest strategy to 
cell sort macrophages using only surface markers. This would enable us to minimize 
the staining steps to a minimum and avoid cell membrane permeabilisation that 
would likely affect RNA quality. We showed that the membrane scavenger receptor 
CD36 was co-expressed by the majority of CD68+ cells in tonsil SCSs (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 CD68+ cells co-express the membrane scavenger receptor CD36.  
5.0x105 cells were fixed and permeabilised for intracellular staining with CD68. Cells are gated 
on singlets and live cells. Flow plot representative of a single biological replicate. 
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5.4.2 LN single cell suspensions of DLBCL are not representative of the tumour 
content when assessed by flow cytometry 
For this study aiming at comparing the GEP of DLBCL-associated macrophages with 
that of reactive LN macrophages we were able to select 13 DLBCL and six control LN 
samples (Table 5.1). The cell sorting methodology and representative example of the 
sorting strategy were described in Chapter 2. Cell number and viability were assessed 
using an automated haematocytometer prior to antibody staining. From each sample, 
total CD20+ B-cells, CD3+ T-cells and CD36+ macrophages were isolated after gating 
on singlet, live leukocytes (CD45+). Cell yields were retrieved by the cell sorter.  
 
Sample viability on thawing was variable but generally poorer for disease cases (35-
78% for DLBCL compared to 75-90% for controls). Figure 5.3 represents an estimate 
of the percentage of macrophages, B and T-cells in the stored samples taking as 
denominator the total number of viable cells. As can be appreciated, B-cells were not 
the most abundant cell population in DLBCL SCSs, T-cells being more numerous in all 
samples. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Proportion of macrophages, T-cells and B-cells in SCSs of DLBCL and reactive 
conditions.  
Sample cell count and viability were taken using an automated haematocytometer before 
starting the staining protocol. Individual population cell counts were taken at the end of the 
cell sorting. Control samples are identified in red.
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Cell purity after sorting was excellent for B and T-cells (>98% in all except one sample, 
data not shown). As can be appreciated in Table 5.1, macrophage purity after sorting 
was acceptable (median 94%, range 90-99%). However, three samples required 
double sorting in order to guarantee purity >90%. This strategy highly compromised 
cell yield but enabled the use of those samples for transcriptomic analysis.  
 
CD36+ macrophages were a rare population both in malignant and in control 
samples.  Macrophage cell yield was significantly higher for control samples (median 
1.5x105, range 8x104 to 5x105) compared to DLBCL samples (median 5x104, range 
4x103 to 2.4x105, p= 0.01). 
 
5.4.3 Quality assessment of the experimental workflow employed in this study  
As detailed in Chapter 2, macrophages were immediately pelleted after sorting by 
centrifugation at 8000rpm for 10min without any washing step, follow by RNA 
extraction. RNA concentrations and quality were assessed using the Agilent 
bioanalyser pico kit, designed for low RNA amounts. Although macrophage numbers 
were significantly higher in control samples, RIN numbers were excellent and 
comparable across disease and control samples, varying between 7.4 and 10. Figure 
5.4 shows the electropherograms of a number of the samples used in this study and 
an internal control.  
However, and as predicted, the RNA concentrations obtained from sorted DLBCL-
associated macrophages we significantly lower (median 0.42, range 0.03 - 8 ng/uL) 
compared to reactive LN macrophages (median 5.9, range 0.4 - 20 ng/uL, p= 0.03). 
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Figure 5.4 Excellent RNA quality obtained from macrophage populations.  
Representative electropherograms for assessment of RNA quality of samples used in this 
study. With the exception of R8639, all samples had a RIN >9, suggestive of high quality RNA. 
 
 
 
Given these results, nucleic acid amplification was required. RNA quantities taken 
forward for cDNA synthesis and amplification were equivalent across samples. A 
negative control was included with the study samples in two experimental batches. 
As can be appreciated in Table 5.1, cDNA yields and quality were similar across 
samples. Electrophoretic traces for amplified and fragmented cDNA were inspected 
for some samples to confirm integrity (Figure 5.5). 
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Figure 5.5 cDNA fragment size distribution analysis using the Agilent RNA 6000 Nano kit.  
The left side trace represents amplified cDNA; the right side trace represents fragmented 
cDNA. 
 
 
 
After fragmentation, cDNA was biotin-labelled and hybridised to Affymetrix 
GeneChip® Human Gene 1.0 ST Arrays. These microarrays evaluate the expression of 
28869 well-annotated genes with 764885 distinct probes that are distributed across 
the full length of the gene, guaranteeing whole transcript coverage. This is 
particularly useful for studies using potentially degraded samples.  
 
None of the samples was flagged as an outlier using the quality control checks. 
Hybridisation was assured by evaluating the distribution of control probes (Figure 1, 
Appendix).  Also, the ratio of positive versus negative probes was >0.7 (0.82-0.89, 
Figure 2, Appendix), suggesting that hybridisation occurred as expected. Mean 
intensities for all arrays were very consistent, with a variation of 0.05 (Figure 3, 
Appendix), as were mean intensities for PM and background probes (Figure 4, 
Appendix). Regarding the RLE signal (Figure 5, Appendix), sample R8639 stood out has 
having a higher mean compared to the remaining. 
 
Finally, Pearson correlation of intensity signals for the duplicate samples shows a high 
correlation between technical replicates with individual R values 0.99 (Shown in 
Figure 5.6). 
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Figure 5.6 Correlation of intensity signals for the samples hybridised in the two 
experimental batches 
cc, correlation coefficient. 
 
 
 
5.4.4 Unsupervised hierarchical clustering  
As already mentioned, hierarchical clustering is useful to detect similarities between 
samples. Undertaken in an unsupervised fashion means the whole filtered data 
(~12000 probes with highest expression variability) is used.  
As can be appreciated in Figure 5.7, this analysis failed to fully resolve DLBCL TAM 
and control macrophages.  
Whereas reactive LN-associated macrophages cluster together, showing a high 
degree of similarity, DLBCL TAM have higher GEP variability. Within the DLBCL 
samples R8756, R6137, F8146, R9516 and T6932 diverged earlier from the remaining 
samples. Samples R8639, R0433 and R3468 also segregated into a separate cluster. 
The remaining DLBCL TAM samples clustered closer to the control macrophages. We 
excluded this variability was due to a batch effect by observing close clustering of 
samples that were hybridised in different days. 
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Figure 5.7 Unsupervised hierarchical clustering of DLBCL and reactive LN-associated 
macrophages.  
Clustering based on RMA normalised expression of the top 12000 probes with the highest 
variability. Data is correlated by Euclidean distance using Ward linkage to define the 
dendogram. 
 
 
 
5.4.5 Statistical analysis of differentially expressed genes between DLBCL TAM and 
reactive LN macrophages 
A supervised hierarchical clustering analysis was performed to recognize the 
differentially expressed genes between DLBCL TAM and control macrophages. This 
was calculated by dividing the average logarithmic expression data for each group, 
generating a FC ratio. The FC cut-off selected for this experiment was ≥2 (Log2 ≥1). P-
values were corrected with BH False Discovery Rate (FDR) and a value of ≤0.05 
accepted. Using these criteria, 208 probe sets for 202 well annotated genes were 
differentially expressed between the two groups. Of those, 63 were downregulated 
and the remaining were upregulated in DLBCL-associated macrophages versus 
reactive LN macrophages (Figure 5.8). The full data set for all significant differentially 
expressed genes is shown in detail in Table 1, Appendix. 
DLBCL 
Reactive 
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Figure 5.8 DLBCL TAM and reactive LN macrophages differ in expression of 202 genes. 
Supervised hierarchical clustering analysis using a Euclidean distance measure and Ward 
linkage. Each column represents one sample, each row a transcript. Gene expression levels 
are represented on a scale of green to red colour indicative of low to high expression.
Reactive 
DLBCL 
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As can be visually appreciated in the heatmap, control samples have a more 
coordinated expression of the differentially expressed genes. To substantiate this, the 
six most highly differentially expressed transcripts are represented in Figure 5.9 
plotted by sample. Representing the data in this manner suggests a higher level of 
heterogeneity in the GEP of TAM compared to controls.
 
 
 
 
Figure 5.9 Expression heterogeneity of most differentially expressed genes in DLBCL and 
control macrophages.  
Graphs represent each transcript and columns each sample. Log expression is represented for 
each gene and sample. Control samples are represented in purple and DLBCL samples in 
green. p-values were adjusted according to BH test.
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5.4.6 Confirmation of differentially expressed genes by qRT-PCR 
To validate expression of selected genes from our list, qRT-PCR was used. The 
transcripts chosen were among the highest differentially expressed.  
In addition to the seven genes represented (Figure 5.10), ALOX15 was also tested. 
However, ALOX15 genes levels could be measured in control samples but were 
undetected in DLBCL TAM samples by qRT-PCR, which renders statistical analysis 
impossible. This corroborates the microarray data (Figure 5.9, right bottom graph) 
showing a significantly lower expression of ALOX15 in DLBCL TAM compared to 
controls.  
 
As shown in Figure 5.10, GEP results could be validated by qRT-PCR, suggesting that 
the transcriptomic data indeed represents biological differences between the two 
groups. Although RQ values were not significantly different for CD1E, the FC direction 
was confirmed (Figure 5.10, B). FC results were higher for upregulated genes and 
lower for downregulated genes when tested by qRT-PCR compared to microarrays
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Figure 5.10 Validation of targeted differentially expressed genes by qRT-PCR.  
50 ng of amplified cDNA was used in triplicate for each sample and analysed by qRT-PCR. CT 
values were normalised to B2M. A. Average RQ values were compared using T-test and p-
values <0.05 deemed significant. Results plotted using mean +- SEM. B. Average fold change 
of gene expression in DLBCL TAM compared to controls using microarray and qRT-PCR 
methodologies. 
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5.4.7 Hierarchical clustering of targeted gene expression by qRT-PCR 
An unsupervised hierarchical cluster analysis was performed on the RQ values for the 
eight genes tested by qRT-PCR. This simplified methodology divided DLBCL TAM in a 
separate cluster from control samples (Figure 5.11). Regarding control samples, C5 
(T5424) clustered closer to lymphoma samples, whereas C1 (T5175) clustered 
separately from all other samples. The remaining control samples collected in a 
separate group. 
 
 
 
 
Figure 5.11 Hierarchical cluster analysis of RQ values of seven transcripts resolves DLBCL 
TAM from controls.  
Data is correlated using Euclidean distance and an average agglomeration to define the 
linkage tree. Each column represents one sample, each row a gene. Expression is represented 
in a continuum from red (for high expression) to green (for low expression). Absent data is 
coloured in gray. DLBCL samples are labelled from D1 – D12 and reactive samples are labelled 
from C1 to C6.
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5.4.8 Gene enrichment analysis establishes links between our gene set, the “LN 
signature” of DLBCL and M1 and M2 polarised macrophage functions 
The most relevant results retrieved by Toppfun are presented here according to 
category. More comprehensive information for each of the sub-sections will be 
provided in Appendix, Table 2. All p-values stated are corrected for the FDR with the 
BH test. 
 
5.4.8.1 Gene ontology (GO) 
The GO consortium gathers several genome databases that use a standardized 
nomenclature for gene products according to biological processes and molecular 
functions where they have been implicated.  
An important finding that highly supports our methodological approach and results 
was that our differentially expressed genes are significantly implicated in cellular 
functions where macrophages are known to play a role: immune response (p=1.5x10-
35), defence response (p=1.1x10-27), innate immune response (p=2.5x10-18) or 
inflammatory response (p=5.6x10-21). This subanalysis suggests that both M1 and M2-
related genes are present in our dataset as both “Response to IFN-γ” and “Response 
to LPS”, prototypic M1 stimuli; or “Response to wounding”, a prototypic M2 
functional activation, were on our top 20 GO cellular functions (Figure 5.12, A). 
Receptor activation and signalling were molecular functions implicated in our dataset 
(Figure 5.11, B). Of note, Ig binding, known to play a role in M2 activation, and LPS 
receptor signalling, involved in M1 activation, were both enriched. 
 
5.4.8.2 Pathways 
Toppfun inquires for overlaps of the data inputed with data sourced in pathway 
databases, such as the Kyoto Encyclopedia of Genes and Genomes or Panther 
database. Again, significant terms point towards conditions in which macrophages 
have a central role. Prototypical M2 diseases were listed: tuberculosis (p=2.034x10-4), 
leishmaniasis (p=9.3x10-4). However, M1-related IFN-γ signalling pathway appeared 
Chapter 5 Results 
182 
B 
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more significantly enriched (p=8.9x10-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 GO enrichment analysis.  
A. Most highly represented cellular functions, p-values between 1.5x10-35 and 3.1x10-11. B. 
Most highly enriched molecular functions, p-values between 3.9x10-8 and 5.0x10-4. Bars 
correspond to the number of genes from our list implicated in each function, decreasing in 
significance from the bottom of the graph.
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5.4.8.3 Co-expression 
Toppfun also overlaps gene lists provided with annotated gene signatures indexed in 
Pubmed and gathered in the Gene Signature DataBase.  
 
The most significant hit in the co-expression category (p=4.6 x10-60), and in fact the 
top hit from this bioinformatics analysis, was a GEP study by Van Loo et al.340 on full 
tissue sections of THRLBCL, a pathological DLBCL sub-entity where the bulk of the 
tumour is composed of T-cells and macrophages. Sixty-three of our upregulated 
genes in DLBCL were amongst a list of 373 the authors described as being 
upregulated in THRLBCL compared to nodular lymphocyte predominant Hodgkin 
Lymphoma (NLPHL) and reactive LNs. Whereas NLPHL and reactive LNs 
overexpressed established B-cell genes, THRLBCL genes were related to the 
microenvironment. Importantly, 11/20 of our top differentially expressed genes were 
overlapping with Van Loo’s data, including: C3AR1 (#2), ANKRD22 (#3), FCGR1A (#4), 
IDO1 (#8) or CXCL10 (#9). 
 
Another interesting finding of this sub-analysis was an over-representation of gene 
sets that represent cell states and perturbations within the immune system 
generated as part of the Human Immunology Project Consortium and the Mouse 
Immunological Genome Project. Significant overlap was detected between our 
dataset and 18 gene sets of the human project (p-values between 2.7x10-46 and 
4.0x10-18), the vast majority of them referring to differentially expressed genes 
between monocytes and other cells of the immune system, including B-cells.   
 
In the same line, we found a highly significant overlap between our differentially 
expressed genes and the ones defining several mouse immune cell populations. The 
50 most significant hits (p-values between 4.4x10-55 and 1.3x10-22) correspond to 
myeloid cell populations. 
 
Neither of the two studies defining the LN and “stromal-1” gene signatures figured in 
the Gene Signature DataBase and hence was retrieved in our analysis. Those 
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signatures were enriched for transcripts likely derived from macrophages, but a 
formal demonstration of that was deemed impossible due to the way the original 
studies were designed. However, the LN-signature was introduced by a secondary 
study,341 which permitted it to result in our analysis. We found a significant overlap of 
our gene list with the LN signature (25 out of 161 genes, p=3.5x10-22). Among some of 
those genes were: FCGR1A, CXCL10, CXCL9, CCL2, C3AR1, CD14, or CTSL. On the 
contrary, only six of our transcripts were represented in the “stromal-1” signature.  
 
5.4.8.4 Cancer Modules 
Through an integrated analysis of 1975 microarray studies spanning 22 tumour types, 
Segal et al. defined cancer modules, sets of genes that act in concert to carry out a 
specific function in cancer tissues.342 Toppfun analysis showed that the most enriched 
(53/531 genes, p=1.7x10-27) was the “immune (humoral) and inflammatory response” 
module. Importantly, this module has been shown to be over-represented in DLBCL, 
independently of the molecular subtype. 
 
5.4.8.5 Gene family 
Five metallothionein (MT) genes appeared overexpressed in DLBCL TAM compared to 
controls (p=7.1x10-7). MTs are metal-binding proteins that respond to oxidative stress 
and acute phase cytokines such as IL-1, IL-6, and TNF-α and have been implicated in 
immune regulatory effects.  MT knockout mice show impaired wound healing and 
higher susceptibility to inflammation. It was suggested by a single study that MT 
expression is associated with poor outcome in DLBCL.343 
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5.4.8.6 Upstream regulators 
Finally we used another bioinformatics tool, Ingenuity pathway analysis 
(http://www.ingenuity.com/products/ipa), to inquire for upstream regulators of 
expression of our gene set. Both prototypical M1 (IFN-γ, p=2.5x10-30) and M2 (IL-10, 
p=2.4x10-17; Ig, p=1.5x10-16; IL-13, p=5.0x10-15; IL-1β, p=9.5x10-14; IL-4, p=3.0 x10-6) 
cytokines were significantly reported. The most significant transcription factors 
identified were the M2, IL-10-induced STAT3 (p=5.0 x10-11) and the M1-related STAT1 
(1.9 x10-6). 
 
5.4.9 Comparative analysis with macrophage gene signatures 
As can be appreciated in Figure 5.1, “resting” and “activated” macrophage gene 
signatures were delineating for comparative analysis. Data overlap was tested both 
before and after the filtering step described. 
 
5.4.9.1 Comparison with a “resting” macrophage-specific signature 
To confirm the specificity of the “resting” macrophage signature we plotted the 
expression of the 839 genes across all immune cell populations from the study of 
Abbas et al.338 As can be appreciated in the heatmap (Figure 5.13), monocyte-derived 
macrophage replicates (gray square) showed concerted expression of the genes 
selected. Additionally, a higher degree of similarity was detected between the 
myeloid cells included in the study, particularly monocytes and dendritic cells 
compared to other immune cells. B-cells have a different expression pattern 
compared to macrophages. This data validates the bioinformatics approach to define 
macrophage signatures. 
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Figure 5.13 Heatmap of “resting” macrophage-enriched genes.  
As outlined in Figure 5.1, 704 genes were chosen to represent a macrophage-specific 
signature. Gene expression is represented on a scale with a Log2 range of +6 (red) to -6 (blue). 
 
 
Among the 202 differentially expressed genes between DLBCL TAM and controls, 51 
were also present in the “resting” macrophage-enriched gene list, representing a 
highly significant overlap as per the probability hypergeometric test (p=1.2 x10-39). All 
but six of these were upregulated in DLBCL TAM versus control macrophages.  
Finally we investigated the survival impact of each of the genes in the “resting” 
macrophage signature in an R-CHOP dataset.34 The 51 overlapping genes from our 
dataset were variably associated with OS: 22 with improved OS, 18 with worse OS 
and 11 had no impact. Overlapping genes and survival impact are depicted in Figure 
5.14. 
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Figure 5.14 Comparative analyses of our DLBCL macrophage associated gene signature with 
other macrophage gene signatures.  
Our gene expression signature is depicted in the top box. Overlapping genes between our 
signature and the ones developed by bioinformatics analysis are given in each box. The 
degree of significance was tested using hypergeometric distribution. R-CHOP OS impact of 
“resting” macrophage genes is represented in a colour code of red for worse outcome, blue 
for improved outcome and gray for negligible OS effect. Underlined genes are downregulated 
in DLBCL TAM versus controls. 
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5.4.9.2 Comparison with “activated” macrophage signature 
Martinez et al.194 stated in their original publication that the transcriptional profile 
variance from “resting” to M1 polarised is significantly greater than to M2 polarised 
(90% versus 8%), which can be explained by two reasons: M1 activators are more 
potent than M2 activators; and the addition of CSF-1 during the in vitro maturation 
process already switches cells towards an M2 phenotype, hence decreasing the 
impact of M2 activation. This justifies the identification of smaller M2-specific 
datasets compared to M1-specific datasets (see Figure 5.1). 
Given that it is conceivable that macrophage activation triggers expression of other 
than macrophage-restricted genes (for example expression of a chemokine), 
enrichment analysis was performed before the B-cell expression-filtering step (Figure 
5.1). 
The M1-polarised signature comprised 3705 genes, whereas the M2-polarised 
signature contained 959 genes (data not shown). As can be appreciated in Figure 5.1, 
these figures reduced to 318 M1 and 129 M2 genes after the expression-filtering 
step. Some transcripts were overlapping in M1 and M2 signatures, which is expected 
as selection was based on both up and downregulation compared to the remaining 
experimental conditions. Typically, overlapping genes between the two activation 
states were upregulated in LPS/IFN-γ and downregulated in IL4-treated macrophages. 
 
A comparative analysis between macrophage-polarised signatures and our own 
signature of 202 genes demonstrated that 99 genes were in common with an M1 
transcriptome (p=9.3 x10-42) and 34 (p=1.3 x10-16) were shared with an M2 
transcriptome. The majority of the overlapping genes were upregulated in DLBCL 
TAM compared to reactive LN macrophages, irrespective of the polarisation status 
(Figure 5.13).  
 
An additional 83 genes were exclusive to the DLBCL TAM transcriptome. Interestingly, 
within this gene set, a significantly higher number of transcripts were downregulated 
in DLBCL TAM compared to controls: 29 of 133 genes in polarised signatures 
compared to 39 of 83 genes in unique signature, p=0.0001. Fifteen of these genes 
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were among the ones overlapping with the “resting”-macrophage signature. Whereas 
this kind of analysis supports the quality of our methodology and suggests that a 
bidirectional macrophage polarisation is present in DLBCL, among our DLBCL TAM 
signature are relevant genes that have not been retrieved in this comparative 
analysis, including some FcγR genes (FCGR1A, FCGR1B, FCGR2A), the macrophage 
attractant CCL2,221 or the prototypic human M2 gene CTSD.195 Additionally, specific 
genes have been functionally validated in murine models studying TAM, such as 
GPNMB235 or C1QC. 
 
 
 
5.5 Discussion 
Our aim for this chapter was to recognize changes in gene expression within 
macrophages selected from LN infiltrated with DLBCL compared to macrophages 
selected from reactive LN. The underlying premise for using a high throughput 
approach was that, contrary to targeted protein studies, GEP could improve our 
understanding of the macrophage functional variability in DLBCL. To date there is a 
lack of global GEP from TAM selected from human cancer, thereby most assumptions 
regarding TAM functional features are derived from inbred mouse tumour models. 
 
The choice of DLBCL samples was totally dependent on availability of enough vials to 
perform cell sorting. Under this limitation, cases included in this study are not as 
representative of DLBCL heterogeneity as we wanted, with a bias towards a better 
biology group (low median age at diagnosis - 59 years - and 77% of cases with 
low/low-intermediate IPI). Age-matching control samples would be ideal in any study 
of immune cell function, but was impossible, since most LN reactive pathologies are 
diagnosed in young adults. These limitations raise even more the requirement of 
future validation of these findings in larger datasets. 
 
CD36 is a membrane scavenger receptor that participates in the recognition of 
apoptotic cells,344 thereby assuming an important role in maintaining homeostasis in 
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tissues populated by B-cells with a high proliferation index. The expression of CD36 is 
enhanced in macrophages by IL-4345 and CSF-1, traditional M2 cytokines. Using mouse 
and human CD36-deficient macrophages, Huang et al. proposed that this receptor is 
required for the acquisition of phenotypic and functional attributes of M2 
activation.346 This suggests that macrophage isolation based on CD36 expression is 
biased towards an alternatively activated population. Using flow cytometry, we saw 
that CD36 is homogeneously expressed in the whole population of CD68+ 
macrophages in tonsils, therefore being an excellent marker for cell sorting. 
Moreover, expression of well-recognized M1 markers was also detected in the 
transcriptomic analysis, suggesting that CD36-expressing macrophages might not be 
on the extreme of cell activation spectrum but have a mixed activation pattern 
adjusted to the requirements of their vicinity. 
 
Even using a single marker, therefore minimizing the risk of cell loss during sample 
preparation, CD36+ cells are rare in stored samples of both lymphoma and reactive 
samples. It is possible that macrophages are more prone to cell death during storage 
and preparation. That should also be the case of malignant B-cells, since we found 
that, although these should be the most abundant cells in DLBCL samples, T-cells 
outnumbered them. To examine this we would have to test fresh samples in parallel 
with frozen samples and this is planned for future studies, but is not within the scope 
of this thesis.  
 
Given that we were working with stored samples with poor viability and the low 
macrophage cell numbers obtained by flow sorting, it was of paramount priority to 
perform quality controls in all experimental steps of this study. Despite these 
features, except for sample R8639, which had a low but still acceptable RIN for GEP 
studies, RNA quality was excellent for all the remaining samples, supporting our 
protocol for cell isolation and RNA extraction when working with rare cell 
populations.  
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Even though samples with as low as 50 ng of cDNA are feasibly studied by GEP, not all 
samples in our study reached that amount of RNA. Therefore, cDNA amplification had 
to be performed. The Ovation Pico WTA System used here for cDNA synthesis and 
amplification has some unique features, including: (1) the use of random primers 
scattered along the transcriptome, which circumvents the amplification bias towards 
3’ regions of the gene when only oligo-DT primers are used; and (2) the use of a linear 
amplification method that retrieves multiple copies of single stranded DNA that is 
complementary to the mRNA and can be directly hybridised to probes immobilized on 
various microarray platforms. In a comparative analysis of amplifications methods for 
low RNA yields, it has been shown that the WT-Ovation pico system was the most 
suitable, providing reproducible results and good quality transcriptome analysis.347 
Indeed we obtained adequate electrophoretic traces after amplification. Moreover, 
none of the samples was flagged as defective in the quality control performed after 
array hybridisation, suggesting that the experimental work-flow undertaken was well 
thought.  
 
Sample R8639 had the lowest RIN and the most variable relative log expression. Since 
no formal recommendation was given by the quality control checks to consider this 
sample an outlier, we did not exclude it in the current study. Yet, given the known 
impact of potential outliers in array data normalisation, leading to decreased 
statistical power and biological significance of results, it would be worth performing a 
new analysis in the future excluding R8639. 
 
Unsupervised hierarchical clustering did not resolve DLBCL TAM samples from 
reactive macrophage samples. This, in itself is an interesting finding indicating that 
macrophage heterogeneity in DLBCL should be considered and bringing into question 
what would be suitable controls for this study. In any case, a perfect clustering of 
DLBCL and control macrophages would be surprising for two main reasons: (1) the 
cells from the microenvironment are being influenced by the tumour cells, but 
unlikely in a homogeneous fashion; and (2) as discussed in the introduction, 
macrophage functional heterogeneity is to be expected, even in tumour samples.  
Chapter 5 Results 
192 
 
The supervised analysis identified 202 genes that were differentially expressed in 
DLBCL TAM relative to reactive controls. The identification of substantial gene 
expression variability in DLBCL TAM by unsupervised analysis suggested that 
corrected p-values would be modest and therefore the gene set would be small. Even 
among the genes that passed inclusion criteria, expression heterogeneity in DLBCL 
TAM was evident (Figure 5.9) and greater than that of control macrophages. Although 
these findings could potentially reflect technical problems with our data, we do not 
have clear evidence for that and instead interpret them as biological variability that is 
inherent of human samples, particularly in bystander cells of the tumour 
microenvironment. Going back to our original hypothesis of DLBCL cells influencing 
macrophage behaviour, it will be interesting to test whether such GEP variability of 
macrophages is related to unknown underlying differences of the tumour cells.  
 
The accuracy of microarray platforms has improved substantially since the 
introduction of these technologies. Whole transcriptome profiling represents an 
opportunity to functionally model a disease and bioinformatics approaches can help 
in giving biological meaning to high throughput data. However, when it comes to 
teasing out the significance at the single gene level, confirmation of expression 
differences by other methods, such as qRT-PCR is highly advisable. With microarray 
technologies gene expression values can be widely affected by sampling, 
normalisation techniques and the analysis strategies used. As can be appreciated in 
Figure 5.10, GEP results could be validated by qRT-PCR, suggesting that the 
transcriptomic data is trustfully representing biological differences between the two 
groups. However we should bear in mind that amplified cDNA was used in the 
validation step. Ideally results should have been checked with non-amplified material. 
A change in the magnitude of fold change values when array and qPCR experiments 
have been compared has been noted in our data (Figure 5.10) and previously in the 
literature.348 
 
Although our primary aim when performing validation by qRT-PCR was to ascertain 
Chapter 5 Results 
193 
the validity of the transcriptomic data, we thought of testing whether the expression 
patterns of the eight genes studied could resolve DLBCL TAM from reactive controls. 
Surprisingly, qRT-PCR results for only eight genes that were among the highest 
differentially expressed of our dataset helped clustering DLBCL TAM samples apart 
from controls. This suggests that simpler and more feasible strategies can be used to 
explore differences between these two groups. Therefore, qRT-PCR will be taken 
forward for validation studies explained in Chapter 6. 
 
 
 
A common approach to functionally contextualize transcriptomic data is to perform 
gene enrichment analysis. We used a free, online tool that performs a thorough 
comparative analysis using a large number of data sources. This, in turn, increases the 
depth of functional annotation of the data inputted.  
The functional enrichment analysis undertaken here exposed critical elements of our 
data that sustain their quality and highlight their novelty: 
 
(1) Functional annotations are macrophage-related 
As can be appreciated, macrophages have instrumental roles in the GO cellular 
functions suggested, including innate immune and defence responses. Moreover, our 
gene set overlaps with gene signatures of myeloid cell populations, in particular 
monocyte and macrophage populations developed by the Human Immunology 
Project Consortium and the Mouse Immunological Genome Project. 
Additionally, a quarter of our genes were represented in the “immune and 
inflammatory response” gene cluster developed using cancer transcriptomes. 
Importantly, the expression of genes of this group was detected in both GCB and ABC 
DLBCL datasets, which might suggest that relevant features of the microenvironment 
are independent of the molecular features of the malignant B-cells. 
Furthermore, the top hit of this enrichment analysis was a GEP study on THRLBCL, a 
pathological DLBCL sub-entity where the bulk of the tumour is composed of 
macrophages.  
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We believe these findings provide additional support that our data not only reflects 
the transcriptomic features of macrophages, but also unique GEP changes 
characteristic of the DLBCL TAM. In consequence, our study has potential to generate 
hypotheses for functional validation of macrophage biology in human DLBCL.  
 
(2) The LN signature of DLBCL is derived from transcriptomic features of TAM in the 
microenvironment 
One of the most significant hits in the bioinformatics analysis was the overlap 
between our and the LN signature described by Rosenwald and collaborators,76 
providing compelling evidence that this signature genes result from transcriptional 
activation of the macrophages in the stromal microenvironment. This signature was 
linked to a better OS, contradicting what is found in other tumour models where TAM 
have a pro-tumoural behaviour.  
 
(3) DLBCL TAM have a bidirectional M1 and M2 functional activation 
A finding of utmost relevance is the differential expression of both M1 and M2 genes 
by DLBCL TAM. Evidence for this comes from different layers of our analysis. Over-
representation analysis retrieved functional attributes of M1 and M2 activated 
macrophages.  
Pro-inflammatory M1 cytokines, including IFN-γ, are likely more abundant in DLBCL 
than in reactive pathologies, as “Response to IFN-γ”, “IFN-γ signalling pathway” or 
“Inflammatory response” were enriched terms. Indeed, a significant upstream 
regulator of expression of our genes was the prototypical M1 cytokine IFN-γ. STAT1, 
an IFN-γ-induced transcription factor that induces expression of M1 genes was also 
detected. 
However, all traditional M2 cytokines (IL-4, IL-13, IL-10) were significantly reported, 
suggesting that a number of our differentially expressed genes are M2-skewed. Most 
importantly, our data allows hypothesizing that B-cells are interacting with 
macrophages, driving them towards an alternative phenotype. Fcγ receptor activation 
by Igs is known to shift towards an M2 immunossupressive phenotype. This 
phenomenon might be in place in DLBCL, since “Ig binding” was the most enriched 
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GO molecular function identified and FcγR genes were highly overexpressed in DLBCL 
compared to controls.  
 
The development of macrophage signatures served two purposes in this project. We 
wanted to reinforce two statements that could be withdrawn from the analysis 
already discussed: 
 
(1) Firstly, that the methodology used is appropriate to explore the GEP of rare 
populations in human complex tissues. To support it, we compared our genes of 
interest with a list of macrophage-specific genes. Finding a significant enrichment 
would be an indication of accuracy of our results. In fact, a comparative analysis 
between a macrophage-enriched signature and our own signature revealed a highly 
significant overlap. To tease out the prognostic relevance of the expression of those 
genes, we used GEP data from R-CHOP treated patients and demonstrated that the 
51 overlapping genes were variably associated with OS, with 22 being associated with 
improved OS. It would be interesting to explore the outcome impact of the remaining 
genes from our signature and develop multivariate prognostic models together with 
the IPI. 
 
(2) Secondly, we would like to provide additional evidence for the functional 
heterogeneity of DLBCL TAM. Again reiterating this phenomenon, a comparative 
analysis between macrophage-polarised signatures and our own signature 
demonstrated that 99 genes were in common with an M1 transcriptome and 34 were 
shared with an M2 transcriptome, the larger part of them being upregulated in DLBCL 
TAM compared to control macrophages, irrespective of the polarisation status.  
 
A large number of genes from our DLBCL TAM transcriptomic signature were, 
however, not represented in the macrophage signatures, reflecting the limitations of 
this kind of bioinformatics approaches.  Some of those have an established role in 
TAM biology. However, others are quite novel and may open a window for the 
recognition of TAM specificities in DLBCL. Although we do not have a mechanistic 
Chapter 5 Results 
196 
explanation for this, we found that within this unique gene set, a significantly higher 
number of transcripts were downregulated in DLBCL TAM compared to controls: 29 
of 133 genes in polarised signatures compared to 39 of 83 genes in unique signature, 
p=0.0001.  
 
Some relevant data could only be identified by performing literature searches, which 
highlights the problem of relying solely on annotated data for microarray 
interpretation. It is known that while two-thirds of all the genes are annotated by at 
least one functional annotation, the remaining one-third is yet to be annotated. We 
used individual gene names to complete the knowledge of their functional 
implications in the context of macrophage biology and searched for studies 
implicating pertinent genes and lymphoma biology. During this literature search two 
papers were found of most relevance for our work. 
 
Hartmann et al.208 performed GEP of minute amounts of macrophages selected by 
laser-microdissection from the DLBCL subtype THRLBCL. This study conveys key 
findings that overlap with our own and therefore helps to support some of our 
conclusions for this chapter:  
 
(1) GEP changes in macrophages might be independent of the pathological subtypes 
of DLBCL and are not a mere reflection of the extent of infiltration of this cell type 
within the tumour microenvironment;  
(2) LN macrophages have a high degree of transcriptomic resemblance, 
independently of pathologic alterations, impeding a clear-cut clustering by 
unsupervised hierarchical analysis; 
(3) DLBCL macrophages overexpressed genes codifying for the metal-binding proteins 
MTs (overlapping with our signature MT2A, MT1G, MT1X), suggesting a role for these 
molecules in macrophage biology in DLBCL that could be functionally teased out; 
(4) DLBCL TAM have a unique bi-directional M1 and M2 transcriptome. 
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Finally, by acknowledging fundamental differences that exist between ours and their 
study design, method of cell selection, array normalisation and statistical testing of 
differentially expressed genes, the coincident findings are more surprising and should 
be taken as biologically genuine.  
 
To overcome the need for cell isolation, with inherent potential for inducing changes 
in the GEP of selected cells, bioinformatics analysis can be used to determine cell-
specific gene signatures in the tumour microenvironment. Doig et al.349 described 
GEP clusters reflecting stromal elements conserved across a variety of tumour 
datasets, including DLBCL. Using Lenz et al.34 dataset, the authors discovered that 
well known macrophage-specific transcripts (e.g. CD14, CSF1R, CD163) and previously 
unrecognised macrophage-related genes showed very similar, potentially concerted 
expression profiles across all patients and other cancer datasets.  
 
We found a very significant enrichment of our signature with transcripts belonging to 
this macrophage signature (39 of 161 genes, p=7.8 x10-48), which again suggests:  
(1) that our approach to define the DLBCL TAM transcriptome is valid and is likely 
providing authentic data despite all potential biases introduced by technically 
manipulation;  
(2) whereas the expression of the common genes between ours and the macrophage  
signature might be, as the authors state, an expected finding resulting from the 
relatively higher abundance of macrophages in the microenvironment of DLBCL 
compared to reactive LNs, other differentially expressed genes can potentially reflect 
the uniqueness of the DLBCL TAM; 
(3) these data similarities also validate in silico approaches to explore the function of 
cell subsets that are hard to study due to limited amounts or sensitiveness to 
laboratory manipulation, including macrophages. 
 
The impact of stromal cells in transcriptomic features of whole tumours is 
indisputable. The microenvironment contribution on GEP reflects not only the extent 
of infiltration of a given cell and the relative abundance of all cells on the 
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microenvironment, but also likely the functional attributes of those same cell 
populations within the tumours.  All transcriptomic analysis of DLBCL tumours 
described the impact of stromal and macrophage transcripts for prediction outcome 
modelling, before and after the introduction of R-CHOP. Our data provides novel 
insights on the functional heterogeneity of macrophages in DLBCL.
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Chapter 6 Attempts for functional validation of transcriptomic analysis 
 
6.1 Introduction  
As already discussed in Chapter 1, independent transcriptomic studies demonstrated 
that whole DLBCL tumours display a distinctive macrophage and stromal remodelling 
gene signature that distinguishes these patients from patients with other histological 
subtypes of NHL. In our previous chapter we showed that the GEP of macrophages 
selected from DLBCL LN exhibits significant similarities with other transcriptomic 
analyses undertaken using DLBCL human samples. Therefore, it is conceivable that 
the malignant DLBCL cells are influencing macrophages towards this specific 
transcriptome, either directly or indirectly by inducing changes in other cells of the 
microenvironment.  
 
A limited number of publications tried to explore this hypothesis in functional studies.  
Mueller et al. used co-culture experiments to provide a mechanism by which human 
DLBCL B-cells can directly influence monocyte function.350 The authors suggested that 
B-cell-derived CCL5 was the culprit monocyte attractant to tumours. The later in turn 
sustained normal and malignant B-cell survival and proliferation through production 
of B-cell activating factor (BAFF) and IL-2.  
 
Lin et al. explored functional changes of CD14+ peripheral blood monocytes in 
patients with DLBCL.351 The authors demonstrated that immunossupressive HLA-DR-
/low monocytes are expanded in DLBCL and are able to decrease T-cell proliferation 
and Th1 responses to foreign antigens. Although likely, this study does not formally 
demonstrate that DLBCL B-cells drive monocyte immunossupressive functions.  
 
Using follicular lymphoma as a model, Guilloton et al. showed that malignant cells can 
induce the production of CCL2 by autologous mesenchymal stromal cells, which in 
turn attracts and skews monocytes towards an IL-10 secreting immunossupressive 
phenotype.221 This effect could be abolished by CCL2 inhibition. The same group was 
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able to establish another mechanism by which macrophages favour B-cell 
proliferation.284 Monocytes and monocyte-derived macrophages could trans-present 
IL-15 to B-cells, and in cooperation with T-cell derived CD40L, favour B-cell 
proliferation through STAT5 activation. 
 
In this chapter we worked under the hypothesis that DLBCL TAM transcriptome and 
proteome is shaped by the malignant B-cells. 
 
 
6.2 Aims  
For this chapter we aimed to perform a functional validation towards recognizing the 
effect of malignant B-cells in macrophage GEP and protein phenotype. The 
experimental design was based on the findings from Chapter 5.   
 
 
6.3 Materials and methods  
6.3.1 Samples 
PBMCs from healthy donors were isolated from buffy cones as described in section 
2.1.3 and used to select monocytes. Tonsil SCSs were obtained from our tissue bank 
storage, prepared as described in section 2.1.2 and used to select control B-cells. Two 
DLBCL cell lines were selected for co-culture experiments based on their molecular 
profile. The GCB cell line Su-DHL4 was gifted from Dr. A Letai and the ABC cell line Ri1 
was gifted from Dr. M Capasso. Both cell lines were maintained as described in 
section 2.1.4. 
 
6.3.2 Co-culture experiments 
Healthy CD14+ monocytes were positively selected from PBMCs using microbeads as 
described in section 2.8.1. Monocyte purity checks were performed by flow 
cytometry using CD14 antibody (Pacific Blue™ anti-human CD14 antibody, clone 
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M5E2, eBiosciences). Monocytes were matured for 7 days in petri dishes at 
4.5x106/ml concentration in DMEM medium with 10% human AB serum. The 
adherent cell fraction was then harvested using a cell scraper, washed and re-
adhered at a concentration of 2 - 5 X106/ml at 37oC into 24-well plates for 24h prior 
to co-culture set-up (see section 2.8.3). 
Reactive B-cells were positively selected from tonsil SCSs as detailed in section 2.8.2 
and resuspended in DMEM medium with 10% human AB serum. These and DLBCL cell 
lines with acceptable viability (>85%) were layered in triplicate over the adherent 
macrophages at a 1:1 concentration or placed in transwell inserts as detailed in 
section 2.8.4. Macrophages treated with 100ng/ml of LPS were used as positive 
control. Macrophages cultured alone constituted our negative internal controls for 
each biological experiment.  
 
After 24h, co-culture supernatant was centrifuged and stored at -20oC for cytokine 
quantification (see section 2.9). Adherent macrophages were harvested and used for 
surface marker analysis using flow cytometry (see section 2.4.2). Antibodies used are 
described in Table 6.1. A minimum of 10000 events gated on compensated viable-
singlet cells were acquired using the four laser BD Fortessa flow cytometer. Results 
are expressed as the difference of MFI compared to macrophages cultured alone in 
each individual experiment.  
 
Additionally, macrophages were sorted using size and intracellular complexity 
allowing clear separation from contaminant B-cells. After sorting, RNA was extracted 
from each cell pellet, assessed for quality, converted to cDNA and analysed by qRT-PCR. 
NanoDrop spectrophotometer 260/280 values were comparable across all samples and 
were within the accepted ranges for good quality RNA (data not provided). CT values 
generated by the qRT-PCR reaction were normalised to GAPDH and converted to RQ 
values as described in section 2.7.2.2. The TaqMan® Gene Expression Assays tested were 
described in Chapter 5.  
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6.3.3 Statistical analysis  
Statistical analyses were performed with GraphPad Prism software using the Students 
T-test or Mann Whitney U-test when appropriate.  
 
 
Table 6.1 Antibodies used in this study 
Marker Clone Isotype Fluorochrome Source 
CD80 L307.4 Mouse IgG1, κ PE BD 
CD86 2331 (FUN-1) Mouse IgG1, κ FITC BD 
PD-L1 MIH1 Mouse IgG1, κ APC BD 
HLA-DR G46-6 Mouse IgG2a, κ APC-H7 BD 
CD36 CB38 Mouse IgM, κ APC BD 
Fixable viability dye   eFluor® 780 eBioscience 
 
 
 
6.4 Results  
6.4.1 Investigating changes in the expression of macrophage activation markers 
after co-culture 
Given we had no previous experience with this experimental model, the first 
approach was to investigate the dynamics of expression of macrophage activation 
markers after co-culture. None of the markers explored was found to be differentially 
expressed in our GEP studies. However we thought they could be informative of the 
utility of the model. 
 
As can be appreciated in Figure 6.1, LPS significantly enhanced the expression of 
CD80, CD86 and HLA-DR, suggesting macrophage responsiveness and that this model 
could be valuable to test the influence of B-cells.  
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LPS significantly increased CD86 expression compared to untreated macrophages and 
all remaining co-culture conditions. Whereas reactive B-cells cultured in contact with 
macrophages had no significant impact on CD86 expression, all other experimental 
conditions significantly decreased CD86 expression. This is visually clearer in the right 
side graph of Figure 6.1 A, representing CD86 expression dynamics for each replicate. 
Co-culture with the ABC cell line Ri1 produced the most significant reduction 
compared to untreated macrophages and macrophages cultured with reactive B-cells.  
 
Likewise, CD80 expression was upregulated by LPS. However the magnitude of 
change was more heterogeneous across biological replicates. In two of six of the 
replicates, LPS decreased CD80 expression. In fact, these two biological replicates 
display a different expression dynamics suggestive of being less responsive in co-
culture. Otherwise, experimental conditions were associated with enhanced 
expression of CD80, particularly in contact with B-cells and the Ri1 cell line. 
 
HLA-DR expression varied in a more heterogeneous fashion in all experimental 
conditions, and contrary to the results of the other markers, HLA-DR did not exhibit a 
normal distribution (data not shown). Even applying the Wilcoxon matched-pairs 
ranked test we did not find any significant results, supporting experimental 
heterogeneity. 
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Figure 6.1 Expression dynamics of activation markers CD80 (A), CD86 (B) and HLA-DR (C) in 
macrophages harvested from co-culture.  
Samples were incubated with conjugated mAbs for 30mins on ice in the dark and analysed by 
flow cytometry. The left side graphs represent the change of MFI compared to macrophages 
cultured alone (median +- SEM of six independent experiments). The right side graphs 
portray the expression dynamics according to each biological replicate. Paired Students T-test 
with *p <0.05, ** p <0.005. Brown symbols represent comparisons with control 
macrophages. 
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6.4.2 Exploring whether changes in gene expression found by GEP can be mimicked 
using the co-culture system 
In order to comprehend the expression dynamics of selected transcripts in 
macrophages in this co-culture model we had to sort them after co-culture. Although 
several methods were used to eliminate B-cells from the harvested cell pellet (from 
extensive washing to treatment with trypsin or less aggressive digesting solutions), 
contamination with B-cells could not be avoided (confirmed by flow cytometry, data 
not shown). Macrophages were selected according to size and intracellular 
complexity using the forward and side scatter pattern.  
 
The transcripts studied in three independent biological replicates were chosen from 
the top differentially expressed genes between DLBCL TAM compared to reactive 
macrophages in GEP studies (Chapter 5). The transcripts studied were AQP9, which 
was among the most upregulated; and IDO1 and CDH1, both among the most 
downregulated in DLBCL TAM compared to reactive macrophages.  
 
Given the necessity to select macrophages after co-culture, we firstly explored 
whether the sorting affected gene expression results.  
Indeed, relevant changes occurred after flow sorting in expression of the transcripts 
investigated. However, this effect did not seem to be similar neither across genes nor 
across samples. mRNA levels for the three assays changed in an heterogeneous 
fashion, as is illustrated in Figure 6.2.  
 
Next we are going to describe the findings for each of the three genes studied using 
qRT-PCR. 
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Figure 6.2 Targeted mRNA expression is affected by sorting after co-culture.  
50ng of amplified cDNA was used in triplicate for each sample and analysed by qRT-PCR. CT 
values were normalised to GAPDH. RQ values, calculated using as calibrator the average ΔCT 
of untreated macrophages, are represented for unsorted and sorted macrophages. 
 
 
 
AQP9 belongs to the family of aquaporins (AQP) which are water-selective membrane 
channels critical for the regulation of cell volume and migration.352 AQP9 is the most 
prominent AQP in human inflammatory cells,353 including macrophages, and was the 
sixth most upregulated gene in DLBCL TAM compared to reactive LN macrophages in 
our array studies (Log2 FC 3,35, adjusted p-value 0.003).  
 
AQP9 is among the transcripts defining an M1 signature (Figure 5.13) and hence 
should increase when macrophages are triggered by LPS. Accordingly, we were able 
to document a rise in this membrane channel in macrophages under LPS treatment 
(Figure 6.3 A). Compared to untreated macrophages, all conditions induced a 
decrease in AQP9, with the exception of two of the three samples when in contact 
with B-cells. As can be appreciated in Figure 6.3 A, right side panel, reactive B-cells 
did not induce a significant change in AQP9 expression when in contact due to sample 
heterogeneity, but decreased it when in transwell in all samples.  
 
The second molecule investigated, e-cadherin (CDH1), was among the most 
downregulated genes in our TAM signature (Log2 FC -2,6, adjusted p-value 0,03). Van 
den Bossche et al. described that CDH1 expression is enhanced in macrophages 
exposed to the prototypic M2 cytokine IL-4 and IL-10.354 Mechanistically, e-cadherin 
was shown to be involved in macrophage interactions with T-cells in a Th2 immune 
context. In addition, M1 stimuli repress CDH1 in macrophages.354 
CDH1 expression in untreated macrophages was variable, as can be appreciated in 
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Figure 6.3 B. In all experimental conditions a decrease of CDH1 mRNA levels was 
detected compared to controls particularly in contact conditions with both reactive 
and B-cell lines. As predicted, the M1 stimuli LPS induced a decrease in CDH1 
expression. 
 
Finally, we investigated the expression dynamics of indoleamine 2,3-dioxygenase 1 
(IDO1), a catalyser of the rate-limiting step in the immunoregulatory pathway of 
tryptophan catabolism. IDO1 activity in human macrophages is triggered by direct 
interaction with CD4+ T-cells and controlled by the M1 cytokine IFN-γ.355 
 
Contact with reactive B-cells led to an important increase in IDO1 mRNA levels in 
macrophages, and even more so with LPS treatment (Figure 6.3 C), corroborating 
published data. All other conditions induced a more depreciable and heterogeneous 
increase in IDO1 transcript levels compared to untreated macrophages. We also 
inspected IDO1 protein expression and results will be discussed in our next chapter. 
 
Moreover, we addressed whether we could mirror, using this co-culture model, the 
expression changes documented in our transcriptomic analysis in two other genes, 
CTSL1 and C3AR1. Both genes increased in all conditions compared to untreated 
macrophages, with no significant differences detected (data not shown).
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Figure 6.3 Gene expression changes of targeted genes in macrophages harvested from co-
culture.  
50ng of amplified cDNA was used in triplicate for each sample and analysed by qRT-PCR. CT 
values were normalised to GAPDH. The left side graphs represent RQ values (median +- SEM 
of three independent experiments). The right side graphs depict the expression dynamics 
according to each biological replicate. Paired Students T-test with *p <0.05, **p <0.005. 
Brown symbols represent comparisons with control macrophages. 
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6.4.3 Expression dynamics of the immunoregulatory molecule PD-L1 
TAM can exhibit immunossupressive functions (see Figure 1.2) through diverse 
mechanisms, from the production of soluble molecules, including IDO-1; to the direct 
crosstalk with T-cells through, for instance, e-cadherin or PD-L1. Macrophages can 
induce profound suppression of T-cell proliferation and cytokine secretion through 
crosstalk between PD-L1 (CD274) and the T-cell surface receptor PD-1.228,237,356 
According to published data, PD-L1 can be induced in macrophages by both M1 (LPS 
and IFN-γ)357 and M2 (IL-4 and IL-10) cytokines.358 
In our transcriptomic studies, PD-L1 was upregulated in DLBCL TAM compared to 
controls. We hence decided to investigate PD-L1 protein expression dynamics in 
macrophages after co-culture (Figure 6.4).  
 
 
 
 
 
Figure 6.4 Expression of PD-L1 protein in macrophages after co-culture.  
PD-L1 protein expression was tested using flow cytometry, results being the ratio of MFI 
compared to untreated macrophages. Paired Students T-test with *p <0.05, **p <0.005. 
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Using flow cytometry we confirmed that LPS induces an increase in PD-L1 basal levels 
in macrophages. Reactive B-cells enhanced, whereas DLBCL cell lines decreased PD-L1 
expression. However responses were variable across the three replicates studied. 
 
6.4.4 Investigating changes in CD36 expression in macrophages after co-culture 
Given that CD36 was used for positive selection of macrophages in our GEP studies, 
we investigated the dynamics of expression of this scavenger receptor in 
macrophages after co-culture (Figure 6.5).  
 
 
 
 
 
Figure 6.5 CD36 expression dynamics in macrophages harvested from co-culture.  
Sample were incubated with an anti-CD36 APC-conjugated mAb for 30mins on ice in the dark, 
washed and analysed by flow cytometry. Bars represent the change of MFI compared to 
macrophages cultured alone. Mean and SEM of six independent biological experiments are 
displayed. Paired Students T-test with *p <0.05, **p <0.005. 
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CD36 expression was detected in 100% of macrophages and differences in expression 
intensity according to co-culture conditions were modest, as can be appreciated in 
Figure 6.5. 
The Ri1 ABC cell line significantly increased CD36 expression in macrophages 
compared to control macrophages. Co-culture in contact with reactive B-cells was the 
only condition inducing a decrease of CD36 expression in macrophages compared to 
control. The magnitude of reduction in expression intensity induced by reactive B-
cells was significantly different from the ones detected when reactive B-cells were 
cultured in transwell, when macrophages were cultured in contact with Ri1 cell lines 
or when the GCB Su-DHL4 cell line was placed in transwell. 
 
 
6.5 Discussion 
Over the last decade an abundance of transcriptomic studies have been reported in 
DLBCL. This high throughtput technique led to major findings in DLBCL biology. The 
COO model illuminated on the heterogeneity of this disease and served as starting 
point for a multiplicity of functional studies of genetic aberrations shown to be 
specific to each molecular subgroup.  
On the contrary, whereas GEP of whole DLBCL tumours hinted towards the 
importance of a stromal response in disease biology and outcome, the lack of further 
functional validation of this hypothesis is remarkable.  
 
GEP consensus clustering analysis performed by Margaret Shipp’s group in 2005 
delineated three groups of DLBCL independently of the molecular COO. Following this 
discovery, the group elegantly provided validation data and novel insights into 
disease pathogenesis. For example, Caro et al. demonstrated that the DLBCL cluster 
harbouring an oxidative phosphorylation GEP signature displayed enhanced 
mitochondrial energy transduction and glutathione levels and was, notably, 
selectively sensitive to manipulation of glutathione synthesis compared to the 
remaining patient’s subsets.359 We believe that with additional, more comprehensive 
validation, GEP signatures of the microenvironment in DLBCL can provide similar 
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insights into the biology of DLBCL.  
Towards that end, we defined the transcriptome of the DLBCL TAM and suggested 
that macrophages are indeed implicated in the expression of prognostic immune 
signatures previously reported in this disease and hence constitute an excellent cell 
population to study at the functional level.  
 
Under the hypothesis that differences in GEP detailed in Chapter 5 result from the 
influence of malignant B-cells on macrophages we used a co-culture system involving 
these two cell types.  
 
Work presented in this chapter using the current co-culture model does not fully 
support this hypothesis. 
 
In order to determine whether this model could be used to study the dynamics of 
macrophage phenotype, we firstly investigated the expression pattern of the 
macrophage activation markers CD80, CD86 and HLA-DR after 24h in co-culture.  
 
The co-stimulatory molecules CD80 and CD86 are important deliverers of T-cell 
activation signals during immune responses. It is established that CD80 and CD86 help 
determining to what extent macrophages are skewed towards a pro-inflammatory 
phenotype, since their expression increases when macrophages are stimulated with 
LPS.360 However, it has been suggested that the expression dynamics of both 
molecules is differential under IFN-y stimulation, with CD86 expression increasing and 
CD80 expression decreasing.360 Moreover, the kinetics of modulation is also different, 
with changes occurring between 18 and 42h after activation and with CD86 preceding 
CD80 expression after LPS treatment for approximately 12h.361 
 
In our snapshot analysis at 24h, we indeed confirmed that, in most cases, LPS 
increased the expression of CD80, CD86 and HLA-DR. The lack of response to such 
potent activation in some replicates regarding CD80 and HLA-DR most likely 
represents inter-sample heterogeneity, given that the same samples responded to 
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LPS by increasing CD86 expression. These dampened responses could be attributed to 
a pre-existent activation state towards a pro-inflammatory phenotype in basal 
conditions or to a different kinetics with later responses in some cases.  
After 24h, CD86 expression decreased in all experimental conditions compared to 
control macrophages, with only two biological replicates being exceptions when 
cultured in contact with reactive B-cells. On the other hand CD80 expression 
increased throughout, particularly when macrophages were cultured in contact with 
reactive B-cells and the ABC cell line Ri1. Overall no clear differences were induced by 
reactive B-cells compared to cell lines at 24h of co-culture and the relevance of this 
expression pattern is unclear. Since only one time point was applied, we are unaware 
of the kinetics of expression of these molecules, which could help clarifying the 
significance of these findings. 
 
We then intended to demonstrate that macrophage gene expression changes 
revealed in our microarray studies could be mirrored using the co-culture model. We 
recognize that a more comprehensive approach using whole transcriptomic analysis 
or customized qRT-PCR arrays would probably be more useful to demonstrate this 
assumption. 
 
Whereas B-cell contamination did not constitute a problem for protein studies using 
flow cytometry due to differences in cell size and internal complexity, it made 
macrophage sorting necessary before qRT-PCR. We demonstrated that targeted gene 
expression is affected by the sorting, a phenomenon that is remarkably under-
reported in the literature. Changes were heterogeneous and suggested that the 
effect of cell sorting could not be predicted, nor was dependent on the biological 
sample. Our approach was to sort macrophages from all co-culture conditions. This 
was taken forward in three independent biological replicates.  
 
We chose to study transcripts that: (1) were maximally differentially regulated 
between reactive and DLBCL macrophages; (2) have been previously implicated in T-
cell regulatory functions; (3) have not been properly studied in DLBCL. If we could 
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prove a direct influence of B-cells on expression of these genes in macrophages, it 
would constitute an interesting mechanism of immunoregulation in DLBCL that 
should be experimentally tested.  
In agreement with previously published data, AQP9 and IDO1 were upregulated and 
CDH1 repressed by LPS. CDH1 basal levels were extremely variable in the three 
samples tested. This biological heterogeneity can be related to differences in cytokine 
levels or oxygen tension in healthy donors. 
 
The expression dynamics of AQP9 and CDH1 was similar, with a decrease in 
expression being induced in all experimental conditions compared to untreated 
macrophages. Contrary to our transcriptomic data, no clear differences arose from 
culture with reactive B-cells and DLBCL cell lines. Moreover, IDO1 was clearly 
upregulated by reactive B-cells compared to cell lines, again not substantiating GEP 
findings. This discrepancy in the kinetics of expression of the M1 molecules AQP9 and 
IDO1 suggests that related cytokines such as IFN-y might not play an import role in 
this model.  
We also attempted to demonstrate a differential effect of co-culture conditions in the 
expression of macrophage PD-L1 protein. However responses were variable across 
the three samples studied.  
 
A number of aspects related to the experimental design can justify the heterogeneity 
of our results and, as a consequence, the inability to support our hypothesis. 
 
For this investigation we used healthy human monocyte-derived macrophages that 
were matured in vitro in DMEM media and human serum. After our experiments 
were finalized an important consensus publication was published proposing a 
standardized methodology for macrophage studies that will allow achieving more 
reproducibility across experiments and laboratories.213 The panel of experts 
suggested that monocytes should be matured in media with purified endotoxin-free 
recombinant CSF-1. We recognize that using different batches of human serum as the 
source of CSF-1 increases the potential of obtaining experimental variability. 
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Additionally it is likely that commercialized serum will contain variable amounts of 
IFN that can cause confounding effects. We tested this hypothesis and did not detect 
IFN- in supernatants (see following chapter). However, it has to be hypothesized that 
soluble factors present in human serum (including CSF-1) influence macrophage 
activation. Our choice to use human serum was based on data demonstrating that 
CSF-1 directs macrophages towards an M2 phenotype.  
 
Additionally, peripheral blood monocytes from different donors (from which no 
clinical or demographical information is available) are likely to be differently 
activated.  
We believe to have overcome these two limitations by establishing as controls 
unmanipulated macrophages that were cultured in the same circumstances in each 
biological experiment. 
 
The main drawback of our co-culture model is the use of DLBCL cell lines. Although 
malignant cell lines provide valuable preliminary data, they have limitations. Their 
infinite growth in culture, independent of microenvironment signals, likely make 
them unsuitable cells to tease out the potential effect of cell interactions in vivo in 
the original tumour. Moreover they are unable to reflect patient tumour 
heterogeneity.  
 
Finally, due to a complex experimental design and cumbersome procedural 
manipulations, the analysis had to be limited to a single time-point and to reduced 
read-out analysis. In our opinion this is an extremely important aspect that limits 
interpretation of the co-culture system.  
 
It was entirely expected that such simplified model was limited to replicate the 
complex crosstalk that can be established between DLBCL malignant cells and the 
non-malignant cells in the microenvironment. An in vitro culture system using patient 
samples, which much more closely resemble the original tumour, would be a valuable 
tool to test our hypothesis. This was intended but deemed impossible in the current 
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studies. The extremely low viability on thawing of primary B-cells (data not shown, 
but indirectly illustrated by the modest RIN numbers) was not surprising, given that 
SCSs were previously stored, submitted to cell sorting and then re-stored.  
 
A three cell (macrophages, B and T-cells in an autologous setting) co-culture model 
using fresh samples, and testing a larger panel of markers would help us to finally 
address our hypothesis.
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Chapter 7 Exploring macrophage heterogeneity in diffuse large B-cell 
lymphoma 
 
7.1 Introduction 
As already mentioned, there are limited studies towards understanding the 
polarisation status and effector function heterogeneity of macrophages in human 
cancer. Our data presented in Chapter 4 highlights important differences between 
the DLBCL TAM and reactive LN macrophages. The GEP analysis undertaken also hints 
towards genuine macrophage heterogeneity within the DLBCL samples, not related to 
patient characteristics. This is an interesting finding, likely related to a distinct impact 
of the tumour cells on macrophage function that has potential prognostic value.  
 
Remarkably, most GEP findings were hardly validated at the protein level, likely due 
to problems inherent to IHC analysis of macrophages. CD68 is a non-specific pan-
macrophage marker highly difficult to analyse.329 Diagnostic DLBCL samples have 
heterogeneous infiltrations of CD68+ macrophages. In chapter 4, we suggested that 
the extent of total macrophages has no impact on patient’s outcome, contradicting 
the prognostic models developed using transcriptomic analysis of DLBCL LNs. This 
data exposes a major limitation of IHC studies to functionally characterise TAM in the 
microenvironment. CD163 has been claimed to specifically identify M2 macrophages. 
A subset of STAT1+ M1 macrophages has been identified using double IF staining in 
follicular lymphoma and linked to a worse outcome.362 However recognizing global 
M1 and M2 populations using broad prototypic markers brings limited information 
regarding the detailed functional activation of macrophage subsets in the 
microenvironment. Identifying novel proteins, as SPARC has been identified, might be 
the way forward to recognize subsets of macrophages with more restricted functions, 
with an outcome impact potential and amenable to be targeted. 
 
In this study we aimed to consolidate our previous finding that macrophages are 
functionally heterogeneous in the DLBCL microenvironment. And with the assumption 
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that the malignant B-cells are partially contributing to macrophage polarisation in 
DLBCL, we hypothesized that a deeper analysis of GEP of TAM could help to segregate 
different groups of DLBCL establishing different patterns of crosstalk with 
macrophages in the microenvironment. 
Additionally, we predicted that novel markers discovered using GEP could help to 
better characterise the functional polarisation of TAM in the DLBCL 
microenvironment. 
 
 
7.2 Aims 
In this study we aimed at exploring the DLBCL TAM trancriptomic heterogeneity. 
After depicting subgroups within the TAM samples studied in Chapter 5, we intended 
to explore the cytokine and chemokine profile of corresponding malignant B-cells, 
hoping to illuminate on potential molecules partially responsible for the different 
macrophage polarisation statuses identified in the transcriptomic analysis. 
In the same line, we wanted to reinforce the underlying macrophage heterogeneity 
by demonstrating that DLBCL TAM express previously unexplored M1 and M2 
proteins.  
 
 
7.3 Materials and methods 
7.3.1 Samples 
The transcriptomic analysis was performed using samples described in Chapter 5.  
IHC and IF studies were performed using FFPE tissue from DLBCL patients treated 
with R-CHOP at St. Bartholomew’s Hospital. Patient’s characteristics have been 
described in Chapter 3.  
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7.3.2 Cytokine studies 
CBAs were used to test for the presence of cytokines and chemokines in culture 
media. These studies were undertaken using samples from the co-culture 
experiments explained in Chapter 6 and from cell line supernatant. A detailed 
methodology is given in Chapter 2. 
 
7.3.3 IHC Staining and IF analysis 
Single protein immunostainings were performed as previously described. IF was used 
in this study to detect co-expression of two proteins of interest in macrophages in 
FFPE tissue of DLBCL and reactive LNs. A detailed staining protocol is provided in 
section 2.3. Primary antibodies and conditions of use are described in Table 7.1.  
Slides were scanned using an Olympus BX61 microscope and analyzed using the Ariol 
SL-50 visual analysis software. Scanned slides were observed on a computer screen. 
Single channel and overlapping images were used for final analysis quantifying single 
and double positive cell counts.  
 
7.3.4 Statistical analysis  
Statistical analyses were performed with GraphPad Prism software using the Students 
T-test or Mann Whitney U-test when appropriate.  
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Table 7.1 Antibodies used in this study 
Antibody Clone Species Dilution Source 
CD68 PGM1 Mouse 1/400 Dako 
CD163 10D6 Mouse 1/2800 Leica Biosystems 
ALOX15 3D8 Mouse 1/250 AbD Serotec 
IDO1 polyclonal Rabbit 1/50 Sigma-Aldrich 
 
 
 
7.4 Results 
7.4.1 Transcriptome heterogeneity in DLBCL TAM 
The gene and protein expression studies just described suggest that the co-culture 
model developed does not mirror the GEP data. This was entirely expected, and 
limitations of the model were already discussed.  
 
In this context, we considered addressing the previous finding of macrophage GEP 
heterogeneity within DLBCL TAM.  
Microarray unsupervised hierarchical clustering based on the 12000 most variables 
probesets of the 13 samples studied showed that DLBCL TAM agglomerated in two 
main clusters (Figure 7.1 A). No differences in clinical features were detected 
between these two groups (data not shown). 
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We hence thought of interrogating for differential expressed genes between the two 
groups (identified in Figure 7.1 A and B in gray and blue). Using a FC 3 and adjusted 
p-value 0.05 we identified 150 well-annotated genes that were differentially 
expressed between the DLBCL TAM groups. The genes we investigated in our co-
culture model were among the differentially expressed genes between the two 
groups, as can be visualized in Figure 7.1 C. This could be expected by simply 
inspecting the two-dimensional scaling image, showing that the DLBCL TAM 
population 1 (in gray) clusters closer to reactive LN macrophages. Indeed, both CD1E 
and CDH1, found to be upregulated in reactive controls versus the whole DLBCL TAM 
group, were both upregulated in the DLBCL TAM population 1. To test the degree of 
similarity between the reactive macrophages DLBCL TAM population 1, we looked at 
differentially expressed genes between the two groups. Top transcripts from our 
original analysis were still differentially expressed, including FCγR genes, MT genes, 
ANKRD22, AQP9, IDO1, C3AR1 or CTSL1.  
 
7.4.2 Investigating soluble factors differentially expressed between DLBCL TAM 
groups 
As has already been described, it is likely that malignant B-cells influence macrophage 
polarisation and function through the production of soluble factors. Cytokines and 
chemokines are deregulated in tumours. These can contribute in an autocrine fashion 
to tumour growth, but can also affect the microenvironment. 
 
We hypothesized that the differences documented in DLBCL TAM GEP profiles relate 
to differences in the cytokine and chemokine profile of corresponding malignant B-
cells.  
To this end we selected, among the pure (>95%) B-cell samples stored from DLBCL 
and reactive LN, three samples from each group (group 1: R0433, T2628, T4570; 
group 2: T6932, R8756, R9516) and two from reactive B-cell samples (T5900, T5996) 
and performed whole trancriptome analysis using Affymetrix U133 Plus 2.0 arrays. A 
targeted analysis of cytokines, chemokines and adhesion molecules was undertaken. 
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Figure 7.1 GEP analysis suggesting two groups of DLBCL TAM.  
A. Two-dimensional scaling based on expression of 12,000 genes, distances between samples 
calculated using Euclidean distance metrics. B. Heatmap representing differentially expressed 
genes between the two patient groups with a FC4 and adjusted p-value ≤0.05. Euclidean 
distance and Ward linkage applied. C. qRT-PCR results for targeted genes comparing the two 
DLBCL TAM groups. Bars represent mean + SEM, unpaired T-test, * p-value ≤0.05, ** p-value 
≤0.005.  
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Within the archetypal molecules involved in macrophage activation, the expression of 
M2 cytokines IL-4, IL-13 and IL-10 or IL-6 was not significantly different between B-
cells of both DLBCL groups and controls. On the contrary, IFN-γ, the prototypical M1 
cytokine was the most differentially expressed soluble factor between DLBCL B-cells, 
with an absolute FC of group 1 versus group 2 of -9.4 and an adjusted p-value of 
6.4X10-5 (Figure 6.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Differentially expressed soluble factors between B-cells.  
Initial RNA integrity was comparable across samples (RIN between 7.4 and 8.9). 12.5 g of 
fragmented and labelled aRNA were hybridised to Affymetrix U133 Plus 2.0 arrays according 
to manufacturer’s recommendations and analysed in a single batch. Data was normalised 
using RMA and filtered using 20% standard deviation of signal intensity as threshold on O-
miner (http://o-miner.org/onlinetool/index.html). Differentially expressed genes were tested 
using the limma method. Boxplots represent the log intensity for each group, and significance 
was tested using BH FDR.
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We hence explored whether there was a predominance of M1-skewed genes 
overexpressed in the DLBCL TAM group 2 compared to group 1. We confirmed that 
DLBCL TAM group 2 preferentially upregulated M1 genes compared to group 2 (56 of 
62 M1 genes upregulated in group 2 versus 5 of 62 in group 1).  
 
As can be appreciated in Figure 7.2, the two reactive B-cell samples profiled showed a 
much lower and tighter expression of IFN-γ, CCL4 or CCL5 compared to DLBCL 
samples. CCL5, previously implicated in interactions between DLBCL cells and 
monocytes was also significantly upregulated in group 2 compared to group 1. CCL4 
expression between DLBCL groups was also strikingly different. Although CCL4 is 
predominantly produced by macrophages, it can be secreted by normal and 
malignant B-cells upon BCR crosslinking, suggesting that differences in serum levels of 
this chemokine can be expected in DLBCL according to oncogenic BCR signalling 
activation.  
 
We then investigated whether DLBCL cell lines exhibited constitutional secretion of 
IFN-γ or CCL5 using CBAs. This experiment had as objective identifying cell lines with a 
discrepant cytokine profile that could be used in co-culture models instead of primary 
cells.  
 
Using CBA as described in Chapter 2, DLBCL cell lines did not seem to secrete either 
IFN-γ or CCL5 in the conditions tested.  
IFN-γ was undetectable in all conditions (data not shown). The two culture media 
where DLBCL cell lines are generally maintained, RPMI or IMDM with FCS, had 
undetectable CCL5 (Figure 7.3). However, human serum utilised to mature 
macrophages in vitro and in our co-culture system, contains traceable amounts of 
CCL5. DMEM with human serum had similar levels of CCL5 as the same media 
extracted from wells where cell lines where grown for 24h. DMEM media alone had 
undetectable CCL5.
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Figure 7.3 CCL5 is detected in the cell culture media used in co-culture experiments.  
DLBCL cell lines were cultured in triplicate in 24 well plates in DMEM and human AB serum 
(HAS) for 24h, in an attempt to mimic co-culture conditions. For each condition, 50 ml of 
culture media was tested in triplicate using CBAs. Media only was tested in parallel. Bars 
represent the mean and SEM. 
 
 
In this context, we treated macrophages for 24h with the five soluble factors 
described in Figure 7.2 and analysed the expression of CD80 and PD-L1. The objective 
of this experiment was to investigate whether such factors could induce expression 
changes similar to the ones obtained in our co-culture models.  
 
In the absence of standardized protocols for macrophage stimulation with some of 
the molecules, different concentrations of CCL4 (10 and 20 ng/ml), CCL5 (1 and 5 
ng/ml) and IL-15 (50 and 100 ng/ml) were used. The data presented refers to the 
dose inducing relevant expression changes compared to untreated macrophages. In 
this pilot experiment (Figure 7.4) we confirmed our previous and others data 
describing LPS and IFN-γ as potent activators and CD80 and PD-L1 as M1-induced 
proteins in macrophages. With the exception of LPS and IFN-γ, the added molecules 
produced modest changes compared to untreated macrophages. However, those 
changes were within the range of the ones induced by reactive B-cells or DLBCL cell 
lines (see Figures 6.1 and 6.3).
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Figure 7.4 Expression of CD80 and PD-L1 in macrophages treated with soluble factors.  
Cells were harvested from 24 well plates 24h after treatment, stained for CD80 and PD-L1 by 
flow cytometry. Bars represent the difference in MFI compared to untreated macrophages 
from one biological replicate. 
 
 
All treatment conditions induced an increase of CD80 and PD-L1 MFI compared to 
controls. We found the same effect on CD80 in all co-culture settings, but a different 
effect on PD-L1, which expression decreased when DLBCL cell lines were added in 
contact or in transwell. 
 
7.4.3 Investigating Th1 and Th2 cytokines in co-culture supernatant 
Finally we investigated whether we could identify Th1 and Th2 cytokines in co-culture 
media. IFN-γ was undetectable in all five experiments. The Th1 cytokine TNF-α and 
the Th2 cytokines IL-6 and IL-10 could be identified in our model (Figure 7.5). 
Stimulation with LPS led to a considerable secretion of these cytokines by 
macrophages. Although in a significantly lower concentration IL-6, IL-10 and TNF-α 
were traced in supernatants from macrophages and reactive B-cells in contact 
conditions. When reactive B-cells were cultured alone, none of the three cytokines 
could be identified. All remaining conditions were negative. 
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Figure 7.5 Detection of Th1 and Th2 cytokines in co-culture supernatants.  
50 ml of co-culture supernatant was tested using CBA as described. Results represent the 
mean and SEM of five independent experiments. Bars represent mean + SEM, unpaired T-
test, * p-value ≤0.05. 
 
 
 
7.4.4 Using immunohistochemistry and immunofluorescence to discover specific 
macrophage subsets in the microenvironment 
We hypothesized that the expression of proteins codified by M1 and M2 genes 
previously identified by GEP could help identifying subsets of macrophages in the 
microenvironment, as well as corroborating the existence of macrophage 
heterogeneity in human DLBCL. Using novel markers might aid defining cell subsets 
with potentially different functions. 
 
Most studies trying to define M2 macrophage density in lymphoma used IHC for 
CD163. We claim that, in some circumstances, this is an inadequate approach for the 
Chapter 7 Results 
228 
purpose.  
Manual counting of both markers would likely produce ambiguous data, with CD163 
outnumbering CD68, particularly in cases with heavy infiltration (Figure 7.6 A, case 1). 
This can be better appreciated in a correlation plot (Figure 7.6 C) showing a significant 
number of cases (~ 25%) scored higher for CD163 than for CD68. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Analysis of CD68 and CD163 immunostainings.  
A. Consecutive TMA sections were stained with CD68-KP1 and CD163. Images taken from the 
same core areas for two illustrative cases of heavy and low cell density. Amplification x20 and 
x40. B. Distribution of cases according to % stained area for CD68 and CD163 using 
Pannoramic Viewer. C. Correlation between results plotted in Figure B. 
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7.4.4.1 ALOX15 helps identifying a macrophages M2 subset in DLBCL 
Arachidonate 15-Lipoxygenase (ALOX15) is a lipid-peroxiding enzyme involved in the 
clearance of apoptotic cells by macrophages. It has been demonstrated that ALOX15 
belongs to an IL-4-induced, M2 transcriptional programme in human macrophages 
controlled by the transcription factor MYC. Coordinate induction of PPAR- and 
ALOX15 mediates interleukin-4-dependent transcription of the CD36 in macrophages.  
Immunostaining for ALOX15 in reactive LN TMAs suggested its expression was 
restricted to the stromal compartment (illustrative example pictured in Figure 7.7 A).  
 
Morphologically, a substantial number of ALOX15+ cells in DLBCL were smaller than 
macrophages, likely representing monocytes. By performing IF in TMAs we 
determined that ALOX15 expression is circumscribed to a small subset of CD68+ cells 
in DLBCL (Figure 7.7 A). Hence, a comparative analysis could be done using single 
ALOX15 immunostaining.  
 
Quantification of ALOX15+ cells in TMA corroborated GEP data (logFC -2,513 of DLBCL 
TAM versus controls, p=0.003). R-CHOP treated DLBCL showed a significantly lower 
expression of this enzyme compared to reactive LNs (Figure 7.7 B). Although a 
relatively small number of DLBCL cases were investigated (results available for 64 of 
the 77 patients treated with R-CHOP at Bart’s), a training validation method 
suggested that having ALOX15+ cells in the stromal compartment was associated with 
an improved PFS (Figure 7.7 C). It will now important to validate these results in an 
independent cohort.
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Figure 7.7 Expression of ALOX15 in reactive LNs and DLBCL.  
A. HRP-DAB immunostaining for ALOX15 in representative cases of reactive LN (x20 and x40 
magnification) and DLBCL (x40 magnification). IF studies performed in DLBCL TMAs showed 
that ALOX15 is restricted to CD68+ cells (white arrows, 20x magnification). B. Manual 
quantification of ALOX15 in DLBCL (64 cases) and reactive LN (29 cases) TMAs. Mann-Whitney 
U-test p-value <0.001. C. PFS according to absence or presence of ALOX15 expression (HR for 
negative cases 2.6, 95% CI 1.120-9.891). 
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7.4.4.2 IDO1 helps identifying a macrophages M1 subset in DLBCL 
IDO1 transcript levels were upregulated in DLBCL macrophages compared to reactive 
controls, particularly in a subset of patients (group 2). Its promoter includes 
transcription factor sites that confer responsiveness to IFN- and it has been shown 
that macrophages, DCs and endothelial cells increase IDO1 expression when exposed 
to this cytokine and to LPS.  
IDO1 protein expression was previously explored in DLBCL by a single group. The 
authors established a direct correlation of IDO1 expression by malignant B-cells with 
a worse survival in R-CHOP treated patients.  
 
Corroborating previous findings, IDO1 expression was detected in stromal cells in 
reactive and DLBCL LN, likely in monocytes/macrophages, DCs and endothelial cells. 
In some cases (on example is illustrated in Figure 7.8, case 1), IDO1 appears to be 
expressed by malignant B-cells, but with a much lower intensity compared to stromal 
cells. Even within the stromal compartment, expression was variable, as is illustrated 
in case 2.  
 
IF staining in DLBCL and reactive LN TMA showed co-localization of IDO1 and CD68 in 
the cytoplasm of a subset of small and large, interdigitating cells (identified in Figure 
7.8 A). Both CD68+/IDO- macrophages and CD68-/IDO1+ cells were also identified. 
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Figure 7.8 Expression of IDO1 in reactive LNs and DLBCL.  
A. HRP-DAB immunostaining for IDO1 in representative cases of reactive LN (x20 and x40 
magnification) and DLBCL (x40 magnification). Representative IF results for case 2 are 
illustrated, with white arrows identifying CD68+/IDO+ cells (40x and 63x magnification). B. 
The %CD68+/IDO1+ within the total macrophage population in DLBCL and control cases was 
manually quantified using IF.  
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IF analysis was performed manually on a computer screen. Firstly, CD68+ cells were 
quantified using the green channel. By switching the red channel on and off, 
CD68+/IDO1+ cells were then estimated for each case. Results for 59 R-CHOP treated 
patients and ten reactive LN samples are presented (Figure 7.8 B). 
According to our data, the proportion of IDO1+ macrophages in DLBCL is variable. 
Two-thirds of DLBCL patients had <12.5% infiltration, whereas the remaining had a 
denser infiltration of dual positive cells. This is in accordance to our transcriptomic 
studies, in which IDO1 transcript was upregulated in a smaller DLBCL subset (group 2, 
five patients) compared to the remaining (group 1, eight patients). Additionally, 
although control cases studied are scarce, the proportion of IDO1+ macrophages 
seems to be lower than in DLBCL, again supporting our GEP results. These findings, 
however, need to be validated in a larger dataset. 
 
 
7.5 Discussion 
Given the impossibility of designing an optimal co-culture model, we thought of 
addressing DLBCL TAM heterogeneity that was hinted by the initial unsupervised 
hierarchical clustering of GEP clusters.  
 
Supervised analysis showed that transcripts investigated in our co-culture model 
were among the differentially expressed genes between the two groups. However we 
believe these results do not devaluate the initial GEP results, which put into relevance 
the homogeneity of reactive LN macrophage GEP compared to DLBCL TAM GEP. To 
corroborate this, when results from reactive macrophages and samples belonging to 
the DLBCL TAM population 1 were compared, top transcripts were still differentially 
expressed. This is visually illustrated in the multidimensional scaling results placing 
DLBCL TAM population 1 in an intermediate position between controls and DLBCL 
TAM population 2.  
 
We then postulated that TAM GEP relate to differences in the cytokine and 
chemokine profile of corresponding malignant B-cells. Recognizing differentially 
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expressed soluble factors could help to design simpler models to test their influence 
in macrophage transcriptome and proteome and to illuminate on potential cell 
interactions. 
 
Emulating T helper-cell functional classification, it has been proposed that effector B-
cell subsets can be identified by the pattern of cytokines secreted when stimulated 
with antigen and T helper cells.263 When triggered by Th1 cells, B-cells are able to 
produce Th1 cytokines including IFN-, which in turn are able to amplify a Th1 
immune response by affecting T-cell polarisation. This effector classification has not 
been addressed in the context of B-cell malignancies. 
 
ABC DLBCL cell lines harbouring MYD88 mutations can secrete IL-6 and IL-10.125 
Studies using human DLBCL samples confirmed an increase in these JAK/STAT 
pathway-related serum cytokines and established a link between higher levels and a 
worse outcome.363-365 It can be envisaged that DLBCL-derived IL-6 and IL-10, similarly 
to what has been described for IL-10 in BL and in other tumour contexts, polarise 
macrophages towards an M2, immunossupressive phenotype and sustain their 
survival in the microenvironment. Data developed in our laboratory (Hallam, SL, 
unpublished) confirmed a rise in circulating concentrations of IL-10 and IL-6 in mice 
transplanted with an aggressive B-cell NHL. In this model IL-6 decreased after 
macrophage ablation. 
 
The expression of genes codifying the M2 cytokines IL-4, IL-13 and IL-10 or IL-6 was 
not significantly different between B-cells of both DLBCL groups and controls. 
However, the prototypical M1 cytokine IFN-γ was the most differentially expressed 
soluble factor between DLBCL B-cell groups. It is possible that B-cell-derived IFN-γ can 
intervene in macrophage M1 polarisation. We confirmed that DLBCL TAM group 2 
preferentially upregulated M1 genes compared to group 2, which could corroborate 
the existence of different B-cell polarised effector population and an IFN-γ enriched 
milieu.  
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However, correlations between cytokine mRNA levels and secretion are generally 
poor. In an attempt to identify cell lines with a discrepant cytokine profile that could 
be used in co-culture models instead of primary cells, we measured cytokines in 
supernatants. None of the six DLBCL cell lines exhibited constitutional secretion of 
IFN-γ or other molecules tested, which could have been predicted given the lack of 
polarising triggers.  
 
Measuring cytokines in DLBCL LN immediately after collection, yet not revealing their 
source, would be the only way to support the relevance of our findings. This could not 
be performed in our studies and is hard to pursue given the obstacles in obtaining 
fresh material. Although FFPE immunostaining could be used, we suggest that 
problems of quantification would be encountered. 
 
IFN-γ was also undetected in all co-culture conditions, suggesting: (1) that this model 
is not adequate to demonstrate B-cell polarisation; (2) that IFN-γ, if produced, is not 
release to the media. On the other hand, TNF-α and the Th2 cytokines IL-6 and IL-10 
were identified in supernatants and likely are macrophage-derived. Stimulation with 
LPS led to a considerable secretion of these cytokines, suggesting that macrophages 
are able to establish a secretory response to pro-inflammatory stimuli. Moreover, 
reactive B-cells cultured alone did not secrete any of the three molecules. Cell lines 
had no influence on cytokine secretion. Instead, IL-6, IL-10 and TNF-α were detected 
in supernatants from macrophages and reactive B-cells in contact conditions, 
suggesting macrophage activation by B-cells. However, this was not formally 
demonstrated in our experiments. It would be interesting to perform intracellular 
cytokine staining by flow cytometry of both B-cells and macrophages, since there is a 
possibility that both cell subsets trigger each other to produce these cytokines. These 
findings should be pursued in future experiments using primary DLBCL B-cells.  
 
 
Other approach to validate GEP data is to perform protein studies using IHC. The 
availability of TMAs of DLBCL and reactive LN in our laboratory permitted analysing 
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protein expression patterns in DLBCL TAM and reactive macrophages in parallel, 
emulating the transcriptomic studies. 
 
In this part of our investigations we wanted to clarify whether both M1 and M2 
macrophages, expressing novel markers identified by GEP, are present in DLBCL 
tumours.  
 
As already mentioned, it has been postulated that CD163 identifies M2 macrophages 
in the microenvironment of lymphoma. We think defining smaller, functionally 
skewed subsets would be more useful. Moreover, we claim that CD163, yet being a 
macrophage specific marker, is an inadequate M2 marker and hope to convey it by 
showing that one quarter of cases analysed for % stained area of CD68 and CD163 in 
parallel score higher for CD163 than for CD68. 
 
Within the list of differentially expressed genes resulting from our transcriptomic 
studies we investigated several markers, but chose to show only results for ALOX15 
and IDO-1 due to holding more comprehensive results. The remaining proteins 
(ANKRD22, CTSL1, PD-L1, AQP9, CDH1) are still under investigation.  
The expression pattern of ALOX15 in LNs is underreported in the literature. According 
to our data, ALOX15 expression is restricted to cells of the microenvironment in 
DLBCL and reactive LNs and co-localizes with CD68 in all cases studied. Some double 
positive cells have morphology not suggestive of macrophages. It is possible that 
these are monocytes instead. It is known that CD68 staining can be identified in cells 
other than macrophages, such as mast cells. In our studies we used the monoclonal 
antibody PGM1, which is more specific to macrophages, giving less positivity to mast 
cells than the monoclonal antibody KP1. However, due to staining pattern of ALOX15 
and its universal co-localization with CD68, it would be important to perform co-
staining with triptase to exclude we are observing mast cells. Certainly, ALOX15 
allows identifying only a subset of CD68+ cells, which is easily quantifiable using HRP-
DAB immunostaining. Quantification of ALOX15+ cells in TMA corroborated GEP data 
with DLBCL cases showing a significantly lower expression of this enzyme compared 
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to reactive LNs. We suggest that ALOX15 presence in the microenvironment of DLBCL 
is associated with a longer PFS, but agree that an independent study performed in a 
larger dataset needs to be undertaken to validate this potential biomarker.  
Similarly, we suggest that IF using IDO1 and CD68 permits identifying an M1 
macrophage subset, likely displaying immunoregulatory functions in the 
microenvironment. By analysing a small dataset of patients and controls, we found 
that the proportion of IDO1+ macrophages in DLBCL is variable, being heavier in one 
third of patients. These cases can approximate to the ones belonging to DLBCL TAM 
group 2, which had a higher IDO1 gene expression. These findings, however, need to 
be validated in a larger dataset. Moreover, we need to gain more experience in 
analysing IF data before suggesting any methodology to replicate such results in 
independent studies. We recognize that interpretation of IDO1 is difficult due to a 
wide expression intensity range in LN cells. Automated analysis would certainly 
increase reproducibility and a method is being devised for that purpose using the 
Ariol system. 
Despite some limitations, we demonstrate in these studies that M1 and M2 
macrophage subsets co-inhabit in DLBCL tumours. Using novel markers that have a 
better functional translation might help to interpret the role of subpopulations in the 
microenvironment. 
 
Although it is plausible that a single cell is able to express both M1 and M2 markers 
simultaneously, we currently do not have data demonstrating it. RNA in situ 
hybridisation and IF using M1 and M2 proteins will help to address this hypothesis. 
However, it is possible that studying targeted markers using these techniques still 
does not rule out this hypothesis, and we plan to perform macrophage single cell 
sorting and RNA sequencing to definitely clarify this matter.
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Chapter 8 Final discussion and further work 
Whereas only the IPI is established as a robust prognostic model, a number of 
biomarkers have the potential of better identifying poor-risk DLBCL patients. The 
underlying biological diversity of this disease explains the heterogeneous responses 
to first line chemoimmunotherapy and warrants the development of novel prognostic 
models for this disease incorporating such biomarkers. In this thesis we investigated 
biomarkers of the tumour and the microenvironment of DLBCL.  
 
The hypotheses underlying our investigation were based on two critical findings of 
transcriptomic analysis of DLBCL: 
 
 Two molecularly distinct forms based upon the cell-of-origin (COO) of DLBCL could 
be identified using GEP, which assume distinct genetic changes, oncogenic 
signalling pathways and response to R-CHOP. Thus, the COO molecular 
classification provides prospects for individualized treatment approaches that 
could improve patient’s outcome. The obstacle to this enticing clinical scenario is 
the inexistence of robust strategies that enable us to recognize patients with GCB 
and ABC DLBCL. 
 
 The differential expression of genes derived from the microenvironment can be 
used to identify patients with different outcome after R-CHOP. GEP-based 
prognostic signatures devised by independent research groups using independent 
patient cohorts incorporated genes encoding for tumour-infiltrating macrophages 
and matrix components. However, this data largely lacks independent validation. 
Moreover, a clear understanding of the macrophage functional heterogeneity in 
DLBCL is lacking. 
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The translational impact of transcriptomic studies has been demonstrated to be much 
limited compared to what is proposed in the original studies.  
 
A number of obstacles to the acceptance of GEP-derived biomarkers can be 
acknowledged, including:  
 Biomarkers need to be easily studied in any laboratory;  
 Validation processes need to be robust; 
 Microarray technology is still reserved to the research setting.  
 
Undoubtedly, the methodology applied in independent studies exploring GEP-based 
biomarkers has an important impact on their validation. IHC has been used both as a 
surrogate to classify patients according to the COO classification and to enumerate 
and functionally characterize the microenvironment in DLBCL. Importantly, the Hans 
algorithm is being utilised to recognize ABC-DLBCLs in clinical trials offering NF-kB 
targeting agents to patients with this subtype.  
 
Our first two studies encapsulate the problems and hopes of IHC methodologies for 
validation of prognostic biomarkers in DLBCL.  
 
Our first study provides evidence that IHC algorithms are unreliable predictors of the 
molecular classification and hence should not be used for clinical decisions in DLBCL. 
Our second study establishes semi-automated methods as the best for IHC studies 
assessing cell infiltration in large tissue areas using TMAs.  
 
While we suggest that the strategies used in previous investigations defining COO IHC 
algorithms are hardly replicated, we do not fully discard the notion that IHC can be 
used for the molecular classification of DLBCL.  
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We propose several approaches that could help demonstrating whether IHC can 
indeed be utilised for this purpose: 
 
 Future investigations could be done in RCTs involving expert 
haematopathologists, haemato-oncologists and statisticians from different 
countries; 
 
 An exhaustive document could arise from these trials that details guidelines for 
every single procedural step known to impact on IHC results, from tissue fixation 
to image and statistical analysis;  
 
 In order to demonstrate that the methodologies can indeed be put in place in a 
robust manner, fresh tissue samples from a single patient could be distributed to 
different laboratories and final results could be compared; 
 
 Once this is confirmed, the dissemination of this protocol could be done by 
experts in international meetings gathering other pathologists responsible for 
optimization of the techniques in their own countries; 
 
 Different institutions could be invited to report their results in follow-up 
meetings, stimulating discussion and further optimization of the established 
guidelines.  
 
 While we used the immune microenvironment in DLBCL as a model, the findings 
from our second study suggest that computerized systems eliminate the 
underlying variability of manual counting of IHC immunostainings and could also 
be explored for the analysis of proteins incorporated in the COO algorithms. A 
consensus methodological approach could be developed in the context of RCTs 
incorporating different systems of semi-automated analysis as delineated above.  
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Our subsequent studies address the unmet need for comprehensive analysis of 
macrophage  activation status and effector function in human DLBCL. We conducted 
transcriptomic studies on purified macrophages from DLBCL and reactive LN. Using 
this data we explored in vitro cell systems to capture the functional dialogue of 
malignant B-cells and macrophages in the microenvironment. In the last study we 
explore macrophage heterogeneity in DLBCL, either by dissecting the findings of the 
transcriptome analysis and establishing parallels with paired B-cell analysis, or by 
exploring double IF staining to recognize macrophage populations in LN. 
 
 
Previous publications using GEP of DLBCL correlated macrophage gene expression 
and outcome in DLBCL. Immunostaining for CD68 is taken as a surrogate of the extent 
of macrophage infiltration in tissues. However, difficulties posed by its analysis have 
to date hampered the ability to obtain consistent results. The computerized analysis 
of CD68 undertaken here using different machines and methods showed extremely 
good correlation, suggesting that this approach will be useful in clarifying the role of 
CD68 in outcome prediction in lymphoma. However, macrophages are highly plastic 
cells, assuming unique phenotypes and functions contextualized in their dynamic 
microenvironment. Consequently, IHC analysis of single markers is unable to 
represent subsets of polarised macrophages.  
 
Our approach was to use GEP to clarify the functional repertoire of macrophages in 
DLBCL. A number of technical aspects could detract from our findings. However, we 
assured that all procedural steps were subjected to strict quality controls and 
demonstrate that it is feasible to undertake this kind of study in stored samples. 
 
Unsupervised hierarchical clustering alone did not resolve disease from control 
samples in our study. This is an enticing discovery suggesting macrophage 
heterogeneity in DLBCL. In fact, it is doubtful that microenvironmental influences of 
the tumour cells work in a homogeneous fashion.  
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By performing a supervised hierarchical clustering analysis, we identified a 202-gene 
signature that distinguishes DLBCL TAM from reactive controls. The recognition of 
substantial gene expression variability in DLBCL TAM by unsupervised analysis 
suggested that corrected p-values would be modest and therefore the gene set 
would be small. Indeed expression variability was higher in DLBCL TAM. Although 
these findings could potentially reflect technical problems with our data, we do not 
have clear evidence for that and instead interpret them as biological variability that is 
inherent of human samples, particularly in bystander cells of the tumour 
microenvironment. In future studies we would like to test whether such GEP 
variability of macrophages is paralleled by underlying differences of the malignant B-
cells. 
 
A key approach taken in our GEP studies was the bioinformatics analysis. Whole 
transcriptome profiling represents an opportunity to functionally model a disease and 
bioinformatics approaches can help in giving biological meaning to high throughput 
data.  
 
The functional enrichment analysis undertaken exposes that our data not only 
reflects the transcriptomic features of macrophages, but also unique GEP changes 
characteristic of the DLBCL TAM. Our gene expression signature significantly overlaps 
with other GEP-defined signatures of DLBCL, including the LN-signature and others 
developed in THRLBCL. Moreover, an enrichment of our macrophage-related genes 
was detected in both GCB and ABC cases, suggesting that relevant features of the 
microenvironment are independent of the molecular features of the malignant B-
cells.  
 
Our studies suggest that DLBCL TAM have a bidirectional M1 and M2 functional 
activation. Additionally, univariate survival analysis points towards a variable impact 
of the expression of M2 genes in R-CHOP treated cases, refuting the common 
assumption that M2 macrophage activation is necessarily associated with poor 
survival. In future studies we would like to explore the outcome impact of the 
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remaining genes from our signature and develop multivariate prognostic models 
together with the IPI. 
 
Overall, these data commonalities validate in silico approaches to explore the 
function of cell subsets in complex tissues that are hard to study due to limited cell 
amounts or sensitiveness to laboratory manipulation. However, functional studies are 
the only ones able to provide definitive biological explanations towards the impact of 
specific molecules. In this context we conducted in vitro studies to functionally 
validate the trancriptomic studies. 
 
Macrophage activation is influenced by a multitude of factors. Numerous cells, 
cytokines and growth factors interact in vivo to determine macrophage function. 
Ultimately there is no macrophage identical to another, as dynamic changes in the 
microenvironment have a great potential to affect the cell transcriptome and 
function. Such microenvironmental complexity is hardly mimicked in a culture plate, 
more so when using a two-cell co-culture system, as we did in our fourth results 
chapter.  
 
In our last study we propose B-cell derived IFN-γ as the culprit molecule involved in a 
preferential M1 activation pattern in a subset of DLBCL TAM. However we did not 
formally test this experimentally in the current investigations and this will be subject 
of future experiments. To robustly demonstrate the hypothesis that the malignant 
DLBCL cells are influencing macrophages towards a specific transcriptome, we 
suggest in the future using three cell (macrophages, B and T-cells) co-culture models 
of primary samples, in an autologous setting and investigating a larger panel of 
markers. In this manner we shall better replicate the complex crosstalk that can be 
established between malignant and non-malignant cells in the microenvironment.  
 
Using molecules that have a better functional translation might help to interpret the 
role of macrophage subpopulations in the microenvironment. By studying novel 
markers depicted from the transcriptomic analysis we clarify that macrophages 
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express both M1 and M2 markers in DLBCL tumours.  
 
Although it is likely that a single macrophage is able to express both M1 and M2 
molecules simultaneously, we do not yet have data demonstrating this. As our own 
and other genomic data become available underlining macrophage heterogeneity, 
novel techniques to label several proteins and RNA transcripts concurrently in situ 
will be required to validate potential prognostic subsets in large datasets of patients. 
Furthermore, transcriptomic studies of single macrophages acquired by cell sorting 
would help clarifying whether subsets of macrophages within DLBCL have different 
activation profiles or whether a macrophage can acquire a unique and hybrid 
activation pattern. We suspect both situations are in place in vivo and aim to 
demonstrate it in future studies. 
 
In conclusion, the work developed in this thesis significantly deepened the 
understanding of the role of IHC methodologies for the validation of biomarkers for 
DLBCL. Although there are still large gaps to fulfil in order to comprehend the more 
complex phenomenon of macrophage activation in DLBCL, our investigations 
significantly moved the field forward by demonstrating cell functional heterogeneity 
and raising novel questions that will hardly be answered through simplified 
experimental designs.  
 
Chapter 9 References 
245 
Chapter 9 References 
 
1 Swerdlow SH, C. E., Harris NL, et al. . WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues 4th Edition edn,  (IARC Press, 2008). 
2 Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 
countries in 2012. European journal of cancer 49, 1374-1403, doi:10.1016/j.ejca.2012.12.027 
(2013). 
3 Montoto, S. & Fitzgibbon, J. Transformation of indolent B-cell lymphomas. J Clin 
Oncol 29, 1827-1834, doi:10.1200/JCO.2010.32.7577 (2011). 
4 Coutinho, R. et al. HIV status does not impair the outcome of patients diagnosed with 
diffuse large B-cell lymphoma treated with R-CHOP in the cART era. Aids 28, 689-697, 
doi:10.1097/QAD.0000000000000133 (2014). 
5 Ok, C. Y. et al. Prevalence and clinical implications of epstein-barr virus infection in de 
novo diffuse large B-cell lymphoma in Western countries. Clinical cancer research : an official 
journal of the American Association for Cancer Research 20, 2338-2349, doi:10.1158/1078-
0432.CCR-13-3157 (2014). 
6 Lopez-Guillermo, A. et al. Diffuse large B-cell lymphoma: clinical and biological 
characterization and outcome according to the nodal or extranodal primary origin. J Clin 
Oncol 23, 2797-2804, doi:10.1200/JCO.2005.07.155 (2005). 
7 Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W. & Tubiana, M. Report of 
the Committee on Hodgkin's Disease Staging Classification. Cancer research 31, 1860-1861 
(1971). 
8 Sehn, L. H. et al. Impact of concordant and discordant bone marrow involvement on 
outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29, 1452-1457, 
doi:10.1200/JCO.2010.33.3419 (2011). 
9 Cheson, B. D. et al. Recommendations for Initial Evaluation, Staging, and Response 
Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol, 
doi:10.1200/JCO.2013.54.8800 (2014). 
10 Gurbuxani, S., Anastasi, J. & Hyjek, E. Diffuse large B-cell lymphoma--more than a 
diffuse collection of large B cells: an entity in search of a meaningful classification. Arch 
Pathol Lab Med 133, 1121-1134, doi:10.1043/1543-2165-133.7.1121 (2009). 
11 Achten, R., Verhoef, G., Vanuytsel, L. & De Wolf-Peeters, C. Histiocyte-rich, T-cell-rich 
B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic 
morphologic and immunophenotypic features. Histopathology 40, 31-45 (2002). 
12 Monti, S. et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust 
subtypes including one characterized by host inflammatory response. Blood 105, 1851-1861, 
doi:2004-07-2947 [pii] 
10.1182/blood-2004-07-2947 (2005). 
13 Hummel, M. et al. A biologic definition of Burkitt's lymphoma from transcriptional 
and genomic profiling. N Engl J Med 354, 2419-2430, doi:10.1056/NEJMoa055351 (2006). 
14 Aukema, S. M. et al. Double-hit B-cell lymphomas. Blood 117, 2319-2331, 
doi:10.1182/blood-2010-09-297879 (2011). 
15 Snuderl, M. et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC 
rearrangements are aggressive neoplasms with clinical and pathologic features distinct from 
Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34, 327-340, 
doi:10.1097/PAS.0b013e3181cd3aeb (2010). 
16 Salaverria, I. & Siebert, R. The gray zone between Burkitt's lymphoma and diffuse 
large B-cell lymphoma from a genetics perspective. J Clin Oncol 29, 1835-1843, 
doi:10.1200/JCO.2010.32.8385 (2011). 
Chapter 9 References 
246 
17 Proctor, I. E., McNamara, C., Rodriguez-Justo, M., Isaacson, P. G. & Ramsay, A. 
Importance of expert central review in the diagnosis of lymphoid malignancies in a regional 
cancer network. J Clin Oncol 29, 1431-1435, doi:10.1200/JCO.2010.31.2223 (2011). 
18 McKelvey, E. M. et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy 
in malignant lymphoma. Cancer 38, 1484-1493 (1976). 
19 Fisher, R. I. et al. Comparison of a standard regimen (CHOP) with three intensive 
chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328, 1002-
1006, doi:10.1056/NEJM199304083281404 (1993). 
20 Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in 
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346, 235-242, 
doi:10.1056/NEJMoa011795 (2002). 
21 Coiffier, B. et al. Long-term outcome of patients in the LNH-98.5 trial, the first 
randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL 
patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116, 2040-2045, 
doi:10.1182/blood-2010-03-276246 (2010). 
22 Sehn, L. H. et al. Introduction of combined CHOP plus rituximab therapy dramatically 
improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23, 5027-
5033, doi:10.1200/JCO.2005.09.137 (2005). 
23 Pfreundschuh, M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like 
chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a 
randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 
7, 379-391, doi:10.1016/S1470-2045(06)70664-7 (2006). 
24 Pfreundschuh, M. et al. CHOP-like chemotherapy with or without rituximab in young 
patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label 
randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12, 1013-
1022, doi:10.1016/S1470-2045(11)70235-2 (2011). 
25 Delarue, R. et al. Dose-dense rituximab-CHOP compared with standard rituximab-
CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a 
randomised phase 3 trial. Lancet Oncol 14, 525-533, doi:10.1016/S1470-2045(13)70122-0 
(2013). 
26 Cunningham, D. et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and 
prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a 
phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, 
doi:10.1016/S0140-6736(13)60313-X (2013). 
27 Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed 
large B-cell lymphoma in the rituximab era. J Clin Oncol 28, 4184-4190, 
doi:10.1200/JCO.2010.28.1618 (2010). 
28 Schumacher, M., Binder, H. & Gerds, T. Assessment of survival prediction models 
based on microarray data. Bioinformatics 23, 1768-1774, doi:10.1093/bioinformatics/btm232 
(2007). 
29 Mehta, S. et al. Predictive and prognostic molecular markers for cancer medicine. 
Therapeutic advances in medical oncology 2, 125-148, doi:10.1177/1758834009360519 
(2010). 
30 A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-
Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329, 987-994, 
doi:10.1056/NEJM199309303291402 (1993). 
31 Sehn, L. H. et al. The revised International Prognostic Index (R-IPI) is a better 
predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma 
treated with R-CHOP. Blood 109, 1857-1861, doi:10.1182/blood-2006-08-038257 (2007). 
32 Ziepert, M. et al. Standard International prognostic index remains a valid predictor of 
outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin 
Chapter 9 References 
247 
Oncol 28, 2373-2380, doi:10.1200/JCO.2009.26.2493 (2010). 
33 Zhou, Z. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients 
with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123, 837-842, 
doi:10.1182/blood-2013-09-524108 (2014). 
34 Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359, 
2313-2323, doi:359/22/2313 [pii] 
10.1056/NEJMoa0802885 (2008). 
35 Savage, K. J. et al. MYC gene rearrangements are associated with a poor prognosis in 
diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114, 3533-
3537, doi:blood-2009-05-220095 [pii] 
10.1182/blood-2009-05-220095 (2009). 
36 Barrans, S. L. et al. The t(14;18) is associated with germinal center-derived diffuse 
large B-cell lymphoma and is a strong predictor of outcome. Clinical cancer research : an 
official journal of the American Association for Cancer Research 9, 2133-2139 (2003). 
37 Barrans, S. L. et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor 
prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 117, 322-332 (2002). 
38 Klapper, W. et al. Patient age at diagnosis is associated with the molecular 
characteristics of diffuse large B-cell lymphoma. Blood 119, 1882-1887, doi:10.1182/blood-
2011-10-388470 (2012). 
39 Riihijarvi, S., Taskinen, M., Jerkeman, M. & Leppa, S. Male gender is an adverse 
prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. European 
journal of haematology 86, 124-128, doi:10.1111/j.1600-0609.2010.01541.x (2011). 
40 Michael Pfreundschuh , G. H., Samira Zeynalova , Viola Pöschel , Andreas Viardot , 
Matthias Hänel, Ulrich Keller , Marcel Reiser , Markus Löffler, Niels Murawski. in 53rd ASH 
Annual Meeting and Exposition Vol. 118   (Blood, San Diego, 2011). 
41 Carson, K. R. et al. Increased body mass index is associated with improved survival in 
United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 30, 3217-3222, 
doi:10.1200/JCO.2011.39.2100 (2012). 
42 Larsson, S. C. & Wolk, A. Body mass index and risk of non-Hodgkin's and Hodgkin's 
lymphoma: a meta-analysis of prospective studies. European journal of cancer 47, 2422-2430, 
doi:10.1016/j.ejca.2011.06.029 (2011). 
43 Hong, F. et al. The role of body mass index in survival outcome for lymphoma 
patients: US intergroup experience. Annals of oncology : official journal of the European 
Society for Medical Oncology / ESMO 25, 669-674, doi:10.1093/annonc/mdt594 (2014). 
44 Pfreundschuh, M. et al. Prognostic significance of maximum tumour (bulk) diameter 
in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like 
chemotherapy with or without rituximab: an exploratory analysis of the MabThera 
International Trial Group (MInT) study. Lancet Oncol 9, 435-444, doi:10.1016/S1470-
2045(08)70078-0 (2008). 
45 Recher, C. et al. Intensified chemotherapy with ACVBP plus rituximab versus standard 
CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-
label randomised phase 3 trial. Lancet 378, 1858-1867, doi:10.1016/S0140-6736(11)61040-4 
(2011). 
46 Chung, R. et al. Concordant but not discordant bone marrow involvement in diffuse 
large B-cell lymphoma predicts a poor clinical outcome independent of the International 
Prognostic Index. Blood 110, 1278-1282, doi:10.1182/blood-2007-01-070300 (2007). 
47 Takahashi, H. et al. Prognostic impact of extranodal involvement in diffuse large B-
cell lymphoma in the rituximab era. Cancer 118, 4166-4172, doi:10.1002/cncr.27381 (2012). 
48 Gutierrez-Garcia, G. et al. Clinico-biological characterization and outcome of primary 
nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 51, 
1225-1232, doi:10.3109/10428194.2010.483301 (2010). 
Chapter 9 References 
248 
49 Moskowitz, C. H. et al. Risk-adapted dose-dense immunochemotherapy determined 
by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol 28, 1896-
1903, doi:10.1200/JCO.2009.26.5942 (2010). 
50 Casasnovas, R. O. et al. SUVmax reduction improves early prognosis value of interim 
positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118, 37-43, 
doi:10.1182/blood-2010-12-327767 (2011). 
51 Ott, G. et al. Immunoblastic morphology but not the immunohistochemical 
GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 
trial of the DSHNHL. Blood 116, 4916-4925, doi:10.1182/blood-2010-03-276766 (2010). 
52 Montes-Moreno, S. et al. Aggressive large B-cell lymphoma with plasma cell 
differentiation: immunohistochemical characterization of plasmablastic lymphoma and 
diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 95, 1342-
1349, doi:10.3324/haematol.2009.016113 (2010). 
53 Kobayashi, T. et al. Microarray reveals differences in both tumors and vascular 
specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer 
research 63, 60-66 (2003). 
54 Tagawa, H. et al. Comparison of genome profiles for identification of distinct 
subgroups of diffuse large B-cell lymphoma. Blood 106, 1770-1777, doi:10.1182/blood-2005-
02-0542 (2005). 
55 Ennishi, D. et al. CD5 expression is potentially predictive of poor outcome among 
biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP 
therapy. Annals of oncology : official journal of the European Society for Medical Oncology / 
ESMO 19, 1921-1926, doi:10.1093/annonc/mdn392 (2008). 
56 Johnson, N. A. et al. Diffuse large B-cell lymphoma: reduced CD20 expression is 
associated with an inferior survival. Blood 113, 3773-3780, doi:10.1182/blood-2008-09-
177469 (2009). 
57 Kuppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nature reviews. Cancer 5, 
251-262, doi:10.1038/nrc1589 (2005). 
58 de Villartay, J. P., Fischer, A. & Durandy, A. The mechanisms of immune 
diversification and their disorders. Nature reviews. Immunology 3, 962-972, 
doi:10.1038/nri1247 (2003). 
59 Shaffer, A. L., Rosenwald, A. & Staudt, L. M. Lymphoid malignancies: the dark side of 
B-cell differentiation. Nature reviews. Immunology 2, 920-932, doi:10.1038/nri953 
nri953 [pii] (2002). 
60 Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and 
malignancy. Nature reviews. Immunology 8, 22-33, doi:nri2217 [pii] 
10.1038/nri2217 (2008). 
61 Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their 
microenvironment. Trends Genet 25, 30-38, doi:S0168-9525(08)00309-0 [pii] 
10.1016/j.tig.2008.10.012 (2009). 
62 Limpens, J. et al. Lymphoma-associated translocation t(14;18) in blood B cells of 
normal individuals. Blood 85, 2528-2536 (1995). 
63 Klein, U. et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl 
Acad Sci U S A 100, 2639-2644, doi:10.1073/pnas.0437996100 (2003). 
64 Wagner, S. D. & Neuberger, M. S. Somatic hypermutation of immunoglobulin genes. 
Annu Rev Immunol 14, 441-457, doi:10.1146/annurev.immunol.14.1.441 (1996). 
65 Shen, H. M., Peters, A., Baron, B., Zhu, X. & Storb, U. Mutation of BCL-6 gene in 
normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750-1752 
(1998). 
66 Peled, J. U. et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 26, 
481-511, doi:10.1146/annurev.immunol.26.021607.090236 (2008). 
Chapter 9 References 
249 
67 Cattoretti, G. et al. Deregulated BCL6 expression recapitulates the pathogenesis of 
human diffuse large B cell lymphomas in mice. Cancer Cell 7, 445-455, 
doi:10.1016/j.ccr.2005.03.037 (2005). 
68 Saito, M. et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B 
cell lymphoma. Proc Natl Acad Sci U S A 106, 11294-11299, doi:10.1073/pnas.0903854106 
(2009). 
69 Ranuncolo, S. M., Polo, J. M. & Melnick, A. BCL6 represses CHEK1 and suppresses 
DNA damage pathways in normal and malignant B-cells. Blood Cells Mol Dis 41, 95-99, 
doi:10.1016/j.bcmd.2008.02.003 (2008). 
70 Ye, B. H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and 
Th2-type inflammation. Nat Genet 16, 161-170, doi:10.1038/ng0697-161 (1997). 
71 Tunyaplin, C. et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic 
differentiation. Journal of immunology 173, 1158-1165 (2004). 
72 Basso, K. & Dalla-Favera, R. BCL6: master regulator of the germinal center reaction 
and key oncogene in B cell lymphomagenesis. Adv Immunol 105, 193-210, 
doi:10.1016/S0065-2776(10)05007-8 (2010). 
73 Bubendorf, L. et al. Hormone therapy failure in human prostate cancer: analysis by 
complementary DNA and tissue microarrays. Journal of the National Cancer Institute 91, 
1758-1764 (1999). 
74 Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene 
expression profiling. Nature 403, 503-511, doi:10.1038/35000501 (2000). 
75 Alizadeh, A. et al. The lymphochip: a specialized cDNA microarray for the genomic-
scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor 
symposia on quantitative biology 64, 71-78 (1999). 
76 Rosenwald, A. et al. The use of molecular profiling to predict survival after 
chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346, 1937-1947, 
doi:10.1056/NEJMoa012914 
346/25/1937 [pii] (2002). 
77 Williams, P. M. et al. A novel method of amplification of FFPET-derived RNA enables 
accurate disease classification with microarrays. J Mol Diagn 12, 680-686, 
doi:10.2353/jmoldx.2010.090164 (2010). 
78 Rimsza, L. M. et al. Gene expression predicts overall survival in paraffin-embedded 
tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112, 3425-3433, 
doi:10.1182/blood-2008-02-137372 (2008). 
79 Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell 
lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123, 
1214-1217, doi:10.1182/blood-2013-11-536433 (2014). 
80 Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-
expression profiling and supervised machine learning. Nat Med 8, 68-74, 
doi:10.1038/nm0102-68 
nm0102-68 [pii] (2002). 
81 Lossos, I. S. et al. Ongoing immunoglobulin somatic mutation in germinal center B 
cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 
97, 10209-10213, doi:10.1073/pnas.180316097 
180316097 [pii] (2000). 
82 Lenz, G. et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct 
genetic pathways. Proc Natl Acad Sci U S A 105, 13520-13525, doi:0804295105 [pii] 
10.1073/pnas.0804295105 (2008). 
83 Shaffer, A. L., 3rd, Young, R. M. & Staudt, L. M. Pathogenesis of human B cell 
lymphomas. Annu Rev Immunol 30, 565-610, doi:10.1146/annurev-immunol-020711-075027 
(2012). 
Chapter 9 References 
250 
84 Jardin, F. Next generation sequencing and the management of diffuse large B-cell 
lymphoma: from whole exome analysis to targeted therapy. Discovery medicine 18, 51-65 
(2014). 
85 Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl 
Acad Sci U S A 110, 1398-1403, doi:10.1073/pnas.1205299110 (2013). 
86 Xu-Monette, Z. Y. et al. Mutational profile and prognostic significance of TP53 in 
diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International 
DLBCL Rituximab-CHOP Consortium Program Study. Blood 120, 3986-3996, 
doi:10.1182/blood-2012-05-433334 (2012). 
87 Ichikawa, A. et al. Mutations of the p53 gene as a prognostic factor in aggressive B-
cell lymphoma. N Engl J Med 337, 529-534, doi:10.1056/NEJM199708213370804 (1997). 
88 Wilson, W. H. et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug 
resistance in non-Hodgkin's lymphomas. Blood 89, 601-609 (1997). 
89 Young, K. H. et al. Structural profiles of TP53 gene mutations predict clinical outcome 
in diffuse large B-cell lymphoma: an international collaborative study. Blood 112, 3088-3098, 
doi:10.1182/blood-2008-01-129783 (2008). 
90 Zainuddin, N. et al. TP53 mutations predict for poor survival in de novo diffuse large 
B-cell lymphoma of germinal center subtype. Leuk Res 33, 60-66, 
doi:10.1016/j.leukres.2008.06.022 (2009). 
91 Bea, S. et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles 
that influence tumor biology and improve gene-expression-based survival prediction. Blood 
106, 3183-3190, doi:10.1182/blood-2005-04-1399 (2005). 
92 Wright, G. et al. A gene expression-based method to diagnose clinically distinct 
subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100, 9991-9996, 
doi:10.1073/pnas.1732008100 
1732008100 [pii] (2003). 
93 Coutinho, R. et al. Poor concordance among nine immunohistochemistry classifiers of 
cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. 
Clinical cancer research : an official journal of the American Association for Cancer Research 
19, 6686-6695, doi:10.1158/1078-0432.CCR-13-1482 (2013). 
94 Berglund, M. et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma 
and its impact on prognosis. Mod Pathol 18, 1113-1120, doi:10.1038/modpathol.3800396 
(2005). 
95 De Paepe, P. & De Wolf-Peeters, C. Diffuse large B-cell lymphoma: a heterogeneous 
group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. 
Leukemia 21, 37-43, doi:2404449 [pii] 
10.1038/sj.leu.2404449 (2007). 
96 Barrans, S. L. et al. Germinal center phenotype and bcl-2 expression combined with 
the International Prognostic Index improves patient risk stratification in diffuse large B-cell 
lymphoma. Blood 99, 1136-1143 (2002). 
97 Iqbal, J. et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell 
lymphoma treated with CHOP-like therapy and rituximab. Clinical cancer research : an official 
journal of the American Association for Cancer Research 17, 7785-7795, doi:10.1158/1078-
0432.CCR-11-0267 (2011). 
98 Klapper, W. et al. Structural aberrations affecting the MYC locus indicate a poor 
prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within 
randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group 
(DSHNHL). Leukemia : official journal of the Leukemia Society of America, Leukemia Research 
Fund, U.K 22, 2226-2229, doi:10.1038/leu.2008.230 (2008). 
99 Johnson, N. A. et al. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell 
Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and 
Chapter 9 References 
251 
Prednisone. J Clin Oncol, doi:10.1200/JCO.2011.41.0985 (2012). 
100 Obermann, E. C., Csato, M., Dirnhofer, S. & Tzankov, A. Aberrations of the MYC gene 
in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by 
morphological or immunohistochemical assessment. J Clin Pathol 62, 754-756, 
doi:10.1136/jcp.2009.065227 (2009). 
101 Barrans, S. et al. Rearrangement of MYC is associated with poor prognosis in patients 
with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28, 3360-3365, 
doi:10.1200/JCO.2009.26.3947 (2010). 
102 Green, T. M. et al. Immunohistochemical Double-Hit Score Is a Strong Predictor of 
Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus 
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol, 
doi:10.1200/JCO.2011.41.4342 (2012). 
103 Niitsu, N., Okamoto, M., Miura, I. & Hirano, M. Clinical features and prognosis of de 
novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia : 
official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 23, 777-783, 
doi:10.1038/leu.2008.344 (2009). 
104 Balasubramanian, S., Hurley, L. H. & Neidle, S. Targeting G-quadruplexes in gene 
promoters: a novel anticancer strategy? Nature reviews. Drug discovery 10, 261-275, 
doi:10.1038/nrd3428 (2011). 
105 Pasqualucci, L. et al. Mutations of the BCL6 proto-oncogene disrupt its negative 
autoregulation in diffuse large B-cell lymphoma. Blood 101, 2914-2923, doi:10.1182/blood-
2002-11-3387 (2003). 
106 Cerchietti, L. C. et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and 
in vivo. Cancer Cell 17, 400-411, doi:10.1016/j.ccr.2009.12.050 (2010). 
107 Salaverria, I. et al. Translocations activating IRF4 identify a subtype of germinal 
center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 
118, 139-147, doi:10.1182/blood-2011-01-330795 (2011). 
108 Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor 
kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma 
cells. J Exp Med 194, 1861-1874 (2001). 
109 Ferch, U. et al. Inhibition of MALT1 protease activity is selectively toxic for activated B 
cell-like diffuse large B cell lymphoma cells. The Journal of experimental medicine 206, 2313-
2320, doi:10.1084/jem.20091167 (2009). 
110 Hailfinger, S. et al. Essential role of MALT1 protease activity in activated B cell-like 
diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 106, 19946-19951, 
doi:10.1073/pnas.0907511106 (2009). 
111 Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. 
Science 319, 1676-1679, doi:10.1126/science.1153629 (2008). 
112 Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in 
diffuse large B-cell lymphoma. Nature 459, 717-721, doi:nature07968 [pii] 
10.1038/nature07968 (2009). 
113 Ruan, J. et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large 
B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29, 690-697, 
doi:10.1200/JCO.2010.31.1142 (2011). 
114 Ribrag, V. et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with 
B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group 
(GELA). Cancer 115, 4540-4546, doi:10.1002/cncr.24518 (2009). 
115 Refaeli, Y. et al. The B cell antigen receptor and overexpression of MYC can cooperate 
in the genesis of B cell lymphomas. PLoS biology 6, e152, doi:10.1371/journal.pbio.0060152 
(2008). 
Chapter 9 References 
252 
116 Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell 
lymphoma. Nature 463, 88-92, doi:10.1038/nature08638 (2010). 
117 Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell 
lymphoma. Cancer Cell 21, 723-737, doi:10.1016/j.ccr.2012.05.024 (2012). 
118 Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has 
significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31, 88-
94, doi:10.1200/JCO.2012.42.7906 (2013). 
119 Chen, L. et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment 
target in diffuse large B-cell lymphoma. Blood 111, 2230-2237, doi:10.1182/blood-2007-07-
100115 (2008). 
120 Cheng, S. et al. SYK inhibition and response prediction in diffuse large B-cell 
lymphoma. Blood 118, 6342-6352, doi:10.1182/blood-2011-02-333773 (2011). 
121 Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant 
clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 
2578-2585, doi:10.1182/blood-2009-08-236471 (2010). 
122 Naylor, T. L. et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the 
growth of CD79 mutant diffuse large B-cell lymphomas. Cancer research 71, 2643-2653, 
doi:10.1158/0008-5472.CAN-10-2525 (2011). 
123 Kloo, B. et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a 
subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 
108, 272-277, doi:1008969108 [pii] 
10.1073/pnas.1008969108 (2011). 
124 Abubaker, J. et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse 
large B-cell lymphoma. Leukemia 21, 2368-2370, doi:10.1038/sj.leu.2404873 (2007). 
125 Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 
470, 115-119, doi:10.1038/nature09671 (2011). 
126 Lam, L. T. et al. Cooperative signaling through the signal transducer and activator of 
transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell 
lymphoma. Blood 111, 3701-3713, doi:blood-2007-09-111948 [pii] 
10.1182/blood-2007-09-111948 (2008). 
127 Dufner, A. & Schamel, W. W. B cell antigen receptor-induced activation of an IRAK4-
dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model. 
Cell communication and signaling : CCS 9, 6, doi:10.1186/1478-811X-9-6 (2011). 
128 Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin 
lymphoma. Nature 476, 298-303, doi:10.1038/nature10351 (2011). 
129 Beguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 
mutations promote lymphoid transformation. Cancer Cell 23, 677-692, 
doi:10.1016/j.ccr.2013.04.011 (2013). 
130 Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse 
large B-cell lymphomas of germinal-center origin. Nature genetics 42, 181-185, 
doi:10.1038/ng.518 (2010). 
131 McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with 
EZH2-activating mutations. Nature 492, 108-112, doi:10.1038/nature11606 (2012). 
132 Alencar, A. J. et al. MicroRNAs are Independent Predictors of Outcome in Diffuse 
Large B-cell Lymphoma Patients Treated with R-CHOP. Clinical cancer research : an official 
journal of the American Association for Cancer Research, doi:1078-0432.CCR-11-0224 [pii] 
10.1158/1078-0432.CCR-11-0224 (2011). 
133 Montes-Moreno, S. et al. MicroRNA expression in diffuse large B-cell lymphoma 
treated with chemoimmunotherapy. Blood, doi:10.1182/blood-2010-11-321554 (2011). 
134 Staudt, L. M. & Dave, S. The biology of human lymphoid malignancies revealed by 
gene expression profiling. Adv Immunol 87, 163-208, doi:S0065-2776(05)87005-1 [pii] 
Chapter 9 References 
253 
10.1016/S0065-2776(05)87005-1 (2005). 
135 Jais, J. P. et al. The expression of 16 genes related to the cell of origin and immune 
response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with 
CHOP and rituximab. Leukemia : official journal of the Leukemia Society of America, Leukemia 
Research Fund, U.K 22, 1917-1924, doi:10.1038/leu.2008.188 (2008). 
136 Lossos, I. S. et al. Prediction of survival in diffuse large-B-cell lymphoma based on the 
expression of six genes. N Engl J Med 350, 1828-1837, doi:10.1056/NEJMoa032520 
350/18/1828 [pii] (2004). 
137 Alizadeh, A. A. et al. Prediction of survival in diffuse large B-cell lymphoma based on 
the expression of 2 genes reflecting tumor and microenvironment. Blood 118, 1350-1358, 
doi:10.1182/blood-2011-03-345272 (2011). 
138 Efron, B. The bootstrap and Markov-chain Monte Carlo. Journal of biopharmaceutical 
statistics 21, 1052-1062, doi:10.1080/10543406.2011.607736 (2011). 
139 Efron, B. & Tibshirani, R. Empirical bayes methods and false discovery rates for 
microarrays. Genetic epidemiology 23, 70-86, doi:10.1002/gepi.1124 (2002). 
140 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 
646-674, doi:10.1016/j.cell.2011.02.013 (2011). 
141 Pages, F. et al. Immune infiltration in human tumors: a prognostic factor that should 
not be ignored. Oncogene 29, 1093-1102, doi:10.1038/onc.2009.416 (2010). 
142 Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: 
from immunosurveillance to tumor escape. Nat Immunol 3, 991-998, doi:10.1038/ni1102-991 
(2002). 
143 Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 
539-545, doi:10.1016/S0140-6736(00)04046-0 (2001). 
144 DeNardo, D. G., Andreu, P. & Coussens, L. M. Interactions between lymphocytes and 
myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29, 309-316, 
doi:10.1007/s10555-010-9223-6 (2010). 
145 Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 
140, 883-899, doi:10.1016/j.cell.2010.01.025 (2010). 
146 Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and 
metastasis. Cell 141, 39-51, doi:S0092-8674(10)00287-4 [pii] 
10.1016/j.cell.2010.03.014 (2010). 
147 Hsie, A. W. et al. Evidence for reactive oxygen species inducing mutations in 
mammalian cells. Proc Natl Acad Sci U S A 83, 9616-9620 (1986). 
148 Pollard, J. W. Trophic macrophages in development and disease. Nature reviews. 
Immunology 9, 259-270, doi:nri2528 [pii] 
10.1038/nri2528 (2009). 
149 Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte 
subsets: cancer as a paradigm. Nat Immunol 11, 889-896, doi:ni.1937 [pii] 
10.1038/ni.1937 (2010). 
150 Egeblad, M., Nakasone, E. S. & Werb, Z. Tumors as organs: complex tissues that 
interface with the entire organism. Developmental cell 18, 884-901, 
doi:10.1016/j.devcel.2010.05.012 (2010). 
151 MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor 
depletes the resident subset of monocytes and tissue- and tumor-associated macrophages 
but does not inhibit inflammation. Blood 116, 3955-3963, doi:10.1182/blood-2010-02-266296 
(2010). 
152 van Furth, R. et al. The mononuclear phagocyte system: a new classification of 
macrophages, monocytes, and their precursor cells. Bulletin of the World Health Organization 
46, 845-852 (1972). 
153 Varol, C. et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic 
Chapter 9 References 
254 
cells. The Journal of experimental medicine 204, 171-180, doi:10.1084/jem.20061011 (2007). 
154 Wiktor-Jedrzejczak, W. et al. Total absence of colony-stimulating factor 1 in the 
macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A 87, 4828-4832 
(1990). 
155 Dai, X. M. et al. Targeted disruption of the mouse colony-stimulating factor 1 
receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased 
primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111-120 (2002). 
156 DeKoter, R. P., Walsh, J. C. & Singh, H. PU.1 regulates both cytokine-dependent 
proliferation and differentiation of granulocyte/macrophage progenitors. The EMBO journal 
17, 4456-4468, doi:10.1093/emboj/17.15.4456 (1998). 
157 Geissmann, F., Jung, S. & Littman, D. R. Blood monocytes consist of two principal 
subsets with distinct migratory properties. Immunity 19, 71-82, doi:S1074761303001742 [pii] 
(2003). 
158 Auffray, C. et al. Monitoring of blood vessels and tissues by a population of 
monocytes with patrolling behavior. Science 317, 666-670, doi:10.1126/science.1142883 
(2007). 
159 Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte 
subsets with divergent and complementary functions. J Exp Med 204, 3037-3047, 
doi:10.1084/jem.20070885 (2007). 
160 Cros, J. et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses 
via TLR7 and TLR8 receptors. Immunity 33, 375-386, doi:10.1016/j.immuni.2010.08.012 
(2010). 
161 Mildner, A. et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes 
only under defined host conditions. Nat Neurosci 10, 1544-1553, doi:10.1038/nn2015 (2007). 
162 Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. Local self-renewal can 
sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 10, 1538-
1543, doi:10.1038/nn2014 (2007). 
163 Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic 
stem cells. Science 336, 86-90, doi:10.1126/science.1219179 (2012). 
164 Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout 
adult life with minimal contribution from circulating monocytes. Immunity 38, 792-804, 
doi:10.1016/j.immuni.2013.04.004 (2013). 
165 Aziz, A., Soucie, E., Sarrazin, S. & Sieweke, M. H. MafB/c-Maf deficiency enables self-
renewal of differentiated functional macrophages. Science 326, 867-871, 
doi:10.1126/science.1176056 (2009). 
166 Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue 
macrophages under homeostasis. Immunity 38, 79-91, doi:10.1016/j.immuni.2012.12.001 
(2013). 
167 Mossadegh-Keller, N. et al. M-CSF instructs myeloid lineage fate in single 
haematopoietic stem cells. Nature 497, 239-243, doi:10.1038/nature12026 (2013). 
168 Davies, L. C. et al. A quantifiable proliferative burst of tissue macrophages restores 
homeostatic macrophage populations after acute inflammation. Eur J Immunol 41, 2155-
2164, doi:10.1002/eji.201141817 (2011). 
169 Jenkins, S. J. et al. Local macrophage proliferation, rather than recruitment from the 
blood, is a signature of TH2 inflammation. Science 332, 1284-1288, 
doi:10.1126/science.1204351 (2011). 
170 Leuschner, F. et al. Rapid monocyte kinetics in acute myocardial infarction are 
sustained by extramedullary monocytopoiesis. J Exp Med 209, 123-137, 
doi:10.1084/jem.20111009 (2012). 
171 Jenkins, S. J. et al. IL-4 directly signals tissue-resident macrophages to proliferate 
beyond homeostatic levels controlled by CSF-1. J Exp Med 210, 2477-2491, 
Chapter 9 References 
255 
doi:10.1084/jem.20121999 (2013). 
172 Franklin, R. A. et al. The cellular and molecular origin of tumor-associated 
macrophages. Science 344, 921-925, doi:10.1126/science.1252510 (2014). 
173 Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage 
subsets. Nature reviews. Immunology 11, 723-737, doi:10.1038/nri3073 (2011). 
174 Tatano, Y., Shimizu, T. & Tomioka, H. Unique macrophages different from M1/M2 
macrophages inhibit T cell mitogenesis while upregulating Th17 polarization. Scientific reports 
4, 4146, doi:10.1038/srep04146 (2014). 
175 Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, 
homeostasis and disease. Nature 496, 445-455, doi:10.1038/nature12034 (2013). 
176 Sasmono, R. T. et al. A macrophage colony-stimulating factor receptor-green 
fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of 
the mouse. Blood 101, 1155-1163, doi:10.1182/blood-2002-02-0569 (2003). 
177 Savill, J. Phagocyte clearance of cells dying by apoptosis and the regulation of 
glomerular inflammation. Adv Nephrol Necker Hosp 31, 21-28 (2001). 
178 De Domenico, I., McVey Ward, D. & Kaplan, J. Regulation of iron acquisition and 
storage: consequences for iron-linked disorders. Nature reviews. Molecular cell biology 9, 72-
81, doi:10.1038/nrm2295 (2008). 
179 Corna, G. et al. Polarization dictates iron handling by inflammatory and alternatively 
activated macrophages. Haematologica 95, 1814-1822, doi:10.3324/haematol.2010.023879 
(2010). 
180 Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867, 
doi:10.1038/nature05485 (2006). 
181 Mackaness, G. B. The influence of immunologically committed lymphoid cells on 
macrophage activity in vivo. J Exp Med 129, 973-992 (1969). 
182 Pace, J. L., Russell, S. W., Schreiber, R. D., Altman, A. & Katz, D. H. Macrophage 
activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc 
Natl Acad Sci U S A 80, 3782-3786 (1983). 
183 Celada, A., Gray, P. W., Rinderknecht, E. & Schreiber, R. D. Evidence for a gamma-
interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 160, 55-74 
(1984). 
184 Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two 
types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities 
and secreted proteins. Journal of immunology 136, 2348-2357 (1986). 
185 Doyle, A. G. et al. Interleukin-13 alters the activation state of murine macrophages in 
vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol 24, 1441-1445, 
doi:10.1002/eji.1830240630 (1994). 
186 Stein, M., Keshav, S., Harris, N. & Gordon, S. Interleukin 4 potently enhances murine 
macrophage mannose receptor activity: a marker of alternative immunologic macrophage 
activation. J Exp Med 176, 287-292 (1992). 
187 Mantovani, A. et al. The chemokine system in diverse forms of macrophage 
activation and polarization. Trends Immunol 25, 677-686, doi:S1471-4906(04)00295-9 [pii] 
10.1016/j.it.2004.09.015 (2004). 
188 Hsieh, C. S., Macatonia, S. E., O'Garra, A. & Murphy, K. M. T cell genetic background 
determines default T helper phenotype development in vitro. J Exp Med 181, 713-721 (1995). 
189 Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1/M-2 macrophages 
and the Th1/Th2 paradigm. Journal of immunology 164, 6166-6173 (2000). 
190 Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity. Nature reviews. 
Immunology 5, 953-964, doi:10.1038/nri1733 (2005). 
191 Murdoch, C., Giannoudis, A. & Lewis, C. E. Mechanisms regulating the recruitment of 
macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234, 
Chapter 9 References 
256 
doi:10.1182/blood-2004-03-1109 
2004-03-1109 [pii] (2004). 
192 Bystrom, J. et al. Resolution-phase macrophages possess a unique inflammatory 
phenotype that is controlled by cAMP. Blood 112, 4117-4127, doi:10.1182/blood-2007-12-
129767 (2008). 
193 Stout, R. D. et al. Macrophages sequentially change their functional phenotype in 
response to changes in microenvironmental influences. Journal of immunology 175, 342-349 
(2005). 
194 Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the 
human monocyte-to-macrophage differentiation and polarization: new molecules and 
patterns of gene expression. Journal of immunology 177, 7303-7311, doi:177/10/7303 [pii] 
(2006). 
195 Martinez, F. O. et al. Genetic programs expressed in resting and IL-4 alternatively 
activated mouse and human macrophages: similarities and differences. Blood 121, e57-69, 
doi:10.1182/blood-2012-06-436212 (2013). 
196 Pello, O. M. et al. Role of c-MYC in alternative activation of human macrophages and 
tumor-associated macrophage biology. Blood 119, 411-421, doi:10.1182/blood-2011-02-
339911 (2012). 
197 Pello, O. M. et al. In vivo inhibition of c-MYC in myeloid cells impairs tumor-
associated macrophage maturation and pro-tumoral activities. PloS one 7, e45399, 
doi:10.1371/journal.pone.0045399 (2012). 
198 Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of 
human macrophage activation. Immunity 40, 274-288, doi:10.1016/j.immuni.2014.01.006 
(2014). 
199 Gautier, E. L. et al. Gene-expression profiles and transcriptional regulatory pathways 
that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 13, 1118-
1128, doi:10.1038/ni.2419 (2012). 
200 Medzhitov, R. Toll-like receptors and innate immunity. Nature reviews. Immunology 
1, 135-145, doi:10.1038/35100529 (2001). 
201 Hagemann, T. et al. "Re-educating" tumor-associated macrophages by targeting NF-
kappaB. J Exp Med 205, 1261-1268, doi:jem.20080108 [pii] 
10.1084/jem.20080108 (2008). 
202 Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and 
functions. Immunity 32, 593-604, doi:10.1016/j.immuni.2010.05.007 (2010). 
203 Bouhlel, M. A. et al. PPARgamma activation primes human monocytes into 
alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6, 137-143, 
doi:S1550-4131(07)00166-0 [pii] 
10.1016/j.cmet.2007.06.010 (2007). 
204 Ruffell, D. et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene 
expression and promotes muscle injury repair. Proc Natl Acad Sci U S A 106, 17475-17480, 
doi:10.1073/pnas.0908641106 (2009). 
205 Ivashkiv, L. B. Epigenetic regulation of macrophage polarization and function. Trends 
Immunol 34, 216-223, doi:10.1016/j.it.2012.11.001 (2013). 
206 De Santa, F. et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to 
inhibition of polycomb-mediated gene silencing. Cell 130, 1083-1094, 
doi:10.1016/j.cell.2007.08.019 (2007). 
207 Ghisletti, S. et al. Identification and characterization of enhancers controlling the 
inflammatory gene expression program in macrophages. Immunity 32, 317-328, 
doi:10.1016/j.immuni.2010.02.008 (2010). 
208 Hartmann, S. et al. Macrophages in T cell/histiocyte rich large B cell lymphoma 
strongly express metal-binding proteins and show a bi-activated phenotype. International 
Chapter 9 References 
257 
journal of cancer. Journal international du cancer 133, 2609-2618, doi:10.1002/ijc.28273 
(2013). 
209 Murray, P. J. & Wynn, T. A. Obstacles and opportunities for understanding 
macrophage polarization. Journal of leukocyte biology 89, 557-563, doi:10.1189/jlb.0710409 
(2011). 
210 Schneemann, M. & Schoedon, G. Species differences in macrophage NO production 
are important. Nat Immunol 3, 102, doi:10.1038/ni0202-102a (2002). 
211 Choi, H. S., Rai, P. R., Chu, H. W., Cool, C. & Chan, E. D. Analysis of nitric oxide 
synthase and nitrotyrosine expression in human pulmonary tuberculosis. American journal of 
respiratory and critical care medicine 166, 178-186 (2002). 
212 Schroder, K. et al. Conservation and divergence in Toll-like receptor 4-regulated gene 
expression in primary human versus mouse macrophages. Proc Natl Acad Sci U S A 109, E944-
953, doi:10.1073/pnas.1110156109 (2012). 
213 Murray, P. J. et al. Macrophage Activation and Polarization: Nomenclature and 
Experimental Guidelines. Immunity 41, 14-20, doi:10.1016/j.immuni.2014.06.008 (2014). 
214 Zhu, Z., Wang, D. C., Popescu, L. I. & Wang, X. Single-cell transcriptome in the 
identification of disease biomarkers: opportunities and challenges. Journal of translational 
medicine 12, 212, doi:10.1186/s12967-014-0212-3 (2014). 
215 Stougaard, M., Lohmann, J. S., Zajac, M., Hamilton-Dutoit, S. & Koch, J. In situ 
detection of non-polyadenylated RNA molecules using Turtle Probes and target primed 
rolling circle PRINS. BMC biotechnology 7, 69, doi:10.1186/1472-6750-7-69 (2007). 
216 Zhang, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid 
tumor: a meta-analysis of the literature. PloS one 7, e50946, 
doi:10.1371/journal.pone.0050946 (2012). 
217 Forssell, J. et al. High macrophage infiltration along the tumor front correlates with 
improved survival in colon cancer. Clinical cancer research : an official journal of the American 
Association for Cancer Research 13, 1472-1479, doi:10.1158/1078-0432.CCR-06-2073 (2007). 
218 Piras, F. et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-
D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth 
phase. Cancer 104, 1246-1254, doi:10.1002/cncr.21283 (2005). 
219 Greaves, P. et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the 
microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 31, 
256-262, doi:10.1200/JCO.2011.39.9881 (2013). 
220 Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour 
metastasis. Nature, doi:10.1038/nature10138 (2011). 
221 Guilloton, F. et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell 
niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119, 
2556-2567, doi:10.1182/blood-2011-08-370908 (2012). 
222 Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 
promotes progression of mammary tumors to malignancy. J Exp Med 193, 727-740 (2001). 
223 Sarkar, S. et al. Therapeutic activation of macrophages and microglia to suppress 
brain tumor-initiating cells. Nat Neurosci 17, 46-55, doi:10.1038/nn.3597 (2014). 
224 Wu, Y. & Zheng, L. Dynamic education of macrophages in different areas of human 
tumors. Cancer microenvironment : official journal of the International Cancer 
Microenvironment Society 5, 195-201, doi:10.1007/s12307-012-0113-z (2012). 
225 Deng, L. et al. A novel mouse model of inflammatory bowel disease links mammalian 
target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-
associated tumorigenesis. The American journal of pathology 176, 952-967, 
doi:10.2353/ajpath.2010.090622 (2010). 
226 Munari, F. et al. Tumor-associated macrophages as major source of APRIL in gastric 
MALT lymphoma. Blood, doi:blood-2010-06-293266 [pii] 
Chapter 9 References 
258 
10.1182/blood-2010-06-293266 (2011). 
227 Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461-
465, doi:10.1038/nature04808 (2006). 
228 Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage 
population in human ovarian carcinoma. J Exp Med 203, 871-881, doi:10.1084/jem.20050930 
(2006). 
229 Ojalvo, L. S., Whittaker, C. A., Condeelis, J. S. & Pollard, J. W. Gene expression analysis 
of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating 
their activity in primary mammary tumors. Journal of immunology 184, 702-712, 
doi:jimmunol.0902360 [pii] 
10.4049/jimmunol.0902360 (2010). 
230 Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone 
marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000). 
231 Gocheva, V. et al. IL-4 induces cathepsin protease activity in tumor-associated 
macrophages to promote cancer growth and invasion. Genes Dev 24, 241-255, 
doi:gad.1874010 [pii] 
10.1101/gad.1874010 (2010). 
232 Vasiljeva, O. et al. Tumor cell-derived and macrophage-derived cathepsin B promotes 
progression and lung metastasis of mammary cancer. Cancer research 66, 5242-5250, 
doi:10.1158/0008-5472.CAN-05-4463 (2006). 
233 Wyckoff, J. et al. A paracrine loop between tumor cells and macrophages is required 
for tumor cell migration in mammary tumors. Cancer research 64, 7022-7029, 
doi:10.1158/0008-5472.CAN-04-1449 (2004). 
234 DeNardo, D. G. et al. CD4(+) T cells regulate pulmonary metastasis of mammary 
carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102, 
doi:S1535-6108(09)00216-5 [pii] 
10.1016/j.ccr.2009.06.018 (2009). 
235 Solinas, G. et al. Tumor-conditioned macrophages secrete migration-stimulating 
factor: a new marker for M2-polarization, influencing tumor cell motility. Journal of 
immunology 185, 642-652, doi:10.4049/jimmunol.1000413 (2010). 
236 Torroella-Kouri, M. et al. Identification of a subpopulation of macrophages in 
mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer 
research 69, 4800-4809, doi:10.1158/0008-5472.CAN-08-3427 (2009). 
237 Wu, K., Kryczek, I., Chen, L., Zou, W. & Welling, T. H. Kupffer cell suppression of CD8+ 
T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 
interactions. Cancer research 69, 8067-8075, doi:10.1158/0008-5472.CAN-09-0901 (2009). 
238 Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular 
carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206, 
1327-1337, doi:10.1084/jem.20082173 (2009). 
239 Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced survival. Nature medicine 10, 942-949, 
doi:10.1038/nm1093 (2004). 
240 Du, R. et al. HIF1alpha induces the recruitment of bone marrow-derived vascular 
modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220, 
doi:10.1016/j.ccr.2008.01.034 (2008). 
241 Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells 
accelerates tumorigenesis. Nature 456, 814-818, doi:10.1038/nature07445 (2008). 
242 Lin, E. Y. et al. Vascular endothelial growth factor restores delayed tumor progression 
in tumors depleted of macrophages. Mol Oncol 1, 288-302, 
doi:10.1016/j.molonc.2007.10.003 (2007). 
243 Lewis, C. & Murdoch, C. Macrophage responses to hypoxia: implications for tumor 
Chapter 9 References 
259 
progression and anti-cancer therapies. The American journal of pathology 167, 627-635, 
doi:10.1016/S0002-9440(10)62038-X (2005). 
244 Doedens, A. L. et al. Macrophage expression of hypoxia-inducible factor-1 alpha 
suppresses T-cell function and promotes tumor progression. Cancer research 70, 7465-7475, 
doi:10.1158/0008-5472.CAN-10-1439 (2010). 
245 Pucci, F. et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-
expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests 
common functions and developmental relationships. Blood 114, 901-914, doi:blood-2009-01-
200931 [pii] 
10.1182/blood-2009-01-200931 (2009). 
246 Mazzieri, R. et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis 
by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 
19, 512-526, doi:10.1016/j.ccr.2011.02.005 (2011). 
247 Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by 
Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. 
Cancer Cell 24, 695-709, doi:10.1016/j.ccr.2013.11.007 (2013). 
248 Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram 
the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl 
Acad Sci U S A 109, 17561-17566, doi:10.1073/pnas.1215397109 (2012). 
249 Lewis, C. E. & Pollard, J. W. Distinct role of macrophages in different tumor 
microenvironments. Cancer research 66, 605-612, doi:66/2/605 [pii] 
10.1158/0008-5472.CAN-05-4005 (2006). 
250 Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-
associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 
107, 2112-2122, doi:2005-01-0428 [pii] 
10.1182/blood-2005-01-0428 (2006). 
251 Laoui, D. et al. Tumor-associated macrophages in breast cancer: distinct subsets, 
distinct functions. The International journal of developmental biology 55, 861-867, 
doi:10.1387/ijdb.113371dl (2011). 
252 Movahedi, K. et al. Different tumor microenvironments contain functionally distinct 
subsets of macrophages derived from Ly6C(high) monocytes. Cancer research 70, 5728-5739, 
doi:10.1158/0008-5472.CAN-09-4672 (2010). 
253 Grugan, K. D. et al. Tumor-associated macrophages promote invasion while retaining 
Fc-dependent anti-tumor function. Journal of immunology 189, 5457-5466, 
doi:10.4049/jimmunol.1201889 (2012). 
254 Savage, N. D. et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ 
CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. Journal of 
immunology 181, 2220-2226 (2008). 
255 Porta, C. et al. Tolerance and M2 (alternative) macrophage polarization are related 
processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A 106, 14978-
14983, doi:0809784106 [pii] 
10.1073/pnas.0809784106 (2009). 
256 Stout, R. D., Watkins, S. K. & Suttles, J. Functional plasticity of macrophages: in situ 
reprogramming of tumor-associated macrophages. Journal of leukocyte biology 86, 1105-
1109, doi:10.1189/jlb.0209073 (2009). 
257 Sutterwala, F. S., Noel, G. J., Salgame, P. & Mosser, D. M. Reversal of 
proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 
188, 217-222 (1998). 
258 Zhang, Y. et al. Immune complex/Ig negatively regulate TLR4-triggered inflammatory 
response in macrophages through Fc gamma RIIb-dependent PGE2 production. Journal of 
immunology 182, 554-562 (2009). 
Chapter 9 References 
260 
259 Griffin, D. O., Holodick, N. E. & Rothstein, T. L. Human B1 cells in umbilical cord and 
adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 
208, 67-80, doi:10.1084/jem.20101499 (2011). 
260 Wong, S. C. et al. Macrophage polarization to a unique phenotype driven by B cells. 
Eur J Immunol 40, 2296-2307, doi:10.1002/eji.200940288 (2010). 
261 Andreu, P. et al. FcRgamma activation regulates inflammation-associated squamous 
carcinogenesis. Cancer Cell 17, 121-134, doi:10.1016/j.ccr.2009.12.019 (2010). 
262 Levesque, M. C. Translational Mini-Review Series on B Cell-Directed Therapies: 
Recent advances in B cell-directed biological therapies for autoimmune disorders. Clinical and 
experimental immunology 157, 198-208, doi:10.1111/j.1365-2249.2009.03979.x (2009). 
263 Lund, F. E. & Randall, T. D. Effector and regulatory B cells: modulators of CD4+ T cell 
immunity. Nature reviews. Immunology 10, 236-247, doi:10.1038/nri2729 (2010). 
264 Bouaziz, J. D. et al. Therapeutic B cell depletion impairs adaptive and autoreactive 
CD4+ T cell activation in mice. Proc Natl Acad Sci U S A 104, 20878-20883, 
doi:10.1073/pnas.0709205105 (2007). 
265 O'Neill, S. K. et al. Expression of CD80/86 on B cells is essential for autoreactive T cell 
activation and the development of arthritis. Journal of immunology 179, 5109-5116 (2007). 
266 Shah, S. & Qiao, L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via 
TGF-beta3. Eur J Immunol 38, 2488-2498, doi:10.1002/eji.200838201 (2008). 
267 Harris, D. P. et al. Reciprocal regulation of polarized cytokine production by effector B 
and T cells. Nat Immunol 1, 475-482, doi:10.1038/82717 (2000). 
268 Glennie, M. J., French, R. R., Cragg, M. S. & Taylor, R. P. Mechanisms of killing by anti-
CD20 monoclonal antibodies. Mol Immunol 44, 3823-3837, 
doi:10.1016/j.molimm.2007.06.151 (2007). 
269 Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. & Ravetch, J. V. Fc receptors are 
required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 95, 652-656 
(1998). 
270 Minard-Colin, V. et al. Lymphoma depletion during CD20 immunotherapy in mice is 
mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112, 1205-
1213, doi:10.1182/blood-2008-01-135160 (2008). 
271 Cittera, E. et al. The CCL3 family of chemokines and innate immunity cooperate in 
vivo in the eradication of an established lymphoma xenograft by rituximab. Journal of 
immunology 178, 6616-6623, doi:178/10/6616 [pii] (2007). 
272 Leidi, M. et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets 
more efficiently than m1 cells in vitro. Journal of immunology 182, 4415-4422, 
doi:182/7/4415 [pii] 
10.4049/jimmunol.0713732 (2009). 
273 Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote 
phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713, 
doi:10.1016/j.cell.2010.07.044 (2010). 
274 Steidl, C., Farinha, P. & Gascoyne, R. D. Macrophages predict treatment outcome in 
Hodgkin's lymphoma. Haematologica 96, 186-189, doi:96/2/186 [pii] 
10.3324/haematol.2010.033316 (2011). 
275 Pulford, K. A., Sipos, A., Cordell, J. L., Stross, W. P. & Mason, D. Y. Distribution of the 
CD68 macrophage/myeloid associated antigen. Int Immunol 2, 973-980 (1990). 
276 Gordon, S. & Pluddemann, A. Tissue macrophage heterogeneity: issues and 
prospects. Seminars in immunopathology 35, 533-540, doi:10.1007/s00281-013-0386-4 
(2013). 
277 Vacca, A. et al. Angiogenesis extent and macrophage density increase simultaneously 
with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 79, 965-970, 
doi:10.1038/sj.bjc.6690154 (1999). 
Chapter 9 References 
261 
278 Hasselblom, S. et al. Expression of CD68+ tumor-associated macrophages in patients 
with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 58, 529-532, 
doi:PIN2268 [pii] 
10.1111/j.1440-1827.2008.02268.x (2008). 
279 Cai, Q. C. et al. High expression of tumor-infiltrating macrophages correlates with 
poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol, 
doi:10.1007/s12032-011-0123-6 (2011). 
280 Brandt, S. et al. The combined expression of the stromal markers fibronectin and 
SPARC improves the prediction of survival in diffuse large B-cell lymphoma. Experimental 
hematology & oncology 2, 27, doi:10.1186/2162-3619-2-27 (2013). 
281 Bradshaw, A. D. Diverse biological functions of the SPARC family of proteins. Int J 
Biochem Cell Biol 44, 480-488, doi:10.1016/j.biocel.2011.12.021 (2012). 
282 Meyer, P. N. et al. The stromal cell marker SPARC predicts for survival in patients with 
diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135, 54-61, 
doi:10.1309/AJCPJX4BJV9NLQHY (2011). 
283 Wada, N. et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a 
study of the Osaka Lymphoma Study Group. Histopathology 60, 313-319, doi:10.1111/j.1365-
2559.2011.04096.x (2012). 
284 Epron, G. et al. Monocytes and T cells cooperate to favor normal and follicular 
lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia : official journal of the 
Leukemia Society of America, Leukemia Research Fund, U.K, doi:10.1038/leu.2011.179 (2011). 
285 Evans, R. Phagocytosis of murine lymphoma cells by macrophages. I. Factors affecting 
in vitro phagocytosis. Immunology 20, 67-74 (1971). 
286 Evans, R. Phagocytosis of murine lymphoma cells by macrophages. II. Differences 
between opsonic and cytotoxic activity of mice immunized with lymphoma cells. Immunology 
20, 75-83 (1971). 
287 Gemsa, D., Leser, H. G., Deimann, W. & Resch, K. Suppression of T lymphocyte 
proliferation during lymphoma growth in mice: role of PGE2-producing suppressor 
macrophages. Immunobiology 161, 385-391 (1982). 
288 Savill, J., Dransfield, I., Gregory, C. & Haslett, C. A blast from the past: clearance of 
apoptotic cells regulates immune responses. Nature reviews. Immunology 2, 965-975, 
doi:10.1038/nri957 (2002). 
289 Ronchetti, A. et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, 
antigen-presenting cells, and cytokines. Journal of immunology 163, 130-136 (1999). 
290 Truman, L. A. et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to 
stimulate macrophage chemotaxis. Blood 112, 5026-5036, doi:blood-2008-06-162404 [pii] 
10.1182/blood-2008-06-162404 (2008). 
291 Ogden, C. A. et al. Enhanced apoptotic cell clearance capacity and B cell survival 
factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. 
Journal of immunology 174, 3015-3023 (2005). 
292 Reimann, M. et al. Tumor stroma-derived TGF-beta limits myc-driven 
lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17, 262-272, 
doi:10.1016/j.ccr.2009.12.043 (2010). 
293 Haabeth, O. A. et al. Inflammation driven by tumour-specific Th1 cells protects 
against B-cell cancer. Nat Commun 2, 240, doi:ncomms1239 [pii] 
10.1038/ncomms1239 (2011). 
294 Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor 
specimens. Nat Med 4, 844-847 (1998). 
295 Zettl, A. et al. Immunohistochemical analysis of B-cell lymphoma using tissue 
microarrays identifies particular phenotypic profiles of B-cell lymphomas. Histopathology 43, 
209-219, doi:1702 [pii] (2003). 
Chapter 9 References 
262 
296 Hedvat, C. V. et al. Application of tissue microarray technology to the study of non-
Hodgkin's and Hodgkin's lymphoma. Hum Pathol 33, 968-974, doi:S0046817702000977 [pii] 
(2002). 
297 Nakane, P. K. & Pierce, G. B., Jr. Enzyme-labeled antibodies: preparation and 
application for the localization of antigens. J Histochem Cytochem 14, 929-931 (1966). 
298 Wilfinger, W. W., Mackey, K. & Chomczynski, P. Effect of pH and ionic strength on the 
spectrophotometric assessment of nucleic acid purity. Biotechniques 22, 474-476, 478-481 
(1997). 
299 Schroeder, A. et al. The RIN: an RNA integrity number for assigning integrity values to 
RNA measurements. BMC Mol Biol 7, 3, doi:1471-2199-7-3 [pii] 
10.1186/1471-2199-7-3 (2006). 
300 Dunleavy, K. et al. Differential efficacy of bortezomib plus chemotherapy within 
molecular subtypes of diffuse large B-cell lymphoma. Blood 113, 6069-6076, doi:blood-2009-
01-199679 [pii] 
10.1182/blood-2009-01-199679 (2009). 
301 Hernandez-Ilizaliturri, F. J. et al. Higher response to lenalidomide in 
relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell-like than in 
germinal center b-cell-like phenotype. Cancer, doi:10.1002/cncr.26135 (2011). 
302 Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell 
lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-282, 
doi:10.1182/blood-2003-05-1545 
2003-05-1545 [pii] (2004). 
303 Muris, J. J. et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 
expression improves risk stratification in patients with primary nodal diffuse large B cell 
lymphoma. J Pathol 208, 714-723, doi:10.1002/path.1924 (2006). 
304 Natkunam, Y. et al. LMO2 protein expression predicts survival in patients with diffuse 
large B-cell lymphoma treated with anthracycline-based chemotherapy with and without 
rituximab. J Clin Oncol 26, 447-454, doi:JCO.2007.13.0690 [pii] 
10.1200/JCO.2007.13.0690 (2008). 
305 Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M. L., Banham, A. H. & Leppa, S. 
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma 
patients treated with R-CHOP. Mod Pathol 22, 1094-1101, doi:10.1038/modpathol.2009.73 
(2009). 
306 Choi, W. W. et al. A new immunostain algorithm classifies diffuse large B-cell 
lymphoma into molecular subtypes with high accuracy. Clinical cancer research : an official 
journal of the American Association for Cancer Research 15, 5494-5502, doi:1078-0432.CCR-
09-0113 [pii] 
10.1158/1078-0432.CCR-09-0113 (2009). 
307 Meyer, P. N. et al. Immunohistochemical methods for predicting cell of origin and 
survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29, 
200-207, doi:JCO.2010.30.0368 [pii] 
10.1200/JCO.2010.30.0368 (2011). 
308 Visco, C. et al. Comprehensive gene expression profiling and immunohistochemical 
studies support application of immunophenotypic algorithm for molecular subtype 
classification in diffuse large B-cell lymphoma: a report from the International DLBCL 
Rituximab-CHOP Consortium Program Study. Leukemia : official journal of the Leukemia 
Society of America, Leukemia Research Fund, U.K 26, 2103-2113, doi:10.1038/leu.2012.83 
(2012). 
309 Moskowitz, C. H. et al. Cell of origin, germinal center versus nongerminal center, 
determined by immunohistochemistry on tissue microarray, does not correlate with outcome 
in patients with relapsed and refractory DLBCL. Blood 106, 3383-3385, doi:2005-04-1603 [pii] 
Chapter 9 References 
263 
10.1182/blood-2005-04-1603 (2005). 
310 Ott, M. M., Horn, H., Kaufmann, M. & Ott, G. The Hans classificator does not predict 
outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-
CHOP treated patients. Leuk Res 36, 544-545, doi:10.1016/j.leukres.2012.01.022 (2012). 
311 Gutierrez-Garcia, G. et al. Gene-expression profiling and not immunophenotypic 
algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with 
immunochemotherapy. Blood 117, 4836-4843, doi:10.1182/blood-2010-12-322362 (2011). 
312 Fu, K. et al. Addition of rituximab to standard chemotherapy improves the survival of 
both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse 
large B-cell lymphoma. J Clin Oncol 26, 4587-4594, doi:JCO.2007.15.9277 [pii] 
10.1200/JCO.2007.15.9277 (2008). 
313 Thieblemont, C. et al. The germinal center/activated B-cell subclassification has a 
prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell 
lymphoma: a bio-CORAL study. J Clin Oncol 29, 4079-4087, doi:10.1200/JCO.2011.35.4423 
(2011). 
314 de Jong, D. et al. Immunohistochemical prognostic markers in diffuse large B-cell 
lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a 
study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25, 805-812, 
doi:10.1200/JCO.2006.09.4490 (2007). 
315 Seki, R. et al. Prognostic impact of immunohistochemical biomarkers in diffuse large 
B-cell lymphoma in the rituximab era. Cancer Sci 100, 1842-1847, doi:CAS1268 [pii] 
10.1111/j.1349-7006.2009.01268.x (2009). 
316 Horn, H. et al. MYC status in concert with BCL2 and BCL6 expression predicts 
outcome in diffuse large B-cell lymphoma. Blood 121, 2253-2263, doi:10.1182/blood-2012-
06-435842 (2013). 
317 Montes-Moreno, S. et al. Gcet1 (centerin), a highly restricted marker for a subset of 
germinal center-derived lymphomas. Blood 111, 351-358, doi:blood-2007-06-094151 [pii] 
10.1182/blood-2007-06-094151 (2008). 
318 Barrans, S. L., Fenton, J. A., Banham, A., Owen, R. G. & Jack, A. S. Strong expression of 
FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor 
outcome. Blood 104, 2933-2935, doi:10.1182/blood-2004-03-1209 (2004). 
319 Natkunam, Y. et al. The oncoprotein LMO2 is expressed in normal germinal-center B 
cells and in human B-cell lymphomas. Blood 109, 1636-1642, doi:blood-2006-08-039024 [pii] 
10.1182/blood-2006-08-039024 (2007). 
320 van Imhoff, G. W. et al. Prognostic impact of germinal center-associated proteins and 
chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24, 4135-
4142, doi:10.1200/JCO.2006.05.5897 (2006). 
321 Maeshima, A. M. et al. Bcl-2, Bcl-6, and the International Prognostic Index are 
prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-
containing chemotherapy. Cancer science, doi:10.1111/j.1349-7006.2012.02382.x (2012). 
322 Mounier, N. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated 
resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). 
Blood 101, 4279-4284, doi:10.1182/blood-2002-11-3442 (2003). 
323 Wilson, K. S. et al. CHOP-R therapy overcomes the adverse prognostic influence of 
BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 48, 1102-1109, 
doi:10.1080/10428190701344881 (2007). 
324 Salles, G. et al. Prognostic significance of immunohistochemical biomarkers in diffuse 
large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood, 
doi:blood-2011-04-345256 [pii] 
10.1182/blood-2011-04-345256 (2011). 
325 Challa-Malladi, M. et al. Combined genetic inactivation of beta2-Microglobulin and 
Chapter 9 References 
264 
CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. 
Cancer Cell 20, 728-740, doi:10.1016/j.ccr.2011.11.006 (2011). 
326 Hasselblom, S. et al. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but 
not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J 
Haematol 137, 364-373, doi:BJH6593 [pii] 
10.1111/j.1365-2141.2007.06593.x (2007). 
327 Tzankov, A. et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T 
cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular 
lymphoma and classical Hodgkin's lymphoma. Haematologica 93, 193-200, 
doi:haematol.11702 [pii] 
10.3324/haematol.11702 (2008). 
328 Yhaka, R. a. G. R. R: A language for data analysis and graphics. Journal of 
Computational and Graphical Statistics 5, 299-314 (1996). 
329 Sander, B. et al. The reliability of immunohistochemical analysis of the tumor 
microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma 
Biomarker Consortium. Haematologica 99, 715-725, doi:10.3324/haematol.2013.095257 
(2014). 
330 Wahlin, B. E. et al. T cells in tumors and blood predict outcome in follicular lymphoma 
treated with rituximab. Clinical cancer research : an official journal of the American 
Association for Cancer Research 17, 4136-4144, doi:10.1158/1078-0432.CCR-11-0264 (2011). 
331 Lee, A. M. et al. Number of CD4+ cells and location of forkhead box protein P3-
positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J 
Clin Oncol 24, 5052-5059, doi:10.1200/JCO.2006.06.4642 (2006). 
332 Yang, Z. Z., Novak, A. J., Stenson, M. J., Witzig, T. E. & Ansell, S. M. Intratumoral 
CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-
Hodgkin lymphoma. Blood 107, 3639-3646, doi:2005-08-3376 [pii] 
10.1182/blood-2005-08-3376 (2006). 
333 Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. Attenuation of 
CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. 
Cancer research 66, 10145-10152, doi:66/20/10145 [pii] 
10.1158/0008-5472.CAN-06-1822 (2006). 
334 Galani, I. E. et al. Regulatory T cells control macrophage accumulation and activation 
in lymphoma. International journal of cancer. Journal international du cancer 127, 1131-1140, 
doi:10.1002/ijc.25132 (2010). 
335 Irizarry, R. A. et al. Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics 4, 249-264, 
doi:10.1093/biostatistics/4.2.249 (2003). 
336 Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of 
normalization methods for high density oligonucleotide array data based on variance and 
bias. Bioinformatics 19, 185-193 (2003). 
337 Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display 
of genome-wide expression patterns. Proc Natl Acad Sci U S A 95, 14863-14868 (1998). 
338 Abbas, A. R. et al. Immune response in silico (IRIS): immune-specific genes identified 
from a compendium of microarray expression data. Genes Immun 6, 319-331, 
doi:10.1038/sj.gene.6364173 (2005). 
339 Basso, K. Toward a systems biology approach to investigate cellular networks in 
normal and malignant B cells. Leukemia 23, 1219-1225, doi:10.1038/leu.2009.4 (2009). 
340 Van Loo, P. et al. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional 
features suggestive of a tolerogenic host immune response. Haematologica 95, 440-448, 
doi:10.3324/haematol.2009.009647 (2010). 
341 Tome, M. E. et al. A redox signature score identifies diffuse large B-cell lymphoma 
Chapter 9 References 
265 
patients with a poor prognosis. Blood 106, 3594-3601, doi:10.1182/blood-2005-02-0487 
(2005). 
342 Segal, E., Friedman, N., Kaminski, N., Regev, A. & Koller, D. From signatures to 
models: understanding cancer using microarrays. Nat Genet 37 Suppl, S38-45, 
doi:10.1038/ng1561 (2005). 
343 Poulsen, C. B. et al. Prognostic significance of metallothionein in B-cell lymphomas. 
Blood 108, 3514-3519, doi:10.1182/blood-2006-04-015305 (2006). 
344 Greenberg, M. E. et al. Oxidized phosphatidylserine-CD36 interactions play an 
essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med 203, 
2613-2625, doi:10.1084/jem.20060370 (2006). 
345 Feng, J. et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common 
signaling pathway dependent on protein kinase C and PPAR-gamma. Journal of lipid research 
41, 688-696 (2000). 
346 Huang, S. C. et al. Cell-intrinsic lysosomal lipolysis is essential for alternative 
activation of macrophages. Nat Immunol 15, 846-855, doi:10.1038/ni.2956 (2014). 
347 Clement-Ziza, M. et al. Evaluation of methods for amplification of picogram amounts 
of total RNA for whole genome expression profiling. BMC genomics 10, 246, 
doi:10.1186/1471-2164-10-246 (2009). 
348 Svaren, J. et al. EGR1 target genes in prostate carcinoma cells identified by 
microarray analysis. The Journal of biological chemistry 275, 38524-38531, 
doi:10.1074/jbc.M005220200 (2000). 
349 Doig, T. N. et al. Coexpression analysis of large cancer datasets provides insight into 
the cellular phenotypes of the tumour microenvironment. BMC genomics 14, 469, 
doi:10.1186/1471-2164-14-469 (2013). 
350 Mueller, C. G. et al. Critical role of monocytes to support normal B cell and diffuse 
large B cell lymphoma survival and proliferation. Journal of leukocyte biology 82, 567-575, 
doi:10.1189/jlb.0706481 (2007). 
351 Lin, Y. et al. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-
Hodgkin lymphoma. Blood 117, 872-881, doi:10.1182/blood-2010-05-283820 (2011). 
352 Agre, P. & Kozono, D. Aquaporin water channels: molecular mechanisms for human 
diseases. FEBS letters 555, 72-78 (2003). 
353 Ishibashi, K. et al. Cloning and functional expression of a new aquaporin (AQP9) 
abundantly expressed in the peripheral leukocytes permeable to water and urea, but not to 
glycerol. Biochemical and biophysical research communications 244, 268-274, 
doi:10.1006/bbrc.1998.8252 (1998). 
354 Van den Bossche, J., Malissen, B., Mantovani, A., De Baetselier, P. & Van 
Ginderachter, J. A. Regulation and function of the E-cadherin/catenin complex in cells of the 
monocyte-macrophage lineage and DCs. Blood 119, 1623-1633, doi:10.1182/blood-2011-10-
384289 (2012). 
355 Godin-Ethier, J., Hanafi, L. A., Duvignaud, J. B., Leclerc, D. & Lapointe, R. IDO 
expression by human B lymphocytes in response to T lymphocyte stimuli and TLR 
engagement is biologically inactive. Mol Immunol 49, 253-259, 
doi:10.1016/j.molimm.2011.08.017 (2011). 
356 Greaves, P. & Gribben, J. G. The role of B7 family molecules in hematologic 
malignancy. Blood 121, 734-744, doi:10.1182/blood-2012-10-385591 (2013). 
357 Loke, P. & Allison, J. P. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 
cells. Proc Natl Acad Sci U S A 100, 5336-5341, doi:10.1073/pnas.0931259100 (2003). 
358 Semnani, R. T., Mahapatra, L., Moore, V., Sanprasert, V. & Nutman, T. B. Functional 
and phenotypic characteristics of alternative activation induced in human monocytes by 
interleukin-4 or the parasitic nematode Brugia malayi. Infection and immunity 79, 3957-3965, 
doi:10.1128/IAI.05191-11 (2011). 
Chapter 9 References 
266 
359 Caro, P. et al. Metabolic signatures uncover distinct targets in molecular subsets of 
diffuse large B cell lymphoma. Cancer Cell 22, 547-560, doi:10.1016/j.ccr.2012.08.014 (2012). 
360 Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. & Hodes, R. J. Comparative analysis of 
B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 180, 631-640 (1994). 
361 Orlikowsky, T. W. et al. Expression and regulation of B7 family molecules on 
macrophages (MPhi) in preterm and term neonatal cord blood and peripheral blood of 
adults. Cytometry. Part B, Clinical cytometry 53, 40-47, doi:10.1002/cyto.b.10033 (2003). 
362 Alvaro, T. et al. The presence of STAT1-positive tumor-associated macrophages and 
their relation to outcome in patients with follicular lymphoma. Haematologica 91, 1605-1612 
(2006). 
363 Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M. & Kurzrock, R. Serum 
interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13, 
575-582 (1995). 
364 Lech-Maranda, E. et al. Plasma TNF-alpha and IL-10 level-based prognostic model 
predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups 
defined by the International Prognostic Index. Archivum immunologiae et therapiae 
experimentalis 58, 131-141, doi:10.1007/s00005-010-0066-1 (2010). 
365 Lech-Maranda, E. et al. Elevated IL-10 plasma levels correlate with poor prognosis in 
diffuse large B-cell lymphoma. European cytokine network 17, 60-66 (2006). 
Appendix 
267 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hibridisation intensity of control probesets 
The hibridisation intensity (varying from 8.91 to 13.77) for the spiked-in control probes are 
represented for each sample. bioB, bioC and bioD are genes in the biotin synthesis pathway 
of E. coli, and cre is the recombinase gene from P1 bacteriophage. The intensity pattern for 
these 4 controls should show the increase in target concentration (from bioB to CreX). Other 
patterns would be a sign of bad hybridization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Ratio of hibridisation intensity between positive and negative probes  
This metrics helps to assess the ability to distinguish true signal from noise. All arrays 
analysed had positive versus negative AUC (area under the curve) value of ≥ 0.8 and hence 
passed the quality criteria. 
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Figure 3: Mean hybridisation intensities including all probesets 
The mean value of the hibridisation intensity of all probes for each sample is graphically 
represented to demonstrate the minimal variability (< 0.05) across samples. 
 
 
 
 
 
 
 
 
Figure 4: Mean hybridisation intensities for perfect-match and background probes 
The number of expressed genes is estimated using the differences in intensity between the 
PM (perfect match) and the MM (mismatch) probes. The hibridisation intensity of the last is a 
surrogate of the background intensity of the array.  
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Figure 5: Relative Log Expression signal; mean and standard deviation represented 
The Relative Log Expression (RLE) values for each probe-set correspond to the ratio between 
the expression of a probe-set and the median expression of this probe-set across all arrays of 
the experiment. It is assumed that most probe-sets are not changed across the arrays, so it is 
expected that these ratios are around 0 on a log scale. The boxplots presenting the 
distribution of these log-ratios should then be centered near 0 and have similar spread. 
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Table 1: Differentially expressed probesets between DLBCL TAM and reactive LN control macrophages 
 
HGNC 
symbol 
Probeset Gb accession Description 
Log2 Fold 
Change 
Average 
Expression 
Adjusted p-
value 
ACP2 7947815 NM_001610 acid phosphatase 2, lysosomal 2,334 6,881 0,014 
ACSL1 8103951 NM_001995 acyl-CoA synthetase long-chain family member 1 1,956 7,704 0,027 
ADAMDEC
1 
8145317 NM_014479 ADAM-like, decysin 1 2,495 7,126 0,048 
AFF3 8054254 NM_002285 AF4/FMR2 family, member 3 -1,215 7,170 0,023 
AGTRAP 7897745 NM_020350 angiotensin II receptor-associated protein 1,195 7,762 0,004 
ALOX15 8011680 NM_001140 arachidonate 15-lipoxygenase -2,513 5,078 0,003 
ANKRD22 7934898 NM_144590 ankyrin repeat domain 22 3,882 7,733 0,002 
APCDD1 8020141 NM_153000 adenomatosis polyposis coli down-regulated 1 -1,046 6,500 0,008 
APOBEC3A 8073056 NM_145699 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A 2,035 7,630 0,012 
APOC1 8029536 NM_001645 apolipoprotein C-I 2,863 8,138 0,007 
APP 8069644 NM_000484 amyloid beta (A4) precursor protein -1,024 10,501 0,048 
AQP9 7983910 NM_020980 aquaporin 9 3,351 6,814 0,003 
ASAH2 7927599 NM_019893 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 -1,075 4,266 0,027 
BATF 7975793 NM_006399 basic leucine zipper transcription factor, ATF-like 1,178 7,054 0,041 
BCL2A1 7990818 NM_001114735 BCL2-related protein A1 1,679 8,598 0,012 
C14orf145 7980496 NM_152446 chromosome 14 open reading frame 145 -1,077 6,799 0,039 
C15orf48 7983478 NM_032413 chromosome 15 open reading frame 48 2,552 6,356 0,033 
C1QA 7898793 NM_015991 complement component 1, q subcomponent, A chain 2,492 6,529 0,003 
C1QB 7898805 NM_000491 complement component 1, q subcomponent, B chain 2,203 8,667 0,009 
 271 
C1QC 7898799 NM_001114101 complement component 1, q subcomponent, C chain 2,616 8,946 0,011 
C3AR1 7960874 NM_004054 complement component 3a receptor 1 3,925 8,092 0,000 
C5AR1 8029907 NM_001736 complement component 5a receptor 1 1,853 7,883 0,009 
C6orf192 8129649 NM_052831 chromosome 6 open reading frame 192 -1,323 5,350 0,045 
CA8 8150978 NM_004056 carbonic anhydrase VIII -1,784 5,272 0,025 
CASP5 7951385 NM_004347 caspase 5, apoptosis-related cysteine peptidase 2,071 5,486 0,039 
CCL2 8006433 NM_002982 chemokine (C-C motif) ligand 2 2,478 7,539 0,027 
CCL3 8014369 NM_002983 chemokine (C-C motif) ligand 3 1,353 11,035 0,050 
CCL4 8006602 NM_002984 chemokine (C-C motif) ligand 4 1,875 9,678 0,024 
CCRL2 8079407 NM_003965 chemokine (C-C motif) receptor-like 2 1,829 5,826 0,022 
CCRL2 8093304 NM_003965 chemokine (C-C motif) receptor-like 2 1,645 5,699 0,039 
CD14 8114612 NM_000591 CD14 molecule 2,781 10,282 0,000 
CD151 7937508 NM_004357 CD151 molecule (Raph blood group) 1,160 5,542 0,045 
CD163 7960794 NM_004244 CD163 molecule 2,843 7,676 0,011 
CD1A 7906339 NM_001763 CD1a molecule -1,345 4,813 0,049 
CD1C 7906348 NM_001765 CD1c molecule -1,918 8,858 0,024 
CD1E 7906355 NM_030893 CD1e molecule -2,314 7,937 0,039 
CD207 8052916 NM_015717 CD207 molecule, langerin -1,464 5,357 0,008 
CD274 8154233 NM_014143 CD274 molecule 2,344 7,215 0,038 
CD58 7918902 NM_001779 CD58 molecule 1,159 7,583 0,041 
CD81 7937802 NM_004356 CD81 molecule 1,087 9,165 0,049 
CDCA7L 8138489 NM_018719 cell division cycle associated 7-like -1,344 7,529 0,049 
 272 
CDH1 7996837 NM_004360 cadherin 1, type 1, E-cadherin (epithelial) -2,589 7,756 0,034 
CEBPB 8063386 NM_005194 CCAAT/enhancer binding protein (C/EBP), beta 1,004 6,393 0,012 
CHML 7925500 NM_001821 choroideremia-like (Rab escort protein 2) -1,088 6,799 0,049 
CLEC4D 7953749 NM_080387 C-type lectin domain family 4, member D 1,886 5,733 0,025 
CLEC4E 7960900 NM_014358 C-type lectin domain family 4, member E 2,809 6,340 0,008 
CLEC6A 7953737 NM_001007033 C-type lectin domain family 6, member A 2,587 6,965 0,012 
CLEC7A 7961120 NM_197947 C-type lectin domain family 7, member A 1,310 7,239 0,049 
CREG1 7922051 NM_003851 cellular repressor of E1A-stimulated genes 1 1,103 8,021 0,017 
CRYM 8000117 NM_001888 crystallin, mu -1,047 6,327 0,012 
CSF1R 8115076 NM_005211 colony stimulating factor 1 receptor 1,309 9,169 0,044 
CSF3R 7914950 NM_156039 colony stimulating factor 3 receptor (granulocyte) 1,080 8,104 0,024 
CTSD 7945666 NM_001909 cathepsin D 1,027 9,086 0,018 
CTSL1 8156228 NM_001912 cathepsin L1 3,099 7,806 0,012 
CXCL10 8101126 NM_001565 chemokine (C-X-C motif) ligand 10 3,277 10,407 0,002 
CXCL9 8101118 NM_002416 chemokine (C-X-C motif) ligand 9 3,191 9,471 0,008 
CXCR2 8048227 NM_001557 chemokine (C-X-C motif) receptor 2 -1,180 4,605 0,032 
DAB2 8111772 NM_001343 
disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila) 
-1,079 8,450 0,028 
DENND5B 7962151 NM_144973 DENN/MADD domain containing 5B -1,048 5,736 0,049 
DMXL2 7988789 NM_001174116 Dmx-like 2 1,394 8,152 0,048 
DOCK4 8142345 NM_014705 dedicator of cytokinesis 4 1,694 5,670 0,027 
DRAM1 7958019 NM_018370 DNA-damage regulated autophagy modulator 1 2,036 6,641 0,011 
EMR1 8025103 NM_001974 egf-like module containing, mucin-like, hormone receptor-like 1 1,956 5,578 0,024 
 273 
ENG 8164269 NM_000118 endoglin 1,218 7,740 0,037 
EPB41L3 8022118 NM_012307 erythrocyte membrane protein band 4.1-like 3 1,740 7,318 0,029 
FAM160A1 8097801 NM_001109977 family with sequence similarity 160, member A1 -1,823 6,435 0,014 
FBXO16 8150002 NM_172366 F-box protein 16 -1,064 4,163 0,012 
FCAR 8031374 NM_002000 Fc fragment of IgA, receptor for 1,004 5,965 0,045 
FCER1A 7906443 NM_002001 Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide -1,671 6,511 0,028 
FCER2 8033420 NM_002002 Fc fragment of IgE, low affinity II, receptor for (CD23) -2,420 5,829 0,002 
FCGR1A 7905047 NM_000566 Fc fragment of IgG, high affinity Ia, receptor (CD64) 3,810 8,473 0,001 
FCGR1A 7905060 NM_000566 Fc fragment of IgG, high affinity Ia, receptor (CD64) 3,794 8,801 0,001 
FCGR1B 7919133 NM_001017986 Fc fragment of IgG, high affinity Ib, receptor (CD64) 3,780 8,830 0,000 
FCGR2A 7906757 NM_001136219 Fc fragment of IgG, low affinity IIa, receptor (CD32) 2,313 9,679 0,008 
FCGR3A 7921868 NM_000569 Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 4,184 8,330 0,000 
FCGR3A 7921873 NM_000569 Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 3,672 8,706 0,001 
FCRL1 7921319 NM_052938 Fc receptor-like 1 -1,571 6,400 0,024 
FLT3 7970737 NM_004119 fms-related tyrosine kinase 3 -1,317 7,854 0,024 
FNBP1L 7903092 NM_001024948 formin binding protein 1-like -1,247 5,677 0,025 
FPR1 8038899 NM_002029 formyl peptide receptor 1 2,412 9,463 0,006 
FPR2 8030860 NM_001462 formyl peptide receptor 2 2,402 6,295 0,036 
GAS7 8012605 NM_201433 growth arrest-specific 7 1,007 6,058 0,027 
GBP1 7917516 NM_002053 guanylate binding protein 1, interferon-inducible, 67kDa 2,295 9,863 0,022 
GBP2 7917532 NM_004120 guanylate binding protein 2, interferon-inducible 2,679 7,752 0,003 
GBP4 7917561 NM_052941 guanylate binding protein 4 2,285 8,113 0,018 
 274 
GBP5 7917576 NM_052942 guanylate binding protein 5 2,902 8,467 0,017 
GCH1 7979269 NM_000161 GTP cyclohydrolase 1 1,445 8,073 0,019 
GIMAP5 8137257 NM_018384 GTPase, IMAP family member 5 2,486 8,087 0,011 
GNG10 7946559 NM_001017998 guanine nucleotide binding protein (G protein), gamma 10 1,014 10,540 0,039 
GOLPH3L 7919780 NM_018178 golgi phosphoprotein 3-like -1,122 6,923 0,039 
GPNMB 8131844 NM_001005340 glycoprotein (transmembrane) nmb 2,532 6,225 0,024 
GPR84 7963770 NM_020370 G protein-coupled receptor 84 2,550 7,451 0,003 
HAPLN3 7991224 NM_178232 hyaluronan and proteoglycan link protein 3 1,425 6,794 0,017 
HEATR5B 8051464 NM_019024 HEAT repeat containing 5B -1,065 7,857 0,041 
HHAT 7909510 NM_001170580 hedgehog acyltransferase -1,245 5,940 0,024 
HK3 8115957 NM_002115 hexokinase 3 (white cell) 1,247 5,866 0,031 
HLA-DPB2 8118607 NR_001435 major histocompatibility complex, class II, DP beta 2 (pseudogene) -1,005 6,332 0,013 
HLA-DRB5 8125436 NM_002125 major histocompatibility complex, class II, DR beta 5 -2,316 7,834 0,048 
HMOX1 8072678 NM_002133 heme oxygenase (decycling) 1 1,686 9,062 0,014 
HNMT 8045499 NM_006895 histamine N-methyltransferase 1,516 6,333 0,023 
HOMER2 7991034 NM_199330 homer homolog 2 (Drosophila) -1,886 5,973 0,000 
HSPA6 7906764 NM_002155 heat shock 70kDa protein 6 (HSP70B') 1,490 8,163 0,048 
IDO1 8146092 NM_002164 indoleamine 2,3-dioxygenase 1 3,337 8,055 0,018 
IER3 8124848 NM_003897 immediate early response 3 1,345 9,484 0,029 
IER3 8179704 NM_003897 immediate early response 3 1,345 9,484 0,029 
IER3 8178435 NM_003897 immediate early response 3 1,363 9,777 0,030 
IFITM3 7945371 NM_021034 interferon induced transmembrane protein 3 (1-8U) 1,109 10,160 0,017 
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IFNGR2 8068280 NM_005534 interferon gamma receptor 2 (interferon gamma transducer 1) 1,168 9,628 0,012 
IL15RA 7931899 NM_002189 interleukin 15 receptor, alpha 1,150 7,958 0,049 
IL1R1 8043995 NM_000877 interleukin 1 receptor, type I -1,469 5,217 0,036 
IL4I1 8038487 NM_172374 interleukin 4 induced 1 1,253 7,750 0,010 
IRF1 8114010 NM_002198 interferon regulatory factor 1 1,233 9,154 0,024 
ITGAM 7995096 NM_001145808 integrin, alpha M (complement component 3 receptor 3 subunit) 1,328 7,632 0,049 
KCNA5 7953278 NM_002234 
potassium voltage-gated channel, shaker-related subfamily, member 
5 
-1,252 6,083 0,018 
KCNJ10 7921533 NM_002241 potassium inwardly-rectifying channel, subfamily J, member 10 1,665 5,874 0,044 
KCNK10 7980605 NM_021161 potassium channel, subfamily K, member 10 -1,009 4,494 0,029 
KCTD5 7992685 NM_018992 potassium channel tetramerisation domain containing 5 -1,047 7,454 0,012 
LDOC1 8175539 NM_012317 leucine zipper, down-regulated in cancer 1 -1,018 5,605 0,009 
LEPREL1 8092707 NM_018192 leprecan-like 1 -1,389 6,795 0,040 
LGALS3 7974461 NR_003225 lectin, galactoside-binding, soluble, 3 1,185 7,348 0,008 
LILRA3 8039226 NM_006865 
leukocyte immunoglobulin-like receptor, subfamily A (without TM 
domain), member 3 
2,490 8,123 0,008 
LILRA5 8039236 NM_021250 
leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 5 
1,580 7,254 0,027 
LILRB2 8039212 NM_005874 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and 
ITIM domains), member 2 
1,543 8,983 0,008 
LPAR1 8163257 NM_057159 lysophosphatidic acid receptor 1 1,030 5,414 0,039 
LRP1 7956301 NM_002332 low density lipoprotein receptor-related protein 1 1,327 6,491 0,027 
MAFB 8066266 NM_005461 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) 
2,056 8,373 0,008 
MT1DP 7995813 NR_027781 metallothionein 1D (pseudogene) 1,076 7,464 0,033 
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MT1E 7995797 NM_175617 metallothionein 1E 2,336 7,332 0,011 
MT1G 8001531 NM_005950 metallothionein 1G 2,595 7,651 0,034 
MT1X 7995838 NM_005952 metallothionein 1X 1,480 8,731 0,028 
MT2A 7995783 NM_005953 metallothionein 2A 2,092 11,737 0,001 
MT2A 8095376 NM_005953 metallothionein 2A 2,058 10,375 0,003 
MT2A 8095362 NM_005953 metallothionein 2A 2,170 11,164 0,004 
NET1 7925954 NM_001047160 neuroepithelial cell transforming 1 -1,100 6,981 0,012 
NKG7 8038809 NM_005601 natural killer cell group 7 sequence 1,569 9,396 0,029 
NR1H3 7939751 NM_005693 nuclear receptor subfamily 1, group H, member 3 1,767 6,327 0,011 
NRP1 7932985 NM_003873 neuropilin 1 -1,393 7,770 0,046 
ODF3B 8077116 NM_001014440 outer dense fiber of sperm tails 3B 1,140 7,987 0,019 
P2RX4 7959267 NM_002560 purinergic receptor P2X, ligand-gated ion channel, 4 1,132 7,298 0,048 
P2RX7 7959251 NM_002562 purinergic receptor P2X, ligand-gated ion channel, 7 1,567 6,087 0,011 
PAIP2B 8052940 NM_020459 poly(A) binding protein interacting protein 2B -1,410 5,023 0,033 
PDCD1LG2 8154245 NM_025239 programmed cell death 1 ligand 2 2,371 6,513 0,040 
PHLPP2 8002571 NM_015020 PH domain and leucine rich repeat protein phosphatase 2 -1,061 5,303 0,024 
PILRA 8134814 NM_013439 paired immunoglobin-like type 2 receptor alpha 1,525 9,426 0,012 
PIM1 8119161 NM_002648 pim-1 oncogene 1,126 8,017 0,046 
PLA2G7 8126784 NM_001168357 
phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma) 
2,161 8,046 0,005 
PLD4 7977319 NM_138790 phospholipase D family, member 4 -1,650 8,756 0,050 
PLXNA4 8142997 NM_020911 plexin A4 -1,691 6,803 0,002 
PLXND1 8090591 NM_015103 plexin D1 1,215 7,168 0,025 
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PON2 8141076 NM_000305 paraoxonase 2 -1,174 5,805 0,010 
PPA1 7934133 NM_021129 pyrophosphatase (inorganic) 1 1,435 9,731 0,006 
PSTPIP2 8023043 NM_024430 proline-serine-threonine phosphatase interacting protein 2 2,138 8,337 0,011 
PTGER2 7974366 NM_000956 prostaglandin E receptor 2 (subtype EP2), 53kDa 1,717 5,792 0,027 
RAB20 7972805 NM_017817 RAB20, member RAS oncogene family 1,204 6,712 0,029 
RALGPS2 7907657 NM_152663 Ral GEF with PH domain and SH3 binding motif 2 -1,382 6,865 0,008 
RARRES3 7940775 NM_004585 retinoic acid receptor responder (tazarotene induced) 3 1,892 8,028 0,039 
RASSF4 7927186 NM_032023 Ras association (RalGDS/AF-6) domain family member 4 1,325 7,808 0,017 
RBMS3 8078330 NM_001003793 RNA binding motif, single stranded interacting protein 3 -1,503 5,134 0,008 
RGL1 7908125 NM_015149 ral guanine nucleotide dissociation stimulator-like 1 1,635 8,193 0,013 
RGS7 7925457 NM_002924 regulator of G-protein signaling 7 -1,226 6,730 0,014 
RNF125 8020806 NM_017831 ring finger protein 125 -1,218 6,090 0,050 
S100A12 7920238 NM_005621 S100 calcium binding protein A12 2,292 8,013 0,039 
S100A8 7920244 NM_002964 S100 calcium binding protein A8 1,921 11,019 0,008 
S100A9 7905571 NM_002965 S100 calcium binding protein A9 2,113 10,269 0,004 
SCARB1 7967544 NM_005505 scavenger receptor class B, member 1 -1,064 7,289 0,029 
SCO2 8077099 NM_005138 SCO cytochrome oxidase deficient homolog 2 (yeast) 1,026 8,108 0,041 
SCRN1 8138824 NM_014766 secernin 1 -1,076 8,928 0,049 
SECTM1 8019486 NM_003004 secreted and transmembrane 1 1,375 8,783 0,049 
SERPINA1 7981068 NM_001002236 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
1,678 10,490 0,008 
SERPINB9 8123609 NM_004155 serpin peptidase inhibitor, clade B (ovalbumin), member 9 1,016 9,627 0,049 
SIDT1 8081710 NM_017699 SID1 transmembrane family, member 1 -1,337 6,135 0,040 
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SIGLEC14 8038885 NM_001098612 sialic acid binding Ig-like lectin 14 2,056 7,581 0,017 
SIRPB2 8064451 NM_001122962 signal-regulatory protein beta 2 1,214 5,938 0,037 
SLC11A1 8048283 NM_000578 
solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1 
2,145 6,406 0,006 
SLC1A3 8104930 NM_004172 
solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 
2,417 6,048 0,028 
SLC25A37 8145281 NM_016612 solute carrier family 25, member 37 1,245 7,226 0,025 
SLC37A2 7944931 NM_198277 
solute carrier family 37 (glycerol-3-phosphate transporter), member 
2 
1,226 6,455 0,030 
SLC38A1 7962516 NM_030674 solute carrier family 38, member 1 -1,160 9,610 0,022 
SLC39A10 8047174 NM_001127257 solute carrier family 39 (zinc transporter), member 10 -1,011 6,640 0,046 
SLC41A2 7965964 NM_032148 solute carrier family 41, member 2 -1,575 6,389 0,044 
SLC47A1 8005603 NM_018242 solute carrier family 47, member 1 -1,206 4,810 0,011 
SLC7A7 7977786 NM_003982 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 7 
1,744 8,381 0,049 
SOD2 8130556 NM_001024465 superoxide dismutase 2, mitochondrial 1,972 10,526 0,001 
SPTBN1 8041995 NM_003128 spectrin, beta, non-erythrocytic 1 -1,152 6,773 0,040 
STAB1 8080344 NM_015136 stabilin 1 1,209 6,413 0,011 
STEAP4 8140840 NM_024636 STEAP family member 4 2,319 6,190 0,039 
SYCP2L 8116874 NM_001040274 synaptonemal complex protein 2-like -1,626 4,402 0,008 
TASP1 8065018 NM_017714 taspase, threonine aspartase, 1 -1,055 6,334 0,009 
TBC1D2B 7985224 NM_144572 TBC1 domain family, member 2B 1,195 7,121 0,048 
TBC1D4 7972021 NM_014832 TBC1 domain family, member 4 -1,211 7,739 0,044 
TCF7L2 7930537 NM_001146274 transcription factor 7-like 2 (T-cell specific, HMG-box) 1,638 7,738 0,044 
TCN2 8072360 NM_000355 transcobalamin II 1,373 6,211 0,044 
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TIMP1 8167185 NM_003254 TIMP metallopeptidase inhibitor 1 1,730 10,423 0,033 
TLR10 8099826 NM_030956 toll-like receptor 10 -1,026 7,802 0,044 
TLR2 8097903 NM_003264 toll-like receptor 2 1,619 7,192 0,024 
TLR4 8157524 NR_024168 toll-like receptor 4 2,322 7,912 0,002 
TMEM176
A 
8137264 NM_018487 transmembrane protein 176A 2,514 8,524 0,008 
TNFAIP2 7977046 NM_006291 tumor necrosis factor, alpha-induced protein 2 1,284 7,874 0,029 
TNFSF10 8092169 NM_003810 tumor necrosis factor (ligand) superfamily, member 10 1,662 8,924 0,039 
TREM1 8126303 NM_018643 triggering receptor expressed on myeloid cells 1 1,597 7,886 0,031 
TYMP 8077103 NM_001113756 thymidine phosphorylase 1,395 8,677 0,011 
UBD 8124650 NM_006398 ubiquitin D 1,694 7,030 0,032 
UBD 8178295 NM_006398 ubiquitin D 1,570 6,943 0,039 
UPP1 8132725 NM_003364 uridine phosphorylase 1 1,429 6,242 0,018 
VCAN 8106743 NM_004385 versican 2,091 8,315 0,021 
VSIG6 7981732 
ENST000003385
67 
V-set and immunoglobulin domain containing 6 -2,017 7,491 0,032 
ZNF585B 8036389 NM_152279 zinc finger protein 585B -1,049 5,589 0,036 
ZNF660 8079198 NM_173658 zinc finger protein 660 -1,024 3,907 0,011 
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Table 2. Toppfun Analysis 
GENE ONTOLOGY – CELLULAR FUNCTIONS 
# Name FDR 
# genes 
included/ 
annotated 
Genes 
1 immune response 5.3X10
-32
 77/1416 
CEBPB, IDO1, TNFSF10, CXCL10, GIMAP5, LILRB2, HLADRB5, CLEC7A, GBP1, GBP2, IRF1, GCH1, BCL2A1, HMOX1, ITGAM, 
APOBEC3A, S100A8, S100A9, S100A12, CLEC4E, SERPINB9, FCAR, FCER1A, RNF125, FCER2, GBP4, FCGR1A, FCGR1B, ADAMDEC1, 
GBP5, FCGR2A, FCGR3A, IFITM3, CXCL9, C1QA, C1QB, C1QC, CCL2, CCL3, C3AR1, CCL4, C5AR1, LILRA5, ALOX15, SECTM1, CLEC6A, 
UBD, BATF, SIGLEC14, NR1H3, APP, AQP9, LGALS3, TLR10, IFNGR2, CD1A, CD1C, CD1E, MT2A, CSF1R, SLC11A1, CD14, P2RX7, 
CLEC4D, SCARB1, TLR2, TLR4, TREM1, CD58, CD274, CD81, IL1R1, CDH1, CTSL, CXCR2, PHLPP2, PDCD1LG2 
2 defence response 1.1 X10
-27
 74/1515 
CEBPB, IDO1, CXCL10, GIMAP5, LILRB2, HLADRB5, CLEC7A, GBP1, GBP2, IRF1, GCH1, HMOX1, ITGAM, CD163, APOBEC3A, STAB1, 
S100A8, S100A9, S100A12, SERPINA1, SERPINB9, FCER1A, RNF125, GBP4, FCGR1A, FCGR1B, GBP5, FCGR2A, FCGR3A, IER3, 
IFITM3, KCNJ10, CXCL9, C1QA, C1QB, C1QC, CCL2, CCL3, C3AR1, CCL4, C5AR1, LILRA5, ALOX15, PLA2G7, LILRA3, CLEC6A, UBD, 
BATF, FPR2, CD207, SIGLEC14, CASP5, CCRL2, NR1H3, APP, LGALS3, TLR10, IFNGR2, MT2A, CSF1R, SLC11A1, CD14, CSF3R, P2RX7, 
CLEC4D, SCARB1, TLR2, TLR4, TREM1, CD58, IL1R1, CTSL, CXCR2, PHLPP2 
3 innate immune response 2.5 X10
-18
 48/883 
GIMAP5, HLA-DRB5, CLEC7A, GBP1, GBP2, IRF1, GCH1, ITGAM, APOBEC3A, S100A8, S100A9, S100A12, FCER1A, RNF125, GBP4, 
FCGR1A, FCGR1B, GBP5, FCGR2A, FCGR3A, IFITM3, C1QA, C1QB, C1QC, CCL2, CCL3, LILRA5, CLEC6A, UBD, SIGLEC14, NR1H3, APP, 
LGALS3, TLR10, IFNGR2, MT2A, CSF1R, SLC11A1, CD14, P2RX7, CLEC4D, SCARB1, TLR2, TLR4, TREM1, CD58, CTSL, PHLPP2 
4 inflammatory response 4.9 X10
-18
 40/599 
CEBPB, IDO1, CXCL10, HLA-DRB5, CLEC7A, HMOX1, ITGAM, CD163, STAB1, S100A8, S100A9, S100A12, SERPINA1, SERPINB9, 
FCER1A, FCGR1A, FCGR2A, IER3, KCNJ10, CXCL9, CCL2, CCL3, C3AR1, CCL4, C5AR1, ALOX15, PLA2G7, FPR2, CASP5, CCRL2, NR1H3, 
TLR10, CSF1R, SLC11A1, CD14, P2RX7, TLR2, TLR4, IL1R1, CXCR2 
5 response to biotic stimulus 3.8 X10
-16
 42/760 
CEBPB, IDO1, CXCL10, LILRB2, HLA-DRB5, CLEC7A, GBP1, GBP2,IRF1, GCH1, PTGER2, HNMT, APOBEC3A, STAB1, S100A8, S100A9, 
S100A12, SERPINA1, SERPINB9, GBP4, FCGR1A, FCGR3A, IER3, IFITM3, CXCL9, CCL2, CCL3, CCL4, C5AR1, CLEC6A, BATF, CD207, 
NR1H3, IFNGR2, SLC11A1, CD14, P2RX7, SCARB1, TLR2, TLR4, TREM1, SOD2 
6 
response to other 
organism 
3.8 X10
-18
 41/726 
CEBPB, IDO1, CXCL10, LILRB2, HLA-DRB5, CLEC7A, GBP1, GBP2, IRF1, GCH1, PTGER2, APOBEC3A, STAB1, S100A8, S100A9, 
S100A12, SERPINA1, SERPINB9, GBP4, FCGR1A, FCGR3A, IER3, IFITM3, CXCL9, CCL2, CCL3, CCL4, C5AR1, CLEC6A, BATF, CD207, 
NR1H3, IFNGR2, SLC11A1, CD14, P2RX7, SCARB1, TLR2, TLR4, TREM1, SOD2 
7 
response to external biotic 
stimulus 
3.8 X10
-16
 41/726 
CEBPB, IDO1, CXCL10, LILRB2, HLA-DRB5, CLEC7A, GBP1, GBP2, IRF1, GCH1, PTGER2, APOBEC3A, STAB1, S100A8, S100A9, 
S100A12, SERPINA1, SERPINB9, GBP4, FCGR1A, FCGR3A, IER3, IFITM3, CXCL9, CCL2, CCL3, CCL4, C5AR1, CLEC6A, BATF, CD207, 
NR1H3, IFNGR2, SLC11A1, CD14, P2RX7, SCARB1, TLR2, TLR4, TREM1, SOD2 
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8 response to wounding 1.2 X10
-14
 51/1255 
CEBPB, IDO1, CXCL10, HLA-DRB5, CLEC7A, IRF1, HMOX1, ITGAM, CD163, NRP1, STAB1, S100A8, S100A9, S100A12, SERPINA1, 
SERPINB9, FCER1A, FCGR1A, FCGR2A, IER3, KCNJ10, CXCL9, CCL2, CCL3, C3AR1, CCL4, C5AR1, ALOX15, PLA2G7, FPR2, CASP5, 
CCRL2, NR1H3, APP, SLC7A7, SLC1A3, TLR10, CSF1R, SLC11A1, CD14, P2RX7, TIMP1, SCARB1, TLR2, TLR4, TREM1, CD58, IL1R1, 
ENG, SOD2, CXCR2 
9 
positive regulation of 
immune system process 
1.7 X10
-14
 39/732 
IL15RA, IDO1, CXCL10, GIMAP5, LILRB2, HLA-DRB5, CLEC7A, IRF1, BCL2A1, HMOX1, ITGAM, FCER1A, FCER2, FCGR1A, FCGR2A, 
FCGR3A, C1QA, C1QB, C1QC, CCL2, CCL3, C3AR1, CCL4, C5AR1, PLA2G7, NR1H3, LGALS3, TLR10, SLC11A1, CD14, P2RX7, SCARB1, 
TLR2, TLR4, CD274, CD81, CTSL, CXCR2, PDCD1LG2 
10 
regulation of immune 
system process 
2.7 X10
-13
 48/1212 
IL15RA, IDO1, CXCL10, GIMAP5, LILRB2, HLA-DRB5, CLEC7A, TMEM176A, IRF1, BCL2A1, HMOX1, ITGAM, FCER1A, FCER2, FCGR1A, 
FCGR1B, FCGR2A, FCGR3A, C1QA, C1QB, C1QC, CCL2, CCL3, C3AR1, CCL4, MAFB, C5AR1, ALOX15, PLA2G7, FLT3, NR1H3, LGALS3, 
TLR10, IFNGR2, CSF1R, SLC11A1, CD14, P2RX7, SCARB1, TLR2, TLR4, CD274, CD81, CDH1, CTSL, CXCR2, PHLPP2, PDCD1LG2 
11 response to IFN-γ 2.7 X10
-13
 18/123 
HLA-DRB5, GBP1, GBP2, IRF1, GCH1, GBP4, FCGR1A, FCGR1B, GBP5, IFITM3, CCL2, CCL3, UBD, NR1H3, IFNGR2, MT2A, SLC11A1, 
CD58 
12 response to cytokine 1.1 X10
-12
 34/629 
IL15RA, CXCL10, HLA-DRB5, GBP1, GBP2, IRF1, GCH1, HNMT, ACSL1, SERPINA1, GBP4, FCGR1A, FCGR1B, GBP5, IFITM3, CCL2, 
CCL3, ALOX15, FLT3, UBD, AFF3, CCRL2, NR1H3, IFNGR2, MT1X, MT2A, CSF1R, SLC11A1, CD14, CSF3R, TIMP1, CD58, IL1R1, CXCR2 
13 response to bacterium 1.7 X10
-12
 29/451 
CEBPB, IDO1, CXCL10, LILRB2, HLA-DRB5, GBP2, GCH1, PTGER2, STAB1, S100A8, S100A9, S100A12, SERPINA1, SERPINB9, GBP4, 
FCGR1A, FCGR3A, CCL2, CCL3, C5AR1, NR1H3, SLC11A1, CD14, P2RX7, SCARB1, TLR2, TLR4, TREM1, SOD2 
14 cell chemotaxis 2.0 X10
-12
 21/210 
DOCK4, CXCL10, ITGAM, NRP1, S100A8, S100A9, S100A12, FCGR2A, CXCL9, CCL2, CCL3, C3AR1, CCL4, C5AR1, PLA2G7, LPAR1, 
LGALS3, CSF3R, TREM1, ENG, CXCR2 
15 
positive regulation of 
response to stimulus 
4.6 X10
-12
 53/1584 
IDO1, TNFSF10, CXCL10, GIMAP5, HLA-DRB5, DAB2, CLEC7A, IRF1, BCL2A1, HMOX1, ITGAM, NRP1, S100A8, S100A9, S100A12, 
FCER1A, FCER2, FCGR1A, FCGR2A, FCGR3A, CXCL9, C1QA, C1QB, C1QC, CCL2, CCL3, C3AR1, CCL4, C5AR1, ALOX15, SECTM1, 
PLA2G7, FLT3, TCF7L2, CLEC6A, UBD, FPR1, NR1H3, LPAR1, LGALS3, TLR10, CSF1R, SLC11A1, CD14, P2RX4, P2RX7, SCARB1, TLR2, 
TLR4, CD81, ENG, CTSL, CXCR2 
16 
response to 
lipopolysaccharide 
5.8 X10
-12
 22/250 
CEBPB, IDO1, CXCL10, LILRB2, GBP2, GCH1, PTGER2, S100A8, S100A9, SERPINA1, FCGR3A, CCL2, CCL3, C5AR1, NR1H3, SLC11A1, 
CD14, P2RX7, SCARB1, TLR2, TLR4, SOD2 
17 
response to molecule of 
bacterial origin 
2.4 X10
-11
 22/269 
CEBPB, IDO1, CXCL10, LILRB2, GBP2, GCH1, PTGER2, S100A8, S100A9, SERPINA1, FCGR3A, CCL2, CCL3, C5AR1, NR1H3, SLC11A1, 
CD14, P2RX7, SCARB1, TLR2, TLR4, SOD2 
18 cytokine production 3.1 X10
-11
 29/451 
CEBPB, IDO1, GIMAP5, LILRB2, HLA-DRB5, CLEC7A, IRF1, HMOX1, S100A8, S100A9, S100A12, CLEC4E, FCER1A, RNF125, FCGR2A, 
CCL2, CCL3, C3AR1, CCL4, CLEC6A, BATF, TLR10, CSF1R, SLC11A1, CD14, P2RX7, TLR2, TLR4, TREM1, CD58, CD274 
21 leukocyte activation 6.8 X10
-11
 33/695 
IL15RA, IDO1, GIMAP5, LILRB2, HLA-DRB5, CLEC7A, IRF1, BCL2A1, HMOX1, ITGAM, S100A12, FCER1A, FCGR2A, FCGR3A, CCL2, 
CCL3, MAFB, FLT3, UBD, BATF, NR1H3, LGALS3, CD1C, MT1G, SLC11A1, P2RX7, TLR2, TLR4, CD274, CD81, CD151, CXCR2, 
PDCD1LG2 
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27 immune effector process 6.0 X10
-10
 30/628 
CXCL10, GIMAP5, HLA-DRB5, CLEC7A, GBP1, IRF1, HMOX1, APOBEC3A, SERPINB9, FCER1A, FCER2, FCGR1A, FCGR2A, FCGR3A, 
IFITM3, CXCL9, C1QA, C1QB, C1QC, CCL2, CCL3, BATF, CD207, LGALS3, CD1C, SLC11A1, P2RX7, TLR2, TLR4, TREM1 
GENE ONTOLOGY – MOLECULAR FUNCTIONS 
1 immunoglobulin binding 3.9 X10
-8
 8/23 FCAR, FCER1A, FCER2, FCGR1A, FCGR1B, FCGR2A, FCGR3A, LGALS3 
2 receptor activity 1.3 X10
-5
 42/1617 
IL15RA, LILRB2, DAB2, CLEC7A, GPR84, PLXND1, PTGER2, CD163, NRP1, STAB1, CLEC4E, FCER1A, FCGR1A, FCGR1B, FCGR2A, 
C3AR1, C5AR1, AGTRAP, FLT3, LILRA3, FPR1, FPR2, CCRL2, NR1H3, LPAR1, TLR10, IFNGR2, CSF1R, CD14, CSF3R, P2RX4, P2RX7, 
SCARB1, TLR2, TLR4, PLXNA4, TREM1, LRP1, EMR1, IL1R1, ENG, CXCR2 
3 RAGE receptor binding 2.0 X10
-5
 5/12 S100A8, S100A9, S100A12, FPR1, FPR2 
4 
signaling pattern 
recognition receptor 
activity 
6.7 X10
-5
 5/16 CLEC7A, CD14, SCARB1, TLR2, TLR4 
5 
pattern recognition 
receptor activity 
6.7 X10
-5
 5/16 CLEC7A, CD14, SCARB1, TLR2, TLR4 
6 receptor binding 7.2 X10
-5
 36/1405 
DOCK4, CEBPB, TNFSF10, CXCL10, LILRB2, DAB2, CLEC7A, S100A8, S100A9, S100A12, KCNA5, FCER2, KCNJ10, CXCL9, C1QC, CCL2, 
CCL3, CCL4, GPNMB, HOMER2, SECTM1, FLT3, TCF7L2, FPR1, FPR2, CCRL2, NR1H3, APP, TYMP, P2RX4, P2RX7, TIMP1, LRP1, 
CD58, IL1R1, ENG 
7 
immunoglobulin receptor 
activity 
7.8 X10
-5
 4/8 FCER1A, FCGR1A, FCGR1B, FCGR2A 
8 signalling receptor activity 1.1 X10
-4
 35/1390 
IL15RA, LILRB2, CLEC7A, GPR84, PLXND1, PTGER2, NRP1, FCER1A, FCGR1A, FCGR1B, FCGR2A, C3AR1, C5AR1, AGTRAP, FLT3, 
FPR1, FPR2, CCRL2, NR1H3, LPAR1, TLR10, IFNGR2, CSF1R, CD14, CSF3R, P2RX4, P2RX7, SCARB1, TLR2, TLR4, PLXNA4, EMR1, 
IL1R1, ENG, CXCR2 
9 signal transducer activity 1.2 X10
-4
 40/1730 
IL15RA, LILRB2, CLEC7A, GPR84, PLXND1, HMOX1, PTGER2, NRP1, S100A9, FCER1A, FCGR1A, FCGR1B, FCGR2A, C3AR1, C5AR1, 
GNG10, AGTRAP, SECTM1, FLT3, FPR1, FPR2, CCRL2, NR1H3, LPAR1, RGS7, TLR10, IFNGR2, CSF1R, CD14, CSF3R, P2RX4, P2RX7, 
SCARB1, TLR2, TLR4, PLXNA4, EMR1, IL1R1, ENG, CXCR2 
10 
molecular transducer 
activity 
1.2 X10
-4
 40/1730 
IL15RA, LILRB2, CLEC7A, GPR84, PLXND1, HMOX1, PTGER2, NRP1, S100A9, FCER1A, FCGR1A, FCGR1B, FCGR2A, C3AR1, C5AR1, 
GNG10, AGTRAP, SECTM1, FLT3, FPR1, FPR2, CCRL2, NR1H3, LPAR1, RGS7, TLR10, IFNGR2, CSF1R, CD14, CSF3R, P2RX4, P2RX7, 
SCARB1, TLR2, TLR4, PLXNA4, EMR1, IL1R1, ENG, CXCR2 
11 IgG binding 3.1 X10
-4
 4/12 FCGR1A, FCGR1B, FCGR2A, FCGR3A 
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12 
transmembrane signaling 
receptor activity 
3.1 X10
-4
 32/1228 
IL15RA, LILRB2, GPR84, PLXND1, PTGER2, NRP1, FCER1A, FCGR1A, FCGR1B, FCGR2A, C3AR1, C5AR1, AGTRAP, FLT3, FPR1, FPR2, 
CCRL2, LPAR1, TLR10, IFNGR2, CSF1R, CD14, CSF3R, P2RX4, P2RX7, TLR2, TLR4, PLXNA4, EMR1, IL1R1, ENG, CXCR2 
13 glycosaminoglycan binding 5.0 X10
-4
 11/202 CXCL10, ITGAM, NRP1, STAB1, CCL2, GPNMB, APP, VCAN, TLR2, HAPLN3, ENG 
14 IgE binding 5.0 X10
-4
 3/5 FCER1A, FCER2, LGALS3 
15 
lipopolysaccharide 
receptor activity 
5.0 X10
-4
 3/5 SCARB1, TLR2, TLR4 
PATHWAYS 
1 
Staphylococcus aureus 
infection 
5.5 X10
-10
 13/59 HLA-DRB5, ITGAM, FCAR, FCGR1A, FCGR2A, FCGR3A, C1QA, C1QB, C1QC, C3AR1, C5AR1, FPR1, FPR2 
2 Hematopoietic cell lineage 7.9 X10
-7
 12/88 HLA-DRB5, ITGAM, FCER2, FCGR1A, FLT3, CD1A, CD1C, CD1E, CSF1R, CD14, CSF3R, IL1R1 
3 Interferon gamma signaling 8.9 X10
-4
 10/71 HLA-DRB5, GBP1, GBP2, IRF1, GBP4, FCGR1A, FCGR1B, GBP5, IFNGR2, MT2A 
4 Tuberculosis 2.0 X10
-4
 13/182 CEBPB, HLA-DRB5, CLEC7A, ITGAM, CLEC4E, FCGR1A, FCGR2A, FCGR3A, IFNGR2, CD14, TLR2, TLR4, CTSD 
5 Phagosome 2.3 X10
-4
 12/158 HLA-DRB5, CLEC7A, ITGAM, FCAR, FCGR1A, FCGR2A, FCGR3A, CD14, SCARB1, TLR2, TLR4, CTSL 
6 Leishmaniasis 9.3 X10
-4
 8/76 HLA-DRB5, ITGAM, FCGR1A, FCGR2A, FCGR3A, IFNGR2, TLR2, TLR4 
7 
Peptide ligand-binding 
receptors 
9.3 X10
-4
 12/189 CXCL10, CXCL9, CCL2, CCL3, C3AR1, CCL4, C5AR1, FPR1, FPR2, CCRL2, APP, CXCR2 
8 
Chemokine receptors bind 
chemokines 
9.3 X10
-4
 7/56 CXCL10, CXCL9, CCL2, CCL3, CCL4, CCRL2, CXCR2 
9 Interferon Signaling 2.0 X10
-3
 11/174 HLA-DRB5, GBP1, GBP2, IRF1, GBP4, FCGR1A, FCGR1B, GBP5, IFITM3, IFNGR2, MT2A 
10 
pyrimidine 
deoxyribonucleosides 
degradation 
3.6 X10
-3
 3/6 UPP1, SCO2, TYMP 
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CO-EXPRESSION 
1 THRLBCL, Van Loo et al. 4.5 X10
-60
 63/373 
PDCD1LG2, CREG1, DMXL2, ACSL1, ANKRD22, DOCK4, TLR2, TLR4, ACP2, FCGR1A, CD274, KCNJ10, TNFSF10, CEBPB, SOD2, 
TNFAIP2, CD163, PILRA, AGTRAP, MT1X, APOBEC3A, MT1G, HNMT, MT1E, P2RX4, HK3, GPR84, SLC1A3, CXCL10, IDO1, C1QB, 
LILRB2, C1QA, GCH1, C1QC, C3AR1, IL15RA, GBP1, RASSF4, GBP5, SLC7A7, LRP1, PSTPIP2, PTGER2, S100A9, CCRL2, S100A8, 
SECTM1, IFNGR2, CASP5, RAB20, NR1H3, EPB41L3, RGL1, CD14, LGALS3, CTSD, FPR1, FPR2, CTSL, CSF1R, SERPINA1, CSF3R 
2 cHL EBV +/-, Chetaille et al. 4.9 X10
-38
 46/348 
CREG1, GPNMB, DMXL2, DOCK4, TLR2, ACP2, FCGR1A, TNFSF10, RNF125, CD163, HMOX1, TCF7L2, PILRA, TCN2, MT1G, HK3, 
PLA2G7, SLC1A3, CXCL10, IDO1, C1QB, LILRB2, C1QA, GCH1, C3AR1, MAFB, IL15RA, GBP1, RASSF4, SLC7A7, SLC47A1, GAS7, 
PSTPIP2, PTGER2, SCO2, CCRL2, SECTM1, APOC1, CASP5, RAB20, CXCL9, RGL1, CD14, CTSD, CTSL, SERPINA1 
3 
NPM mutated AML, 
Verhaak et al. 
1.6 X10
-36
 
 
48/427 
FCER1A, DMXL2, ACSL1, TLR4, LILRA5, TNFSF10, SOD2, TNFAIP2, SCRN1, BCL2A1, CD163, TMEM176A, HMOX1, PILRA, APOBEC3A, 
HNMT, HK3, IER3, CXCL10, C1QB, LILRB2, C1QA, GCH1, C3AR1, MAFB, C5AR1, SIDT1, SLC38A1, TYMP, SCO2, SECTM1, APP, 
PLXND1, TREM1, CCL4, EPB41L3, AQP9, CD14, SPTBN1, EMR1, CTSD, CD1C, FPR1, CTSL, VCAN, SERPINA1, CSF3R, LILRA3 
5 
Lymph-node signature, 
Rosenwald et al. 
3.4 X10
-22
 
 
25/155 
IL15RA, CEBPB, CXCL10, DAB2, GBP1, IRF1, CREG1, FCGR1A, IFITM3, CXCL9, CCL2, C3AR1, NKG7, FPR1, FPR2, MT2A, CSF1R, CD14, 
CSF3R, TIMP1, CD81, IL1R1, ENG, CTSL, SOD2 
6 
Low-dose radiotherapy in 
follicular lymphoma, 
Knoops et.al. 
4.9X10
-22
 23/121 
TNFSF10, CXCL10, LILRB2, GBP1, HMOX1, EPB41L3, CREG1, ANKRD22, FCGR1A, ADAMDEC1, GBP5, CXCL9, C1QA, C1QB, GPNMB, 
PLA2G7, TCN2, UBD, NR1H3, APOC1, RAB20, TLR4, CTSD 
7 CD molecules, Zola et al. 3.1 X10
-21
 32/345 
TNFSF10, LILRB2, SIRPB2, ITGAM, CD163, NRP1, FCAR, FCER2, FCGR1A, FCGR2A, FCGR3A, FLT3, LILRA3, CD207, TLR10, CD1A, 
CD1C, CD1E, CSF1R, CD14, CSF3R, TLR2, TLR4, LRP1, CD58, CD274, CD81, CD151, IL1R1, ENG, CDH1, PDCD1LG2 
CANCER MODULES 
1 Genes in module 84 1.7 X10
-27
 53/531 
CREG1, GPNMB, ACSL1, DAB2, TLR2, HSPA6, FCGR3A, FCGR2A, TNFSF10, TNFAIP2, KCNA5, BCL2A1, CD163, RARRES3, ITGAM, 
IRF1, HK3, PLA2G7, IER3, C1QB, LILRB2, GCH1, C1QC, C3AR1, MAFB, HLA-DRB5, GBP1, GBP2, SLC7A7, IL1R1, TBC1D2B , S100A9, 
S100A8, SECTM1, APOC1, IGLJ3, CCL3, IGHM, CCL4, EPB41L3, CCL2, IGKC, AQP9, CXCL9, RGL1, ENG, CD14, LGALS3, FPR1, CSF1R, 
NKG7, CDH1, VCAN, UBD, SERPINA1, CSF3R 
2 Genes in module 5 3.2 X10
-18
 39/423 
GPNMB, ACSL1, DAB2, TLR2, ACP2, PON2, FCGR3A, FCGR2A, TNFSF10, TNFAIP2, CD163, RARRES3, HMOX1, ITGAM, IRF1, IER3, 
C1QB, GBP1, SLC7A7, UPP1, IL1R1, TBC1D2B, S100A9, S100A8, SECTM1, APOC1, PLXND1, STAB1, CCL3, IGHM, EPB41L3, CCL2, 
ENG, CD14, PIM1, NKG7, VCAN, CD151, SERPINA1, CSF3R 
3 Genes in module 46 6.6 X10
-18
 37/386 
CREG1, FCER1A, NRP1, TIMP1, DAB2, TLR2, FCGR3A, FCGR2A, TNFSF10, CEBPB, IFITM3, IRF1, CXCL10, LILRB2, C1QA, C3AR1, 
IL15RA, HLA-DRB5, C5AR1, GBP1, GBP2, LRP1, IL1R1, IFNGR2, CCL3, CCL4, CCL2, AQP9, CXCL9, FLT3, CD14, CD1C, BATF, UBD, 
CSF3R, CD81, LILRA3 
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The cutpoint FDR p-value considered was 1.0 X10
-3
.  From the top 20 hits for each category, the most relevant data is provided
4 Genes in module 75 4.4 X10
-15
 34/391 
CREG1, FCER1A, NRP1, TIMP1, DAB2, TLR2, FCGR3A, FCGR2A, TNFSF10, IFITM3, IRF1, CXCL10, LILRB2, C1QA, C3AR1, IL15RA, HLA-
DRB5, C5AR1, GBP1, GBP2, LRP1, IL1R1, CCL3, CCL4, CCL2, AQP9, CXCL9, FLT3, CD14, CD1C, BATF, UBD, CSF3R, CD81 
5 Genes in module 170 4.5 X10
-13
 18/100 
TIMP1, DAB2, FCGR1A, FCGR2A, TNFSF10, IFITM3, IER3, C3AR1, GBP1, GBP2, IL1R1, CCL2, CXCL9, CD14, FPR1, CTSL, CSF1R, 
CD151 
6 Genes in module 64 4.3 X10
-12
 34/506 
FCER1A, NRP1, TLR2, FCGR1A, FCER2, FCGR3A, FCGR2A, TNFSF10, CD163, ITGAM, P2RX7, HK3, CXCL10, ADAMDEC1, LILRB2, 
C3AR1, IL15RA, HLA-DRB5, C5AR1, IL1R1, S100A9, CCL3, CCL4, CCL2, AQP9, CXCL9, FLT3, CD14, LGALS3, EMR1, CD1C, FPR1, 
NKG7, CSF3R 
7 Genes in module 79 4.3 X10
-12
 17/100 TIMP1, DAB2, FCGR1A, FCGR2A, IFITM3, IER3, C3AR1, GBP1, GBP2, IL1R1, CCL2, CXCL9, CD14, FPR1, CTSL, CSF1R, CD151 
8 Genes in module 45 3.8 X10
-12
 36/563 
ACSL1, TLR2, SLC11A1, HSPA6, FCGR3A, FCGR2A, TNFSF10, SOD2, TNFAIP2, KCNA5, BCL2A1, RARRES3, ITGAM, IRF1, HK3, IER3, 
LILRB2, GCH1, GBP1, GBP2, SLC7A7, TBC1D2B, S100A9, SCO2, S100A8, SECTM1, STAB1, IGHM, AQP9, FLT3, CD14, PIM1, NKG7, 
VCAN, SERPINA1, CSF3R, CD58 
9 Genes in module 128 3.8 X10
-12
 17/98 TIMP1, DAB2, FCGR1A, FCGR2A, IFITM3, IER3, C3AR1, GBP1, GBP2, IL1R1, CCL2, CXCL9, CD14, FPR1, CTSL, CSF1R, CD151 
10 Genes in module 76 2.2 X10
-11
 15/79 TLR2, CEBPB, PLA2G7, CXCL10, C3AR1, ALOX15, IL1R1, S100A9, S100A12, CCL3, CCL4, CCL2, CXCL9, CD14, FPR1 
GENE FAMILY 
1 CD molecules 4.5 X10
-22
 28/276 
ITGAM, CD163, NRP1, FCER2, FCGR1A, FCGR2A, FCGR3A, C5AR1, LILRA5, FLT3, CD207, TLR10, CD1A, CD1C, CD1E, CSF1R, CD14, 
CSF3R, TLR2, TLR4, LRP1, CD58, CD274, CD81, CD151, CDH1, CXCR, PDCD1LG2 
2 Metallothioneins 8.1 X10
-6
 5/20 MT1DP, MT1E, MT1G, MT1X, MT2A 
Appendix 
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Thermal Cycler Programming 
 
 First strand cDNA synthesis 
Program 1: 65°C for 2 min, hold at 4°C 
Program 2: 4°C for 2 min, 25°C for 30 min, 42°C for 15 min, 70°C for 15 min, hold at 
4°C 
 Second strand cDNA synthesis 
Program 3: 4°C for 1 min, 25°C for 10 min, 50°C for 30 min, 80°C for 20 min, hold at 
4°C 
 SPIA amplification 
Program 4: 4°C for 1 min, 47°C for 75 min, 95°C for 5 min, hold at 4°C 
 cDNA fragmentation 
Program 5: 37°C for 30min; 95°C for 2 min, hold at 4°C 
 Biotin labelling 
Program 6: 37°C for 60min, 70°C for 10 min, hold at 4°C 
 
